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Abstract 
 
Bacterial cell survival depends on intact peptidoglycan, an extensive cell wall 
polymer of alternating N-acetylglucosamine and N-acetylmuramic acid residues, 
cross-linked by short peptides.  Peptidoglycan biosynthesis is a viable and validated 
antimicrobial target; the intracellular, membrane-bound and extracellular synthetic 
stages provide a multitude of enzymes for interception with inhibitors.  The ultimate 
phase of peptidoglycan biosynthesis occurs on the extracellular face of the 
cytoplasmic membrane and involves the polymerisation of Lipid II (the monomeric 
peptidoglycan precursor) by the transglycosylase and transpeptidase activities of the 
Penicillin-Binding Proteins (PBPs). 
 
The work presented in this thesis primarily focused on the biochemical 
characterisation of the integral membrane proteins Streptococcus pneumoniae 
PBP1a, PBP2b and PBP2x.  These enzymes are clinically relevant; they are essential 
targets of !-lactam antibiotics and also mediate resistance against this important 
antimicrobial class.  Full-length and truncated forms of the PBPs were cloned, 
expressed and purified to high levels.  Two novel spectrophotometric assays were 
designed and developed to study the enzymology of the individual transglycosylase 
and transpeptidase activities of the PBPs with their natural substrate, Lipid II.  
Preliminary kinetic characterisations of the bifunctional PBP1a transglycosylase 
activity were performed and assay conditions were optimised to recreate an in vivo 
environment.  PBP1a active site mutants revealed that transglycosylase activity was 
elevated in the absence of a functional transpeptidase domain.  PBP1a and PBP2x 
exhibited transpeptidase activity with an apparent substrate preference for glycan 
polymers over Lipid II.  PBP2x transpeptidase activity was not detected.  The 
recorded rates of PBP activity were insufficient to support bacterial cell integrity, 
highlighting a gap in the understanding of PBP requirements.  Finally, the PBPs were 
subjected to crystallisation trials for structural characterisations.   
 
This work provides an excellent foundation for the analysis and elucidation of PBP 
specificities.  Future information attained could contribute to the design of novel 
inhibitors, alleviating the global threat of antibiotic resistance.   
 xxiv 
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Chapter 1. Introduction 
 
1.1. The impact of antimicrobial agents and bacterial resistance 
 
Over the past half century, the introduction and development of antimicrobial agents 
to treat bacterial infectious diseases has been of great medical significance.  The 
landmark discovery of penicillin by Fleming in 1928 and sulphonamides by Domagk 
in 1935 (Wainwright and Kristiansen, 2011) initiated a rapid global response in the 
search for novel antimicrobial structures.  This led to the identification of a plethora 
of new antibiotic classes across two decades, 1940-1960, in what has been coined the 
‘Golden age’ of antimicrobial drug discovery (Walsh and Wright, 2005).  Control 
over infectious diseases triumphed and the availability of antibiotics was regarded as 
sufficient to maintain infection rates at low levels (von Nussbaum et al., 2006).  
Consequently, drug development was focussed towards more profitable treatments 
and away from infectious disease.  During this era, innovative antimicrobial 
compounds were not established to counteract the emerging global threat of 
antimicrobial resistance.  This has resulted in a renewed interest in the study of 
targets for antimicrobial agents from a perspective of understanding resistance 
mechanisms and also in the search for new targets and strategies. 
 
1.2. Antimicrobial agents 
 
1.2.1. Targets of antimicrobial agents 
 
Antimicrobial targets are constituents of a bacterial cell that are fundamental for 
viability and can be distinguished from homologous or equivalent eukaryotic cellular 
components; the selective toxicity of inhibitors allows bacterial cellular processes or 
structures to be impeded without compromising the eukaryotic host.  The advances 
in bioinformatics, molecular biology and microbiological techniques over the past 
decade have enabled the detection of ~200-400 essential bacterial genes that could be 
a priori antimicrobial targets (Walsh, 2003).  There are three classical metabolic 
pathways that consist of enzymes validated as successful targets: protein 
biosynthesis; DNA replication, repair and transcription; bacterial cell wall 
biosynthesis. 
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1.2.1.1. Protein biosynthesis 
 
Protein biosynthesis is a complex process making it an attractive multifaceted target 
for antimicrobial agents.  The bacterial biosynthetic machinery is sufficiently distinct 
from the analogous counterparts in eukaryotes.  The central feature of protein 
synthesis is the bacterial ribosome, a ribonucleoprotein consisting of two subunits 
(30S and 50S) that associate to form a 70S ribosomal assembly (Lodish et al., 2004; 
Steitz, 2010).  The initiation, elongation and termination of protein synthesis provide 
numerous potential binding sites and catalytic stages that could be disrupted by the 
introduction of different classes of antibiotics.  Examples are illustrated in Table 1.1. 
 
1.2.1.2. DNA replication, repair and transcriptional events 
 
In order to access the information contained in DNA sequences, the complementary 
duplex strands of circular bacterial DNA have to be unwound temporarily or 
permanently for bacterial transcription and replication events respectively.  
Organisms possess topoisomerases, which are responsible for controlling DNA 
topology and relieving torsional stress by introducing transient single or double-
strand breaks in the DNA.  DNA gyrase is a topoisomerase unique to prokaryotes 
and is capable of performing the crucial events of both positive and negative DNA 
supercoiling (Champoux, 2001).  Transcriptional events are performed by RNA 
polymerase, which involves the production of mRNA from information encoded 
within the DNA sequence (Cramer, 2002).  The functions of the bacterial DNA 
gyrase and bacterial RNA polymerase are essential for viability, making them 
suitable antimicrobial targets (Table 1.1).   
 
1.2.1.3. Cell wall biosynthesis 
 
The bacterial cell wall is located on the extracellular face of the plasma membrane 
and is essential for viability.  The central component, peptidoglycan, is an extensive 
glycan polymer of repeating disaccharide units with short peptide cross-links.  It acts 
as an exoskeleton, conferring mechanical strength, enabling the cell to endure high 
internal osmotic pressures.  Although peptidoglycan composition can vary greatly 
between different bacterial species, the enzymology of the biosynthetic pathway is 
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highly conserved, permitting a single class of antimicrobial to inhibit homologous 
targets (Lazar and Walker, 2002).  The biosynthesis of peptidoglycan is a primary 
focus of this thesis and therefore Sections 1.5 and 1.6 provide a comprehensive 
overview of its role, chemical structure and biosynthetic pathway. 
 
1.2.2. Major classes of antibiotics and their mode of action 
 
The term antibiotic was initially denoted by Waksman (1944) to describe natural 
growth inhibitors; it is now broadly used to describe natural, semi-synthetic and 
synthetic antimicrobials.  Antibiotics are classed according to common structural 
features.  Table 1.1 illustrates the diverse structures of several different classes of 
antibiotics and the targets they inhibit. 
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Table 1.1:  Classes of antimicrobial agents.  The first year of the commercial availability of each 
antibiotic class is shown.  A member of each class is displayed as a structure, highlighting extensive 
structural disparities.  The mode of action of the antibiotic class is briefly described.  The examples 
are not intended to be an exhausted list of antibiotic classes.  Adapted from von Nussbaum et al. 
(2006). 
 
1.3. Antibiotic resistance 
 
The ability of bacteria to survive in the presence of an antimicrobial compound is not 
a new phenomenon; it is a natural progression of evolution and classical Darwinian 
selection (Normark and Normark, 2002).  Bacterial resistance to many antibiotics is 
often reported prior to the commercial exposure of the drug in a human population.  
As discussed by Harwell and Brown (2000), resistance to optochin, one of the first 
Year 
Class of 
Antibiotic 
Example Mode of Action 
1935 Sulphonamide 
Sulfadimethoxine 
H2N
S
HN
O
O
N
N
O
O  
Corrupts the pathway of folate 
synthesis. 
1940 !-lactam 
Benzylpenicillin 
N
S
H
N
O
OH
O
O
 
Inhibits transpeptidation, the final 
step in peptidoglycan synthesis. 
1945 Tetracycline 
Tetracycline 
OOH
OH
OH
NH2
OOOH
OH
N
 
Binds to the 16S rRNA of the 30S 
ribosomal subunit, preventing the 
binding of the aminoacyl-tRNA, 
inhibiting protein synthesis. 
1952 Macrolide 
Erythromycin 
O
O
OH
HO
O
OH
OO
O
O
N
O
OH
HO
 
Binds to the 50S ribosomal subunit 
and prevents the translocation of 
peptidyl tRNA, inhibiting the 
elongation of the peptide chain 
during protein synthesis. 
1958 Glycopeptide 
Vancomycin 
O O
O
OH
OH
NH2
OH
OH
O
OO
Cl Cl
HO OH
N
H
H
N
N
H
H
N
N
H
O OO
O
H
N
OH2N
O
HN
O
OH
HO OH
HO
O
 
Binds to the D-Ala-D-Ala terminal 
of the pentapeptide side chain of 
the glycan chains, inhibiting the 
final steps of peptidoglycan 
synthesis. 
1962 Quinolone 
Ciprofloxacin 
HN
N N
OH
OO
F
 
Inhibits bacterial DNA gyrase and 
topoisomerase IV, preventing DNA 
replication and transcription. 
2000 Oxazolidinone 
Linezolid 
O N N
O H
N
O
F
O
 
Inhibits the initiation complex 
formation during bacterial protein 
translation. 
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antibiotics administrated to target pneumococcal infections, was reported in 
laboratory animals in 1912 ahead of its generalised release into the community.  
Optochin-resistant clinical isolates were later identified, providing one of the primary 
indications that antibiotic efficacy could be compromised.  The time frame for 
antibiotic resistance development is highly varied.  In the case of vancomycin, 
resistance was not detected until almost 30 years after its clinical introduction 
(Johnson et al., 1990).  As it stands, bacterial resistance to the majority of clinically 
used antibiotics has been documented (Levy and Marshall, 2004); this only becomes 
a problem when the efficacy of the drug therapy is affected.   
 
Bacterial resistance to antimicrobial compounds is not restricted to pathogenic 
strains.  An antibiotic will be active against susceptible, non-pathogenic bacteria, 
whilst selecting for resistant strains.  Thus, non-pathogenic bacteria are able to 
harbour resistance elements within the environment, which can lead to the rapid 
dissemination of resistance genes through different taxonomic and ecological 
bacterial populations (Levy and Marshall, 2004).   
 
1.3.1. Emergence or acquisition of resistance 
 
A bacterial population can be resistant to an antimicrobial prior to its introduction 
into the environment (inherently resistant or containing previously acquired 
resistance elements) or develop or acquire resistance elements following antibiotic 
exposure.  A biological fitness defect is often incurred upon attaining antibiotic 
resistance, which can generally be alleviated by a series of compensatory mutations 
(Andersson and Hughes, 2010).  There are three main routes that enable bacteria to 
acquire resistance: inherent resistance, mutations and gene transfer (described 
below). 
 
1.3.1.1. Inherent resistance 
 
An entire bacterial species that exhibits a characteristic rendering it resistant to a 
specific antibiotic (or class) without further genetic modification is said to be 
inherently resistant (Normark and Normark, 2002).  An unambiguous example is 
exemplified by the resistance to the !-lactam class of antibiotics by Mycoplasma, a 
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species that lack the peptidoglycan constituent of the cell wall (Bebear and Pereyre, 
2005).  A second example is the high level of intrinsic resistance displayed by 
Pseudomonas aeruginosa; a restricted outer-membrane permeability to hydrophobic 
antibiotics and the presence of multidrug efflux pumps impede the entry of 
antibiotics, such as macrolides, into the cell (Lambert, 2002; Normark and Normark, 
2002).  
 
1.3.1.2. Mutation 
 
Under a persistent selection pressure exerted by an antibiotic, resistance can develop 
through spontaneously occurring mutations within the bacterial genome in the form 
of point mutations, deletions, inversions and insertions.  Mutation frequencies 
conferring resistance vary between different bacterial strains depending on the 
efficacy of the DNA repair system and the desired resistance mechanism.  Certain 
bacterial species, such as Mycobacterium tuberculosis, have a limited capability of 
genetic exchange, and solely rely on genetic alterations for resistance to antibiotics 
(Normark and Normark, 2002).  For example, resistance to fluoroquinolones by this 
organism occurs by a series of successive mutations in the ‘quinolone-resistance 
determining regions’ of the targets gyrA and gyrB encoding the DNA gyrase (Takiff 
et al., 1994).  The stepwise development of mutations causing antibiotic resistance 
makes the identification of organisms with low-level resistance paramount; they 
provide the genetic platform for future generations of mutations, which can direct 
higher levels of resistance (Normark and Normark, 2002). 
 
1.3.1.3. Genetic exchange 
 
Sequencing of bacterial genomes has identified that proportions of their DNA 
originate from various sources (Normark and Normark, 2002).  This is made possible 
through a process known as horizontal gene transfer, which is common among 
bacteria of the same genus, and has also been observed between evolutionary distant 
organisms (Alekshun and Levy, 2007).  Resistance genes are collected on a mobile 
genetic element, propagated in the local environment and disseminated to other hosts 
and geographical locations (Levy and Marshall, 2004).   
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The major mechanisms that enable the genetic transfer of antibiotic resistance are 
transduction, transformation and conjugation.  Transduction is the transfer of genetic 
material via bacteriophages.  Transformation is the uptake of environmental naked 
DNA by naturally competent bacteria.  Conjugation is the direct transfer of DNA 
between bacterial cells, which involves cell-cell contact via a sex pilus, linking their 
cytoplasms for genetic exchange. 
 
The mobile genetic elements can be of various forms including plasmids, 
transposons and integrons, discussed briefly below. 
 
1.3.1.3.1.  Plasmids 
 
Plasmids, previously referred to as resistance transfer factors (RTFs), were described 
as the vehicle that drove the spread of antibiotic resistance between bacteria.  They 
are complex genetic elements, varying in size from 1-<100 kb.  Plasmids contain 
several genes conferring resistance against different antibiotic classes, and they also 
encode transmissible functions, enabling self-replication and dissemination amongst 
the bacterial population (Alekshun and Levy, 2007). 
  
1.3.1.3.2.  Transposons 
 
Transposons are mobile genetic elements that can exist in plasmids, other 
transposons or integrate into the chromosome of the host.  They encode a site-
specific transposase, which facilitates their own site-specific insertions and excisions 
(Alekshun and Levy, 2007).  The antibiotic resistances encoded are specific to the 
transposon.  For example, Tn5 encodes resistance to kanamycin, bleomycin and 
streptomycin (Mazodier et al., 1985).  
 
1.3.1.3.3.  Integrons 
 
Integrons are DNA elements that are able to acquire exogenous gene cassettes (that 
often encode antibiotic resistance) and convert them into functional genes.  Integrons 
are unable to promote self-transposition and are stably incorporated into genetic 
elements as either mobile integrons (associating with transposons or plasmids) or 
super integrons (associating with immobile DNA i.e. chromosomes).  They are 
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composed of an integrase (intI, a site-specific recombinase), a primary integration 
site (attI) and a promoter, directing the capture and transcriptional regulation of gene 
cassettes (Mazel, 2006).  The physical association of integrons with stable genetic 
material allows the preservation of integrated gene cassettes in the absence of 
selection pressures (Fluit and Schmitz, 2004). 
 
1.3.2. Biological mechanisms of antibiotic resistance 
 
Bacteria have established and evolved a myriad of physiological mechanisms to 
evade the action of antimicrobial agents.  The three major types are described below.  
A resistant bacterium can accommodate one or more of these mechanisms, thus they 
are not mutually exclusive. 
 
1.3.2.1. Reduced antimicrobial uptake and accumulation 
 
In order to be effective, antibiotics must accumulate to a bacteriocidal, or at least a 
bacteriostatic, level.  Bacteria have developed strategies to prevent this occurrence.  
Gram-negative bacteria contain an outer-membrane (not possessed by Gram-positive 
bacteria), which restricts the permeability of small hydrophilic molecules and 
excludes larger ones, providing a barrier to the penetration of antibiotics (Lambert, 
2002).  The outer membrane contains porins, aqueous channels, which allow the 
acquisition of nutrients and other compounds including !-lactam and quinolone 
antibiotics from the surrounding environment (Lambert, 2002).  P. aeruginosa 
exhibits a reduced absorption efficiency of these molecules through porins, 
accounting for low levels of antibiotic resistance (Lambert, 2002).  
 
Efflux pumps provide an alternative means of preventing antibiotics from reaching 
inhibitory concentrations within the bacterial cell.  They are found in all bacteria, 
where they are situated in the cytoplasmic or outer membrane and function to 
actively extrude toxic substances such as antibiotics, detergents and organic solvents 
from within the cell, driven by an energy source.  Antibiotic resistance develops as a 
result of mutational hyper-expression of the efflux pumps, where transcriptional 
repressors are abolished (Normark and Normark, 2002). The genes encoding these 
systems can be located on the chromosome or on mobile genetic elements.  Efflux 
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pumps exhibit a range of specificity; they may export a single substrate or a range of 
dissimilar compounds (Webber and Piddock, 2003).  P. aeruginosa produces efflux 
pumps with a broad substrate specificity, allowing for a multidrug resistant 
phenotype (Lambert, 2002).  
 
1.3.2.2. Antibiotic structural alterations 
 
Resistance to antibiotics can arise through an enzymatic structural modification of 
the drug, rendering it ineffective.  A prime example of this resistance mechanism 
involves the !-lactamases.  These enzymes inactivate !-lactam-based antibiotics by 
hydrolysing the chemically functional !-lactam ring (Figure 1.1).  This results in a 
structure that can no longer act as a suicide substrate for the inhibition of the 
penicillin-binding proteins (PBPs).  !-lactamases can hydrolyse 103 penicillin 
molecules/sec, allowing the rapid destruction of the drug before it reaches the target 
enzymes (Walsh, 2000).  
 
 
Figure 1.1: !-lactamase hydrolysis of the !-lactam ring.  Common to all !-lactam antibiotics is the 
!-lactam ring (red).  Hydrolysis of this moiety renders the antibiotic inactive.   
 
A second example is the irreversible chemical modification of ribosomally targeted 
agents such as chloramphenicol and the aminoglycoside antibiotics.  Functional 
groups are added to the periphery of the antibiotic by N-acetylation, O-
phosphorylation or O-adenylation performed by acetyl transferases, phosphoryl 
transferases and adenyltransferases respectively (Walsh, 2000).  These alterations to 
the antibiotic structure confer resistance by interfering with the affinity of these 
antimicrobials for their 50S (chloramphenicol) or 30S (aminoglycoside) ribosomal 
targets, thus preventing the inhibition of protein synthesis (Walsh, 2000).   
 
N
O
R1
S
O
OH
HN
S
O
OH
R1
O
HO
!-lactamase
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1.3.2.3. Structural modification of the antibiotic target 
 
Modifications to the antibiotic target can prevent drug recognition and can lead to 
high levels of antibiotic resistance.  A classic example of the target alteration strategy 
is employed by vancomycin resistant enterococci (VRE).  Vancomycin binds to the 
major component of the cell wall, peptidoglycan, and more specifically the D-Ala-D-
Ala terminal of the pentapeptide chain constituent (Nieto and Perkins, 1971), 
obstructing the transpeptidation activity of the PBPs.  This leads to a weakening of 
the cell wall and ultimately cell rupture.  In high-level vancomycin resistant strains, 
the cell wall is reprogrammed by a structural set of genes vanHAX in conjunction 
with the regulatory genes, vanSR.  The products of these genes replace the peptide 
stem terminal D-Ala-D-Ala with D-Ala-D-Lac (Walsh et al., 1996).  The binding of 
vancomycin to the termini of the pentapeptide stem from vancomycin-sensitive and 
resistant strains is depicted in Figure 1.2.  The affinity of vancomycin for the altered 
terminal residues of the pentapeptide stem is decreased by 1000-fold, attributed to 
the loss of a single hydrogen bond and the introduction of a destabilising lone pair of 
electrons on the ester oxygen of D-Lac (McComas et al., 2003).   
 
 
 
 
Figure 1.2: The interaction of vancomycin with the terminal of the pentapeptide stem.  (a) D-
Ala-D-Ala terminal.  (b) D-Ala-D-Lac terminal.  The terminal D-Ala and D-Lac residues are shown in 
orange and yellow respectively.  The hydrogen bonds are displayed as green dashed lines.  The 
presence of D-Lac confers resistance to vancomycin by causing the loss of a single hydrogen bond, 
which significantly reduces the affinity of antibiotic binding.  Figure from Healy et al. (2000).  
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Another elegant example is the modification of the !-lactam targets, the PBPs.  
Mutations in the active site of S. pneumoniae PBPs cause a reduction in affinity for 
the antibiotic whilst maintaining enzyme functionality.  This will be discussed in 
later sections in relation to the work of this thesis. 
 
1.3.3. Strategies to combat antimicrobial resistance 
 
A concerted effort by society to intervene with the emergence and spread of 
antibiotic resistance is paramount; failure to do so could cause a reversion back to the 
pre-World War II era when life-threatening diseases were untreatable.  Emphasis 
should be targeted towards methods to conserve the efficacy and prolong the lifespan 
of existing antibiotics (relying on the response by healthcare organisations) and 
providing new tactics for combating resistance mechanisms (identifying novel 
targets and classes of antibiotics).  With the decline of investment in antimicrobial 
design by the pharmaceutical industry and the prevalence of resistance mechanisms, 
antimicrobial agents are and should be considered a precious and finite source.  
 
1.3.3.1. Healthcare policy 
 
Healthcare organisations represent a key area for the control of antibiotic resistance 
development and dissemination.  The prudent use of current drugs, prevention of 
unnecessary prescriptions and complete dismissal of antimicrobials from treatment 
programs could decrease the occurrence of resistance.  Frequent surveillance of 
administrated drugs can correlate usage with the incidence of resistance.  Thus, 
knowledge of local antibiotic susceptibilities is vital to ensure the appropriate 
therapy is prescribed (Masterton, 2008).   
 
Healthcare environments provide a reservoir for antibiotic resistant bacteria.  Various 
strategies have been implemented to tackle the spread of resistance.  Statistics 
provided by the National Audit Office (2009) have shown that over a four year 
period (2004-2008), a predicted £57 million was spent on national initiatives to deal 
with healthcare associated infections.   
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A new campaign, supported by the Department of Health, has been promoted across 
Europe: the European Antibiotic Awareness Day (EAAD).  This is a single day 
aiming to build on the public awareness of the antibiotic resistance threat, alerting 
the need for prudent and responsible use of antibiotics.   
 
1.3.3.2. Development of new antibiotics and strategies 
 
1.3.3.2.1. Traditional approaches to identify novel antibiotics 
 
Over the past 60 years, natural products have been the focal point in the discovery 
and development of new antimicrobial agents.  Early methods of identifying 
antibiotics from natural sources, such as soil bacteria, were hindered by the high 
volume screening strategies and the rediscovery of established classes of antibiotics: 
22 % of soil actinomycetes produce streptothricin (Taylor and Wright, 2008).  
However, modern detection methods, including mass spectrometry, allow for high-
resolution separation and analysis of small molecules from the environment (Davies, 
2011).  It has been predicted that merely 1-10 % of the metagenome has been 
sampled, thus a plethora of undiscovered molecules remain to be identified (Walsh, 
2003).   
 
Optimisation of established antibiotic structures is a common approach to derive new 
antimicrobial active compounds.  Using existing scaffolds, modifications including 
attachment, removal or substitution of functional groups can provide many 
alternatives to a common structure with desirable pharmacological properties (von 
Nussbaum et al., 2006).  These alterations are often used to replace and consequently 
enhance the efficacy of natural products and represent the semisynthetic group of 
antibiotics.  Between 1983 and 1994, 75 % of compounds were variants of natural 
products (Newman et al., 2003), thus filling the void generated by the absence of 
new structural classes of antibiotics.   
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1.3.3.2.2.  Bioinformatics and genomics 
 
Following the first report of the complete bacterial genome of Haemophilus 
influenzae in 1995 (Fleischmann et al., 1995), bioinformatics and genomics have 
been valuable tools in antibacterial drug discovery.  Genome sequencing has allowed 
the identification of gene clusters involved in the biosynthesis of small compounds.  
From this analysis, it has been revealed that individual species of actinomycetes are 
capable of producing more than 20 secondary metabolites, some of which may have 
antibacterial activity (Baltz, 2008).  
 
Genomics can also be exploited to discover new antimicrobial targets (McDevitt and 
Rosenberg, 2001).  Various studies, such as gene disruption, deletion and over-
expression, have identified essential genes for bacterial viability within a genome.  In 
E. coli, it has been established that there are approximately 300 essential genes, 
which represent approximately 7 % of the genome (Gong et al., 2008; Taylor and 
Wright, 2008).  Comparisons with eukaryotic genomes can identify bacterial genes 
that do not share substantial homology, and consequently could present novel 
antimicrobial targets (Taylor and Wright, 2008).    
 
1.3.3.2.3.  High throughput screening  
 
High-throughput screening involves a library of thousands of potential inhibitors, 
which are screened against a drug target.  The efficacy of this process at identifying 
antimicrobials is illustrated with the following example.  GlaxoSmithKline utilised 
the high-throughput technique to screen 67 antibiotic targets with ~530,000 small 
molecules.  The structure of only five candidates were pursued, none of which 
passed through clinical trials (Payne et al., 2007).   
 
Conventional high-throughput screening methods use libraries containing natural 
products, often large complex molecules, which are less likely to successfully 
interact with a specified target.  These libraries are now being replaced by molecules 
of 250 Da or less.  These smaller and structurally simpler ‘fragments’ are more 
accessible for target binding (Waldrop, 2009).  
 
 14 
1.3.3.2.4. Virtual screening 
 
Virtual screening is a computational technique used to identify compounds of 
interest from chemical databases using two different approaches.  The ligand-based 
method uses the structures of active ligands to retrieve similar compounds, which 
could interact with a target in an analogous manner.  The receptor-based approach 
employs the 3D structure of a target to screen for compounds that bind in an 
equivalent or dissimilar way to known ligands.  The increasing availability of 3D 
structures of drug targets makes virtual screening a valid technique to rapidly 
identify lead compounds (Agarwal and Fishwick, 2010). 
 
1.3.3.2.5. Rational and de novo drug design 
 
Rational drug design is a targeted approach based on significant functional and 
structural information of the drug target.  The structural insights of protein-ligand 
interactions provided by NMR and X-ray crystallography enable structures (often 
substrate derivatives) to be generated and optimised rationally.  
 
De novo computational drug design utilises the known 3D structural features of an 
antimicrobial target to iteratively generate specific inhibitors.  Compounds are 
computationally constructed based on the steric and chemical properties of the target 
site.  SPROUT is an example of such computational software that can be employed 
in de novo drug design (Gillet et al., 1993).  The application of SPROUT to the 3D-
structures of E. coli DdlB (Besong et al., 2005), E. faecium VanA (Sova et al., 2009) 
and E. coli MurD (Horton et al., 2003) has yielded specific inhibitor molecules to 
these important enzymes involved in peptidoglycan biosynthesis.  Although this 
demonstrates the utility of de novo drug design in generation of inhibitory ligands 
against essential bacterial targets, it does not circumvent the problems of penetration 
of the inhibitor to its target.  This is exemplified by the fact that none of these 
molecules possessed antimicrobial properties. 
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1.3.3.2.6.  Inhibition of the resistance mechanisms 
 
Following the characterisation of a resistance mechanism (such as those described in 
Section 1.3.2), a viable strategy is to design drugs for its inhibition.  Although not 
antibiotics themselves, these drugs can be used in combination with an active 
antimicrobial.  This approach can potentially restore and preserve the efficacy of 
therapies against which resistance has developed. 
 
A prime example of this is the secondary metabolite clavulanic acid, a potent !-
lactamase inhibitor, isolated from Streptomyces clavuligerus in 1977 (Reading and 
Cole, 1977).  It has weak intrinsic antibacterial activity, but can be co-administered 
with !-lactam antibiotics such as amoxicillin (augmentin).  Clavulanic acid has a 
higher affinity for the !-lactamase than amoxicillin and can irreversibly bind to the 
active site serine of the !-lactamase catalytic site, forming a stable acylated 
intermediate (Yang et al., 1999).  This combination therapy allows the antibiotic to 
exert its effect without the detrimental interference of a resistance mechanism.  
 
1.3.4. Economic cost of antibiotic resistance 
 
Additional to the importance of combating resistance socially, it is necessary to 
regard the issue from an economic perspective.  Numerous considerations must be 
addressed when establishing the financial cost of antibiotic resistant infections 
including the duration of hospital stay, sick leave payments, treatments (often multi-
faceted), morbidity and mortality.  The cost of antibiotic resistant infections is hard 
to predict.  However, it has been estimated that healthcare associated infections alone 
cost the NHS £4,300 for every avoidable healthcare inflicted infection, amounting to 
£1 billion a year (National Audit Office, 2009).  The burden of antibiotic resistance 
on socio-economic costs justifies the necessity for its eradication.   
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1.4. Does the biosynthesis of peptidoglycan remain a viable 
antibiotic target? 
 
The biosynthesis of the peptidoglycan layer of the bacterial cell wall is an established 
antibiotic target, validated by the action several clinically significant drugs including 
the !-lactam and glycopeptide classes of antimicrobials (Bugg, 1999).  The essential 
nature and complexity of peptidoglycan biosynthesis, containing intracellular, 
membrane bound and extracellular enzymatic steps for interception with inhibitors, 
makes it an attractive target for antimicrobial therapy.  Targeting the extracellular 
catalytic phase alleviates the structural difficulties associated with the design of 
drugs that must penetrate the cytoplasmic membrane, which can hinder antimicrobial 
development.  To date, the peptidoglycan biosynthetic enzymes have been 
underexploited as antibiotic targets, although their appeal remains.  The recent 
advances in molecular and structural biology will aid the future biochemical 
characterisations of the enzymes involved in peptidoglycan biosynthesis with the 
ultimate goal of developing antimicrobials for clinical practice and concomitantly 
conquering antibiotic resistance.   
 
1.5. Peptidoglycan as an antimicrobial target 
 
The work in this thesis focuses on the enzymes involved in the ultimate extracellular 
step of peptidoglycan synthesis, the penicillin-binding proteins (PBPs), with the aim 
of providing a valuable insight into their kinetic and structural characteristics.  PBPs 
are the target of the most extensively used class of antimicrobials: the !-lactam based 
antibiotics.  To demonstrate the role and significance of these enzymes, 
peptidoglycan must be understood in terms of its structural and biochemical 
properties and its biosynthesis; these aspects are summarised in the following 
sections.  
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1.5.1. The peptidoglycan layer of the bacterial cell wall 
 
Peptidoglycan represents a vital dynamic constituent of the cell wall, present in 
nearly all eubacteria (with few exceptions including Chlamidiae sp. (although many 
of the biosynthetic genes have been identified in this species (McCoy and Maurelli, 
2006)) and Mycoplasma) and is found exclusively in these organisms.  Bacteria are 
crudely classified into two major groups, either Gram-positive or Gram-negative 
based on their reaction with the Gram stain (a dye-iodine complex) (Gram, 1884).  In 
Gram-positive bacteria, the Gram reagent becomes trapped in the peptidoglycan 
layer surrounding the cytoplasmic membrane, which ranges from 20-80 nm in 
thickness (Bugg, 1999) and comprises 30-70 % of the cell wall (Schleifer and 
Kandler, 1972).  In Gram-negative bacteria, the stain is not retained in the thin         
2-3 nm peptidoglycan layer (Beveridge and Davies, 1983; Bugg, 1999; Gram, 1884).  
The composition of Gram-positive cell walls exhibits extensive variation between 
species in terms of amino acid composition and cross-linking.  This contrasts the 
relatively constant architecture of Gram-negative cell walls (Schleifer and Kandler, 
1972), which have an additional complex layer of phospholipids, lipoproteins, 
lipopolysaccharides and porins, known as the outer membrane (Bugg, 1999).  Figure 
1.3 highlights the key features of the Gram-negative and Gram-positive bacterial cell 
wall architecture. 
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Figure 1.3: Schematic representation of the major structural components of Gram-positive and Gram-negative cell walls.  Both cell walls have a peptidoglycan layer 
situated outside of the cytoplasmic membrane.  Gram-negative bacteria have an additional lipid bilayer, the outer membrane, which is in close proximity to the peptidoglycan 
layer (Matias et al., 2003).  Figure adapted from Cabeen and Jacobs-Wagner, (2005). 
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1.5.2. The role of peptidoglycan 
 
Peptidoglycan performs the primary function of the cell wall: to endure the high 
internal pressures that can develop within a cell (up to 30 atm for some Gram-
positive bacteria) (Bugg, 1999).  Consequently, peptidoglycan must be mechanically 
strong and flexible, allowing reversible expansion under pressure.  Globular, 
uncharged proteins are able to diffuse through the porous architecture of 
peptidoglycan.  As reviewed by Vollmer et al. (2008a), the pore radii are of similar 
average sizes between Gram-positive and Gram-negative species; when relaxed or 
tort, proteins with molecular weights of 22-24 kDa and greater than 50 kDa 
respectively are able to penetrate the peptidoglycan layer in a non-selective manner.  
Peptidoglycan also serves as a scaffold to anchor external structures including 
proteins and teichoic acids of Gram-positive species and lipoproteins associated with 
the outer membrane of Gram-negative species (Bugg, 1999).  The surface proteins of 
Gram-positive bacteria (covalently anchored to the peptide constituent of the 
peptidoglycan layer by the action of sortases (Mazmanian et al., 1999; Ton-That et 
al., 1999)) often have a part in the pathogenicity of the organism, promoting bacterial 
adhesion to specific tissues, invasion of host cells or resistance to phagocytic killing.  
The secondary role of peptidoglycan is to maintain a defined cell shape, a trait that is 
stable and heritable (Young, 2003), thus peptidoglycan is intimately involved in cell 
growth and division (Vollmer et al., 2008a).   
 
1.5.3. The chemical composition and architecture of peptidoglycan 
 
Peptidoglycan is a continuous covalent macromolecule, consisting of extensive 
polymerised linear glycan strands, cross-linked via short peptide side chains.  It can 
be modified during or after its biosynthesis, concurrent with aging or adaptation to 
environmental conditions, eliciting a great potential for interspecies variation.  The 
basic structure of peptidoglycan, described in the monumental work of Schleifer and 
Kandler (1972), is discussed in the following sections.   
 
1.5.3.1. The glycan strand backbone 
 
The glycan chains are composed of alternating N-acetylglucosamine (GlcNAc) and 
N-acetylmuramic acid (MurNAc) units, integrated as a disaccharide into the 
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elongating strand, linked by !-1,4 glycosidic bonds.  A sequence of up to five amino 
acids (referred to as the pentapeptide) is appended by a peptide bond to the lactoyl 
carbonyl group of the MurNAc sugar ring (Vollmer et al., 2008a).  In Gram-positive 
bacteria, the reducing ends of glycan chains contain either a GlcNAc or MurNAc 
residue.  In all Gram-negative and some Gram-positive bacteria, the glycan chains 
terminate with a 1,6-anhydro-N-acetylmuramic acid residue by the action of lytic 
transglycosylases.  Secondary modifications are frequent in glycan chains including 
N-deacylation, O-acetylation, N-glycolylation and attachment of surface polymers 
(Vollmer, 2008). 
 
1.5.3.2. The pentapeptide side chain or stem 
 
The common residues of the pentapeptide side stem are of the sequence L-Ala-"-D-
Glu-X-D-Ala-D-Ala, where X is a diamino acid generally L-Lys (Gram-positive) or 
meso-diaminopimelic acid (meso-DAP) (Schleifer and Kandler, 1972).  D-amino 
acids are unique to bacteria, formed from the racemisation of L-amino acids, 
providing protection against proteases present in the external medium of the cell 
(Bugg, 1999).  A significant degree of variation can occur at the level of each amino 
acid residue in the pentapeptide stem.  The greatest discrepancies occur at the third 
position of the pentapeptide chain, which is involved in cross-linking in mature 
peptidoglycan; in a few strains, L-Lys, L,L-DAP or meso-DAP can be replaced by 
diverse residues including L-ornithine, 2,4-diaminobutyric acid, L-homoserine or 
meso-lanthionine (Vollmer et al., 2008a).  Notably, it was originally considered that 
position 5 of the stem was invariantly D-Ala.  However, as a result of vancomycin 
resistance, this residue can be substituted by D-Lac or D-Ser in high and low level 
resistant strains respectively (Bugg, 1999).  As the pentapeptide chain is truncated 
typically to four or sometimes three residues in the mature peptidoglycan, it is 
generically referred to as the stem peptide. 
 
1.5.3.3. Stem peptide cross-links 
 
Cross-linking of the peptide side chains provide peptidoglycan with the 
aforementioned tensile strength and introduce further structural and chemical 
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variation that can be used for taxonomic purposes (Schleifer and Kandler, 1972).  
Interstrand cross-links occur between peptide chains situated on adjacent glycan 
chains.  Cross-links formed between the #-amino group belonging to either L-Lys or 
meso-DAP at position 3 and the $-carbonyl group of D-Ala at position 4 of 
individual stem peptides are termed direct 4%3 cross-links (employed by Gram-
negative and Gram-positive bacteria).  Indirect cross-links (used by only Gram-
positive species) are mediated by a chain of amino acids ranging from 1 to 7 amino 
acid residues in length, referred to as an interpeptide bridge.  The amino acid 
residues constituting the interpeptide bridge are assembled via peptide bond 
formation onto the #-amino group of the third position meso-DAP or L-Lys by 
intracellular enzymes (Vollmer et al., 2008a).  In this instance, cross-linking is now 
between the $-amino group of the N-terminal amino acid of the interpeptide bridge 
and the $-carbonyl group of D-Ala at position 4 of an adjacent stem peptide.  
Interpeptide bridges are species specific; examples are demonstrated in Table 1.2. 
 
Bacterial species Interpeptide bridge 
Streptococcus pneumoniae L-Ser-L-Ala, L-Ala-L-Ala 
Staphylococcus aureus Gly-Gly-Gly-Gly-Gly 
Enterococcus faecalis L-Ala-L-Ala 
Lactobacillus viridescens L-Ala-L-Ser 
Enterococcus faecium D-Asp, D-Asn 
Micrococcus roseus L-Ala-L-Ala-L-Ala-L-Thr 
 
Table 1.2: Interpeptide bridges attached to the third position amino acid residue of the 
peptidoglycan stem peptide (Schleifer and Kandler, 1972). The sequence order is carboxyl to amino 
terminal (left to right). 
 
Cross-linking reactions are performed by PBPs (detailed in later Sections).  Although 
4%3 cross-links are the most common, other transpeptide linkages exist in 
peptidoglycan.  PBP-dependent 4%2 indirect cross-links are found in corynebacteria 
(Vollmer et al., 2008a).  PBP-independent 3%3 cross-links constitute a minor 
proportion of the linkages in E. coli (Glauner et al., 1988), but have been found to 
predominate the peptidoglycan layer of non-replicating M. tuberculosis (Lavollay et 
al., 2008) and are found exclusively in the peptidoglycan of a !-lactam resistant 
mutant of E. faecium (Mainardi et al., 2000).  The formation of 3%3 cross-links is 
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catalysed by L,D-transpeptidases, which are unrelated to the PBPs, and consequently 
provide a cross-linking reaction that is insensitive to all !-lactam antibiotics (with the 
exception of carbapenems (Lavollay et al., 2008; Triboulet et al., 2011)). 
 
The degree of cross-linking is species dependent: 25-50 % and 70-90 % of peptides 
are cross-linked in Gram-negative and Gram-positive species respectively, 
accounting for the differences in peptidoglycan rigidity observed between the two 
groups of organisms (Bugg, 1999). 
 
1.5.3.4. Summary of the basic constituents of peptidoglycan 
 
The key features of peptidoglycan architecture, as described in the above sections, 
are represented diagrammatically in Figure 1.4. 
 
Figure 1.4: Key structural components of peptidoglycan.  Gram-positive bacteria generally contain 
L-Lys at position 3 of the pentapeptide stem, whereas Gram-negative bacteria usually contain meso-
DAP (additional carboxyl group (red) on the #-carbon of L-Lys). 
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1.6. Peptidoglycan biosynthesis 
 
Peptidoglycan biosynthesis occurs in three distinct phases, defined by the cellular 
location of each stage in the pathway: the cytoplasmic steps, the intracellular 
membrane bound steps and the extracellular membrane bound steps.  The temporal 
and spatial control of the enzymes involved in the biosynthesis is essential to ensure 
that the integrity of peptidoglycan is not compromised.  The following sections 
provide an overview of the peptidoglycan biosynthetic pathway. 
 
1.6.1. Cytoplasmic steps of peptidoglycan biosynthesis 
 
The cytoplasmic phase of peptidoglycan synthesis encompasses a series of enzymatic 
steps that culminate in the production of uridine-5’-disphospho (UDP)-MurNAc 
pentapeptide from UDP-GlcNAc via a succession of nucleotide precursors.   
 
The first committed stage of peptidoglycan synthesis is constituted by six enzymes: 
MurA-F.  The majority of these enzymes were known by the mid-1970s, and since 
then their catalytic mechanisms have been characterised (Lazar and Walker, 2002).  
Table 1.3 summarises the role of MurA-F. 
 
Enzyme Substrates and cofactors Enzyme role 
MurA UDP-GlcNAc, PEP 
Transfer of enolpyruvate to the hydroxyl 
group at position 3 of UDP-GlcNAc 
MurB 
UDP-GlcNAc-enolpyruvate, 
NADPH 
Reduction of the enol group (forming 
UDP-MurNAc) 
MurC 
UDP-MurNAc, ATP, amino 
acid (usually L-Ala) 
Addition of the first amino acid of the 
peptide stem to the lactoyl ether group of 
UDP-MurNAc 
MurD 
UDP-MurNAc-
monopeptide, ATP, amino 
acid (usually D-Glu) 
Addition of the second amino acid to the 
peptide stem of UDP-MurNAc 
MurE 
UDP-MurNAc-dipeptide, 
ATP, amino acid (usually 
meso-DAP or L-Lys) 
Addition of the third amino acid to the "-
carboxyl group of the previous residue in 
the peptide stem of UDP-MurNAc 
MurF 
UDP-MurNAc-tripeptide, 
ATP, dipeptide (usually D-
Ala-D-Ala) 
Addition of the final two residues forming 
the pentapeptide stem of UDP-MurNAc 
Table 1.3: An overview of the catalytic functions of MurA-F (Barreteau et al., 2008). 
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MurC-F are referred to as the Mur ligases, which sequentially assemble amino acids 
to form the pentapeptide side chain using equivalent catalytic mechanisms.  These 
enzymes share 10-20 % sequence identity (Bugg and Walsh, 1992), with most 
variation locating to the N-terminal domain, allowing specificity for their substrate 
amino acid (Barreteau et al., 2008).  The formation of the peptide stem proceeds as 
follows: the carboxyl group of the terminal amino acid residue of the nucleotide 
substrate is activated by ATP-dependent phosphorylation.  This undergoes 
nucleophilic attack by the amino group of an amino acid or dipeptide, with the 
concomitant release of inorganic phosphate and peptide bond formation (Bouhss et 
al., 1999).   
 
The cytoplasmic phase is completed upon the formation of UDP-MurNAc-
pentapeptide.  Figure 1.5 shows the components involved in this stage of 
peptidoglycan biosynthesis.   
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Figure 1.5: The cytoplasmic steps in peptidoglycan biosynthesis.  UDP-GlcNAc is converted into UDP-MurNAc by MurA and MurB.  The amino ligases, MurC-MurF, 
sequentially add L-Ala, D-Glu, L-Lys (or meso-DAP, not shown) and D-Ala-D-Ala dipeptide to the lactoyl group of UDP-MurNAc, completing the cytoplasmic phase of 
peptidoglycan biosynthesis with the formation of UDP-MurNAc-pentapeptide.  The D-Ala-D-Ala dipeptide substrate of MurF is synthesised by the condensation of two D-
Ala by D-Ala:D-Ala ligase (DDL).  This enzyme is not a member of the Mur ligase family but is specific to peptidoglycan biosynthesis (Barreteau et al., 2008).   
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1.6.2. Intracellular membrane bound steps of peptidoglycan 
biosynthesis 
 
The first membrane bound step of peptidoglycan synthesis occurs on the cytoplasmic 
face of the membrane, linking the product of the cytoplasmic phase to undecaprenyl 
phosphate, C55.  This classical lipid carrier can be synthesised in two ways: direct 
phosphorylation of undecaprenol by a kinase or recycling of undecaprenyl 
pyrophosphate by dephosphorylation (Hartley et al., 2008).  MraY, a translocase, 
catalyses the transfer of the hydrophilic phospho-MurNAc-pentapeptide moiety of 
UDP-MurNAc-pentapeptide onto undecaprenyl phosphate, yielding undecaprenyl 
pyrophosphoryl-MurNAc-pentapeptide (Lipid I) and UMP (Bouhss et al., 2004; 
Lloyd et al., 2004; Ikeda et al., 1991).  The reaction is reversible, but in vivo it is 
drawn in one direction by coupling it to the enzyme involved in the final intracellular 
membrane stage, MurG (Bouhss et al., 2004), which catalyses the transfer of 
GlcNAc from UDP to the hydroxyl group on the carbon at position 4 of the muramyl 
sugar ring of lipid-linked MurNAc-pentapeptide (Ha et al., 1999).  The production of 
undecaprenyl pyrophosphoryl-MurNAc-(GlcNAc)-pentapeptide (Lipid II) completes 
the second phase of peptidoglycan synthesis.  Variations in mature peptidoglycan 
composition are often incorporated onto Lipid II prior to the remaining extracellular 
reactions of the biosynthetic pathway.  Examples include amidation, hydroxylation, 
acetylation and integration of amino acid branches involved in indirect peptide cross-
links (Vollmer et al., 2008a). 
 
1.6.3. Linking the intracellular and extracellular membrane bound 
steps of peptidoglycan biosynthesis 
 
In order for peptidoglycan to be assembled in the extracellular region of the cell, 
Lipid II must be translocated across the cytoplasmic membrane at a rate of 5000 
molecules per sec to match the rate of peptidoglycan synthesis (Sanyal and Menon, 
2009).  Until very recently, the so-called putative flippase responsible this role has 
remained highly elusive.  The potential flippases had to fulfil various requirements; 
they have to be inner membrane proteins, and essential and conserved in 
peptidoglycan producing eubacteria (Ruiz, 2008).  Candidates have been speculated 
for over 30 years, the most plausible being MurJ, FtsW, RodA and SpoVE.  The 
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latter three enzymes belong to the SEDS (shape, elongation, division and 
sporulation) family and are present in complexes involved in elongation, division and 
sporulation respectively.  Mohammadi et al. (2011) have validated that FtsW (and 
not MurJ) is capable of transporting Lipid II across a membrane vesicle or 
proteoliposome.  The identification of the flippase as FtsW will further the 
understanding of peptidoglycan synthesis and cellular growth, as well as presenting a 
new antimicrobial target. 
 
1.6.4. Extracellular membrane bound steps of peptidoglycan 
biosynthesis 
 
The final stage of peptidoglycan synthesis occurs on the extracellular face of the 
cytoplasmic membrane and involves the continuous and tightly coupled 
transglycosylation and transpeptidation activities of the integral membrane proteins, 
the PBPs.  These enzymes are subject to this thesis and will be discussed in detail in 
the following sections.  Briefly, transglycosylation reactions incorporate the 
hydrophilic disaccharide pentapeptide moiety of Lipid II into a pre-existing, 
elongating glycan chain.  The C4 hydroxyl group of the GlcNAc component 
belonging to the attacking Lipid II displaces the undecaprenyl pyrophosphate anchor 
at the terminal MurNAc C1 of a glycan chain, forming a !-1,4-glycosidic bond 
(Bugg, 1999).  The glycan chains of peptidoglycan have varying lengths, specific to 
the PBP catalysing the transglycosylation reaction and its cellular location (Wang et 
al., 2008).  The undecaprenyl pyrophosphate is flipped back across the membrane 
and dephosphorylated, which can occur before or after translocation depending on 
the phosphatase (Tatar et al., 2007), regenerating undecaprenyl phosphate.   
 
The transglycosylation of Lipid II forms a soluble glycan polymer (Ward, 1984).  It 
is not until PBP-mediated transpeptidation occurs perpendicular to the glycan chains 
that the peptidoglycan forms an insoluble matrix, thereby fulfilling its role of 
maintaining structural integrity of the cell (Ward, 1984).  As described in Section 
1.5.3.3 the transpeptidation reactions occur via peptide bond formation between 
peptide stems in close proximity; the amino group side chain of the third position 
amino acid (or an amino acid branch) of one stem (acceptor) forms a peptide bond 
with the carbonyl group of the fourth position D-Ala of an adjacent stem (donor), 
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displacing the terminal D-Ala (Sauvage et al., 2008a).  The resulting 4"3 
transpeptide cross-link contains a tetrapeptide, the terminal of which is no longer 
recognised by the PBPs and thus it can only serve as an acceptor for future 
transpeptidation reactions (Goffin and Ghuysen, 2002).  
 
The intracellular and extracellular membrane-bound stages of peptidoglycan 
biosynthesis are summarised in Figure 1.6. 
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Figure 1.6: The membrane bound steps of peptidoglycan biosynthesis.  The product from the cytoplasmic phase of peptidoglycan biosynthesis, UDP-MurNAc-
pentapeptide, is the substrate for the membrane bound steps.  MraY and MurG substitute UMP for undecaprenyl phosphate and add a GlcNAc moiety respectively, generating 
Lipid II.  Lipid II is translocated across the membrane where it is polymerised by the transglycosylation and transpeptidation activities of the PBPs.  The pathway is 
exemplified with an unmodified L-Lys at position 3 within the stem peptides.  This template applies equally to pathways where the L-Lys is modified by aminoacylation or is 
replaced by meso-DAP. 
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1.6.5. Peptidoglycan remodelling  
 
During different phases of the cell cycle, peptidoglycan undergoes extensive 
remodelling and rebuilding.  The enzymes responsible for the structural adjustments 
and chemical alterations are peptidoglycan hydrolases, a vast group of enzymes with 
diverse activities.  The hydrolases have numerous roles: peptidoglycan maturation; 
regulation of cell wall growth, peptidoglycan expansion and elongation; separation 
of daughter cells during cell division; enlargement of pore size; release of signalling 
molecules from products of peptidoglycan turnover; peptidoglycan cleavage during 
sporulation or spore germination; autolysis, removing damaged cells from a 
population (Vollmer et al., 2008b).  Many hydrolases have been identified and 
characterised in E. coli, examples are given in Figure 1.7. 
 
Figure 1.7: E. coli peptidoglycan hydrolases.  The basic structure of E. coli peptidoglycan is shown.  
The arrows mark the point of cleavage by the stated hydrolase.  Adapted from Bugg (1999). 
 
Temporal and spatial regulation of hydrolase activity is essential to prevent excessive 
peptidoglycan degradation, which would be detrimental to the cell.  This can be 
achieved by various factors (as reviewed by Vollmer et al. (2008b)) including 
transcriptional and translational control, chemical alteration of the substrate and 
targeting the enzyme to specific cellular locations. 
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1.6.6. Peptidoglycan recycling 
 
In 1985, Goodell and Schwarz discovered the important phenomenon of 
peptidoglycan recycling in Gram-negative bacteria, where turnover products from 
the activity of the hydrolases are retained and utilised by the cell.  Peptidoglycan 
recycling has largely been studied in E. coli, identifying the involvement of nine 
cytoplasmic enzymes, an inner membrane permease and a periplasmic peptide 
binding protein (Park and Uehara, 2008).  Recycling plays an important role in 
peptidoglycan metabolism; it has been estimated that E. coli only lose 6-8 % of its 
peptidoglycan per generation (Goodell and Schwarz, 1985); up to 50 % of the 
peptidoglycan is degraded and recycled (Goodell, 1985), which is either used in the 
resynthesis of peptidoglycan or as an energy source (Park and Uehara, 2008).  
 
Peptidoglycan recycling has not been documented in Gram-positive bacteria.  New 
peptidoglycan is incorporated at the inner cell surface, moving and expanding the 
peptidoglycan in an outwards fashion, until it is shed as large fragments into the 
surrounding medium by the action of the hydrolases.  25-50 % of peptidoglycan is 
lost in this way per generation (Goodell, 1985; Park and Uehara, 2008).   
 
1.6.7. Models of peptidoglycan expansion 
 
Peptidoglycan is classically depicted as a static layer, which is far from reality.  It is 
constantly subject to morphological changes to support different stages of the cell 
cycle including elongation and division.  Different models have been proposed to 
explain the controlled turnover of peptidoglycan during the cell cycle.  An ‘inside-to-
outside’ model has been proposed for growth of Gram-positive bacteria (Koch and 
Doyle, 1985).  Nascent peptidoglycan is synthesised directly adjacent to the 
cytoplasmic membrane, causing the layers to move outwards, becoming tort.  The 
conformationally stretched layers then become the target of hydrolase activity.  In 
this model, new covalent layers of peptidoglycan are formed before older ones are 
eliminated, thus the integrity of the cell wall is never compromised (Koch and Doyle, 
1985).   
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A ‘three-for-one’ growth model has been suggested for E. coli (Höltje, 1998).  In this 
model, three newly synthesised cross-linked glycan chains form peptide cross-links 
with glycan chains on either side of a single so-called docking strand.  Specific 
hydrolysis of the covalent links of the pre-existing docking strand leads to its release 
from the peptidoglycan layer (Scheffers and Pinho, 2005).  This model conforms 
with the ‘make-before-break’ strategy proposed by (Koch and Doyle, 1985) where 
three new glycan chains are inserted into the peptidoglycan layer before the removal 
of the old docking strand, avoiding the risk of autolysis (Scheffers and Pinho, 2005). 
 
1.6.8. Antimicrobial inhibitors of peptidoglycan biosynthesis 
 
Peptidoglycan is a validated target for inhibition by antimicrobial agents.  Table 1.4 
summarises the known inhibitors of various committed enzymatic steps of 
peptidoglycan synthesis. 
 
Target Inhibitor 
MurA Fosfomycin 
MurB 
Structural derivatives of 3,5-dioxopyrazolidines 
(Yang et al., 2006) 
Mur ligases Phosphinate compounds (Strancar et al., 2007) 
Ddl D-cycloserine 
MraY Tunicamycin 
MurG Ramoplanin 
PBP: transglycosylase activity Moenomycin 
PBP: transpeptidase activity !-lactams 
Table 1.4: Antibiotics and inhibitors available against various essential steps of peptidoglycan 
synthesis.   
 
1.7. Thesis direction 
 
The work of this thesis focuses on the ultimate stages of peptidoglycan biosynthesis, 
the polymerisation of Lipid II by the action of the PBPs.  The following section 
details the existing knowledge of the PBPs in terms of their classification, structure 
and their inhibition by antibiotics. 
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1.8. The penicillin-binding proteins 
 
In the 1960s, intensive studies on bacterial cell wall biosynthesis identified that 
penicillin irreversibly bound to multiple undefined components locating outside of 
the cell membrane.  Later studies revealed that these ‘penicillin-binding components’ 
(Tipper and Strominger, 1965) represented a group of enzymes sensitive to penicillin 
and !-lactam derivatives, which are now termed the penicillin-binding proteins 
(PBPs).  These enzymes are essential for cell viability, responsible for the tensile 
strength of peptidoglycan, and encompass a family of validated antimicrobial targets 
(Bugg, 1999).   
 
PBPs have been the subject of biochemical investigations for almost half a century 
(Tipper and Strominger, 1965).  In spite of this, these enzymes remain poorly 
characterised in comparison to other members of the peptidoglycan biosynthetic 
pathway.  This can be attributed to the difficulties associated with the study of PBPs, 
the majority of which are integral membrane proteins that require structurally 
complex substrates, such as Lipid II or its polymerised counterpart.  However, the 
recent advances in the field of membrane protein biology and the ability to 
synthesise significant quantities of peptidoglycan precursors have propelled progress 
in this area of research.   
 
1.8.1. Establishing the nomenclature of penicillin-binding proteins 
 
In general, bacteria contain between 1,000 to 10,000 PBP molecules per cell, which 
constitutes approximately 1 % of the entire membrane protein population (Waxman 
and Strominger, 1983).  The number of different PBPs expressed by individual 
bacterial species has been resolved through genome sequencing.  Each bacterial cell 
contains typically three to eight distinct PBPs (with sixteen identified in Bacillus 
subtilis (Sauvage et al., 2008a)) that vary in their relative abundance (Waxman and 
Strominger, 1983).  Historically, once the number of PBPs within an organism had 
been determined, they would be numbered according to their migration through 
SDS-PAGE with decreasing molecular size.  This can lead to confusion, as PBPs 
from different species with comparable properties and molecular weights are often 
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not denoted with the same number; S. aureus PBP1 is equivalent to E. coli PBP3 
(Sauvage et al., 2008a).  Additional PBPs discovered thereafter are designated a 
letter following the appropriate number.  For example, a novel 78 kDa PBP was 
revealed in methicillin-resistant Staphylococcus aureus (MRSA) strains in addition 
to the four native S. aureus PBPs (PBP1, PBP2, PBP3 and PBP4) and so was termed 
PBP2a.  This system avoids renumbering, which could introduce comparative issues 
with older literature (Georgopapadakou, 1993).  
 
1.8.2. Classification and basic topology of the penicillin-binding 
proteins 
 
From analyses of over 200 unique peptidoglycan-producing eubacterial genomes, it 
has been determined that PBPs have multimodular structures, and although they 
share homologous domains, they also exhibit variations (Macheboeuf et al., 2006).  
PBPs are grossly categorised on the basis of their molecular size, amino acid 
sequence similarities and catalytic activity of their N-terminal domain.  Primarily, 
PBPs are segregated into two main groups depending on their size: low molecular 
weight (LMW) (40-50 kDa) and high molecular weight (HMW) (60-140 kDa) 
(Waxman and Strominger, 1983).  
 
The LMW-PBPs (also referred to as Class C PBPs) are either soluble enzymes or are 
associated with the extracellular face of the cytoplasmic membrane by a 
transmembrane or amphiphatic helix (Macheboeuf et al., 2006).  They can be further 
subdivided into classes A, B and C (Ghuysen, 1991).  These enzymes have a single 
catalytic domain that exhibits D,D-carboxypeptidase or endopeptidase activity, 
responsible for controlling the degree of transpeptidation or structural modifications 
of peptidoglycan and are not essential for cell viability (Denome et al., 1999).  
 
The HMW-PBPs are integral membrane proteins and have a basic topology 
consisting of a short N-terminal cytoplasmic tail, an "-helical transmembrane anchor 
and two extracellular domains connected by an inert linker region.  They are divided 
into Classes A and B depending on the activity of the extracellular N-terminal 
domain and further subdivided based on sequence alignments (Goffin and Ghuysen, 
1998; Sauvage et al., 2008a).  Class A HMW-PBPs are bifunctional enzymes with 
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extracellular N-terminal and C-terminal domains exhibiting transglycosylase and 
transpeptidase activity respectively.  Class B HMW-PBPs have only one catalytic 
domain, which is located at the C-terminus and displays transpeptidase activity.  An 
N-terminal domain exists but has unassigned activity; it has been suggested that this 
domain could be involved in cell morphogenesis, protein dimerisation, or function in 
the positioning of the transpeptidase domain of Class B PBPs at an equal distance 
from the membrane as the equivalent domain of Class A PBPs (Macheboeuf et al., 
2006; Sauvage et al., 2008a).   
 
A further group of monofunctional integral membrane proteins of importance are the 
monofunctional glycosyl transferases (MGT) (Di Berardino et al., 1996; Spratt et al., 
1996).  These enzymes are not PBPs as they lack a penicillin-binding domain, but 
they have a complementary role to the transglycosylase activity of HMW Class A 
PBPs and so are highly relevant in peptidoglycan chain polymerisation (Macheboeuf 
et al., 2006).   
 
The classification and domain topology of the PBPs and MGTs are summarised in 
Figure 1.8.  
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Figure 1.8: Classification, enzymatic activities and topology of the Penicillin-Binding Proteins.  Broad classification (left) and the generalised domain topology (right) of 
the enzymes are shown.  TM, transmembrane domain; AH, amphiphatic helix.  *LMW-PBP transpeptidation has been demonstrated in vitro (Kumar and Pratt, 2005). 
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1.8.3. Localisation of PBPs at different stages of the cell cycle 
 
PBPs function at specific points during the cell cycle; some have redundant 
activities, whereas others are unique and essential, causing a loss of viability when 
deletions are incurred.  During the cell cycle, cell wall metabolism can essentially be 
divided into two stages: elongation and division; both processes require precise 
temporal and spatial control of numerous essential proteins, which are conserved in 
all cell wall synthesising bacteria (Morlot et al., 2003).  The localisation of S. 
pneumoniae PBPs will be discussed, as these enzymes are the primary focus of work 
in this thesis.  S. pneumoniae contains one LMW-PBP (PBP3), and five HMW-PBPs 
(class A PBP1a, PBP1b and PBP2a; class B PBP2b and PBP2x) (discussed in 
Section 1.10).   
 
S. pneumoniae are lancet-shaped and are surrounded by an equatorial ring, which is 
signified by an outgrowth of the cell wall.  As the cell grows, the equatorial ring is 
duplicated and the resulting two rings progressively separate, marking the position of 
future division sites of the daughter cells (Higgins and Shockman, 1970).  Nascent 
peptidoglycan is inserted between the duplicated rings, and septal cell wall growth 
occurs perpendicular to the long cell axis at the original position of the equatorial 
ring (before duplication).  FtsZ coordinates division at the septum by initiating the 
interdependent assembly of various proteins.  The polymerisation of FtsZ into a ring-
like structure and its subsequent constriction is believed to drive the division process 
(Morlot et al., 2003).   
 
Elegant localisation studies of S. pneumoniae PBPs have been performed by Morlot 
et al. (2003) and (2004) using immunofluorescence.  In non-dividing cells, HMW-
PBPs are located equatorially with FtsZ.  Immunolabelling revealed that during the 
division process, PBP1a and PBP2x remain at the midcell where the septum forms, 
and PBP2a and PBP2b follow the localisation of the duplicated equatorial rings 
(Figure 1.9).  Interestingly, it was apparent that following recruitment to the septum 
by possible interactions with cell-division proteins, PBP1a and PBP2x persist 
independently of division complex.  PBP1b locates exclusively septally or 
equatorially, but simultaneous localisation never occurs (Morlot et al., 2003).  The 
LMW S. pneumoniae PBP3 is evenly distributed across the hemispheres where 
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mature peptidoglycan exists but is absent from the division site.  The D,D-
carboxypeptidase activity of PBP3 removes the substrate for HMW-PBP 
transpeptidation, thus HMW-PBP localisation is also mediated by substrate 
availability (Morlot et al., 2004).  
 
 
Figure 1.9: Organisation of the HMW-PBPs during S. pneumoniae growth and division.  HMW-
PBPs are located equatorially (turquoise band) in non-dividing cells.  As the cell grows, the equatorial 
rings are duplicated and peripheral peptidoglycan (green) is biosynthesised by PBP2b and PBP2a 
(green squares).  Septal peptidoglycan synthesis (blue) proceeds by the action of PBP2x and PBP1a 
(blue circles).  Following division, the PBPs locate equatorially once again.   
 
1.9. The functional domains of PBPs 
 
The catalytic domains of HMW-PBPs are of great interest from a mechanistic and 
therapeutic perspective.  The present knowledge regarding the transglycosylase and 
transpeptidase activities is described below and in subsequent Chapters.   
 
1.9.1. The transglycosylase domain of HMW-PBPs 
 
1.9.1.1. Structure of the transglycosylase domain 
 
The sole purpose of the transglycosylase domain of PBPs and MGTs is to catalyse 
the polymerisation of Lipid II monomers, which is the initial step in the assembly of 
peptidoglycan.  Proteins that degrade, modify or generate glycosidic bonds can be 
organised by sequence, structural or functional homology into families according to 
the Carbohydrate-Active enZYmes (CAZY) classification scheme (www.cazy.org).  
Peptidoglycan transglycosylases are categorised into the glycosyltransfer family 51 
 
Equatorial ring 
Duplicated 
equatorial rings 
Growing septum 
 39 
(GT51).  This family exhibits a novel structural fold.  The GT51 domains are always 
membrane-bound and use undecaprenyl-based substrates.   
 
Structural insight into the GT51 domain has only become available within the last 5 
years.  To date, X-ray crystal structures exist for three bifunctional PBPs (Aquifex 
aeolicus PBP1a (Yuan et al., 2007), S. aureus PBP2 (Lovering et al., 2007) and E. 
coli PBP1b (Sung et al., 2009)) and one MGT (S. aureus MGT (Heaslet et al., 
2009)).  Of these structures, only E. coli PBP1b is based on the full-length protein 
sequence (devoid only of the short N-terminal cytoplasmic tail); the remaining 
structures are soluble counterparts of the membrane proteins (with the absence of the 
transmembrane anchor).   
 
The elucidated transglycosylase domain structures are in general accordance with 
each other and exhibit a common topological fold.  The GT fold is predominantly !-
helical and is organised into two lobes: a large globular ‘head’ region and a smaller 
‘jaw’ region (Lovering et al., 2007) (Figure 1.10).  The ‘jaw’ is comprised of a 
significant number of hydrophobic residues and is closely associated, if not 
embedded into the extracellular face of the cytoplasmic membrane, and is postulated 
to mediate the interaction with the membrane and the Lipid II substrate (Lovering et 
al., 2007; Yuan et al., 2007).  The two lobes are separated by an extended cleft, 
which contains many conserved residues and constitutes the active site (Yuan et al., 
2007).  There are no direct interactions between the transpeptidase and 
transglycosylase domains of S. aureus PBP2 or A. aeolicus PBP1a.  However, in E. 
coli PBP1b, the transpeptidase and transglycosylase domains are linked by an extra 
domain of five anti-parallel "-sheets and a single !-helix.  This so-called UB2H 
domain has been shown to interact with the outer membrane protein LpoB, which 
directly stimulates the transpeptidase activity of E. coli PBP1b (Paradis-Bleau et al., 
2010; Typas et al., 2010). 
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1.9.1.2. Conserved residues of the transglycosylase domain 
 
Peptidoglycan transglycosylases are defined by five conserved sequence motifs 
revealed through sequence alignments: EDX2FX2H, GXSTXTQQX2K, RKX2E, 
KX2IX3YXN and RX3VL (motifs 1-5 respectively) (Lovering et al., 2008b).  The 
first three motifs are located in the catalytic cleft, whereas motif 4 lines the back wall 
of the cleft and motif 5 is situated further away from the active site in the ‘head’ 
domain (Sauvage et al., 2008a).   
 
Various studies have probed the role of the conserved residues in transglycosylation 
reactions.  Di Guilmi et al. (2003a) generated truncated constructs of S. pneumoniae 
PBP1b and analysed their capability of binding Lipid II.  In the absence of the first 
motif, PBP1b was able to bind Lipid II, indicating that motif 1 had little or no role in 
substrate recognition.  Deletion of both motif 1 and motif 2 from the protein 
sequence eliminated the association with Lipid II, thus indicating that motif 2 is 
essential for substrate binding.  Mutational analysis of the conserved residues, such 
as those performed by Terrak et al. (1999) on E. coli PBP1b, have demonstrated the 
importance of the glutamate residue belonging to the first motif; mutation to 
glutamine caused a reduction in glycan chain polymerisation to 0.2 % of the wild-
type enzyme.  This residue has since been referred to as the catalytic residue.  
Further studies by Terrak et al. (2008) have postulated that the remaining conserved 
residues of motif 1 are important for the positioning of the putative catalytic residue.  
The positively charged lysine and arginine residues of motifs 2 and 3 are proposed to 
position the negatively charged pyrophosphate moiety of the substrate (Lovering et 
al., 2007; Terrak et al., 2008).  The roles of motifs 4 and 5 are believed to be 
regulatory, maintaining the transglycosylase domain structure and active site cleft, 
and stabilising the charges on the catalytic residues (Lovering et al., 2007; Lovering 
et al., 2008b; Terrak et al., 2008).  Figure 1.10 shows a comparison of the 
transglycosylase domain architecture and the location of the conserved motifs of A. 
aeolicus PBP1a, E. coli PBP1b, S. aureus MGT and S. aureus PBP2. 
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Figure 1.10: Structural comparison of the transglycosylase domains from A. aeolicus PBP1a, E. coli PBP1b, S. aureus MGT and S. aureus PBP2.  The overall domain 
is shown in green.  The conserved motifs 1-5 are displayed in blue, red, orange, yellow and magenta respectively.  The putative catalytic Glu of motif 1 is shown in stick form. 
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1.9.1.3. Structural similarities of the transglycosylases to lysozyme 
 
Terrak et al. (1999) first proposed that peptidoglycan transglycosylases are 
reminiscent of lysozyme; the enzymes use similar substrates, where lysozyme 
cleaves the !-1,4-glycosidic bond between the MurNAc and GlcNAc units of 
peptidoglycan, which are generated by the transglycosylases.  Significant secondary 
structural homology exists between the GT51 domains of S. aureus PBP2 and A. 
aeolicus PBP1a with bacteriophage " lysozyme despite low sequence homology 
(Lovering et al., 2007; Yuan et al., 2007).  Both domains are composed of a large 
‘head’ region and a small ‘jaw’ region separated by a cleft.  When superimposed, the 
‘head’ regions have a similar overall topology, but the ‘jaw’ regions differ.  In 
lysozyme, this subdomain is comprised of soluble !-sheets, which contrasts the #-
helical structure of the GT51 domain (Yuan et al., 2007).  The substrate specificity 
could account for these differences (Lovering et al., 2007).  The essential glutamic 
acid residue of bacteriophage " lysozyme overlays the putative catalytic glutamate 
residue of the GT51 domain.  The relationship between the GT51 domain and 
bacteriophage " lysozyme suggests that the bacteriophage could have acquired the 
GT51 domain at a distant point in evolution (Lovering et al., 2007).  The established 
lysozyme catalytic mechanism could provide valuable information to elucidate the 
transglycosylase mechanism (refer to Section 4.1). 
 
1.9.1.4. Moenomycin, an inhibitor of the transglycosylase domain 
 
Moenomycin is a secondary metabolite produced by Streptomyces ghanaensis.  It is 
a complex structure consisting of an oligosaccharide chain attached to a lipid alcohol 
via a phosphoric acid diester and a glycerol acid (Di Guilmi et al., 2002).  Soon after 
its isolation, the highly potent antibiotic properties of moenomycin were revealed.  It 
is more effective at inhibiting Gram-positive bacteria compared to Gram-negative 
species; the minimum inhibitory concentrations (MICs) for the Gram-negative E. 
coli and Gram-positive S. aureus and S. pneumoniae are 80 µM, 0.075 µM and 0.625 
µM respectively (Cheng et al., 2008).  The discrepancies between the MICs are 
owed to the inability of moenomycin to penetrate the outer membrane of Gram-
negative bacteria (Di Guilmi et al., 2002).  Moenomycin exhibits encouraging 
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antimicrobial properties but cannot be used in clinical practice due to its adverse 
pharmacological effects (poor absorption, long half life).  It has been extensively 
used in agriculture as a growth promoter without the development of antibiotic 
resistance as documented with other antimicrobials; significantly resistant isolates 
from humans and animals have not been detected and no plasmid-bourne 
moenomycin resistance has been described (Ostash and Walker, 2010). 
 
Huber and Nesemann (1968) identified that moenomycin interfered with 
peptidoglycan synthesis.  Subsequently, van Heijenoort et al. (1978) established that 
the inhibitor targeted the transglycosylases and it was later speculated by Welzel et 
al. (1987) that moenomycin was a competitive inhibitor of the transglycosylase 
reaction.  The structure of moenomycin, a glycolipid, is reminiscent of Lipid IV (the 
product of a single transglycosylation reaction).  A structural comparison is 
displayed in Figure 1.11. 
 
Figure 1.11: Structural comparisons of moenomycin and peptidoglycan components.  The head 
group of Lipid IV (two disaccharide units) is shown, representing a fragment of the peptidoglycan 
oligosaccharide.  The glycan components of Lipid IV and moenomycin are extremely similar (regions 
in blue highlight regions of structural identity).  The lipid moieties of the peptidoglycan lipid anchor 
and the moenomycin lipid tail are also comparable.  The ring units of the moenomycin 
oligosaccharide are labelled A-F.  TAIL and oligosaccharide (specific to peptidoglycan or 
moenomycin) refer to the phosphorylated lipid component and glycan head group respectively.  
Figure adapted from Lovering et al. (2008a).     
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Upon the binding of moenomycin, the transglycosylase domain is proposed to 
undergo a conformational change.  Binding of moenomycin to S. pneumoniae PBP1b 
caused the enzyme to be more sensitive to chymotrypsin, suggesting that a 
conformational change led to the exposure of regions that are normally concealed in 
the apoenzyme (Di Guilmi et al., 2003a).  Crystal structures of S. aureus PBP2 in the 
apo and ligand-bound form revealed that binding of moenomycin induced a 
conformational change in the ‘jaw’ subdomain (Lovering et al., 2007). 
 
The E. coli PBP1b crystal structure in complex with moenomycin revealed that there 
were no direct interactions between the transmembrane domain and the antibiotic 
(Sung et al., 2009).  This contradicts previous findings that demonstrated the 
dependence of the transmembrane domain on the binding affinity for moenomycin 
(Cheng et al., 2008).  The transglycosylase domain of E. coli PBP1b and S. aureus 
PBP2 (devoid of the transmembrane anchor) exhibit many similarities in topology 
and binding interactions with moenomycin, suggesting that the removal of the 
transmembrane domain does not affect the transglycosylase binding site.  From these 
observations, Sung and coworkers have proposed that the transmembrane domain 
stabilises the protein within the membrane environment, and appropriately orientates 
the protein for interaction with Lipid II or moenomycin (Sung et al., 2009). 
 
Based on the interactions identified in transglycosylase structures complexed with 
moenomycin and the structural similarities between Lipid IV and moenomycin, 
Lovering et al. (2008a) have developed an elegant model for substrate binding and 
transglycosylation.  In this model, the elongating glycan chain of Lipid IV 
superimposes the sugar units B, C, E and F and a portion of the undecaprenyl lipid 
tail overlays the moenomycin C25 isoprenoid chain.  Moenomycin is proposed to 
locate to the donor site of the transglycosylase domain, which conforms to a 
processive model for glycan chain polymerisation (Section 4.1).  Figure 1.12 shows 
the crystal structure of S. aureus PBP2 with the substrate analogue bound. 
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Figure 1.12: The binding of a moenomycin analogue to S. aureus PBP2.  The conserved 
transglycosylase motifs 1-5 are blue, red, orange, yellow and magenta respectively.  The putative 
transglycosylase catalytic Glu of motif 1 is displayed in a stick format.  The moenomycin analogue is 
shown in cyan. (a) Domain architecture of S. aureus PBP2.  The transpeptidase catalytic serine is 
shown in spheres.  Adapted from Lovering et al. (2008b).  (b) Close-up of the transglycosylase active 
site.  The disaccharide constituents of Lipid IV superimpose the rings grouped 1 (F and E) and 2 (C 
and B).  The arrow marks the direction of the elongating transglycosylase product.  The lipid tail of 
moenomycin is likely to be in an equivalent position to the undecaprenyl lipid chain of 
transglycosylase substrates.   
 
Conclusively, studies with the substrate analogue moenomycin have provided a 
valuable insight into the potential mechanism of transglycosylation and inhibition, 
information from which can be exploited in the future development of new 
transglycosylase antibiotics.   
 
1.9.2. The penicillin-binding domain of HMW and LMW-PBPs 
 
1.9.2.1. Discovery of the penicillin-binding proteins mediated by !-lactam 
inhibition 
 
Since 1928, when the antimicrobial effects of penicillin were first identified, the 
mechanism by which the !-lactam antibiotics exert their inhibition has been of 
immense interest.  Gardner (1940) demonstrated that low concentrations of penicillin 
induced morphological changes in E. coli and later Martin (1964) proposed that 
penicillin blocked the formation of peptide cross-links in the linear glycopeptide 
(peptidoglycan).  This was supported by the accumulation of uncross-linked 
peptides, which retained the D-Ala-D-Ala terminal (Tipper and Strominger, 1965).  
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This lead to the theory by Tipper and Strominger (1965), that a transpeptidase 
catalysed the cleavage of the D-Ala-D-Ala terminal of the peptide chain, mediated 
by a covalent enzyme intermediate, which would be resolved by the formation of a 
cross-link.  Further more, it was postulated that penicillin (6-aminopenicillanic acid) 
acted as a structural, cyclic analogue of the D-Ala-D-Ala terminal of the 
pentapeptide side chain (Figure 1.13.), exerting its inhibition by obstructing the 
transpeptidase active site by the formation of a stable, covalent penicilloyl enzyme 
with an active site residue (Tipper and Strominger, 1965).  These transpeptidases 
were denoted Penicillin-Binding Proteins. 
 
Figure 1.13: Structural comparison between !-lactams and the natural substrate of the PBPs.  
(a) D-Ala-D-Ala terminus of the peptidoglycan pentapeptide stem.  (b) Penicillin backbone.  The 
distribution of negative charge is similar in both structures (shown by curves).  Figure from Zapun et 
al. (2008). 
 
It was found that the penicilloyl enzyme was susceptible to an enzymatically 
catalysed release, supporting the hypothesis that both natural substrate and penicillin 
bind to the same residue in the transpeptidase active site.  Through the binding of 
[
14
C]-benzylpenicillin and protease digestion, the active site residue was identified as 
Serine (Frère et al., 1976), to which the substrate also binds (Yocum et al., 1979).  
The mechanism of !-lactam inhibition is illustrated in Figure 1.14. 
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Figure 1.14: Schematic representation of PBP inhibition by !-lactam antibiotics.  The active site 
nucleophilic serine (blue) attacks the carbonyl carbon atom of the !-lactam ring (red), forming a 
covalent ester linkage.  This bond is hydrolysable, but the rate at which this occurs is insignificant in 
comparison to the rate of bacterial division.  !-lactam antibiotics are classed as ‘suicide substrates’; 
opening of the !-lactam ring leads to a biologically inactive compound. 
 
The penicillin-binding domain is not restricted to transpeptidases; it is also present in 
the D,D-carboxypeptidases and endopeptidases, making these enzymes liable to !-
lactam inhibition.  PBPs differ in their susceptibilities to !-lactam antibiotics.  For 
example, LMW-PBPs are less sensitive to penicillin and cephalosporin, whereas 
HMW-PBPs are more sensitive by comparison (Waxman and Strominger, 1983).  
Inactivation of the HMW-PBPs is significant as this group generally include 
enzymes essential for viability.  Following the inhibition of the transpeptidases, there 
is an equilibrium shift towards the augmented activity of the hydrolases (Höltje, 
1998).  These enzymes continue to hydrolyse peptidoglycan to allow the insertion of 
new material into the cell wall.  In the absence of transpeptidation, the peptidoglycan 
becomes fragile threatening the prospect of cell lysis.   
 
Before the introduction of penicillin as a chemotherapeutic agent, resistance had 
already been established in bacteria.  This was primarily noted by Abraham and 
Chain in 1940, where an enzyme capable of neutralising the antibiotic, now known 
as the !-lactamase (detailed in Section 1.3.2.2), had been identified in E. coli 
(Abraham and Chain, 1988).  Over the years, other mechanisms of !-lactam 
resistance also emerged; mutations to the penicillin-binding domain of PBPs can 
distort the active site, restricting the entry of the !-lactam (as employed by S. aureus 
PBP2a in methicillin resistant strains) or mutation can result in the alteration of the 
active site polarity, reducing the affinity of the !-lactam (as achieved by S. 
pneumoniae PBPs) (reviewed by Zapun et al. (2008)).  This latter mechanism of 
acquisition of resistance in pneumococci is discussed in detail in Chapter 3.   
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1.9.2.2. Structure and conserved residues of the penicillin-binding domain 
 
Crystal structures of D,D-carboxypeptidases, endopeptidases and transpeptidases 
have been solved in apo and liganded forms to shed light on the signature fold 
topology and the molecular interactions of the penicillin-binding domain.  The 
overall architecture consists of two subdomains.  One subdomain consists of a 
central five-stranded !-sheet flanked by #-helices on both faces (generally #1 and 
#11 are in front of the sheet and #8 behind), and the second subdomain is all #-
helical (Fonzé et al., 1999; Gordon et al., 2000; Macheboeuf et al., 2005; Morlot et 
al., 2005; Sauvage et al., 2008a).  The active site is positioned at the interface of the 
subdomains, at the bottom of an elongated cleft (Fonzé et al., 1999; Contreras-Martel 
et al., 2006).  A degree of flexibility between the subdomains enables PBPs to have 
varying affinities for different ligands (Sauvage et al., 2008a). 
 
The penicillin-binding domain is defined by three conserved motifs that encompass 
the active site.  The first, SXXK, contains the catalytic serine (Frère et al., 1976; 
Yocum et al., 1979), which is invariably positioned at the N-terminus of #2, 
occupying the centre of the catalytic cleft.  The second, SXN, is located in a loop 
between helices #4 and #5.  The third, KT/SG lines the innermost !3 of the !-sheet.  
The latter two motifs lie on opposite sides of the catalytic cavity (Fonzé et al., 1999; 
Macheboeuf et al., 2005).  A conserved glycine is situated on an extended loop at the 
rear of the active site (Morlot et al., 2005).  The positions of these conserved motifs 
in S. pneumoniae PBP1a, PBP2b and PBP2x are demonstrated in Figure 1.15. 
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Figure 1.15:  Comparison of the transpeptidase domains of S. pneumoniae PBP1a, PBP2b and 
PBP2x.  Ribbon diagram representation of an overview of the transpeptidase domain and a close up of 
the transpeptidase active site (the catalytic serine is labelled) (upper and middle sections respectively).  
Surface representation of the transpeptidase active site (lower section).  In all sections, the conserved 
motifs 1-3 are blue, red and yellow respectively.   
 
The binding of substrate analogues to the penicillin-binding domain has identified 
specific features of the active site and the roles of conserved residues.  An oxyanion 
hole is formed by the amide groups of the catalytic serine and the residue 
immediately following the third motif (Morlot et al., 2005); the backbone carbonyl 
oxygen of the penultimate D-Ala (or !-lactam ring) hydrogen bonds with the 
oxyanion hole (McDonough et al., 2002).  The methyl group of the same D-Ala 
inserts into a hydrophobic pocket, which contains the conserved glycine and is 
important for binding specificity of the penultimate D-Ala (McDonough et al., 2002; 
Morlot et al., 2005).  This explains the stringency of D-Ala at position 4 of the 
PBP1a PBP2b PBP2x 
C 
N N 
C 
N 
C 
 
Ser-370 Ser-391 Ser-337 
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pentapeptide chain in comparison to the terminal (McDonough et al., 2002).  The 
hydroxyl residues of the third motif that comprise !3 orientate the incoming 
substrate as if they were antiparallel extensions of the enzyme !-sheet (Kelly et al., 
1998).  The glycine in this motif is essential in avoiding steric hindrance that could 
prevent substrate entry into the active site.  The Lys of the first motif is essential for 
catalysis.  It is proposed that this residue acts as a base, abstracting a proton from the 
catalytic serine, activating it as a nucleophile for an acylation event (Lee et al., 2001; 
Rhazi et al., 2003).  These interactions position the substrate ready for catalysis and 
stabilise any intermediate species.  Figure 1.16 illustrates the binding of a substrate 
analogue in the active site of Streptomyces R61 D,D-peptidase. 
 
Figure 1.16: Structural representation of Streptomyces R61 D,D-peptidase with a bound 
substrate analogue.  The conserved motifs 1-3 (blue, red and yellow respectively) are shown in stick 
form.  The peptide side stem substrate analogue glycyl-L-#-amino-$-pimelyl-D-Ala-D-Ala (cyan) is 
oriented as an anti-parallel extension of the !-sheet comprising the third conserved motif.  The 
terminal D-Ala is positioned for nucleophilic attack by the Ser-O!.  Following carboxypeptidation, the 
residues lining the active site adjust their interactions with the products glycyl-L-"-amino-#-pimelyl-
D-Ala and D-Ala, which may facilitate product ejection.  Adapted from McDonough et al. (2002). 
 
Recent structures of S. pneumoniae PBP1b have revealed that substrate binding 
induces a conformational change in the active site (Macheboeuf et al., 2005).  In the 
apo form, the active site cavity is closed whereby movement in an intervening loop 
disrupts the antiparallel interaction of !3 with !4, allowing !3 to contact the left 
hand side of the cleft.  In liganded structures, !3 and !4 are perfectly parallel, thus 
the active site is ‘open’.  This change in conformation could regulate the activity of 
Ser 
N 
C 
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the PBP, where until their catalytic activity is required, the enzyme remains in a 
‘closed’, inactive state.  Activation could be brought about by interaction with 
protein complexes or the availability of substrate (Macheboeuf et al., 2005).   
 
A further conformational change has been shown in the active site of Streptomyces 
R61 D,D-peptidase upon binding a tetrapeptide and D-Ala (representative of D,D-
carboxypeptidase products) (McDonough et al., 2002).  In this structure, a water 
molecule binds in the oxyanion hole, causing Thr of the third motif to take up an 
alternative conformation.  As a result, the peptide product loses a hydrogen bond and 
initiates further movements in the active site.  This is believed to facilitate the 
expulsion of the product from the active site (McDonough et al., 2002).   
 
1.9.2.3. The three-stage model of PBP activity 
 
The PBPs (transpeptidases, D,D-carboxypeptidases and endopeptidases) react with 
substrates and inhibitors according to a common three-step mechanism (substrate 
binding, acylation, deacylation) as described in Scheme 1 (E, enzyme; S, substrate; 
ES and ES*; intermediate complexes; P, product). 
 
 
Scheme 1 
 
The reaction proceeds by the rapid, reversible formation of a non-covalent Henri-
Michaelis complex between the D,D-peptidase and the peptidoglycan pentapeptide 
stem (the donor strand).  The nucleophilic serine attacks the carbonyl carbon atom of 
the fourth position D-Ala peptide bond, leading to the formation of tetrahedral 
intermediate and subsequently an acyl enzyme intermediate, with the concomitant 
release of the terminal D-Ala (transpeptidation and D,D-carboxypeptidation) or 
cross-linking peptide stem (endopeptidation).  Depending on the enzyme, 
deacylation occurs either by hydrolysis of the covalent intermediate, or by cross-link 
formation via a second peptide stem (acceptor strand) (Sauvage et al., 2008a).  
Product release enables the enzyme to resume its initial conformation.  The catalytic 
mechanism for transpeptidation and D,D-carboxypeptidation is illustrated in Chapter 
5. 
 
E[ ]+ S[ ]
k1
k-1
! "!!# !!! ES[ ]
k2
! "! ES*[ ]
k3
! "! E[ ]+ P[ ]
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1.9.2.4. The structural and functional relationship between PBPs and !-
lactamases 
 
The PBPs and many !-lactamases are penicilloyl serine transferases (or Active site 
Serine Penicillin Recognising Enzymes, ASPREs).  They share similar structural and 
active site sequence motifs, bind penicillin in the same orientation and have a 
common catalytic mechanism leading to the formation of a stable, covalent acyl-
enzyme intermediate (Ghuysen, 1994).  It was initially proposed by Tipper and 
Strominger (1965) that the !-lactamase was a modified form of the transpeptidase 
and it is now believed that the enzymes are derived from a common ancestor 
(Ghuysen, 1991).  It is in general agreement that the genes from an ancient PBP gave 
rise to a !-lactamase (not vice versa) (Ghuysen, 1991), allowing peptidoglycan to 
become an established component of the bacterial cell wall (Koch, 2000).   
 
The !-lactamases significantly contribute to !-lactam resistance.  They are secretory 
proteins that inactivate !-lactam antibiotics.  Structural analysis of these enzymes has 
revealed that they do not contain peptidoglycan binding sites, abolishing the 
recognition of PBP substrates (Meroueh et al., 2003).  Their reaction with penicillin 
(and !-lactam antibiotics) proceeds in an analogous mechanism to the 
transpeptidases.  However, whereas the transpeptidases are inactivated by the 
formation of a penicilloyl acyl-linked enzyme, the !-lactamases are capable of 
efficiently hydrolysing this moiety, recovering the enzyme with the release of 
penicilloate (a biologically inert compound) (Ghuysen, 1991).  This can be attributed 
to the uninhibited access of a water molecule into the active site of !-lactamases, 
which must be excluded from that of the transpeptidases (allowing the integrity of 
the cross-linking reaction to be maintained) (Ghuysen, 1991).  Class A !-lactamases 
contain a glutamate residue that is essential for deacylation of the active site serine 
(Adachi et al., 1991).  This residue is absent in an equivalent position in the active 
site of PBPs, providing an explanation as to why these enzymes are unable to 
hydrolyse the acyl intermediate at an appreciable rate (Gordon et al., 2000; 
Macheboeuf et al., 2006).  Figure 1.17 summarises the chemistry underpinning the 
turnover of !-lactam antibiotics by the !-lactamases and PBPs. 
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Figure 1.17: Reactions of penicilloyl serine transferases with !-lactam carbonyl donors.  The 
kinetic constants for acylation (k2/(k-1/k1) and deacylation (k3) refer to those of Scheme 1.  The rate of 
k3 determines the efficiency of !-lactam inhibition.  Figure adapted from Ghuysen (1991). 
 
1.10. Streptococcus pneumoniae 
 
The PBPs from S. pneumoniae are the primary focus of this thesis.  The following 
sections describe S. pneumoniae in terms of its clinical significance and its PBP-
mediated resistance to !-lactam antibiotics (additional detail in Section 3.1). 
 
1.10.1. S. pneumoniae and disease 
 
S. pneumoniae is a clinically relevant organism, being one of the leading causes of 
disease globally (Alpuche et al., 2007).  It is a Gram-positive, commensal bacterium, 
which has a carrier state, colonising the nasopharynx of adults (up to 4 % of the 
population) and children (greater than 50 %) (Regev-Yochay et al., 2004).  S. 
pneumoniae is responsible for infections including pneumonia, otitis media, 
meningitis and bacteraemia and is a primary cause of mortality amongst children, the 
elderly and vulnerable patients (Centres for Disease Control and Prevention, 1997).  
 
1.10.2. S. pneumoniae and !-lactam resistance 
 
Despite the availability of antimicrobial agents, mortality rates remain high; in 2005, 
WHO estimated that pneumococcal infections resulted in 1.6 million deaths 
worldwide (World Health Organisation, 2007).  This can be attributed to the 
development of bacterial resistance to !-lactam antibiotics, which are ubiquitously 
employed inhibitors against pneumococcal infections.  S. pneumoniae resistance to 
!-lactam antibiotics is not imparted by the common resistance mechanism of the 
production of !-lactamases; a !-lactamase expressing strain has not been 
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documented.  Instead, S. pneumoniae have evolved a sophisticated resistance 
mechanism that is mediated by the intricate restructuring of the antibiotic target 
(Hakenbeck et al., 1999) (detailed in Section 3.1).  PBPs of resistant strains have a 
reduced affinity for !-lactam antibiotics but vitally retain their natural physiological 
activity (Job et al., 2008).  Thus, S. pneumoniae PBPs are fascinating antimicrobial 
targets.    
 
1.10.3. S. pneumoniae PBPs and the resistance determinants 
 
S. pneumoniae has six penicillin-binding proteins: a single LMW-PBP (PBP3, 41.4 
kDa) and five HMW-PBPs, three of which belong to Class A (PBP1a, 79.7 kDa; 
PBP1b, 89.4 kDa; PBP2a, 80.7 kDa) and the remaining two belong to Class B 
(PBP2b, 74.4 kDa; PBP2x, 82.2 kDa).  Of these enzymes, PBP2b and PBP2x are 
crucial for viability (Kell et al., 1993), PBP3 (Severin et al., 1992) and PBP1b are 
not essential and either PBP1a or PBP2a must be functional (Hoskins et al., 1999). 
PBP2b and PBP2x are classified as primary resistance determinants; mutations in 
these enzymes, selected by !-lactam antibiotics, confer low resistance (Grebe and 
Hakenbeck, 1996).  Low affinity PBP2b and PBP2x are a prerequisite for high 
resistance levels, which are mediated by mutations present in PBP1a (Smith and 
Klugman, 1998). The remaining PBPs obtain fewer mutations in comparison to 
PBP1a, PBP2b and PBP2x and are generally not responsible for elevated resistance 
in clinical isolates (Sanbongi et al., 2004).  Thus, PBP1a, PBP2b and PBP2x are the 
major !-lactam resistance determinants of S. pneumoniae (further discussed in 
Section 3.1) and, accordingly, the biochemical characteristics of these enzymes were 
investigated in this thesis.   
 
 
 
 
 
 
 
 
 55 
1.11. Aims of the thesis 
 
The growing threat of bacterial resistance to clinically prescribed antibiotics presents 
a global health problem.  The discovery or design of new antimicrobial classes is a 
key strategy to evade antimicrobial resistance.  Towards this primary goal, it is a 
necessity to characterise drug targets and resistance mechanisms at a molecular level.  
Information obtained from these studies could provide insight into the structural and 
biochemical substrate specificity of the target enzymes and ultimately contribute to 
the rational development of novel inhibitors.   
 
S. pneumoniae PBPs, more explicitly the enzymes essential for mediating !-lactam 
resistance, are the focus of this thesis.  These enzymes represent the drug target as 
well as providing the basis of resistance.  Whilst the recent advances in biochemical 
and structural characterisation techniques of membrane proteins has led to an 
improved understanding of the transglycosylase activity of HMW-PBPs and MGTs, 
the transpeptidase activity of HMW-PBPs has remained somewhat of a mystery.  
The main aim of this thesis is to develop spectrophotometric assays to enable the 
rapid, kinetic characterisation of the PBP transglycosylase and transpeptidase 
activities, whilst concomitantly establishing conditions in which these activities can 
be detected (including an investigation into substrate specificity of the S. pneumoniae 
!-lactam resistance determinants).  This is a prerequisite for further exploration into 
the enzymology of catalysis and !-lactam resistance mechanisms of these enzymes.  
It is anticipated that conversion of the assays into a high throughput system will 
allow libraries of potential inhibitors to be screened against !-lactam sensitive and 
resistant enzymes.  A secondary aim is to obtain structural information of the integral 
membrane proteins, in the presence or absence of ligands, which together with 
biochemical data, could enhance the understanding of catalytic mechanisms and 
resistance-determining features of S. pneumoniae PBPs.   
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Chapter 2. Materials and Methods 
 
2.1. Buffers and solutions 
 
The buffers and solutions were prepared with Purite Prestige purified water (double 
deionised).  Buffers for use in chromatography, crystallography and 
spectrophotometric measurements were filtered using a 0.2 µm filter (Millipore, 
UK).  The solution pH was determined by inoLAB WTW pH meter using pH 4.01, 
pH 7.01 and pH 10.01 buffer standards (Hanna Instruments) for calibration purposes.   
 
2.2. Growth and maintenance of E. coli strains  
 
2.2.1. Bacterial growth media 
 
2.2.1.1. Super Optimal broth with Catabolite repression (SOC) media 
 
2 % (w/v) peptone, 0.5 % (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, 20 mM glucose. 
 
2.2.1.2. Luria Bertani (LB) broth (Bertani, 1951) 
 
1 % (w/v) tryptone, 0.5 % (w/v) NaCl, 0.5 % (w/v) yeast extract. 
 
2.2.1.3. 2xYT media 
 
1.6 % (w/v) tryptone, 1 % (w/v) yeast extract, 0.5 % (w/v) NaCl, adjusted to pH 7.0. 
 
2.2.1.4. ZY media (Studier, 2005) 
 
1 % (w/v) N-Z amine, 0.5 % (w/v) yeast extract. 
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2.2.1.5. Autoinduction media (Studier, 2005) 
 
ZY media, 1 mM MgSO4, 1 ! NPS (final concentrations of 25 mM ammonium 
sulphate, 50 mM potassium dihydrogen phosphate, 50 mM disodium hydrogen 
phosphate) and 1 ! 5052 (final concentrations of 0.5 % (v/v) glycerol, 0.05 % (w/v) 
glucose, 0.2 % (w/v) #-lactose) with appropriate antibiotics.   
 
All growth media were prepared to one litre and autoclaved. 
 
2.2.1.6. Preparation of LB-agar plates 
 
LB-agar plates were composed of LB media with 1.5 % (w/v) bacto-agar and 
sterilised by autoclaving.  The media was cooled to 50°C and appropriate antibiotics 
were added before pouring 25 mL into sterile Petri dishes.  Plates were stored at 4°C.   
 
2.2.2. Bacterial strains 
 
E. coli 
strain 
Genotype Reference 
TOP10 
F
-
 mcrA %(mrr-hsdRMS-mcrBC) &80lacZ%M15 
%lacX74 deoR recA1 araD139 % (ara-leu)7697 galU 
galK rpsL (Str
R
) endA1 nupG 
Grant et al. 
(1990) 
NovaBlue 
endA1 hsdR17(rK12
- 
mK12
+
) supE44 thi-1 recA1 
gyrA96 relA1 lac F’[proA
+
B
+
 lacI
q
Z%M15::Tn10 
(Tc
R
)] 
Merck-
Chemicals 
BL21 
(DE3) 
F
-
 ompT hsdSB(rB–, mB–) gal dcm (DE3) 
Studier and 
Moffatt 
(1986) 
BL21 Star 
(DE3) 
F- ompT hsdSB (rB
-
 mB
-
) gal dcm rne131 (DE3) 
Lopez et al. 
(1999) 
C41 (DE3) 
Derivative of E. coli BL21 (DE3): F- ompT hsdSB (rB
-
 
mB
-
) gal dcm (DE3)) and contains at least one 
uncharacterised mutation.  Prevents cell death 
associated with expression of toxic recombinant 
proteins. 
Miroux and 
Walker 
(1996) 
C43 (DE3) 
Derivative of C41 (DE3) obtained using F-ATPase 
subunit gene, contains no plasmid. 
Miroux and 
Walker 
(1996) 
Table 2.1: Bacterial strains used for DNA cloning and protein over-expression. 
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2.2.3. Preparation of chemically competent cells for DNA 
transformation 
 
E. coli cells were used to inoculate 5 mL sterile LB broth containing the appropriate 
antibiotic.  The cells were grown at 37°C, with shaking at 180 rpm overnight.  250 
mL sterile LB containing 20 mM MgSO4 and antibiotics (in a 1 L conical flask to 
allow optimum aeration) was inoculated with 2.5 mL of the overnight culture and 
incubated at 37°C with shaking at 180 rpm until the optical density at A600nm 
(OD600nm) reached between 0.4 and 0.6.  The cells were pelleted by centrifugation at 
4,500 ! g (Beckman JA-14 rotor) for 5 min.  From this point forward, cells and 
buffers were cooled to 4°C.  The cell pellet was gently resuspended in 100 mL TFB1 
buffer (30 mM potassium acetate, 10 mM calcium chloride, 50 mM manganese 
chloride, 100 mM rubidium chloride, 15% (v/v) glycerol, pH 5.8), incubated on ice 
for 5 min, centrifuged at 4,500 ! g for 5 min, resuspended in 10 mL TFB2 buffer (10 
mM MOPS, pH 6.5, 75 mM calcium chloride, 10 mM rubidium chloride, 15 % (v/v) 
glycerol) and incubated on ice for 1 h.  The competent cells were immediately frozen 
in 50 µL aliquots using liquid nitrogen and stored at -80°C. 
 
2.2.4. DNA transformation of E. coli 
 
A 50 µL aliquot of competent cells was thawed on ice and incubated with 1 µL DNA 
(25-100 ng) for 30 min on ice.  The cells were then incubated at 42°C for 30 sec and 
incubated on ice for a further 2 min.  250 µL of LB was added to the cells, which 
were then incubated at 37°C for 30-60 min with shaking.  100 µL of the transformed 
cells were plated onto LB-agar plates containing the appropriate antibiotic for 
selection.  The plates were incubated at 37°C overnight.  
 
2.2.5. Preparation of Glycerol Stocks 
 
An E. coli colony from a fresh transformation was used to inoculate 5 mL LB media 
containing the appropriate antibiotic and cultured at 37°C with shaking at 180 rpm 
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overnight.  1 mL of the culture was aseptically mixed with 1 mL sterile 100 % (v/v) 
glycerol in a Corning cryo-vial, frozen in liquid nitrogen and stored at -80°C. 
 
2.3. DNA manipulation and cloning techniques 
 
2.3.1. Oligonucleotides 
 
DNA oligonucleotides were designed according to the specified DNA manipulation 
technique against a target gene and ordered from Integrated DNA Technologies 
(UK).   
 
2.3.2. DNA concentration determination 
 
DNA quantification was determined using a NanoDrop ND-1000 spectrophotometer 
(Thermo Scientific) using 1.5 µL samples. 
 
2.3.3. Polymerase Chain Reaction (PCR) 
 
DNA amplification was achieved using AccuPrime Taq DNA Polymerase High 
Fidelity or Taq Polymerase following the manufacturer’s (Invitrogen) instructions.  
Unless otherwise stated, a 100 µL master mix of reagents was prepared and divided 
into five 20 µL aliquots.  The PCR was carried out in an Eppendorf Mastercycler 
Gradient thermocycler over an annealing temperature gradient of (45-65°C).  A 
negative control was used in each PCR where the template DNA was replaced with 
an equal volume of water.   
 
2.3.4. Restriction enzyme digestion of DNA 
 
Single, double and triple restriction enzyme digests were performed using restriction 
enzymes and buffer system according to the manufacturer’s (NEB) instructions.  500 
ng of plasmid DNA was used and the reactions were incubated at 37°C overnight.  In 
the event of star activity, the reaction was repeated with an incubation time of 2 h to 
limit this activity.    
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2.3.5. Purification of DNA from PCR and restriction digests 
 
DNA was purified following PCR and restriction digests to remove polymerases and 
endonucleases using the Wizard PCR Extraction kit (Promega) according to the 
manufacturer’s instructions.  
 
2.3.6. Preparation of Plasmid DNA 
 
Following a transformation and overnight culture, plasmid DNA was extracted from 
E. coli TOP10 cells using a miniprep extraction kit (Qiagen or Fermentas) according 
to the manufacturer’s instructions.  
 
2.3.7. Agarose Gel Electrophoresis 
 
A 0.8 % (w/v) solution of high-melting point agarose was prepared by adding 2 g of 
agarose to 250 mL of 1 ! Tris-acetate-EDTA (TAE, 40 mM Tris acetate, 1 mM 
EDTA) buffer and heating in a microwave oven until complete dissolution.  The 
solution was cooled to hand-heat and 25 µL of a 10,000 ! solution of SYBR
 
Safe 
(Invitrogen) DNA gel stain was added.  The solution was poured into a gel cast and 
allowed to set.  The gel was submerged in a gel tank (Geneflow) containing 1 ! 
TAE.  The DNA samples were loaded into the wells with a 1 in 6 dilution of 6 ! 
DNA loading dye solution (0.25 % (w/v) bromophenol blue, 0.25 % (w/v) xylene 
cyanol FF and 15 % (v/v) Ficoll 400) (Fermentas).  5 µL of DNA standard 1 Kb 
ladder (pre-mixed with loading buffer) (Fermentas) was loaded to allow size 
determination of the DNA samples.  Electrophoresis was performed at 100 V for 40 
min and the gel was visualised under ultraviolet light using a Syngene GeneSnap 
G:Box gel illuminator and analysis system.   
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2.3.8. Ligation independent cloning 
 
In this work, each target gene was cloned into the pET46 Ek/LIC vector (Figure 2.1) 
(Merck Chemicals).  
 
 
 
Figure 2.1:Vector map of pET-46 Ek/LIC.  The vector map was obtained from Novagen, Merck 
Chemicals.  The cloning site, situated 3’ to the vector encoded hexa-histidine fusion tag and the 
enterokinase cleavage site, is indicated.   
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This vector system employs ligation independent cloning (LIC), outlined in Figure 
2.2, eliminating the need of restriction digests and ligation reactions of traditional 
cloning methods (Aslanidis and de Jong, 1990). 
 
 
 
Figure 2.2: Ligation independent cloning.  The Figure was taken from Novagen Ek/LIC cloning kit 
protocol (Merck Chemicals).  Specific bases are engineered onto the 5’ and 3’ terminals of the insert 
by PCR.  LIC uses the 3’-5’ exonuclease activity of T4 DNA polymerase to create specific 13- or 14-
base single-stranded overhangs on the Ek/LIC vector and insert.  T4 DNA polymerase treatment of 
the insert occurs in the presence of a single dNTP (in this case dATP), where the exonuclease activity 
excises nucleotides until the first adenine (corresponding to the single dNTP) is encountered.  The 5’-
3’ polymerase activity then becomes dominant, opposing the exonuclease activity, preventing further 
excision.  Plasmid sequences adjacent to the linearization site are non-complementary, preventing re-
annealing of the vector.  The 5’ extensions of the insert are compatible with the vector, allowing 
cohesion of the insert in the desired orientation.   
 
The cloning of the PCR-amplified gene into the pET46 Ek/LIC vector (Merck 
Chemicals) was performed according to the manufacturer’s instructions.  A positive 
control ligation was performed using a !-galactosidase PCR product provided with 
the kit. 
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2.3.9. DNA Sequencing of plasmid constructs 
 
DNA constructs were sequenced to ensure the cloned gene had been inserted into the 
plasmid vector in the desired orientation in the correct reading frame and no 
mutations were introduced by PCR errors.  250-400 ng of plasmid DNA and 10 pmol 
primer (specific to the promoter and terminator regions of the pET vectors (Table 
2.2)) were used per sequencing reaction in a total reaction volume of 10 µL.  The 
reactions were submitted to the Molecular Biology Sequencing Service (University 
of Warwick).  The sequences were blasted against a database 
(www.ncbi.nih.gov/BLAST; Altschul et al. (1990)) and aligned using ClustalW 
(Larkin et al., 2007) to check for point mutations.  The start and stop codons were 
identified manually. 
 
Primer Primer sequence (5’-3’ orientation) 
T7 promoter TAA TAC GAC TCA CTA TAG GG 
pET-46 Ek/LIC terminator AGG GGT TAT GCT AGT TAT TGC TCC G 
Table 2.2: Sequences of the T7 promoter and pET-46 Ek/LIC terminator primers for use in 
DNA sequencing.  
 
2.3.10. Site-directed mutagenesis of DNA constructs 
 
Single point mutations were created in various gene constructs using the Stratagene 
Site-Directed Mutagenesis QuikChange II kit, according to the manufacturer’s 
instructions.  Oligonucleotides containing the desired mutations were designed (see 
tables in relevant text) to replace parental DNA.  This was achieved through PCR 
using PfuUlta DNA polymerase.  Parental DNA was denatured at 95°C for 30 sec, 
followed by eighteen cycles of 95°C for 30 sec (to denature double stranded DNA), 
55°C for 1 min (to anneal primers), 68°C for 1 min/kb of plasmid length (to extend 
mutagenic primers in a 5’-3’ direction).  Finally, a 68°C step for 5 min ensured 
complete primer extension.   
 
Parental DNA was digested using the endonuclease Dpn I, leaving the mutated 
plasmid, which was used to transform E. coli TOP10 cells (Section 2.2.4).  The 
plasmid DNA was extracted from overnight cultures of positive clones (Section 
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2.3.6) and submitted for sequencing (Section 2.3.9).  The sequence was aligned and 
compared to the wild-type sequence to identify clones containing the desired 
mutation.   
 
2.3.11. Plasmid vectors used in this project 
 
Vector Purpose 
Antibiotic 
selection 
Supplier 
pET28d Cloning Kanamycin Novagen 
pET46 Ek/LIC Cloning Ampicillin Novagen 
pTrcHis60 Cloning Ampicillin 
Amersham 
Pharmacia Biotech 
pET3a Cloning Ampicillin Novagen 
pLysS 
Reduction of basal 
expression of 
recombinant genes 
Chloramphenicol Novagen 
pRosetta 
Rare codon over-
expression 
Chloramphenicol Novagen 
pRIL 
Rare codon over-
expression 
Chloramphenicol Novagen 
pRARE 
Rare codon over-
expression 
Chloramphenicol Novagen 
Table 2.3: Commercial vectors used in this project for cloning and to aid protein over-
expression. 
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2.3.12. Gene constructs used in this project 
 
Construct Selection Description 
pET46::pbp1a Ampicillin 
pET46 vector containing S. pneumoniae 
D39 pbp1a 
pET46::pbp1a-!30 Ampicillin 
pET46 vector containing S. pneumoniae 
D39 pbp1a-!30 
pET46::pbp1a-S370A Ampicillin 
pET46 vector containing S. pneumoniae 
D39 pbp1a, Ser-370 replaced with Ala 
pET46::pbp1a-E91Q Ampicillin 
pET46 vector containing S. pneumoniae 
D39 pbp1a, Glu-91 replaced with Gln 
pET46::pbp1a-5204 Ampicillin 
pET46 vector containing S. pneumoniae 
5204 pbp1a 
pET46::pbp2b Ampicillin 
pET46 vector containing S. pneumoniae 
D39 pbp2b 
pET46::pbp2b-!39 Ampicillin 
pET46 vector containing S. pneumoniae 
D39 pbp2b-!39 
pET46::pbp2b-S391A Ampicillin 
pET46 vector containing S. pneumoniae 
D39 pbp2b, Ser-391 replaced with Ala 
pET46::pbp2b-5204 Ampicillin 
pET46 vector containing S. pneumoniae 
5204 pbp2b 
pET46::pbp2x Ampicillin 
pET46 vector containing S. pneumoniae 
D39 pbp2x 
pET46::pbp2x-!48 Ampicillin 
pET46 vector containing S. pneumoniae 
D39 pbp2x-!48 
pET46::pbp2x-S337A Ampicillin 
pET46 vector containing S. pneumoniae 
D39 pbp2x, Ser-337 replaced with Ala 
pET46::pbp2x-5204 Ampicillin 
pET46 vector containing S. pneumoniae 
5204 pbp2x 
pET46::mgt* Ampicillin 
pET46 vector containing S. aureus MGT 
(%67) 
pET46::mgt-E100Q Ampicillin 
pET46 vector containing S. aureus MGT 
(%67), Glu-100 replaced with Gln 
pTrcHis60::pgpB* Ampicillin 
pTrcHis60 vector containing E. coli 
PgpB 
pET28d::vanA* Kanamycin 
pET28d vector containing E. faecalis 
VanA 
pET3a::murG* Ampicillin pET3a vector containing E. coli MurG 
Table 2.4: Gene constructs generated and provided (*) for use in this project. 
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2.4. Cytoplasmic protein expression and purification 
 
2.4.1. Protein over-expression in E. coli 
 
Recombinant proteins were over-expressed in a number of E. coli strains suitable for 
protein expression (Table 2.1).  Strains were made competent (Section 2.2.3) and 
transformed (Section 2.2.4) with an expression plasmid containing the recombinant 
gene and plated onto the appropriate selective media.  The cell colonies were treated 
differently depending on the induction method specified. 
 
2.4.1.1. Isopropyl-!-D-thiogalactopyranoside (IPTG) induction  
 
A single colony from a fresh transformation was used to inoculate a small-scale 
culture of 10 mL LB containing 0.2 % (v/v) glucose and the appropriate antibiotic.  
Cells were cultured at 37°C, with shaking at 180 rpm overnight.  The whole 
overnight culture was used to inoculate 1 L LB with antibiotic selection and grown at 
37°C with shaking at 180 rpm.  At OD600nm of 0.5, the cultures were induced with 0.5 
mM IPTG and incubated at 25°C for 18 h (unless otherwise stated).  Cells were 
harvested at 10,000 ! g using a Beckman JLA-8.100 rotor.  The cell pellet was 
resuspended in 3 mL/g wet cell weight of phosphate buffered saline (PBS: 8.1 mM 
Na2HPO4, 137 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, pH 7.4) unless otherwise 
stated and stored at -20°C. 
 
2.4.1.2. Autoinduction 
 
The method used in this work was adapted from the Studier Autoinduction System 
(Studier, 2005).  A freshly transformed colony from an LB-Agar plate supplemented 
with 1 % (w/v) glucose was used to inoculate 2 mL ZYP-0.8G medium (ZY, 1 mM 
MgSO4, 0.8 % (w/v) glucose, NPS) with appropriate antibiotic selection and grown 
overnight at 25°C with 225 rpm shaking.  1 mL of overnight culture was used to 
inoculate 1 L of ZYP-5052 rich medium (ZY, 1 mM MgSO4, 5052, NPS) for 
autoinduction with the appropriate antibiotic selection.  The cells were cultured at 
25°C for 22 h with agitation at 225 rpm.  Cells were harvested at 10,000 ! g using a 
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Beckman JLA-8.100 rotor at 4°C.  The cell pellet was resuspended in 3 mL/g wet 
cell weight of PBS and subsequently stored at -20°C. 
 
2.4.2. Preparation of crude cell lysates 
 
Cell lysates were prepared from previously frozen cells (Section 2.4.1).  Following 
thawing on ice, the cell suspension was supplemented with 2.5 mg/mL chicken egg 
white lysozyme (Calbiochem) and incubated at 4°C with agitation for 30 min.  The 
lysozyme-treated cells were sonicated on ice for four bursts of 30 sec at 70 % power 
using a Bandelin Sonoplus sonicator.  The cell debris was pelleted at 20,000 ! g for 
20 min using a Beckman JA-25.50 rotor at 4°C.  The location of the target protein, 
either in the supernatant or the pellet, directed the following stages of the protocol. 
 
2.4.2.1. Soluble protein 
 
Following the 20,000 ! g centrifugation step (Section 2.4.2), the supernatant 
(containing soluble and membrane-bound proteins) was centrifuged at 50,000 ! g 
for 20 min at 4°C using a Beckman JA-25.50 rotor to pellet the membranes, 
producing clear cell lysates.  The clarified cell lysates were ready for the purification 
of the target protein. 
 
2.4.2.2. Insoluble proteins 
 
Following the 20,000 ! g centrifugation step (Section 2.4.2), the pellet (containing 
the target protein expressed in the insoluble fraction of the cells) was resuspended in 
25 mL 50 mM sodium phosphate, 500 mM NaCl, 20 % (v/v) glycerol, 1 % (w/v) n-
Dodecyl-$-D-Maltopyranoside (DDM) pH 7.6, frozen at -20°C and then thawed to 
promote the solubilisation process.  A centrifugation step of 50,000 ! g for 20 min 
(using a Beckman JA-25.50 rotor) pelleted the remaining insoluble material.  The 
supernatant contained detergent-solubilised proteins and was ready for the 
purification of the target protein. 
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2.4.3. Protein purification 
 
2.4.3.1. Affinity chromatography 
 
Purification of proteins with hexa- or dodeca-histidine affinity tags was carried out 
using immobilised metal affinity chromatography (IMAC) unless otherwise stated.  
Columns were prepared with TALON Metal Affinity Resin (Cobalt metal ions, 
Clontech) and developed using gravity-flow.   
 
Columns were prepared using a 10 mL syringe barrel.  A final volume of 5 mL resin 
was used to form the column bed, with glass wool acting as a frit to retain the resin 
in the barrel.  The column was washed with 10 column volumes sterile water and 
equilibrated with the required buffer (typically PBS, with additional 150 mM NaCl 
(287mM final [NaCl], unless otherwise stated).  The soluble proteins from Section 
2.4.2 were loaded directly onto the column and the flow-through was collected.  The 
column was washed with 10 column volumes of buffer to remove unbound proteins.  
Columns were developed by washing with 100 mL buffer containing 15 mM 
imidazole and the target protein was eluted with 60 mL buffer containing 300 mM 
imidazole, collected in 10 mL fractions (unless otherwise stated).  After use, columns 
were washed with 10 column volumes of buffer containing 1 M imidazole, 10 
column volumes of sterile water and 10 column volumes of 20 % (v/v) ethanol, in 
which the column was stored at 4°C. 
 
2.4.3.2. Size exclusion chromatography 
 
Proteins were separated on the basis of size using Superdex 75 or 200 resin (GE 
Healthcare) (separation of proteins with a mass range of 3-75 kDa or 10-600 kDa 
respectively) on a 26/60 column attached to either AKTA Prime or AKTA 10/100 
purifier systems (GE Healthcare) unless otherwise stated.  The resolution of 
Superdex resin is dependent on the dextran components, which are covalently bound 
to highly cross-linked porous agarose beads.  Columns were equilibrated with 1.5 
column volumes of the stated buffer.  Samples were loaded onto the column via an 
injection loop in volumes of 5 mL or less to prevent loss of resolution due to sample 
smearing.  Buffer was passed through the column at a rate of 1 mL/min for one 
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column volume and 10 mL fractions were collected.  Protein elution was monitored 
by an increase in absorbance at 280 nm.   
 
2.4.3.3. Anion exchange chromatography 
 
Anion exchange was carried out using a MonoQ HR 5/5 column (10 µm beads) 
attached to an AKTA purifier system (GE Healthcare).  MonoQ resin (Q Sepharose) 
contains a quaternary amine group, providing a strong positive charge over the 
stationary phase surface between pH 2 and 12.  The positively charged functional 
groups were neutralised by a negatively charged ion (Cl
-
) by washing the column 
with 10 column volumes of 20 mM Tris, pH 7.5 containing 1 M NaCl, followed by a 
wash with 20 mM Tris, pH 7.5 to remove any non-bound Cl
-
 ions.  The protein was 
loaded onto the column via an injection loop in a low salt buffer with a pH of 7.5, 
which is at least 1 pH unit above the protein isoelectric point to ensure a net negative 
charge, allowing the protein to bind strongly to the positively charged resin.  A salt 
gradient was applied to the column from 0-1 M (in 20 mM Tris, pH 7.5) over 10 
column volumes with a flow-rate of 0.5 mL/min.  The Cl
-
 ions displaced the proteins 
with differing net surface charges, allowing protein separation.  1 mL fractions were 
collected throughout the gradient and the eluting protein was monitored by an 
increase at A280nm. 
 
2.4.4. Buffer exchange and protein concentration 
 
Protein solutions were buffer exchanged using Vivaspin centrifugal concentrator 
membranes with a molecular weight cut-off of either 10,000 or 30,000 Da (as stated).  
Protein solution was placed in the top chamber of the concentrator, and centrifuged 
at 3,000 ! g at 4°C in a bench-top centrifuge (Eppendorf Centrifuge 5810R) for a 
specified time period.  The top chamber containing the protein was refilled with the 
exchange buffer and the flow-through in the bottom chamber was discarded.  The 
process was repeated a number of times depending on the dilution factors calculated 
for acceptable buffer exchange.  The protein was concentrated and monitored 
intermittently until the desired volume of protein solution was reached.  
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2.5. Membrane protein expression and purification 
 
2.5.1. Protein over-expression in E. coli 
 
The over-expression of membrane proteins was carried out in an analogous manner 
to that of cytoplasmic proteins, described in Section 2.4.  However, treatment of the 
resulting cell pellet varied as detailed in the following sections.  The PBP variants 
were all expressed in E. coli BL21 Star (DE3) harbouring the pRosetta plasmid. 
 
2.5.2. Small-scale production of membrane protein lysates 
 
For a small-scale production, membrane protein lysates were prepared as described 
in Ward et al. (2000), with few modifications.  Cells from a 100 mL overnight 
expression of a target membrane protein (Section 2.4) were harvested at 10,000 ! g 
in a Beckman JA-25.50 rotor (rotor used throughout this protocol) at 4°C for 10 min.  
The cell pellet was resuspended in 5 mL 0.2 M Tris pH 8.0 and incubated at 25°C 
with shaking at 180 rpm for 20 min.  9.7 mL sucrose buffer (1 M sucrose, 1 mM 
EDTA, 0.2 M Tris pH 8.0) was added, followed by 1.3 mg/mL lysozyme and 20 ml 
deionised water before incubation at 25°C for 1 h with shaking at 180 rpm.  The 
spheroplasts formed were pelleted at 20,000 ! g at 4°C for 20 min and resuspended 
in 30 mL deionised water using a hand-held homogeniser and allowed to stand for 30 
min at 25°C.  Membranes were sedimented at 30,000 ! g at 4°C for 20 min and the 
supernatant containing the cytoplasmic fraction of the cells was retained.  The 
membranes were washed three times in 15 mL of membrane resuspension buffer (0.1 
M sodium phosphate pH 7.2, 1 mM !-mercaptoethanol) using a hand-held 
homogeniser to resuspend the pellet each time.  After the final wash, membranes 
were resuspended in 0.5 mL membrane resuspension buffer with 1 mM MgCl2 and 
20 µg/ml DNAse.  Preparations were incubated at 37°C for 30 min before the 
addition of 1 mM EDTA.  The cytoplasmic and membrane fractions were analysed 
by SDS-PAGE (Section 2.6.2), frozen in liquid nitrogen and stored at -80°C. 
 
This protocol was also used to evaluate protein expression in large-scale cultures by 
analysing a fraction of the cells.  
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2.5.3. Preparation of E. coli membranes 
 
The frozen cell pellet containing the over-expressed target membrane protein 
(Section 2.5.1) was thawed on ice before the addition of 20 µg/mL DNAse, 1 mM 
MgCl2, 2.5 mg/mL lysozyme, and submitted to rotatory shaking at 4°C for 1 h.  Cells 
were lysed by passing twice through a continuous cell disruptor (Constant Cell 
Disruption Systems) (pre-equilibrated in ice-cold PBS) at 28 kpsi at 4°C.  The lysates 
were centrifuged for 12 min at 24,000 ! g (Beckman JA-25.50 rotor) at 4°C.  The 
resulting pellet was discarded and the centrifugation step was repeated with the 
supernatant to remove cellular debris.  The supernatant was transferred to 
ultracentrifuge tubes and centrifuged at 150,000 ! g for 1 h at 4°C using a Beckman 
Ti45 rotor in an ultracentrifuge (Beckman Coulter Optima L-90K) to pellet the 
membrane fraction.  The membranes were resuspended in PBS (10 mL/original 1 L 
cell culture), frozen in liquid nitrogen and stored at -80°C. 
 
2.5.4. Detergent solubilisation screen 
 
1 mL prepared membranes (from Section 2.5.3) was incubated with 1 % (w/v) 
detergent (assuming this percentage was at least 2-3 ! greater than the critical 
micellar concentration (CMC)) for 1 h with rotatory shaking at 4°C.  The insoluble 
material was pelleted at 150,000 ! g for 30 min at 4°C using a Beckman Ti45 rotor 
in an ultracentrifuge.  The soluble and insoluble fractions were analysed by SDS-
PAGE and Western blot.  
 
2.5.5. Membrane protein solubilisation and purification 
 
2.5.5.1. Membrane protein solubilisation 
 
Prepared membranes (in PBS) were thawed on ice and 1 % (w/v) sodium 
deoxycholate (CMC, 0.08-0.25 % (w/v); micellar molecular weight, ~1.2-5 kDa, 
Sigma-Aldrich) (employed based on the solubilisation screen, Section 2.5.4) was 
added before membranes were incubated at 4°C with rotatory shaking for 3 h.  The 
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solubilised preparation was transferred to ultracentrifuge tubes, which were filled to 
the maximum volume by the general purification buffer PBS, 0.1 % (w/v) DDM 
(Sigma-Aldrich) (CMC, 0.01 % (w/v), micellar molecular weight, ~40-75 kDa, 
Anatrace, Affymetrix) with additional 150 mM NaCl, unless otherwise stated.  
Addition of DDM in the buffer gradually began detergent exchange to minimise 
protein aggregation and precipitation that could occur if this process were rapid.  The 
solubilised membranes were centrifuged at 150,000 ! g for 30 min at 4°C using the 
Beckman Ti45 rotor and ultracentrifuge (Beckman Coulter Optima L-90K) to pellet 
any remaining insoluble membranes.  The supernatant containing solubilised 
membrane proteins was ready for target protein purification. 
 
2.5.5.2. Affinity chromatography 
 
Purification of membrane proteins with hexa- or dodeca-histidine affinity tags was 
carried out using TALON Metal Affinity Resin (Cobalt ions) via immobilised metal 
affinity chromatography (IMAC) under gravity.  5 mL resin was pelleted at 800 ! g 
for 5 min, washed twice in sterile water, and washed twice in the buffer used for 
purification (PBS, 150 mM NaCl, 0.1 % (w/v) DDM) to equilibrate the resin.  
Following the final centrifugation, the buffer was discarded from the resin pellet and 
the solubilised membranes (Section 2.5.5.1) were incubated with the resin with 
stirring at 4°C for 3 h.  The protein-resin mix was poured into a column (length 9 cm, 
diameter 2 cm) and the resin bed allowed to settle.  Flow-through was collected and 
retained for analysis before the column was resolved with a step gradient of 
imidazole: 100 mL buffer with 15 mM imidazole (collected as 10 mL fractions), 50 
mL buffer with 50 mM imidazole (collected as 5 mL fractions) and 50 mL buffer 
with 250 mM imidazole (collected as 5 mL fractions), unless otherwise stated.  
Samples at different stages of the purification were analysed by SDS-PAGE (Section 
2.6.2).  
 
2.5.5.3. Size exclusion chromatography 
 
Size exclusion chromatography was used to further purify the protein in addition to 
detergent and buffer exchange.  Size exclusion chromatography was performed using 
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the analytical Superose 6 (cross-linked agarose-based medium, separating capability 
of 5-5000 kDa) 10/300 GL column (GE Healthcare) attached to an AKTA purifier 
100 system (GE Healthcare).  The smaller column size reduces the volume of buffer 
required, which often contains expensive detergent, but can successfully resolve 
membrane proteins given their substantially lower yield compared to cytoplasmic 
proteins.  The column was equilibrated in 1.5 column volumes of 20 mM Tris pH 
7.5, 150 mM NaCl, 0.03 % (w/v) DDM.  500 µL protein was loaded onto the column 
via an injection loop.  Buffer was passed through the column with a flow rate of 0.4 
mL/min and 0.5 mL fractions were collected in a 96-well plate.  The elution of the 
protein was monitored by a change in absorbance at 280 nm.  The column was 
washed in 5 column volumes sterile water and stored in 20 % (v/v) ethanol.  
Following size exclusion chromatography, the fractions containing protein of the 
highest level of purity (as determined by SDS-PAGE, Section 2.6.2) were combined, 
concentrated and stored at -20°C in 50 % (v/v) glycerol. 
 
2.6. Protein analysis and detection 
 
2.6.1. Protein Quantification 
 
2.6.1.1. Soluble proteins 
 
The concentration of soluble proteins was determined using a colourimetric assay at 
595 nm (BioRad) (Bradford, 1976).  For the BioRad reagent method, 10 µL of 
protein solution was added to 200 µL of BioRad reagent and 790 µL water in a 
cuvette, mixed and allowed to stand for 5 minutes.  The absorbance was measured at 
595 nm using a Jenway 6305 UV-visible spectrophotometer.  The procedure was 
repeated to get an average reading.  If the reading was outside the linear range of the 
assay (above 0.6 at 595 nm), the protein solutions were diluted and reanalysed.  The 
protein concentration (µg/mL) was calculated using the following formula according 
to the manufacturer’s instructions: 
 
[Protein] (µg/mL) = (A595nm/0.1) ! 1.95 ! dilution factor ! (1000/volumed assayed) 
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2.6.1.2. Membrane proteins 
 
The concentration of membrane proteins was established using the bicinchoninic 
acid (BCA) assay (Pierce) (Smith et al., 1985), where unlike other methods, the 
presence of detergent does not interfere with the protein quantification.  The BCA 
assay was carried out according to the manufacturer’s instructions.  Reagents A and 
B were mixed in a 50:1 ratio and 2 mL of this working reagent was added to 100 µL 
of each sample.  Reagents were incubated at 37°C before cooling to room 
temperature.  The absorbance of the samples was measured at 562 nm using a 
Jenway 6305 UV-visible spectrophotometer.  Protein concentrations were calculated 
based on a bovine serum albumin standard curve.  The assay has a working range of 
20-2000 µg/mL. 
 
2.6.2. SDS-Polyacrylamide Gel Electrophoresis 
 
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) Tris-glycine buffer system 
(Laemmli, 1970) was used to separate and visualise polypeptides under denaturing 
conditions on a discontinuous gel system: resolving gel, pH 8.8; stacking gel, pH 6.8.  
5 mL resolving gel (375 mM Tris pH 8.8, 0.4 % (w/v) SDS, 12 % acrylamide:bis-
acrylamide (29:1) was prepared, allowing the resolution of proteins between 25 and 
75 kDa.  Gels were cast using the Hoeffer Mighty Small gel kit and polymerised by 
the addition of 100 µL 10 % (w/v) APS (ammonium persulfate) and 10 µL 
N,N,N',N'-Tetramethylethylenediamine (TEMED), then overlaid with 100 % (v/v) 
ethanol to remove the gel meniscus.  2 mL stacking gel (125 mM Tris pH 6.8, 0.4 % 
(w/v) SDS, 4 % acrylamide:bis-acrylamide (29:1)) was prepared, polymerised with 
50 µL 10 % (w/v) APS and 10 µL TEMED, and pipetted on top of the polymerised 
resolving gel (removing the ethanol first).  A plastic comb was added to form the 
wells. 
 
25 µg protein samples (or a maximum volume of 20 µL if the [protein] was too 
dilute) were prepared for analysis in 1 ! loading buffer (6 !; 63.5 mM Tris pH 6.8, 
0.4 % (w/v) SDS, 5 % (v/v) !-mercaptoethanol, 20 % (v/v) glycerol, 2.5 % (w/v) 
bromophenol blue.  The samples were heat-denatured at 95°C for 10 min and cooled 
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to 4°C for 2 min using an Eppendorf Mastercycler Gradient thermocycler.  The gel 
comb was removed, wells were washed with SDS-PAGE running buffer (25 mM 
Tris pH 8.3, 0.19 M glycine, 0.1 % (w/v) SDS) and the samples were pipetted into 
the wells.  The gels were run in SDS-PAGE running buffer at 180 V or until the gel 
front reached the base of the gel, typically 55 min. 
 
2.6.2.1. Development of SDS-PAGE gels 
 
Proteins separated by SDS-PAGE were detected using Colloidal-Coomassie stain (8 
% (w/v) ammonium sulphate, 0.08 % (w/v) Coomassie G-250, 1.6 % (v/v) 
phosphoric acid, 20 % (v/v) ethanol).  Following SDS-PAGE, gels were rinsed in 
water for 5 min before staining overnight.  Gels were destained in water and imaged 
using Syngene GeneSnap G:Box Gel Doc and analysis system. 
 
2.6.3. Western blotting for probing with antibodies 
 
SDS-PAGE gels destined for a Western blot analysis were run with a BenchMark 
His-tagged Protein Standard (molecular weight markers, Invitrogen).  Polypeptides 
that had been resolved by SDS-PAGE (Section 2.6.2) were transferred from the gel 
to a polyvinylidene difluoride (PVDF) membrane (Hybond-P, Amersham 
Biosciences) (pre-treated with a 5 minute wash in methanol and a 5 minute wash in 
the Western Transfer buffer (50 mM Tris, 40 mM Glycine, 0.04 % (w/v) SDS, 20 % 
(v/v) methanol)).  The transfer took place in Western Transfer buffer at 90 mA 
overnight using an Electrophoretic Protein Blotting Tank (BioRad) at 4°C.   
 
The PVDF membrane was placed in 50 mL blocking solution (comprised of PBS 
containing 10 % (w/v) skimmed milk powder) for 1 h to prevent non-specific 
antibody binding to the membrane.  The membranes were then washed 3 times for 15 
min in 50 mL PBS containing 0.1 % polyoxyethylene (20) sorbitan monolaurate 
(Tween 20) (PBS-Tween).  The blot was then incubated for 1 h with 50 mL PBS-
Tween and 50 µL of mouse monoclonal antibody raised against a C-terminal 6-
histidine tag (Roche).  Three 50 mL PBS-Tween wash steps followed.  The blot was 
incubated in 50 mL PBS-Tween containing 30 µL of the secondary rabbit antibody 
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raised against mouse IgG (whole molecule) conjugated to horseradish peroxidase 
(Sigma) for 1 h.  After a further 3 washes in PBS-Tween, the blot was reacted with 5 
mL of enhanced chemiluminescence (ECL) detection reagents 1 and 2 (Amersham 
Biosciences) for 5 min.  The blot was wrapped in cling film and placed in a cassette 
containing KODAK BioMax MR film.  The exposure time ranged from 5 min to 30 
min depending on the antibody concentration applied and intensity of bands required.  
The film was developed using an AGFA Curix 60 developing machine.   
 
2.7. Lipid I and II synthesis 
 
2.7.1. UDP-MurNAc-pentapeptide preparation (Adapted from Lloyd 
et al. (2008)) 
 
2.7.1.1. Biosynthesis 
 
Typically, biosynthesis of UDP-MurNAc-pentapeptide occurred in a 2 mL total 
volume and contained the following components: 50 mM 4-(2-hydroxyethyl)-1-
piperazinethanesulphonic acid (HEPES) pH 7.5, 10 mM MgCl2, 200 mM 
phosphoenol pyruvate (PEP), 50 mM KCl, 1 mM dithiolthreitol (DTT), 10mM UDP-
N-acetyl glucosamine (UDP-GlcNAc), 30 mM L-Ala, 30 mM D-Glu, 30 mM L-Lys, 
30 mM D-Ala-D-Ala, 200 µM NADPH, 6 mM ATP, 25 mM isocitrate, 8 units of 
isocitrate dehydrogenase (Sigma-Aldrich), 500 units of pyruvate kinase (Sigma-
Aldrich), 400 µg of MurA, 2000 µg of MurB, 300 µg of MurC, 350 µg of MurD, 750 
µg of MurE and 350 µg of MurF (Mur enzymes provided by A. Catherwood).  The 
reaction components were incubated overnight at 37°C, after which 5 mL sterile 
water was added and the enzymes were removed by ultrafiltration with a Vivaspin 
centrifugal concentrator (cut-off of 10,000 Da).  The filtrate was ready to be purified. 
 
2.7.1.2. Purification 
 
The UDP-MurNAc-pentapeptide was purified by anion exchange chromatography 
using a Source 30Q column (26 ! 120 mm) attached to the AKTA purifier 100 
system (Amersham Biosciences).  The column was sequentially equilibrated with 6 
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column volumes each of 10 mM ammonium acetate pH 7.6, 1 M ammonium acetate 
pH 7.6 and 10 mM ammonium acetate pH 7.6 to ensure that the resin was charged 
with the appropriate ion and no excess salt was present.  10 mM ammonium acetate 
pH 7.6 was added to the filtrate (from Section 2.7.1.1) to a final volume of 200 mL 
and loaded onto the column via an injection loop at a rate of 15 mL/min.  The 
column was washed with three column volumes of 10 mM ammonium acetate pH 
7.6.  An ammonium acetate gradient was set up from 10 mM to 1 M over 18 column 
volumes (15 mL/min for 60 min).  Fractions of 10 mL were collected throughout the 
gradient and the presence of the eluted UDP-MurNAc-pentapeptide was judged by 
an increase in absorbance at 254 nm.  The fractions comprising the peak of the UDP-
MurNAc-pentapeptide were freeze-dried to remove trace amounts of buffer, 
dissolved in 250 µL sterile water and stored at -20°C.   
 
The concentration of UDP-MurNAc-pentapeptide synthesised was calculated by 
measuring the absorbance of the solution at 260 nm, where the uracil moiety of the 
pentapeptide has an extinction coefficient of 10,000 M
-1
cm
-1
. 
 
2.7.2. Micrococcus flavus membrane preparation providing lipid-
linked intermediates 
 
2.7.2.1. Culturing M. flavus 
 
M. flavus cells from a frozen glycerol stock were used to inoculate 100 mL of 
tryptone soya broth (TSB) and the cells were cultured overnight at 37°C with 180 
rpm agitation.  10 mL of the overnight culture was used to inoculate 8 ! 650 mL 
TSB and the liquid cultures were incubated at 37°C with agitation at 180 rpm until 
OD600nm reached 4.0 (mid-exponential phase).  The cells were harvested by 
centrifugation at 10,000 ! g for 10 min using a Beckman JLA-8.100 rotor. 
 
2.7.2.2. M. flavus membrane preparation 
 
The M. flavus cell pellet (from Section 2.7.2.1) was washed once in the ice-cold 
membrane buffer (20 mM Tris, 1 mM MgCl2 and 2 mM !-mercaptoethanol, pH 7.5) 
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and the final pellet was resuspended in 3 mL/g of cells of the membrane buffer 
supplemented with 2.5 mg/mL of chicken egg white lysozyme.  After a 15 min 
incubation on ice, the M. flavus cells were disrupted by passage through a continuous 
cell disrupter at 30,000 psi.  Unbroken cells and particulate debris were removed by 
centrifugation at 10,000 ! g for 1 h at 4°C.  The supernatant was centrifuged at 
50,000 ! g for 1 h at 4°C to pellet the membranes.  The pellet was resuspended in 
membrane buffer at three times the volume of the pellet.  The membranes were 
centrifuged at 50,000 ! g for 1 h at 4°C and the final membrane pellet was 
resuspended in 3 mL of membrane buffer.  The protein concentration of the 
membranes was calculated using the BioRad assay (Section 2.6.1.1).  The 
membranes were stored at -80°C.  
 
2.7.3. Lipid I and II preparation 
 
2.7.3.1. Synthesis 
 
Lipid I and Lipid II syntheses were performed in an adaptation of the method of 
Breukink et al. (2003).  In a glass vial, with a final reaction volume of 3.5 mL, M. 
flavus membranes (3.5 mg/ml) were incubated together with 1.62 mM undecaprenyl 
phosphate (Larodan Fine Chemicals AB, Sweden), 2 mM UDP-MurNAc 
pentapeptide and 35 mM UDP-GlcNAc (Sigma), in a buffer containing 100 mM Tris, 
pH 8.5, 5 mM MgCl2, and 1 % (v/v) Triton X-100.  The UDP-GlcNAc was omitted 
during the synthesis of Lipid I.  The reaction components were incubated at 37°C for 
2.5 h.  The lipids were then extracted by the sequential addition of 3.5 mL of 6 M 
pyridinium acetate pH 4.2 and 7 mL n-butanol.  The top layer (n-butanol) was 
collected after centrifugation (3,000 ! g, 10 min, 4°C) and washed with an equal 
volume of water to remove any water-soluble impurities from the lipid phase (mainly 
pyridine).  The mixture was centrifuged (3,000 ! g, 10 min, 4°C) and the top phase 
(containing lipid) was evaporated under reduced pressure and stored at -80°C prior to 
purification. 
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2.7.3.2. Purification 
 
Lipid I and II were purified using anion exchange on a DEAE-Sephacel column.  
The column was run using organic solvents to retain the lipids in a soluble phase.  
The organic nature of the solvents dictated that glassware was used to avoid 
contamination with plasticizers, which can interfere with mass spectrometric 
analysis.  The column was prepared by pouring a final volume of 3 mL DEAE-
Sephacel into a sawn-off 20 mL glass burette with glass wool acting as a fret to 
prevent the resin escaping from the column base.  The column was washed 
consecutively with 40 mL 1 M ammonium acetate (to charge the Sephacel resin with 
acetate groups), 60 mL water and 40 mL chloroform/methanol/water 2:3:1 (v/v) 
(solvent A).  The dried lipid was resuspended in 6 mL solvent A and pipetted onto 
the solvent bed and the flow-through was collected.  The column was developed with 
a step-wise gradient using four column volumes of various percentages of 
chloroform/methanol/1 M ammonium bicarbonate 2:3:1 (v/v) (solvent B) (0 %, 5 %, 
10 %, 15 %, 20 %, 25 %, 30 %, 50 % and 100 %) in solvent A.  The fractions were 
collected accordingly and analysed by thin-layer chromatography (TLC) (Section 
2.7.4).  Fractions containing the desired lipid were evaporated under reduced 
pressure, resuspended in 10 mL/fraction of sterile water and freeze-dried to remove 
the ammonium bicarbonate.  The lipid was ultimately resuspended in 1.5 mL solvent 
A and stored in a glass vial at -80°C. 
 
2.7.4. Analysis by thin layer chromatography 
 
High performance silica thin layer chromatography (HPTLC) was performed to 
separate the lipid components.  Initially, 0.5 mL of each fraction from the 
purification step (Section 2.7.3.2) was dried under reduced pressure and the samples 
were resuspended in 25 µL of chloroform/methanol/water 2:3:1 (v/v).  The samples 
were loaded onto the HPTLC plate at marked positions: 2 cm apart and 1.5 cm from 
the base of the plate.  Samples were loaded in 5 µL aliquots with air drying to 
prevent the spot size from getting too large.  The sheet was placed evenly in a tank 
containing a 1 cm depth of chloroform/methanol/water/0.88 ammonia 88:48:10:1 
(v/v) (Breukink et al., 2003).  Chromatography was carried out for 3.5 h at room 
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temperature.  The HPTLC plate was removed and the solvent front marked with 
pencil and allowed to dry before placing in a sealed tank, containing solid iodine to 
stain the sample components using iodine vapour.  The HPTLC plate was removed 
from the tank after 30 min and because iodine staining is not permanent, the image 
was recorded immediately using a flat-bed scanner attached to a computer (Appendix 
A).    
 
2.7.5. Concentration determination 
 
Two 50 µL lipid samples and 50 µL chloroform/methanol/water 2:3:1 (v/v) (acting 
as a blank) were dried down and resuspended in 50 µL 50 mM HEPES, 10 mM 
MgCl2, 30 mM KCl, 1.5 % (w/v) CHAPS, pH 7.6.  One of the lipid samples and the 
blank were treated with: 50 µL 1 M HCl, boiled for 30 min, centrifuged at 3,000 ! g 
for 5 min, and readjusted to pH 7.6.   
 
The inorganic phosphate hydrolysed from the lipids was quantified using a Pi 
detection assay (Section 2.8.1).  In a 200 µL spectrophotometric assay containing 50 
mM HEPES, pH 7.6, 10 mM MgCl2, 200 µM 7-methyl-6-thioguanosine (MESG) 
(Berry and Associates, USA), 1 unit purine nucleoside phosphorylase (PNP), 1 unit 
inorganic pyrophosphatase (IPP), a stable baseline was reached by measuring the 
absorbance at 360 nm before addition of 10 µL lipid sample.  The concentration of 
the lipid was calculated based on the knowledge that there are two Pi per molecule 
Lipid I or Lipid II and the extinction coefficient of the change in absorbance at 
A360nm by 1 M Pi is 10,000 M
-1
cm
-1
 (caused by the phosphorolysis of MESG). 
 
2.7.6. Mass spectrometry 
 
The lipid samples were analysed by Biological Mass Spectrometry and proteomics 
service (School of Life Sciences, University of Warwick).  Mass estimates were 
obtained by negative ion electrospray ionisation mass spectrometry (ESI-MS). 
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2.7.7. Preparation of [14C]-labelled Lipid II 
 
2.7.7.1. [14C]-labelled Lipid II synthesis 
 
This method was designed based on the synthesis of non-radiolabelled Lipid II and a 
method described by Bertsche et al. (2005).  The synthesis of radiolabelled Lipid II 
was performed as in Section 2.7.3.1 with minor adjustments.  The components were 
assembled in 3.5 mL, replacing UDP-GlcNAc with 100 µL 78.88 µM [
14
C]-UDP-
GlcNAc (317 mCi/mmol, supplied in 200 µL, Amersham Biosciences) providing 5 
µCi/15.78 nmol.  140 µg E. coli MurG (prepared as described by Ha et al. (1999); 
pET3a::murG construct kindly provided by S. Walker (Harvard University)) was 
used to supplement the MurG in the M. flavus membranes, enhancing the formation 
of Lipid II from Lipid I.  The reaction was incubated in a water bath at 37°C for 1 h 
to allow optimum conditions for the incorporation of the radiolabelled GlcNAc 
moiety.  Non-radiolabelled UDP-GlcNAc was added to provide a final concentration 
of 35 mM UDP-GlcNAc (radiolabelled and non-radiolabelled) and the reaction was 
incubated for a further 2 h with intermittent agitation.  The reaction was stopped and 
the lipid constituents were extracted as for non-radiolabelled Lipid II (Section 
2.7.3.1).   
 
2.7.7.2. [14C]-Lipid II purification 
 
Purification of [
14
C]-Lipid II used an identical approach to the purification of non-
radiolabelled Lipid II (Section 2.7.3.2).  The only divergence to the protocol was the 
development of the column, where fewer steps of the solvent B gradient were applied 
to minimise the amount of radioactive waste.  The solvent B gradient washes 
occurred using four column volumes as follows: 0 %, 10 %, 25 % ((v/v) of solvent B 
in solvent A).  From the Lipid II synthesis, it was apparent that all lipid contaminants 
were removed with 25 % (v/v) solvent B, and at percentages higher than this, Lipid 
II eluted. [
14
C]-Lipid II was eluted with eight column volumes of 100 % (v/v) solvent 
B to ensure no lipids were retained on the column and the overall yield of lipid was 
maximal.  The fractions were analysed for radioactivity by scintillation counting 
using a Packard Liquid Scintillation Analyser Tri-Carb 2900TR.  Radioactivity was 
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solely detected in the 100 % (v/v) solvent B fractions, which were dried under 
reduced pressure and the purified [
14
C]-Lipid II was freeze dried to remove the 
ammonium bicarbonate.  The [
14
C]-Lipid II was resuspended in 1.5 mL solvent A 
and stored in a glass vial at -80°C.  A sample was assessed by scintillation to 
determine the radioactivity of [
14
C]-Lipid II in terms of counts per minute (cpm).   
 
2.7.8. Concentration and purity determination by HPTLC 
 
To avoid contaminating equipment with radioactivity, the concentration and purity of 
[
14
C]-Lipid II were determined concomitantly using a different approach compared 
to non-radiolabelled Lipid II.  HPTLC was performed as described in Section 2.7.4.  
Standards of non-radiolabelled Lipid II with known concentrations were loaded onto 
the silica TLC plate in addition to 15 µL of [
14
C]-Lipid II.  Chromatography was 
carried out as in Section 2.7.4.  Following removal from the tank, the solvents were 
evaporated from the HPTLC plate for 1 h to ensure complete dryness.  The plate was 
then exposed to a phosphoimaging plate for 48 h.  The phosphoimaging plate was 
imaged using the Fujifilm FLA-5000 imaging system.  The HPTLC plate was stained 
using iodine vapour and immediately imaged as described in Section 2.7.4. 
 
Image Processing and Analysis in Java (ImageJ) software (Abràmoff et al., 2004) 
was used to analyse the intensity of the iodine-stained Lipid II bands, which enabled 
the quantity of [
14
C]-Lipid II to be estimated by comparing the mean grey values of 
the [
14
C]-Lipid II sample with the standards containing known amounts of Lipid II.   
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2.8. Assays to analyse transglycosylase activity 
 
2.8.1. Biochemical spectrophotometric assays 
 
This assay is based on the release of Pi due to the dephosphorylation of undecaprenyl 
pyrophosphate (a product of transglycosylation) by the coupling enzyme, 
undecaprenyl pyrophosphate phosphatase.  PNP depends on Pi to convert MESG 
(strong absorbance at 330 nm) to ribose-1-phosphate and 7-methyl-6-guanine (strong 
absorbance maximum at 360 nm), which can be measured spectrophotometrically 
(Webb, 1992).  The assay principle is outlined in Figure 4.4 and discussed in the 
accompanying text. 
 
2.8.1.1. Continuous spectrophotometric assay for the coupling enzyme 
activity 
 
The activity of E. coli PgpB, the undecaprenyl pyrophosphate phosphatase 
(characterised by Touzé et al. (2008)) was analysed using the natural substrate, 
undecaprenyl pyrophosphate (a kind gift from E. Kula-Swiezewska, Institute of 
Biochemistry and Biophysics, Poland).  The substrate was supplied in volatile 
solvents; the solvents were evaporated prior to use and the lipid was resuspended in 5 
µL 0.1 % (w/v) DDM.  The following reaction components were mixed together in a 
cuvette in a final volume of 200 µL: 20 mM Tris pH 7.5, 150 mM NaCl, 0.1 % (w/v) 
DDM (to maintain membrane proteins and lipids in a solubilised state), 1 unit PNP, 
400 µM MESG, 0-817 µM undecaprenyl pyrophosphate and up to 10 µL PgpB to a 
final concentration of 1.78 µM.  Enzyme or substrate initiated the reactions.  Assays 
were performed using a Varian Cary 100 spectrophotometer equipped with a cell 
changer at 360 nm and 37°C.  Controls of different potential lipid substrates were 
evaluated in an identical manner at final concentrations of 200 µM. 
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2.8.1.2. Discontinuous spectrophotometric assay for transglycosylation 
 
The reaction of a transglycosylase with its substrate was performed in a 
discontinuous manner, and the products were analysed using the PgpB-coupled 
spectrophotometric assay. 
 
2.8.1.2.1. Discontinous transglycosylase assays 
 
The following text describes the basic reaction conditions for transglycosylase 
activity; optimisation of these conditions is described in Chapter 4.  The 
transglycosylase reactions of S. aureus MGT and S. pneumoniae PBP1a variants 
occurred in a reaction volume of 15 µL and 18 µL respectively unless otherwise 
stated.  The solvents of the Lipid II substrate were removed by evaporation and Lipid 
II (present at concentrations between 0 and 1.47 mM) was resuspended in the 
reaction buffer: 20 mM Tris pH 8.0, 10 mM MgCl2, 0.1% (w/v) DDM by vigorous 
vortexing followed by a centrifugation, to ensure the maximum amount of Lipid II 
had solubilised.  The addition of 155 µM MGT or 77 µM PBP1a variants (unless 
otherwise stated) initiated the reaction.  The reactions of the PBP1a variants were 
immediately sonicated in a water bath at 20°C for 30 sec.  The reactions were 
performed in duplicate at 20°C over a specified time frame before heat inactivating 
the protein at 60°C for 10 min.  The reactions were centrifuged for 5 min at 10,000 ! 
g to pellet the precipitated protein.   
 
When transglycosylase activity was measured at time points, a master mix was 
prepared and 15 µL (MGT) or 18 µL (PBP1a) aliquots were sampled at given times.   
 
2.8.1.2.2. Spectrophotometric assay 
 
The components of the spectrophotometric assay are described in Section 2.8.1.1.  13 
µL and 16 µL of the MGT and PBP1a transglycosylation reactions were sampled 
from the total discontinuous reaction volume (to avoid the protein pellet) and added 
to the cuvette.  A baseline at 360 nm was obtained prior to the addition of 4.4 µM 
PgpB. 
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2.8.2. Analysis of transglycosylation products by SDS-PAGE 
 
2.8.2.1. SDS-PAGE conditions 
 
SDS-PAGE gels were prepared as described by Barrett et al. (2007) for the detection 
of glycan chains with few modifications to the protocol.  Gels were cast using the 
Hoeffer Mighty Small gel kit with a 10 mL gel recipe of 0.5 M Tris pH 8.45, 0.1 % 
(w/v) SDS, 9 % T (total percentage concentration of both acrylamide and bis-
acrylamide), 2.6 % C (percentage bis-acrylamide relative to T) and polymerised by 
the addition of 30 µL of 10 % (w/v) APS and 7.5 µL TEMED.  The samples were 
loaded with a 25 % volume of sample buffer: 120 mM Tris pH 8.8, 2 % (w/v) SDS, 
50 % (v/v) glycerol without heat denaturation.  Bromophenol blue was omitted from 
the sample buffer, as the constituents can impede the detection of transglycosylation 
products.  In a single lane, sample buffer with bromophenol blue was loaded to 
monitor migration.  Gels were run in anode buffer (0.1 M Tris, pH 8.8) and cathode 
buffer (0.1 M Tris, 0.1 M Tricine, 0.1 % (w/v) SDS, pH 8.25) at 100 V for 1 h.   
 
2.8.2.2. Detection of glycan chains separated by SDS-PAGE 
 
2.8.2.2.1. [14C]-Lipid II detection 
 
Transglycosylase reactions were performed as described in Section 2.8.1.2.1 
replacing non-radiolabelled Lipid II with its radioactive counterpart.  A higher 
concentration of the [
14
C]-Lipid II was used to ensure a signal could be detected (as 
stated in the corresponding text), dependent on the specific activity of [
14
C]-Lipid II.  
The transglycosylation reactions were quenched by heat-denaturation and the 
precipitated protein was removed by centrifugation prior to sample preparation.  Gels 
were prepared and run according to Section 2.8.2.1. 
 
Gels were dried for 3 h using a BioRad Model 583 gel drier before being exposed to 
a phosphoimaging plate for 14 days.  Phosphoimaging plates were imaged using the 
Fujifilm FLA-5000 imaging system.   
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2.8.2.2.2. VanFL detection 
 
Transglycosylase reactions were performed as described in Section 2.8.1.2.1 using 2 
mM Lipid II substrate.  The reactions were stopped by heat denaturation and the 
precipitated material was removed by centrifugation.  VanFL was added at a final 
concentration of 24 µM to the reactions, which were incubated in the dark (to reduce 
fluorescence quenching) for 5 min, prior to loading onto the gel.  Gels were prepared 
and run according to Section 2.8.2.1 in the dark.  VanFL fluorescence was detected 
using Syngene GeneSnap G:Box Gel Doc and analysis system with the blue light 
converter with appropriate filter for detecting VanFL-specific fluorescence (emission 
maximum, 512 nm).  
 
2.9. Assays to analyse D-Ala release  
 
2.9.1. Continuous spectrophotometric assay for D-Ala release 
 
2.9.1.1.  VanA-coupled assay 
 
The basis of this assay is the VanA-dependent ligation of D-Lac and D-Ala (released 
from transpeptidation or D,D-carboxypeptidation reactions) with the concomitant 
hydrolysis of ATP producing ADP and Pi, both of which can be detected 
spectrophotometrically (outlined in Figure 5.5a and discussed in the accompanying 
text).   
 
2.9.1.1.1.  Detection of ADP 
 
ADP is linked to NADH oxidation by the coupling enzyme pyruvate kinase and 
lactate dehydrogenase (as described by Wampler and Westhead (1968)).  The 
following components were mixed together in a cuvette with a final volume of      
200 µL: 50 mM HEPES pH 7.6, 10 mM MgCl2, 20 µM VanA, 100 mM D-Lac, 1 
mM ATP, 2 mM PEP, 100 µM NADH, 1.6 units pyruvate kinase, 2.4 units lactate 
dehydrogenase, 0-4 mM UDP-MurNAc-L-Ala-'-D-Glu-L-Lys-D-Ala-D-Ala.  The 
reaction was monitored at 340 nm at 37°C using the Varian Cary 100 
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spectrophotometer.  A baseline was obtained before the addition of 35 nM 
Actinomadura R39 D,D-peptidase, which initiated the reactions. 
 
2.9.1.1.2.  Detection of Pi 
 
Pi was monitored by the phosphorolysis of MESG as described in Section 2.8.1.  The 
following components were mixed together in a cuvette with the final volume of 200 
µL: 50 mM HEPES pH 7.6, 10 mM MgCl2, 20 µM VanA, 100 mM D-Lac, 1 mM 
ATP, 1 unit PNP, 400 µM MESG, 0-320 µM UDP-MurNAc-L-Ala-'-D-Glu-meso-
DAP-D-Ala-D-Ala.  The reaction was monitored at 360 nm at 37°C and initiated by 
the addition of 35 nM Actinomadura R39 D,D-peptidase. 
 
2.9.2. Discontinuous spectrophotometric assay for D-Ala release 
 
The VanA coupled assay was not sufficiently sensitive to detect D-Ala release from 
S. pneumoniae PBPs under investigation, thus the Amplex Red assay was employed 
(assay principle outlined in Figure 5.5b).     
 
2.9.2.1.  Discontinuous D-Ala release assay 
 
The D-Ala release assays of S. pneumoniae PBP1a, PBP2b and PBP2x variants took 
place in 30 µL.  The solvents were evaporated from Lipid II, which was thoroughly 
resuspended in 20 mM Tris pH 8.0, 1 mM MgCl2, 0.1 % (w/v) DDM, 22 mM Decyl 
PEG, 20 % (v/v) DMSO, giving a final concentration of 0.33 mM Lipid II.  In 
reactions requiring a polymerised form of Lipid II, 120 µM MGT or 45 µM PBP1a-
S370A were incubated with Lipid II for 1 h at 20°C, and remained present during the 
D-Ala release reactions.  45 µM of each PBP was added to individual reactions and 
incubated for 18 h at 20°C.  Proteins were inactivated by heat denaturation at 60°C 
for 10 min and the precipitated protein was removed by centrifugation at 10,000 ! g 
for 10 min.   
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2.9.2.2.  Spectrophotometric assay 
 
The following components were mixed together in a cuvette with a final reaction 
volume of 200 µL: 50 mM HEPES pH 7.6, 10 mM MgCl2, 0.1 % (w/v) DDM, 0.75 
units D-amino acid oxidase (DAAO), 2.5 units horseradish peroxidase, 50 µM 
Amplex Red reagent.  Addition of 20 µL of the 30 µL discontinued reaction initiated 
the detection of D-Ala, measured at 555 nm, 37°C.  Assays were performed in a 
Varian Cary 100 spectrophotometer.   
 
2.9.3. Analysis of transpeptidase or D,D-carboxypeptidase products by 
SDS-PAGE 
 
Transpeptidation or D,D-carboxypeptidation reactions were performed in a similar 
manner as described in Section 2.9.2.1 (omitting Decyl PEG and DMSO) in a total 
volume of 18 µL with 2 mM Lipid II.  In reactions requiring a glycan chain 
substrate, 155 µM MGT was initially incubated with Lipid II.  77 µM S. pneumoniae 
PBP variants were added to initiate the reactions with Lipid II, which were incubated 
at 20°C for 3 h.  Enzymes were heat-inactivated and the precipitated protein was 
removed by centrifugation.  The reaction products were incubated with 24 µM 
VanFL and separated by SDS-PAGE according to Section 2.8.2.1.  VanFL 
fluorescence was detected as detailed in Section 2.8.2.2.2. 
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2.10. Protein crystallisation 
 
2.10.1. Vapour diffusion crystallisation method 
 
In order for a protein to crystallise, internal changes to a system are required to cause 
the protein to exceed its limit of solubility, resulting in a transition from a 
thermodynamically stable state to an unstable supersaturated state.  This can be 
achieved by adjusting the parameters of a system including composition of the 
aqueous protein solution (precipitants or additives); pH; temperature.  It is during 
supersaturation where the protein can form intermolecular contacts, spontaneously 
generating either crystal nuclei or amorphous precipitate.  Following nucleation, 
crystal growth can proceed, sequestering protein from the surrounding solution.   
 
Vapour diffusion is the conventional method for altering the precipitant 
concentration and bringing the protein into a supersaturated state.  The sitting drop 
and hanging drop methods of vapour diffusion were used in this work and are 
explained diagrammatically with the corresponding phase diagram in Figure 2.3. 
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Figure 2.3: Crystallisation by vapour diffusion.  (a) A cross-section of the experimental set-up of 
vapour diffusion methods.  An unsaturated protein solution containing precipitant ‘sitting’ in a well 
((i) sitting drop) or suspended over the precipitant reservoir ((ii) hanging drop).  The [protein] 
increases as vapour equilibration between the droplet and reservoir occurs, bringing the protein into a 
supersaturated state.  (b) Phase diagram of vapour diffusion.  Vapour diffusion results in the trajectory 
of the protein solution from an unsaturated to a supersaturated state.  Nucleation and crystal growth 
occur in the supersaturated zone but require distinct conditions: high (labile) and low (metastable) 
supersaturated states respectively.  Nucleation does not occur if the supersaturated state is too low 
(metastable zone) or too high (precipitation zone, which leads to the formation of precipitate).  
Following nucleation in the labile zone, the protein will be sequestered as the crystal grows, returning 
the solution to the metastable zone.  The black arrow indicates the ideal strategy for crystal growth. 
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2.10.2. Sparse matrix screens 
 
Sparse matrix screens have been developed with a bias towards conditions that have 
successfully generated protein crystals with an emphasis on either soluble or 
transmembrane proteins.  The screens are used as a starting point when studying a 
protein that has not been previously crystallised.  Soluble protein sparse matrix 
screens utilised include: Wizard I screen (Emerald Biosciences); Newcastle I screen 
(University of Newcastle); Clear Strategy I screen (Molecular Dimensions); Index 
screen (Hampton Research); JCSG-plus (Molecular Dimensions) and PACT-premier 
(Molecular Dimensions).  Transmembrane protein sparse matrix screens include: 
MemStart (Molecular Dimensions), MemSys (Molecular Dimensions) and MemGold 
(Molecular Dimensions).  The Honeybee 963 crystallisation robot (Digilab) was used 
as an automated facility to set up the crystallisation screens in a sitting-drop format 
in 96-well Greiner plates or 96-well MRC plates, using a volume of 100 µL 
precipitant per reservoir.  The sitting drops consisted of 200 nL protein mixed with 
200 nL precipitant and the trials were carried out at 18°C unless otherwise stated. 
 
2.10.3. Optimisation screening 
 
2.10.3.1.  In-house screen development 
 
Following an indication of a successful crystal nucleation and growth in a sparse 
matrix condition, the reproducibility of the crystals and improvements in crystal 
quality were pursued by traversing the initial condition across buffer pH, precipitant 
concentrations, protein concentrations and protein to precipitant ratio.  Crystal 
screens were set-up using the hanging drop method of vapour diffusion in a 24-well 
plate, with 1 mL precipitant solution in the reservoir and total droplet size of 2 µL 
(containing protein and precipitant).  The trials were carried out at 18°C.   
 
2.10.3.2.  Additive screen 
 
The Additive screen (Hampton Research) is a library of small molecules introduced 
into crystallisation screens to manipulate the conditions.  The crystallisation trials 
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were performed according to the manufacturer’s instructions in a 96-well plate using 
the sitting drop vapour diffusion method.  The trials were carried out at 18°C. 
 
2.10.3.3.   Silver Bullet screen 
 
The Silver Bullet screen (Hampton Research) contains small molecules that have 
been documented to promote crystal lattice formation.  The crystallisation trials were 
performed according to the manufacturer’s instructions using the sitting drop vapour 
diffusion method in a 96-well plate.  The trials were carried out at 18°C. 
 
2.10.4. Cryoprotection 
 
The X-ray exposure to protein crystals can cause secondary radiation damage within 
the crystal lattice, where free radicals are generated at room temperature (Garman 
and Doublié, 2003).  To minimise this effect and to preserve the life of the crystal, 
data collection was carried out at 100°K in a nitrogen vapour stream, allowing better 
quality data to be obtained at a higher resolution.  Cryoprotectants were employed 
during the freezing of the crystal to allow the formation of vitreous ice as opposed to 
crystalline ice, by reducing the water molecules in contact with each other, thus 
avoiding disruption of the crystal lattice.  In this work, 20-30 % (v/v) glycerol was 
used as a cryoprotectant.  Crystals were mounted with rayon fibre tubes of 0.05-0.3 
mm, held within the loop by surface tension.  Crystals were transferred to 5 µL drop 
of mother liquor containing cryoprotectant (replacing the appropriate volume of 
water).  In the cryoprotectant of 30 % (v/v) glycerol, crystals were soaked in a three-
step gradient.  The loop was plunged into liquid nitrogen to freeze the crystal.  
Frozen crystals were stored in a Taylor Wharton dewar.    
 
2.10.5. Data collection 
 
Preliminary diffraction data was obtained using the in-house X-ray facility.  
Complete data sets were collected at the Diamond Lightsource Radiation Facility 
(UK) on the I24 microfocus beamline using a Pilatus 6M solid state detector with an 
oscillation angle of 0.2° and a crystal to detector distance of 416 mm. 
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Chapter 3. Cloning, expression and purification of 
Streptococcus pneumoniae PBP1a, PBP2b and PBP2x 
 
3.1. Introduction 
 
The penicillin-binding proteins of S. pneumoniae have been subjected to intense 
investigation with regards to their role in !-lactam resistance.  Of the six PBPs from 
S. pneumoniae, PBP1a, PBP2b and PBP2x are regarded as the major resistance 
determinants (as described in Section 1.10.3).  In resistant clinical isolates (such as S. 
pneumoniae 5204), these enzymes are found to be genetically altered; certain 
mutations are integral to the resistance mechanism and confer a reduced affinity of 
the PBP for !-lactam antibiotics (Zapun et al., 2008).   
 
3.1.1. S. pneumoniae D39 and 5204 strains 
 
The work in this Chapter focuses on PBPs from two different strains of S. 
pneumoniae: D39 and 5204.  S. pneumoniae D39 is a penicillin-susceptible strain 
and is the progenitor of S. pneumoniae R6 (Williams et al., 2007), which is a 
common standard used in comparative experiments of !-lactam sensitive and 
resistant strains (examples are included in Chesnel et al. (2005), Contreras-Martel et 
al. (2009) and Job et al. (2008)).  There are no deviations at the nucleotide level of 
the pbp genes between the D39 and R6 strain as identified by sequence comparisons. 
S. pneumoniae 5204 was first isolated from sputum in 1999 in Grenoble, France 
(Chesnel et al., 2003).  It is highly resistant to !-lactam antibiotics: penicillin G MIC 
is 6.0 µg/ml; cefotaxime MIC is 12 µg/ml (Chesnel et al., 2005).  Given these high 
MICs, the 5204 strain can be used as a credible reference for low affinity PBPs.    
 
3.1.2. Generation of PBPs with a low affinity for !-lactam antibiotics 
 
The S. pneumoniae pbps of penicillin-sensitive isolates are genetically uniform 
(Dowson, et al., 1989).  However, the pbps from penicillin-resistant isolates exhibit 
diverse genetic alterations, which develop either through a series of step-wise 
spontaneous point mutations (Grebe and Hakenbeck, 1996) or by recombination 
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events between homologous pbp genes of S. pneumoniae and related species 
(Dowson et al., 1989; 1990).  The pbp1a, pbp2b and pbp2x genes from penicillin-
resistant pneumococci contain sequence blocks that are identical in the homologous 
genes of at least two streptococcal species (Dowson et al., 1989; Laible et al., 1991; 
Martin et al., 1992).  Thus, these processes can generate highly mosaic pbp genes.  
For example, the sequence of pbp2b from a penicillin-resistant strain of S. 
pneumoniae (DN87/557) was found to contain blocks of nucleotides that diverged 
from the S. pneumoniae R6 sequence by up to 21 % (Dowson et al., 1990). Genes 
conferring low affinity for the antibiotic can be disseminated by horizontal gene 
transfer.  Evidence for this process is provided by the >99.6 % nucleotide sequence 
identity of PBP2b between penicillin-resistant strains of S. pneumoniae and S. oralis, 
whereas sequences of PBP2b between penicillin-susceptible strains diverge by ~20 
% (Coffey et al., 1993).  The resulting amino acid substitutions have a higher 
occurrence in the transpeptidase domain (exemplified in Table 3.1), indicating that 
the antibiotic pressure promotes genetic rearrangement in the antimicrobial target 
region (Sanbongi et al., 2004).  Only a restricted set of the substitutions are 
important in the !-lactam resistance mechanism (Chesnel et al., 2003).  
 
Enzyme 
Total number 
of amino acid 
substitutions 
Number of amino acid 
substitutions specific to the 
transpeptidase domain 
Reference 
PBP1a 48 45 Job et al. (2008) 
PBP2b 58 44 
Contreras-Martel et al. 
(2009), Pagliero et al. 
(2004) 
PBP2x 80 41 Chesnel et al. (2003) 
Table 3.1: Amino acid substitutions in the major resistance determinants of S. pneumoniae 5204.   
 
3.1.3. Mutations of the S. pneumoniae resistance determinants 
implicated in !-lactam resistance  
 
The following section discusses important mutations that are relevant in the !-lactam 
resistance mechanism of S. pneumoniae PBP1a, PBP2b and PBP2x.   
 
3.1.3.1. PBP2x 
 
PBP2x is normally the first PBP to be modified under the selection pressure of !-
lactam antibiotics (Grebe and Hakenbeck, 1996).  The sequences of PBP2x from 
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clinical strains are normally categorised into three groups.  The first includes 
sequences that are comparable to the !-lactam sensitive reference, S. pneumoniae 
R6.  The other two groups represent PBP2x sequences from !-lactam resistant stains 
and are classified according to the presence of either T338A or Q552E mutation 
(Chesnel et al., 2003).  The different substitutions confer a reduced susceptibility of 
PBP2x for !-lactam antibiotics via two independent mechanisms, which are not 
necessarily mutually exclusive (Carapito et al., 2006).  S. pneumoniae 5204 PBP2x is 
a member of the T338A family of resistant protein sequences (Carapito et al., 2006).  
Out of the numerous amino acid substitutions in S. pneumoniae 5204 PBP2x, only 
six have been shown to be essential for high levels of resistance (Carapito et al., 
2006).  The individual roles of the mutations are described in Table 3.2. 
 
Amino acid 
substitution 
Role in the !-lactam resistance mechanism Reference 
Q552E The substitution indroduces a negative charge at the 
entrance to the active site, disfavouring the binding 
of the negatively charged !-lactam. 
Mouz et 
al. (1999)  
T338A Located in the first conserved motif, the substitution 
reduces the acylation efficiency of the catalytic 
serine.  It has been implemented in the loss of a water 
molecule, which results in the destabilisation of the 
active site. 
Mouz et 
al. (1998)  
M339F The substitution in conjunction with T338A, causes 
the distortion of the active site, causing the 
reorientation of the active site serine hydroxyl group. 
Chesnel et 
al. (2003) 
M400T The substitution potentiates the effect of the M339F 
mutation. 
Carapito et 
al. (2006) 
I371T and 
R384G 
Co-operation between the two mutations is believed 
to increase the flexibility of the loop in which they 
are situated, remodelling the active site and 
consequently weakening the non-covalent 
interactions with the antibiotic and potentially 
affecting the reactivity of the catalytic serine. 
Carapito et 
al. (2006) 
N605T The substitution directly impacts the acylation 
efficiency of the catalytic serine by destabilising a 
hydrogen bond network.  The loss of a hydrogen 
bond could participate in the disruption of a loop that 
borders the active site. 
Carapito et 
al. (2006) 
Table 3.2: The roles of the essential amino acid substitutions in S. pneumoniae 5204 PBP2x 
implemented in high levels of !-lactam resistance.  Although it is not found in the sequence of S. 
pneumoniae 5204 PBP2x, the role of the Q552E substitution is described as it is an important 
mutation in other resistant sequences of PBP2x.  
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Carapito et al. (2006) found that reversion of the six amino acid substitutions in 
PBP2x (strain 5204) back to the original amino acids of the !-lactam sensitive 
sequence caused the acylation efficiency for the !-lactam to increase by 1000-fold.  
However, if the converse mutations were made to !-lactam sensitive sequence of 
PBP2x, the acylation efficiency decreases by only 100-fold, an order of magnitude 
lower.  This discrepancy is believed to result from the cooperativity of additional 
uncharacterised mutations that collectively impact the level of resistance. 
 
3.1.3.2. PBP2b 
 
PBP2b has not been subjected to such a vigorous investigation unlike PBP2x.  This 
is presumably due to the difficulties in obtaining X-ray crystal structural information 
of truncated forms of PBP2b (Zapun et al., 2008).  The T446A mutation is prominent 
in all identified !-lactam resistant sequences and lies downstream of the SSN 
conserved motif.  It is believed to directly affect the affinity of antibiotics, although 
its effect is propagated by other uncharacterised substitutions (Pagliero et al., 2004).  
Applying this mutation to the S. pneumoniae R6 sequence decreases the affinity of 
PBP2b for penicillin G by 60 %.  Other substitutions including E476G and T489S/A 
are frequently found in the PBP2b sequences of highly resistant strains, although 
their roles have not been thoroughly investigated (Pagliero et al., 2004).   
 
3.1.3.3. PBP1a 
 
PBP1a is clinically important due to its essential requirement for the development of 
high levels of !-lactam resistance.  A common substitution found in sequences of 
resistant strains is T371A, which lies adjacent to the catalytic serine (Smith and 
Klugman, 1998).  This mutation results in the loss of a hydrogen bond, which 
normally forms between T371 and W368, and causes the catalytic serine to change 
its orientation (Job et al., 2008).  Similar blocks of mutations have been identified in 
the PBP1a sequences from !-lactam resistant clinical isolates; in the majority of drug 
resistant strains, NTGY replaces the TSQF sequence at positions 574-577 (Job et al., 
2008; Smith and Klugman, 1998).  This sequence is situated in a loop that borders 
the active site.  The substituted residues are proposed to increase the local 
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hydrophilicity, which can interfere with the antibiotic recognition.  Substituting 
NTGY into the PBP1a sequence from the R6 strain causes the acylation efficiency 
for penicillin G to decrease 49-fold (Job et al., 2008).  
 
3.1.4. PBPs to be investigated in this study 
 
The major resistance determinants of S. pneumoniae strains D39 and 5204 are the 
focal point of this thesis.  The key objective is to obtain a greater understanding of 
these PBPs in terms of their natural enzymology and the complex !-lactam resistance 
mechanisms they impart.  This chapter discusses the cloning, expression and 
purification of PBP1a, PBP2b and PBP2x, which is a prerequisite for future 
biochemical and structural characterisations.   
 
3.2. Experimental Aims 
 
• To clone the major !-lactam resistance determinants of S. pneumoniae, 
pbp1a, pbp2b and pbp2x, from the penicillin-sensitive strain, D39, and the 
penicillin-resistant strain, 5204, into an appropriate vector for expression in 
E. coli 
 
• To clone S. pneumoniae D39 pbp1a, pbp2b and pbp2x, devoid of the 
cytoplasmic and membrane domains, into an appropriate vector for 
expression in E. coli 
 
• To create single desired mutations in the active site domains of the S. 
pneumoniae D39 Class A, PBP1a, and Class B, PBP2b and PBP2x, 
eliminating transglycosylase or transpeptidase activity 
 
• To optimise the expression conditions of the S. pneumoniae PBP variants in 
E. coli, providing the highest level of protein expression with the lowest level 
of degradation 
 
• To optimise the solubilisation and purification conditions of each S. 
pneumoniae PBP variant, obtaining suitable quantities for prospective kinetic 
and structural characterisations 
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3.3. The cloning of PBP1a, PBP2b and PBP2x variants from S. 
pneumoniae strains D39 and 5204 as N-terminal dodeca-
histidine fusion proteins 
 
There are many challenges associated with the study of integral membrane proteins; 
difficulties in obtaining adequate quantities of homogenous, monodisperse protein 
impedes biochemical and structural analysis.  Consequently, two cloning strategies 
were adopted for S. pneumoniae pbp1a, pbp2b and pbp2x: cloning of the full-length 
genes and the corresponding genes devoid of the sequence encoding the membrane-
spanning region.  Thus, if the study of the full-length forms proved problematic, the 
more readily soluble counterpart could be analysed.  Additionally, these constructs 
would allow the role of the membrane-spanning region to be investigated, which is 
proposed to be involved in protein stability, PBP association with proteins, lipids, or 
substrate or the localisation of the enzyme within a cell (Potluri et al., 2010; Sung et 
al., 2009).   
 
3.3.1. Prediction of the transmembrane domain region 
 
S. pneumoniae PBP1a, PBP2b and PBP2x are integral membrane proteins.  The 
PBPs are translated with a short N-terminal cytoplasmic sequence that is connected 
by a hydrophobic segment to the bulk of the polypeptide (comprising the catalytic 
domains) residing on the extracellular face of the cytoplasmic membrane.  This 
hydrophobic sequence functions as a non-cleavable secretion signal, enabling the 
translocation of the C-terminal of the protein across the cytoplasmic membrane.  It 
also acts as a stop transfer sequence, forming a single #-helical membrane anchor 
(Ghuysen, 1991).  It has been well documented that removal of the hydrophobic 
stretch can lead to a soluble protein (Di Guilmi et al., 2003a; Di Guilmi et al., 1998; 
Pagliero et al., 2004). 
 
The TransMembrane Hidden Markov Model (TMHMM) (Krogh et al., 2001), a 
programme designed to predict the topology of membrane proteins, was used to 
locate the exact position of the N-terminal transmembrane domain of each PBP 
under investigation (Table 3.3).  Using this specialised model, various factors 
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(including the length of transmembrane helices, location of helical caps (cytoplasmic 
or non-cytoplasmic), identification of regions close to the membrane, globular 
domains and cytoplasmic and non-cytoplasmic regions) can be estimated with 97-98 
% accuracy, constraining the possible topologies and increasing the reliability of the 
transmembrane domain prediction (Krogh et al., 2001).   
 
To design the truncated PBP constructs, the N-terminal amino acid residues 
encompassing the predicted transmembrane domain and cytoplasmic sequences 
needed to be eliminated.  The lengths of the desired amino acid truncations are 
documented in Table 3.3.  The corresponding codons were eliminated from the gene 
sequence during the primer design (Section 3.3.2) to create the truncated constructs 
during the cloning procedure.   
 
Sequence length comprising each domain S. pneumoniae 
PBP Cytoplasmic Transmembrane Extracellular 
Length of 
truncation 
PBP1a 0-12 13-30 31-719 %30 
PBP2b 0-20 21-39 40-685 %39 
PBP2x 0-28 29-48 49-750 %48 
 
Table 3.3: S. pneumoniae PBP domain prediction and length of required truncation.  The 
sequence length of each domain was predicted using TMHMM.  The number of N-terminal amino 
acid residues required to eliminate the transmembrane region is denoted by ‘%’.  The truncated 
constructs were designed on this basis.  
 
3.3.2. Primer design 
 
The S. pneumoniae pbps were cloned into the expression vector pET46 Ek/LIC 
(vector map displayed in Figure 2.1).  The vector encodes a hexa-histidine tag, which 
yields an N-terminal fusion upon protein translation, a desirable property for future 
protein purification considerations.  The N-terminal fusion tag should not interfere 
with the enzyme activity, being located far from the catalytic sites.   
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3.3.2.1. Primer design with an engineered dodeca-histidine fusion tag 
 
The primers for the PCR were designed according to the Ek/LIC cloning system, 
following the manufacturer’s instructions (Section 2.3.8, Figure 2.2).  A sequence of 
nucleotides specific to the cloning procedure was incorporated 5’ and 3’ to the insert 
specific sequences of the sense and antisense primers respectively.  An Nde I site and 
codons for six histidine residues were additionally integrated into the sense primer 
directly 5’ to the insert specific sequence (Table 3.4).  Upon expression of the fusion 
protein, the vector and primer-encoded six histidine residues would be in close 
proximity (separated by a short sequence of amino acid residues), essentially creating 
a dodeca-histidine tag (proposed to aid protein purification) (Figure 3.1).  The Nde I 
restriction site was incorporated as a precaution, in case an alternative cloning 
method was required.  The start codon, ATG, was eliminated from the gene-specific 
sequence, due to its presence in the Nde I site.  The stop codon, TAA, remained in 
the gene-specific sequence of the antisense primer to terminate translation.   
 
3.3.2.2. Sequences of primers for the pET46 Ek/LIC cloning 
 
The sense and antisense primers for the ligation independent cloning (LIC) of S. 
pneumoniae PBP variants into the pET46 vector are recorded in Table 3.4.  It is 
noteworthy that the full-length S. pneumoniae 5204 pbp2b and pbp2x gene sequences 
are unknown; the sequences at the 5’ ends (and thus N-termini of the proteins) were 
undefined.  The 3’ sequences of S. pneumoniae 5204 pbp1a, pbp2b and pbp2x are 
known, thus the insert specific sequences of the antisense primers were designed 
accordingly.  The S. pneumoniae 5204 pbp1a gene sequence directly at the 5’ end 
does not differ from that of the D39 strain, permitting identical sense primers to be 
employed.  It was therefore assumed that S. pneumoniae 5204 pbp2b and pbp2x gene 
sequences at the 5’ ends also do not differ from those of the D39 strain, allowing 
sense primers to be designed (identical to the sense primers of the strain D39 PBPs).  
The 5’ ends of the gene sequences from the penicillin-resistant strain are unlikely to 
deviate from the penicillin-sensitive strain as they encode residues located distant to 
the transpeptidase domain, which is subject to antibiotic selection pressures.  Any 
disregarded amino acid changes at the N-terminal would be unlikely to affect the 
resistance mechanism of the S. pneumoniae 5204 PBP or impede its activity. 
 101 
S. pneumoniae 
pbp gene target 
Description of 
primer 
Primer sequence (5’-3’ orientation) 
Sense primer (FL) GAC GAC GAC AAG ATG CAT ATG CAC CAT CAC CAT CAC CAT AAC AAA CCA ACG ATT CTG CGC C 
Sense primer         
(-TM, !30) 
GAC GAC GAC AAG ATG CAT ATG CAC CAT CAC CAT CAC CAT GTT TTT TTC TAC TAC GTT AGC AAG D39 pbp1a 
Antisense primer GAG GAG AAG CCC GGT TTA TGG TTG TGC TGG TTG AGG ATT C 
Sense primer (FL) GAC GAC GAC AAG ATG CAT ATG CAC CAT CAC CAT CAC CAT AAC AAA CCA ACG ATT CTG CGC C 
5204 pbp1a 
Antisense primer GAG GAG AAG CCC GGT TTA TGG TTG TGC TGG TTG AGG ATT C 
Sense primer (FL) 
GAC GAC GAC AAG ATG CAT ATG CAC CAT CAC CAT CAC CAT AGA CTG ATT TGT ATG AGA AAA TTT 
AAC AGC 
Sense primer         
(-TM, !39) 
GAC GAC GAC AAG ATG CAT ATG CAC CAT CAC CAT CAC CAT CAG GTT TTG AAC AAG GAT TTT TAC 
G 
D39 pbp2b 
Antisense primer GAG GAG AAG CCC GGT CTA ATT CAT TGG ATG GTA TTT TTG ATA CAG 
Sense primer (FL) 
GAC GAC GAC AAG ATG CAT ATG CAC CAT CAC CAT CAC CAT AGA CTG ATT TGT ATG AGA AAA TTT 
AAC AGC 5204 pbp2b 
Antisense primer GAG GAG AAG CCC GGT CTA ATT CAT TGG ATG GTG TTG G 
Sense primer (FL) GAC GAC GAC AAG ATG CAT ATG CAC CAT CAC CAT CAC CAT AAG TGG ACA AAA AGA GTA ATC CG 
Sense primer       
(-TM, !48) 
GAC GAC GAC AAG ATG CAT ATG CAC CAT CAC CAT CAC CAT GGG ACA GGC ACT CGC TTT GGA 
ACA G 
D39 pbp2x 
Antisense primer GAG GAG AAG CCC GGT TTA GTC TCC TAA AGT TAA TGT AAT TTT TTT AAT G 
Sense primer (FL) GAC GAC GAC AAG ATG CAT ATG CAC CAT CAC CAT CAC CAT AAG TGG ACA AAA AGA GTA ATC CG 
5204 pbp2x 
Antisense primer GAG GAG AAG CCC GGT TTA GTC TCC TAA AGT TAA TTT AAT TTT TTT AAT G 
 
Table 3.4: The primers required to amplify different variants of pbp1a, pbp2b and pbp2x for cloning into the pET46 vector.  The regions in bold, black type indicate 
the nucleotides that are a cloning-specific requirement as dictated in the manufacturer’s instructions.  The sequence GAC GAC GAC AAG ATG encodes the enterokinase 
cleavage site that is incorporated at the 5’ terminal of the gene sequence.  The bold, red type represents the Nde I restriction enzyme cleavage site.  The bold, blue type shows 
the engineered codons for the extra six histidine residues.  The plain text shows the 5’ or 3’ gene specific sequences, essential for annealing during the PCR.  FL, full-length 
sequence; -TM, sequence devoid of the transmembrane and cytoplasmic region, where the length of protein truncation is denoted.   
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The ATG codon, required for the functionality of the protein enterokinase restriction 
site, and the DNA Nde I site, were assumed not to act as start codons; a vector-
specific ATG codon, locating 5’ to the vector-encoded histidine tag, fulfilled this 
role, being in close proximity to the vector ribosomal binding site.  Following protein 
expression, a recombinant protein would be produced as illustrated in Figure 3.1. 
 
 
 
 
 
 
Figure 3.1: Domain organisation of the recombinant proteins.  The recombinant protein contains 
an N-terminal vector-encoded cleavable six histidine tag (6His1), separated from a primer-encoded 
non-cleavable six histidine tag (6His2) (not anticipated to interfere with enzyme activity) by a short 
sequence of amino acids encompassing an enterokinase cleavage site (Ek) and the amino acids 
encoded by the Nde I site (histidine and methionine).  The locations of the start (ATG) and stop 
(TAA) codons are indicated.  N, amino-terminus; C, carboxy-terminus.   
 
3.3.3. Polymerase chain reaction  
 
The genes pbp1a, pbp2b and pbp2x (with and without transmembrane domains) were 
amplified by PCR from S. pneumoniae D39 genomic DNA using specific 
oligonucleotide primers (Table 3.4) and AccuPrime Taq High Fidelity polymerase, 
as described in Section 2.3.3.  The annealing stage of the PCR was performed over a 
temperature gradient (45.1, 47.3, 54.4, 59.7 and 65.2°C).  The PCR products were 
analysed on a 0.8 % (w/v) agarose gel (Section 2.3.7) to establish the occurrence of 
gene amplification. 
 
The PCR-dependent amplification of S. pneumoniae 5204 pbp1a, pbp2b and pbp2x 
from genomic DNA was performed by A. Zapun (Institut de Biologie Structurale, 
Grenoble) using the primers in Table 3.4. 
 
6His1 Ek 6His2 
Nde I 
site 
Protein sequence 
ATG TAA 
H M 
Vector 
encoded 
Primer 
encoded 
N C 
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The PCR products corresponding to the correct gene size were combined and 
purified using the Wizard PCR purification system (Section 2.3.5) to remove 
remnants of the PCR that could interfere with the imminent cloning procedure.   
 
3.3.4. Ligation independent cloning 
 
Ligation independent cloning was performed as described in Section 2.3.8, allowing 
the directional insertion of the PCR product and eliminating the requirement of 
restriction enzyme digestions and ligation reactions.  In brief, complimentary 
overhangs were generated in the vector and PCR product due to the 3’-5’ 
exonuclease activity of T4 DNA polymerase (Aslanidis and de Jong, 1990).  
Annealing of the compatible overhangs enabled the PCR product to be integrated 
into the vector.  Transformation into competent E. coli NovaBlue GigaSingles cells 
allowed the covalent bond formation at the vector-insert junction, creating a 
circularised plasmid.  Following an overnight culture of positive transformants, 
plasmid DNA was extracted (Section 2.3.6) for future analytical procedures. 
 
3.3.5. Verification of the construct 
 
3.3.5.1. Diagnostic restriction digest 
 
Plasmid constructs were analysed to ensure the correct insert sequence was 
integrated into the vector.  Single, double and triple diagnostic DNA restriction 
digests were performed using various restriction enzymes, which were chosen based 
on the location of the restriction site within the gene sequence.  The digested DNA 
fragments were analysed on a 0.8 % (w/v) agarose gel, displayed in Figure 3.2. 
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Figure 3.2: 0.8 % (w/v) agarose gel of the diagnostic restriction digests.  (a) Restriction digests of pbp1a variants.  Full length S. pneumoniae D39 pbp1a has a size of 
2169 bp, containing two restriction sites for Hind III.  (b) Restriction digests of pbp2b variants.  Full length S. pneumoniae D39 pbp2b has a size of 2040 bp, containing one 
restriction site for Xba I.  (c) Restriction digests of pbp2x variants.  Full length S. pneumoniae D39 pbp2x has a size of 2253 bp, containing one restriction site for EcoR V.  
The constructs all contain a single Nde I site, integrated into the sequence through the primer design, and a single vector encoded Xba I and Xho I site located on opposite 
sides of the multiple cloning site.  The DNA ladder (bp), constructs and restriction enzymes employed are displayed on the figure.  Linearised pET26b vector (with Xba I), 
highly similar in size to pET46, was used as a vector size comparison.  (*), incompletely digested DNA. 
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The expected size DNA fragments from the restriction digests provided evidence that 
the correct pbp gene inserts were present in the constructs.  The restriction digest was 
not used to analyse the plasmid constructs containing S. pneumoniae 5204 pbp2b and 
pbp2x because the full gene sequences (and hence the number of restriction sites for 
a particular restriction enzyme) were unknown.  Instead, a diagnostic PCR with Taq 
DNA polymerise was performed using the oligonucleotides specific to the 5’ and 3’ 
sites of the multiple cloning region of the pET46 vector (T7 promoter and pET46 
terminator, Table 2.2).  Analysis of the PCR products on an agarose gel showed the 
expected gene size had been amplified, and thus the correct gene had been inserted 
into the vector.   
 
3.3.5.2. Sequencing 
 
Constructs that contained the correct sized gene inserts (identified from the 
diagnostic restriction digests and PCR) were sequenced using the T7 promoter and 
pET46 terminator oligonucleotides (as described in Section 2.3.9) to ensure the 
sequences did not deviate from the original genomic sequence.  Additional 
oligonucleotides were required to sequence the entire genes, shown in Table 3.5. 
 
Name of primer Region sequenced 
Primer sequence (5’-3’ 
orientation) 
pbp1a 5’ middle 
The middle section of pbp1a 
towards the 5’ end. 
GGG GGA TTG ATA CCA 
TCC G 
pbp1a 3’ middle 
The middle section of pbp1a 
towards the 3’ end. 
GCC CAA GAC CGC CGA 
AAC TTG G 
pbp2b 5’ middle 
The middle section of pbp2b 
towards the 5’ end. 
GGC TTT CCA AGA TAG 
CGT GGA TGC 
pbp2b 3’ middle 
The middle section of pbp2b 
towards the 3’ end. 
GGA AAC TTT GCG ACA 
GGA ACC ATT GC 
pbp2x 5’ middle 
The middle section of pbp2x 
towards the 5’ end. 
GGA AGC TGC AGA GGT 
CAA GGG G 
pbp2x 3’ middle 
The middle section of pbp2x 
towards the 3’ end. 
GAT GCC ACG ATT CGA 
GAT TGG GAC G 
Table 3.5: Additional primers used to sequence the middle regions of the pbp genes.  The region 
of the gene sequenced by using each oligo is specified along with the nucleotide sequence. 
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3.3.6. Site-directed mutagenesis 
 
For future analytical purposes, it was desirable to create mutations within the active 
site of the PBP transglycosylase domain or transpeptidase domain, to essentially 
eliminate the activity.  This can be achieved by replacing catalytic residues with 
amino acid residues that do not have complimentary properties for catalysis.  It has 
been established that a glutamate residue, present in the first conserved motif of the 
transglycosylase domain, is essential for transglycosylation as documented for: E. 
coli PBP1b (Terrak et al., 1999), S. pneumoniae PBP1b (Liu and Wong, 2006), S. 
aureus MGT (Terrak and Nguyen-Distèche, 2006) and A. aeolicus PBP1a (Barrett et 
al., 2007).  It was decided to substitute the conserved glutamate residue of the 
transglycosylase domain with glutamine, effectively replacing the carboxyl group 
proposed to deprotonate Lipid II with an amide, which is unable to perform the 
equivalent catalytic role.  The catalytic serine residue, present in the first conserved 
motif of the transpeptidase domain, forms a covalent intermediate with the 
penultimate D-Ala residue of the Lipid II pentapeptide during transpeptidation or 
D,D-carboxypeptidation (Frère et al., 1976; Yocum et al., 1979).  An inert residue, 
alanine, was chosen to replace the transpeptidase active site serine residue, having no 
side chains with charged residues that could affect the topology of the active site. 
 
Site-directed mutagenesis was performed on pET46 constructs containing S. 
pneumoniae D39 pbp1a, pbp2b and pbp2x using the Stratagene QuikChange II kit, 
following the procedures recommended by the manufacturer (Section 2.3.10).  
Primers for the mutagenic PCR (Table 3.6) were designed to introduce a single, 
specified mutation, where the positions of the codons encoding the crucial catalytic 
residues were identified by locating the conserved sequences within the polypeptide 
chain and the gene sequence counterpart.   
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Target Mutation Primer sequence (5’-3’ orientation) 
S: CAAACCGCGACTGGGGAGCAACTATGAAACCGATC PBP1a 
Ser370 
Ser to Ala 
AS: GATCGGTTTCATAGTTGCTCCCCAGTCGCGGTTTG 
S: GTTAAGGCAATCGTTTCTATCCAAGACCATCGCTTCTTCGAC PBP1a 
Glu91 
Glu to Gln 
AS: GTCGAAGAAGCGATGGTCTTGGATAGAAACGATTGCCTTAAC 
S: GTCTTTGTTCCAGGTGCGGTTGTCAAGGCG PBP2b 
Ser391 
Ser to Ala 
AS: CGCCTTGACAACCGCACCTGGAACAAAGAC 
S: GTAACTATGAGCCAGGTGCCACTATGAAAGTGATG PBP2x 
Ser337 
Ser to Ala 
AS: CATCACTTTCATAGTGGCACCTGGCTCATAGTTAC 
Table 3.6: Primer sequences for site-directed mutagenesis of the S. pneumoniae pbps.  The 
oligonucleotide sequences for mutagenesis of the target amino acid residue are shown.  The red type 
identifies the site-directed mutation, which is embedded within the bold type, highlighting the codon 
of the target amino acid residue to be mutated.  S, sense primer; AS, antisense primer. 
 
Following PCR, the parental non-mutated plasmid DNA was digested by Dpn I 
treatment (selective for methylated and hemimethylated DNA) and the products were 
analysed on a 0.8 % (w/v) agarose gel as shown in Figure 3.3.   
 
Figure 3.3: 0.8 % (w/v) agarose gel of amplified plasmid DNA following site-directed 
mutagenesis.  Lanes contain pET46::pbp constructs amplified with mutagenic primers (shown by 
arrows) and are labelled according to the mutated gene insert. DNA ladder, 1 kb. 
 
Given the small quantity of parental plasmid DNA used in the mutagenic PCR, the 
intense bands on the agarose gel were expected to be amplified DNA containing the 
desired mutation.  The PCR products were transformed into competent E. coli Top10 
10,000 
8,000 
6,000 
5,000 
4,000 
3,500 
3,000 
2,500 
2,000 
1,500 
 
1,000 
 
 
750 
 
500 
 
 
250 
DNA 
ladder 
pbp1a-
S370A 
pbp2x-
S337A 
pbp1a-
E91Q 
pbp2b-
S391A 
DNA 
ladder 
 108 
cells (to circularise the nicked plasmid), and following an overnight culture, the 
plasmid was extracted and sequenced, confirming the presence of the designed 
mutation.   
 
3.3.7. Final constructs generated 
 
The nomenclature and domain architecture of the constructs generated from cloning 
and site-directed mutagenesis are depicted in Figure 3.4 and displayed in Table 2.4.  
From this point forward, PBPs derived from S. pneumoniae are assumed to be from 
strain D39 unless otherwise denoted (S. pneumoniae 5204, PBP-5204). 
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Figure 3.4 (continues on subsequent page): The constructs generated and domain architecture of S. pneumoniae PBP variants.  (a) Nomenclature of constructs and 
equivalent proteins.  (b) Molecular weight of the recombinant proteins.  (c) Protein domain architecture corresponding to the proteins described in (a).  The histidine tag is 
located on the N-terminal of each recombinant protein.  Amino acid residues at the start and end of each domain are numbered accordingly and the residues of the first 
conserved transglycosylase motif (PBP1a only) and the three conserved transpeptidase motifs are highlighted. 
 
 
Construct generated/Protein name  
 
 
 
 
 
pET46::pbp1a/PBP1a 
 
pET46::pbp1a-S370A/PBP1a-S370A 
 
pET46::pbp1a-E91Q/PBP1a-E91Q 
 
pET46::pbp1a-5204/PBP1a-5204 
 
 
 
pET46::pbp1a-!30/PBP1a-!30 
 
 
Molecular 
weight 
 
 
 
 
 
 
 
 
79.7 kDa 
 
 
 
 
 
 
76.5 kDa 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TM 
Non penicillin-binding 
domain:   
transglycosylase domain 
Penicillin-binding domain:   
transpeptidase domain 
(a) (b) (c) 
30 13 222 54 332  622 1 719 
C N  E91DHRFFDH S370TMK   S428RN K557TG 
192  24 302  592 1 689 
C N  E61DHRFFDH S340TMK   S398RN K527TG 
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TM 
Non penicillin-binding 
domain: putative 
dimerisation domain 
Penicillin-binding domain:   
transpeptidase domain 
39 21 297 63 
 
349  675 1 685 
C N  S391VVK   S448SN K620TG  
258  24 310  636 1 646 
C N  S352VVK   S409SN K547TG  
48 29 249 71 289  609 1 750 
C N  S337TMK   S395SN K557SG  
201  23 241  561 1 702 
C N  S289TMK   S347SN K509SG  
 
 
Construct generated/Protein name  
 
 
 
 
 
pET46::pbp2b/PBP2b 
 
pET46::pbp2b-S391A/PBP2b-S391A 
 
pET46::pbp2b-5204/PBP2b-5204 
 
 
 
pET46::pbp2b-!39/PBP2b-!39 
 
 
 
 
 
pET46::pbp2x/PBP2x 
 
pET46::pbp2x-S337A/PBP2x-S337A 
 
pET46::pbp2x-5204/PBP2x-5204 
 
 
 
pET46::pbp2x-!48/PBP2x-!48 
 
 
Molecular 
weight 
 
 
 
 
 
 
 
74.4 kDa 
 
 
 
 
 
69.8 kDa 
 
 
 
 
 
 
 
 
 
 
82.2 kDa 
 
 
 
 
 
76.7 kDa 
 
 
 
 
 
 
 
 
 
 
 
(a) (b) (c) 
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3.4. The expression of S. pneumoniae PBP1a, PBP2b and PBP2x 
variants as N-terminal dodeca-histidine fusion proteins 
 
3.4.1. Establishing an optimal expression system for PBP1a, PBP2b 
and PBP2x 
 
The expressions of PBP1a, PBP2b and PBP2x as full-length proteins were evaluated 
under a large number of conditions to establish a system that provided optimum 
levels of protein expression in the membrane fraction of cells with minimal 
aggregation and degradation.  In brief, expression trials were performed in 100 mL 
cultures (containing the appropriate antibiotic selection) inoculated with 200 µL 
uninduced cells from an overnight culture and protein over-expression was induced 
by either IPTG or autoinduction (Section 2.4.1).  A crude membrane preparation was 
prepared using water-lysis (described in Section 2.5.2) and proteins expressed in the 
cytoplasmic and membrane fractions of the cells were analysed by SDS-PAGE 
(Section 2.6.2) and Western blots (Section 2.6.3).  Different E. coli expression cell 
lines, induction methods and induction temperatures were investigated and the 
results are summarised in Table 3.7. 
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Detectable protein 
expression 
E. coli 
expression 
system 
Induction 
temperature 
(°C) 
Induction 
method 
PBP1a PBP2b PBP2x 
0.5 mM IPTG    
12 
Autoinduction    
0.5 mM IPTG    
C41 (DE3) 
25 
Autoinduction    
0.5 mM IPTG    
C41 (DE3) pRIL 12 
Autoinduction    
0.5 mM IPTG    C41 (DE3) 
pRARE 
12 
Autoinduction    
0.5 mM IPTG    
C43 (DE3) 12 
Autoinduction    
0.5 mM IPTG    
C43 (DE3) pRIL 12 
Autoinduction    
0.5 mM IPTG    C43 (DE3) 
pRARE 
12 
Autoinduction    
12    BL21 Star 
(DE3) pRosetta 25 
Autoinduction 
   
Table 3.7: Expression levels of full-length PBP1a, PBP2b and PBP2x under different conditions.  
Detectable protein expression was classified as a band on a Western Blot of correct molecular weight 
size: !, no detectable protein expression; !, detectable expression at varying low levels (faint, thin 
bands on the blot); ! substantial expression levels (large, intense bands on the blot). IPTG induction, 
cells were cultured at 37°C until OD600nm reached 0.5, where they were transferred to and induced at 
the temperature stated; autoinduction, cells were cultured and induced at the stated temperature.   
 
Substantial expression of the full-length membrane proteins was achieved in BL21 
Star (DE3) pRosetta cells under autoinduction at 25°C, where the expression levels 
were great enough to distinguish target protein expression from E. coli host proteins 
on an SDS-PAGE gel. 
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3.4.2. Expression of S. pneumoniae 5204 PBPs and the active site 
mutants of S. pneumoniae D39 
 
Given the high sequence similarity of S. pneumoniae D39 PBPs with the 
corresponding transpeptidase and transglycosylase active site mutant and the S. 
pneumoniae 5204 PBPs, it was anticipated that the established expression conditions 
for the former proteins could be used to yield similar levels of expression of the latter 
recombinant proteins.  The different constructs were transformed into BL21 Star 
(DE3) pRosetta and ultimately the protein was expressed using autoinduction at 
25°C.  The membrane fraction was extracted from the E. coli host cells and 
expression levels were analysed by SDS-PAGE, Figure 3.5. 
 
Figure 3.5: A 12 % SDS-PAGE Coomassie-stained gel of the membrane fractions of E. coli cells 
expressing S. pneumoniae D39 PBP active site mutants and S. pneumoniae 5204 PBPs.  (a) S. 
pneumoniae D39 PBPs with a single point mutation in the catalytic sites of the transglycosylase or 
transpeptidase domains.  (b) S. pneumoniae 5204 PBPs.  Mr, molecular weight markers (kDa).  The 
arrows signify the presence of the over-expressed recombinant proteins. 
 
The expression levels of the membrane proteins are efficiently high, enabling the 
recombinant proteins to be distinguished from the E. coli host proteins by SDS-
PAGE.  Thus, the requirement of the highly sensitive Western blot to detect low 
levels of protein expression was eliminated. 
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3.4.3. Expression and cellular localisation of PBPs devoid of 
transmembrane domains 
 
The expressions of PBP1a-!30, PBP2b-!39 and PBP2x-!48 were performed using 
the established optimum conditions for the full-length counterparts (Section 3.4.1) 
with a similar success.  On the basis that PBPs have hydrophobic regions on the 
protein surface that associate or are in close proximity with the membrane, the sub-
cellular localisations of the truncated proteins (devoid of the membrane anchor) were 
determined. 
 
The membrane fractions of induced E. coli host cells were extracted following the 
protocol outlined in Section 2.5.3.  The pellet following 24,000 ! g centrifugation 
step represented the insoluble fraction of the cells, containing cellular debris, 
aggregated protein, inclusion bodies and large pieces of membranes that were not 
completely fragmented upon cell disruption.  E. coli membranes were pelleted during 
the 150,000 ! g centrifugation step, where the supernatant contained the soluble, 
cytoplasmic proteins.  The protein content of the fractions was analysed by SDS-
PAGE, Figure 3.6. 
 
Figure 3.6: SDS-PAGE analysis of the cellular localisations of PBP1a-!30, PBP2b-!39 and 
PBP2x-!48.  The lanes are labelled according to the cellular fraction: IS, insoluble fraction; S, 
soluble cytoplasmic fraction; M, membrane fraction.  The protein was visualised by Coomassie 
staining.  Mr, molecular weight markers (kDa).  Arrows show the position of the over-expressed 
protein. 
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Expression of each PBP truncate was detected in the insoluble and membrane 
fractions of the cells, due to protein aggregation or inclusion body formation and 
association with the membrane (despite the absence of the membrane anchor) 
respectively.  PBP1a-!30 was poorly expressed in the soluble fraction of the cells.  
Conversely, soluble forms of PBP2b-!39 and PBP2x-!48 expressed to high levels in 
the cytoplasmic fractions. 
 
3.5. Purification of the PBP variants as integral membrane 
proteins 
 
3.5.1. Detergent solubilisation of membrane proteins 
 
A prerequisite to purification is the isolation of the integral membrane proteins from 
the membrane by the use of detergents.  Detergents interact with proteins and 
surrounding lipid membranes as micelles.  Micelles, formed by a process of 
micellisation (thermodynamically driven association of non-polar groups in an 
aqueous environment), are dynamic structures, exhibiting rapid exchange of 
detergent monomers within a micelle and solution (Wennerström and Lindman, 
1979).  Solubilisation of membrane proteins is initiated by the penetration of 
detergent monomers into a lipid bilayer.  The bilayer becomes destabilised forming 
lipid-detergent mixed fragments.  Further integration of detergent causes bilayer 
dissolution and the protein becomes surrounded by a lipid-detergent monolayer (le 
Maire et al., 2000). 
 
A solubilisation screen of the PBPs (full-length and devoid of the transmembrane 
domain) was performed (Section 2.5.4) using a variety of detergents (Table 3.8) with 
differing properties to establish the ideal conditions that provided the greatest 
solubilisation efficiency of the specific proteins.  
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Detergent Type CMC (% (w/v)) 
Triton X-100 Non-ionic 0.01-0.02 (v/v) 
n-Dodecyl-"-D-maltopyranoside (DDM) Non-ionic 0.01 
N-lauroyl sarcosine Ionic (anionic) 0.42* 
Sodium deoxycholate Ionic (anionic) 0.08-0.25 
3-[(3-Cholamidopropyl)dimethylammonio]-1- 
propanesulfonate (CHAPS) 
Zwitterionic 0.49 
Lauryldimethylamine oxide (LDAO) Zwitterionic 0.02 
Table 3.8: Detergents used in the solubilisation trials.  The percentage CMC of each detergent is 
shown (data taken from Anatrace-Affymetrix and (*) Sigma-Aldrich).   
 
In short, membranes were solubilised in 1 % (w/v) detergent (given this percentage is 
significantly (at least 2-3 times) greater than the critical micellar concentration 
(CMC), enabling micelles to form) for 1 h, the insoluble material pelleted and the 
protein content in solution and the insoluble pellet was analysed by Western blot.  
The solubilisation trial of PBP1a is shown in Figure 3.7. 
 
Figure 3.7: Western blot of PBP1a detergent solubilisation trial.  The detergents used in the 
solubilisation of PBP1a are labelled above the corresponding lanes.  The total solubilised PBP cannot 
be quantified.  Equivalent amounts of protein were loaded into each lane of the SDS-PAGE gel prior 
to the Western blot, thus the size of the target protein bands are comparable.  The protein was detected 
by probing with antibodies and ECL reagents.  Mr, molecular weight markers (kDa).  IM, insoluble 
membrane proteins; SM, solubilised membrane proteins.   
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Analogous to PBP1a, the detergent providing the greatest level of protein 
solubilisation for each PBP was sodium deoxycholate.  It was therefore assumed that 
this detergent would have a similar successful solubilisation efficiency towards the 
active site mutants and PBPs-5204.  This analysis does not give an indication of the 
stability of the proteins in the detergent micelle.  However, sodium deoxycholate, a 
bile acid salt, is a mild ionic detergent having minimal deactivating properties in 
comparison to linear chain detergents (Seddon et al., 2004).  A large quantity of PBP 
remained insoluble after 1 h.  Longer incubation periods could rectify this, but the 
stability of the protein could be jeopardised, where it has been found that long 
periods of solubilisation promote protein degradation and aggregation.   
 
3.5.2. Affinity chromatography 
 
The preliminary technique to purify the full-length PBPs was immobilised metal 
affinity chromatography (IMAC), which exploits the reversible high affinity of 
histidine tags of fusion proteins for specific divalent metal ions, most commonly 
cobalt or nickel ions.   
 
3.5.2.1. Experimental design for the general IMAC purification of 
membrane proteins 
 
The solubilisation and IMAC purification of the full-length PBPs is described in 
Section 2.5.5.2.  Briefly, E. coli membranes in PBS containing over-expressed target 
proteins were solubilised in 1 % (w/v) sodium deoxycholate for 3 h (a compromise 
between optimum protein solubilisation and minimal protein aggregation).  Sodium 
deoxycholate, although an effective emulsifier, exhibits unfavourable properties, 
causing buffer solutions to become highly viscous in the presence of high salt 
concentrations (from previous observations and also documented by Murata et al. 
(1982)).  Therefore, following solubilisation, the insoluble membranes were pelleted 
by centrifugation at 150,000 ! g for 30 min, concomitantly with gradual detergent 
exchange from sodium deoxycholate to 0.1 % (w/v) DDM (by addition of buffer 
containing the latter and not the former detergent).  DDM, a universally used 
detergent in membrane protein purification, has mild, non-denaturing properties, 
maintaining proteins in a biologically active form (Privé, 2007).  This detergent is 
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regularly used during the successful growth of membrane protein crystals, indicating 
that it does not disrupt protein structure (Privé, 2007).  The supernatant, containing 
solubilised proteins, was incubated for 3 h with 5 mL cobalt-chelated sepharose resin 
pre-equilibrated in the purification buffer (PBS, 0.1 % (w/v) DDM with additional 
150 mM NaCl) with stirring at 4°C.  Earlier evaluations established that histidine-
tagged protein affinity with the IMAC resin reached an equilibrium after an 
incubation of 2-3 h, where longer incubation periods promoted protein aggregation 
without an increase in resin binding.  The protein-resin mix was poured to form a 
column and the column was developed.  Fractions from the different stages of 
purification were collected and analysed by SDS-PAGE.  An example of PBP1a 
purification by IMAC is displayed in Figure 3.8. 
 
 
Figure 3.8: A 12 % SDS-PAGE Coomassie-stained gel of PBP1a purification by IMAC.  Mr, 
molecular weight markers (kDa); TM, total membrane fraction; IM, insoluble membrane proteins 
following detergent treatment; SM, detergent-solubilised membrane proteins incubated with cobalt 
resin; FT, flow through; 15 mM, 100 mL buffer with 15 mM imidazole; 50 mM and 250 mM, 
consecutive fractions from 50 mL buffer with 50 mM and 250 mM imidazole.  The arrow shows the 
position of the target protein. 
 
Protein fractions containing the highest level of target protein purity were combined 
and concentrated for future purification techniques. 
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3.5.2.2. Optimisation of IMAC to improve the level of purity of PBP2b and 
PBP2x and S. pneumoniae 5204 PBPs 
 
PBP1a and its active site mutant counterparts, purified to a high level following the 
generalised method of IMAC.  However, the wild-type and transpeptidase active site 
mutants of PBP2b and PBP2x and the PBPs-5204 co-purified with a higher level of 
E. coli host protein contaminants.  A variety of parameters were addressed to 
alleviate this problem: buffer constituents (salt concentration, non-specific ionic 
interactions; glycerol, hydrophobic interactions; pH, protein surface charge); 
concentration of imidazole wash steps; incubation period of protein with cobalt resin; 
micelle disruption (reducing the detergent concentration to below the CMC (0.003 % 
(w/v) DDM)) in the presence of 5 mM imidazole following protein binding to the 
column). 
 
The greatest improvement of target protein purity was achieved by introducing an 
extensive column wash step of buffer containing 20 mM imidazole (replacing 15 
mM imidazole), causing a higher degree of non-specifically bound contaminants to 
elute (final level of purity shown in Figure 3.11).  The level of purity subsequently 
obtained was suitable for the next purification technique.   
 
3.5.3. Size exclusion chromatography 
 
Following IMAC purification, the full-length PBP variants were subjected to size 
exclusion chromatography to endeavour to purify the target protein further and to 
separate aggregated and non-aggregated protein.  The protein was injected onto the 
analytical Superose 6 10/300 GL gel filtration column pre-equilibrated in 20 mM 
Tris pH 7.5, 150 mM NaCl, 0.03 % (w/v) DDM.  The lower detergent concentration 
(just above the CMC) enabled the removal of excess micelles devoid of protein that 
could interfere with future structural analyses (Chapter 6).  The chromatogram trace 
for the purification of PBP1a is displayed in Figure 3.9. 
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Figure 3.9: Chromatogram of PBP1a from size exclusion chromatography using a Superose 6 
10/300 GL column. 
 
3.5.4. Protein storage conditions and degradation analysis  
 
The storage conditions of the proteins are essential to maintain the enzyme in a 
stable, functionally active state.  Three conditions were trialled for the storage of 
PBP1a: gel filtration buffer (20 mM Tris pH 7.5, 150 mM NaCl, 0.03% (w/v) DDM) 
4°C; gel filtration buffer with 50 % (v/v) glycerol, -20°C; gel filtration buffer with 50 
% (v/v) glycerol, -80°C.  After a five day storage, the protein samples were analysed 
for degradation by SDS-PAGE and a Western blot, shown in Figure 3.10.   
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Figure 3.10: Degradation analysis of PBP1a in different storage conditions. (a) 12 % SDS-PAGE 
Coomassie-stained gel.  (b) Western blot (protein probed with antibodies and ECL reagents).  Equal 
amounts of protein were loaded into each lane (20 µg).  Lanes are labelled with the storage conditions 
trialled.  Mr, molecular weight markers (kDa); B, buffer: 20 mM Tris pH 7.5, 150 mM NaCl, 0.03% 
(w/v) DDM; G, 50 % (v/v) glycerol.  Arrows indicate the position of PBP1a on the gel and blot.   
 
The Western blot identifies that there was no observable degradation of PBP1a from 
the C-terminus in any of the storage conditions trialled.  Exopeptidase degradation 
from the N-terminus could not be established using this method, where the 
antibodies employed were specific for the N-terminal histidine tag.  Antibodies 
specific to the target protein would solve this dilemma. 
 
Purified proteins were stored in 20 mM Tris pH 7.5, 150 mM NaCl, 0.03% (w/v) 
DDM, 50 % (v/v) glycerol, -20°C.  Storage at  -20°C minimises the loss of enzyme 
activity compared to higher (4°C) and lower (-80°C) temperatures (as observed from 
activity assays (Chapters 4 and 5).  The inclusion of 50 % (v/v) glycerol enhances the 
stability of proteins by reducing conformational freedom and prevents the protein 
solution from freezing at the selected temperature, eliminating the production of ice 
crystals, which can disrupt the structural and functional integrity of the enzyme. 
 
3.5.5. Final levels of purity of all full-length PBP variants 
 
The integral membrane proteins were extracted from the membranes and purified by 
IMAC and size exclusion chromatography under near-identical procedures; specific 
proteins required minor adaptations from the generic protocol (as discussed).  The 
final level of purity of each full-length PBP variant is exhibited in Figure 3.11. 
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Figure 3.11: SDS-PAGE Coomassie-stained gels of the final level of purity and protein yield of each full-length PBP under investigation.  Lanes are labelled with the 
corresponding PBP and are grouped according to the bacterial origin of the protein sequence.  Protein yield refers to the total amount of purified target protein extracted from 
1 L E. coli culture.  Mr, molecular weight markers (kDa). 
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3.6. Purification of PBPs devoid of the membrane anchor 
 
Due to the cellular localisation of PBP1a-!30, PBP2b-!39 and PBP2x-!48 over-
expression (established in Section 3.4.3), two different purification strategies were 
required.  PBP1a-!30, poorly expressed in the soluble fraction, was detected in the 
membrane fraction of the cells (though to a lesser extent compared to its full-length 
counterpart).  Thus, PBP1a-!30 was treated analogously to the full-length membrane 
proteins throughout purification.  PBP2b-!39 and PBP2x-!48 were substantially 
over-expressed in the soluble and membrane fractions of the cells.  Proteins locating 
to the former cellular fraction were selected for purification, where it was 
advantageous to work in the absence of detergent.    
 
3.6.1. Purification of PBP1a-!30 
 
It was anticipated that PBP1a-!30 could require a detergent for solubilisation as 
documented for a number of PBPs devoid of the membrane anchor, including S. 
pneumoniae PBP2a (Di Guilmi et al., 1999).  It has been identified through structural 
studies that bifunctional PBPs have a membrane interaction site, distinct from the 
transmembrane anchor, enabling partial submersion of the transglycosylase domain 
into the lipid bilayer, which is believed to allow access to the Lipid II substrate 
(Lovering et al., 2007; Sung et al., 2009). 
 
PBP1a-!30 was purified by IMAC and size exclusion chromatography in an 
identical approach to the purification of the full-length equivalent.  The final level of 
purity is demonstrated on the SDS-PAGE gel in Figure 3.13.  The overall yield of 
purified protein was significantly lower compared to the other full-length and 
truncated PBPs studied.  This is a consequence of the initial low levels of expression 
(illustrated in Figure 3.6). 
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3.6.2. Purification of PBP2b-!39 and PBP2x-!48 
 
High levels of PBP2b-!39 and PBP2x-!48 expression in the cytoplasmic fraction of 
the cells allowed the enzymes to be treated as stable, soluble proteins, alleviating the 
need for detergents.  The soluble cellular fractions were prepared (Section 2.4.2.1) 
and the target proteins were purified by IMAC (Figure 3.12a) (Section 2.4.3.1), 
followed by size exclusion chromatography (Figure 3.12b) (Section 2.4.3.2) and 
anion exchange chromatography (Figure 3.12c) (Section 2.4.3.3).  Fractions were 
analysed by SDS-PAGE and those containing the highest level of target protein 
purity were selected for future analyses.   
 
 
 
Figure 3.12: Summary of the techniques employed for the purification of PBP2b-!39 and 
PBP2x-!48. (a) 12 % SDS-PAGE Coomassie-stained gel following IMAC.  Mr, molecular weight 
markers (kDa); S, soluble cell extract before loading onto the IMAC column; FT, flow through; 15 
mM, 50 mM and 250 mM, buffer washes containing the corresponding concentrations of imidazole.  
(b) Chromatogram from size exclusion chromatography (Superdex 200 26/60 column; 20 mM Tris pH 
7.5, 150 mM NaCl). (c) Chromatogram from anion exchange chromatography (MonoQ HR 5/5 
column; 20 mM Tris pH 7.5).  Absorbance at 280 nm (
____
); Conductivity (mS/cm) (
____
).  (i) denotes 
PBP2b-!39 or PBP2x-!48 elution on Figures (b) and (c). 
(c) 
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3.6.3. Final levels of purity of PBP1a-!30, PBP2b-!39 and PBP2x-!48 
 
The final levels of purity of the PBPs devoid of the transmembrane (and 
cytoplasmic) domain are demonstrated in SDS-PAGE gels in Figure 3.13, achieved 
by the different purification techniques as described in the above sections.   
 
 
 
 
 
 
Figure 3.13: SDS-PAGE Coomassie-stained gels showing the purity and protein yield of the 
truncated PBPs after purification.  (a) PBP1a-!30: expressed in the membrane fraction of cells; 
detergent-extracted from membranes; purified by IMAC and size exclusion chromatography in the 
presence of detergent.  (b) PBP2b-!39 and (c) PBP2x-!48: expressed as soluble proteins in the 
cytoplasmic fraction of cells; purified by IMAC, size exclusion chromatography and anion exchange 
chromatography.  Protein yield refers to the total amount of purified target protein extracted from 1 L 
E. coli culture.  Mr, molecular weight markers (kDa). 
 
3.7. Binding of fluorescent-labelled penicillin to PBPs 
 
The commercially available BOCILLIN FL is a fluorescent-labelled penicillin.  The 
penicillin moiety binds to the penicillin-binding domain of PBPs via a covalent bond 
with the catalytic serine residue, labelling PBPs with a fluorophore.  This is an 
established sensitive technique to detect PBPs (Zhao et al., 1999) and can be used to 
 Protein yield (mg)  0.5-0.8  30-40  30-40 
97.0 
 
66.0 
 
 
 
45.0 
 
 
 
 
31.0 
 
 
 
 
20.1 
 
 
97.0 
 
66.0 
 
 
45.0 
 
 
 
 
31.0 
 
 
 
 
20.1 
 
 
 
Mr Mr Mr 
97.0 
 
66.0 
 
 
45.0 
 
 
 
 
 
31.0 
 
 
 
 
20.1 
 
 
PBP1a-
!30 
PBP2b-
!39 
PBP2x-
!48 
S. pneumoniae D39 
(a) (b) (c) 
 126 
assess the native conformation of the penicillin-binding domain.  PBPs were 
incubated with BOCILLIN FL (3:1 molar ratio) at 37°C for 1 h (in the dark to 
preserve the integrity of the fluorescent label).  The binding of BOCILLIN FL to the 
PBPs was analysed by SDS-PAGE.  Figure 3.14 shows the Coomassie-stained SDS-
PAGE gels and the BOCILLIN FL specific fluorescence.  Fluorescence was detected 
prior to staining. 
 
 
Figure 3.14: BOCILLIN FL, a labelling reagent for the detection of PBPs.  (a) A 12 % SDS-
PAGE Coomassie-stained gel of the PBP variants incubated with BOCILLIN FL.  (b) BOCILLIN FL-
specific fluorescence (identified by arrows) of the equivalent SDS-PAGE gel of (a).  Lanes are 
labelled according to the PBP denominations, and are grouped depending on the protein origin (S. 
pneumoniae D39 or 5204).  Mr, molecular weight markers (kDa).  Fluorescence was detected using 
the Syngene GeneSnap G:Box Gel Doc with the blue light converter and filter for detecting 
BOCILLIN FL emission at 520 nm.  (a) shows the non-specific protein staining by Colloidal-
Coomassie, highlighting contaminating proteins, whereas (b) shows BOCILLIN FL fluorescence, 
specific to PBP binding, signifying protein degradation or the presence of contaminating host PBPs.  
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The BOCILLIN FL-specific fluorescent bands on the SDS-PAGE gel of Figure 
3.14b are in corresponding positions to the Colloidal-Coomassie-stained protein, 
indicating the labelling of the PBPs with BOCILLIN FL.  In order for this to occur, 
the transpeptidase active sites must be in at least a near-native conformation, 
enabling the correct positioning of the active site serine for attack of the "-lactam 
scissile bond.  Information regarding the structural integrity of the bifunctional PBP 
transglycosylase domain cannot be established using this technique.  The S. 
pneumoniae D39 PBPs, full-length and truncated, are able to bind BOCILLIN FL, 
indicating the truncation did not interfere with the conformation of the transpeptidase 
domain.  The transpeptidase active site serine mutants were unable to bind 
BOCILLIN FL as expected, although the effect of the mutation on the penicillin-
binding domain architecture cannot be analysed.  S. pneumoniae PBPs from clinical 
resistant isolates can bind "-lactam antibiotics (example in Pagliero et al. (2004)) 
and Figure 3.14 demonstrates that the PBPs from the S. pneumoniae penicillin-
resistant strain 5204 were capable of binding BOCILLIN FL.  In principle, their 
affinity for BOCILLIN FL would be lower in comparison to the PBPs derived from 
the penicillin-sensitive strain, thus the intensity of the fluorescent signal would be 
lower.  This is not evident on Figure 3.14b where the exposure conditions were 
adjusted to optimise the visualisation of the BOCILLIN FL-protein bands. 
 
3.8. Discussion  
 
The work presented in this Chapter details strategies to produce quantities of PBP 
variants for future biochemical characterisations.  The following section discusses 
the results in terms of the successes, providing the rational behind the techniques 
employed.  Areas for improvement are highlighted and strategies to solve problems 
encountered are described.   
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3.8.1. Cloning and expression of PBP variants 
 
3.8.1.1. Constructs generated 
 
Varying constructs of S. pneumoniae pbp1a, pbp2b and pbp2x were cloned into the 
pET46 vector and specified site-directed mutants were generated.  Codons for six 
histidine residues were integrated onto the 5’ terminal of the target gene sequence, 
additional to those encoded by the vector sequence.  Upon expression, a recombinant 
protein with an N-terminal dodeca-histidine tag was produced.  The additional 
histidine residues were proposed to allow the tag to clearly protrude from the 
detergent micelle and to augment the binding affinity to the affinity chromatography 
resin, enhancing the yield and level of purity of the low abundant membrane 
proteins.  Construction of a cleavage site between the target protein and the 
engineered histidine residues is a future consideration; biochemical analyses could be 
impeded by the presence of the histidine tag, where only the vector-encoded 
sequence was removable via an enterokinase cleavage site.  
 
3.8.1.2. Expression conditions 
 
Optimal expression conditions were established for S. pneumoniae PBP1a, PBP2b 
and PBP2x.  The enzymes were expressed substantially in E. coli BL21 Star (DE3) 
pRosetta cells under autoinduction at 25°C.  These conditions were evaluated for the 
over-expression of the remaining PBP variants, yielding a similar degree of success 
(with the exception of PBP1a-!30).  The over-expression of integral membrane 
proteins often results in toxicity due to the overloading of secretory machinery 
(which targets the protein to the membrane) in conjunction with the insertion of 
unnaturally large quantities of typically low abundant proteins into the membrane.  
Cells were cultured and induced at a low temperature, reducing basal levels of 
expression and maximising the efficiency of protein insertion into the membrane.   
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3.8.1.3. Protein stability estimations 
 
Expression levels of PBP1a-!30 were lower than the full-length counterpart.  This 
was unexpected and prompted an exploration into PBP1a-!30 stability.  The PBP1a 
protein sequence was analysed using Regional Order Neural Network software 
(RONN, Yang et al. (2005)), which provides an image of predicted natively 
disordered regions in proteins (Figure 3.15).  The position of truncation was not 
located in a region of disorder at the N-terminal (predicted disorder, residues 40-78). 
 
 
Figure 3.15: Probability of disorder for PBP1a.  RONN software was used to predict regions of 
disorder in PBP1a.  The first region of disorder is between amino acid residues 40-78.   
 
Different lengths of sequence truncation from the N-terminal could provide a more 
stable protein devoid of the membrane anchor ensuring the transglycosylase domain 
is not impacted upon (residues 54-222).  RONN analysis predicted a large region of 
disorder at the C-terminal of the protein; truncation of the terminal 69 residues could 
improve protein stability.  Prior to future truncations, disorder of the protein 
sequence should be addressed by RONN analysis.   
 
3.8.1.4. Molecular weight predictions of membrane proteins by SDS-PAGE 
 
SDS-PAGE and Western blot analysis underestimated the molecular weight of the 
recombinant proteins.  Due to the hydrophobic properties, membrane proteins bind a 
different ratio of SDS and travel through the gels at different rates during 
electrophoresis compared to soluble proteins.  Thus, it has been documented that the 
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molecular masses of integral membrane proteins can be underestimated by 30-35 % 
(Henderson et al., 2000) explaining the discrepancy between the true size of the 
protein and that predicted by SDS-PAGE.  
 
3.8.2. Detergent solubilisation trials of membrane proteins 
 
A solubilisation screen was performed to identify a detergent that isolated the target 
protein from the membranes with optimum efficiency.  The screen was limited by the 
inability to detect detergent-imposed protein aggregation.  Separation of a partially 
purified protein by size exclusion chromatography using a calibrated column would 
identify protein elution in the void volume (exceeding the exclusion limit), indicative 
of protein aggregation.  This would allow the detergent to be selected on the basis of 
solubilisation efficiency and the ability to maintain protein integrity.   
 
3.8.2.1. SMALPs: a novel technique for membrane protein solubilisation 
 
Detergent solubilisation often renders the membrane protein in a functionally 
inactive state by: promoting protein aggregation and precipitation; removing 
essential natively-associating lipids; co-concentrating detergent micelles; affecting 
enzyme activity and native interactions.  A novel technique provides a solution to 
many of these issues: Styrene Maleic Acid copolymer Lipid Polymer (SMALP) 
technology (structure shown in Figure 3.16). 
 
H
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Figure 3.16: SMALP structure.  SMALPs consist of a copolymer of styrene and maleic anhydride 
(hydrolysed to maleic acid), containing a pendant phenyl group and a weakly negatively charged 
pendant group (Tonge and Tighe, 2001). 
 
At the appropriate pH (above its pKa), the copolymer enters a hypercoiled state 
(Tonge and Tighe, 2001).  A uniformly sized disc forms, 11 nm in diameter, 
encapsulating a protein (with its surrounding lipids) from the membrane in a 
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monodisperse state, enabling access to both cytoplasmic and extracellular faces of 
the membrane protein (Knowles et al., 2009).  
 
This strategy could be investigated to solubilise the PBPs from the membranes if 
detergent extraction rendered the enzymes inactive.  
 
3.8.3. Membrane protein purification 
 
3.8.3.1. Detergent exchange 
 
Following solubilisation of the membrane proteins, sodium deoxycholate was 
exchanged for DDM (a detergent frequently used in the study of membrane 
proteins).  In addition to avoiding the adverse effects of sodium deoxycholate on 
buffer solutions, detergent exchange had a role in enhancing protein purification.  
The distribution of proteins within a detergent micelle is largely unknown; single or 
multiple natively associating or non-associating proteins could exist in the same 
micelle as the target protein.  Disruption of the micelle during detergent exchange 
aims to isolate the target protein, thus eliminating contaminating proteins and 
improving protein purity.   
 
3.8.3.2. Affinity chromatography and size exclusion 
 
Two purification strategies were employed in the purification of the integral 
membrane proteins to minimise the loss of protein incurred.  The preliminary 
purification step of affinity chromatography was developed to optimise target protein 
association with affinity resin, whilst minimising the aggregation potential.   
 
Size exclusion chromatography was performed with three objectives: to purify 
proteins based on size, to remove aggregated material and to buffer exchange.  The 
membrane proteins eluted from the column as a relatively broad peak (as 
demonstrated by PBP1a, Figure 3.9), which could indicate that the protein was not 
monodispersed, present in a range of conformations, associating with contaminants 
or degrading.  Isolated membrane proteins are not single entities; they are in a 
detergent micelle complex.  The detergent micelle of DDM varies in size (~40-75 
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kDa (Anatrace-Affymetrix)), which would also contribute to the broad elution peak 
of the protein.  This issue could be solved by using a detergent with a smaller, 
uniform micelle size.  CHAPS, with a micelle size of 6 kDa (Sigma-Aldrich), was 
trialled in the size exclusion chromatography of PBP1a, PBP2b and PBP2x but 
caused severe protein aggregation, which was evident from the elution of the protein 
in the column void volume.  Many other small micellar weight detergents could be 
tested for suitability during the size exclusion chromatography of the membrane 
proteins such as N-lauroyl sarcosine (average micellar weight of 0.6 kDa, Sigma-
Aldrich). 
 
3.8.3.3. Final levels of protein purity 
 
PBP1a purified to a marginally higher level compared to PBP2b and PBP2x and the 
counterparts from S. pneumoniae 5204.  The expression levels of the S. pneumoniae 
5204 PBPs were slightly lower compared to those from the penicillin-sensitive strain 
and thus during affinity chromatography, E. coli host proteins were more prominent 
as contaminants.  Despite the similarity of PBP1a, PBP2b and PBP2x expression 
levels, PBP1a purified with fewer contaminants.  It was anticipated that the PBPs 
would be expressed as active enzymes within the E. coli expression system.  
Therefore, these enzymes could interact with host proteins in an analogous manner to 
the native associations formed in S. pneumoniae, such as the localisation of PBPs to 
cell division machinery (Morlot et al., 2003).  If these interactions were not disrupted 
by detergent solubilisation, the contaminants could co-purify.  
 
3.9. Conclusion 
 
The major "-lactam resistance determinants of S. pneumoniae were successfully 
cloned as different length constructs from the penicillin-sensitive and penicillin-
resistant strains, D39 and 5204.  Mutations to active site residues of the full-length S. 
pneumoniae D39 PBPs were generated.  Each variant was successfully expressed and 
purified to greater than 90 % homogeneity, providing sufficient quantities for future 
biochemical characterisations.   
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Chapter 4. Enzymology of transglycosylation: assay 
development and preliminary kinetic characterisations of 
Staphylococcus aureus MGT and Streptococcus pneumoniae 
PBP1a 
 
4.1. Introduction 
 
The peptidoglycan transglycosylases belong to the highly conserved GT51 family of 
carbohydrate active enzymes (www.cazy.org).  These enzymes have a vital role in 
peptidoglycan synthesis: they catalyse the polymerisation of the disaccharide 
constituent of Lipid II, although the precise catalytic mechanism is yet to be fully 
resolved (Lovering et al., 2007).  The elucidation of this mechanism and the 
biochemical characterisation of the transglycosylases will guide the future design of 
antimicrobials against this desirable, underexploited antibiotic target. 
 
4.1.1. Mechanistic features of transglycosylation 
 
To begin to establish the catalytic mechanism, details of transglycosylation need to 
be defined including the direction of glycan chain elongation, the length of glycan 
chains and whether transglycosylation conforms to a processive or dispersive model 
of substrate polymerisation.  These features are addressed in the following sections.   
 
Perlstein et al. (2007) provided the first biochemical data determining the direction 
of glycan chain polymerisation.  In the study, "-1,4-galactosyltransferase was used to 
transfer [
14
C]-labelled-galactose to the C4 hydroxyl group of the terminal GlcNAc 
(the non-reducing end) of Lipid II substrate analogues, preventing this end from 
serving as a glycosyl acceptor.  These labelled substrates were incubated with four 
transglycosylases (E. coli PBP1a, E. coli PBP1b, S. aureus PBP2 and A. aeolicus 
PBP1a) and Lipid II.  Despite obstruction at the non-reducing end, chain extension 
was observed, indicating that the transglycosylases polymerised Lipid II by 
integrating the disaccharide units onto the diphospholipid, reducing (although not a 
lactol) terminus (Perlstein et al., 2007).   
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By general agreement, transglycosylases are processive rather than dispersive, where 
they catalyse multiple rounds of polymerisation without releasing the elongating 
glycan polymer (Yuan et al., 2007).  The processive model has been validated by the 
use of high-resolution gel electrophoresis, which allows the separation of glycan 
chains to a single disaccharide resolution, enabling the length of the glycan chains to 
be established (Barrett et al., 2007; Yuan et al., 2007).  This technique was used to 
analyse the distribution of transglycosylase products following time-dependent 
incubations of E. coli PBP1a and A. aeolicus PBP1a with heptaprenyl-[
14
C]-Lipid II.  
Long glycan chains appeared without the accumulation of short chains, concurrent 
with the processive model of transglycosylation (Barrett et al., 2007).  The crystal 
structure of A. aeolicus PBP1a is also consistent with the processive model of 
transglycosylation.  A flap exists that folds over the active site cleft, which has been 
proposed to prevent the dissociation of the elongating polymer from the active site 
(Yuan et al., 2007).   
 
The gel electrophoresis technique was also used by Wang et al. (2008) to establish 
whether transglycosylases have a specific limiting chain length.  It was discovered 
that E. coli PBP1a, E. coli PBP1b, S. aureus PBP2 and E. faecalis PBP2a had 
limiting chain lengths of approximately 30, 50, 15 and 15 disaccharide units 
respectively and these values remained unchanged upon varying the 
enzyme:substrate ratio.  Due to the processive nature of the transglycosylases, there 
must be an unidentified intrinsic mechanism that limits chain length and allows the 
glycan product to be released once a threshold length is reached (Wang et al., 2008).   
 
4.1.2. The proposed catalytic mechanism 
 
Although the precise details are not fully understood, a combination of structural and 
biochemical analyses has led to the proposal of the catalytic mechanism for 
transglycosylation.  The recent transglycosylase crystal structures in complex with 
the inhibitor moenomycin have been fundamental in elucidating whether Lipid II 
acts as a donor or acceptor during the polymerisation reactions (Heaslet et al., 2009; 
Lovering et al., 2007; Sung et al., 2009).  In the S. aureus PBP2 (Lovering et al., 
2007) and E. coli PBP1b (Sung et al., 2009) moenomycin co-crystal structures, the 
elongating glycan chain can be modelled onto moenomycin, where moenomycin 
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rings E and F (Figure 1.11) correspond to the GlcNAc and MurNAc constituents of 
the reducing terminal of the glycan polymer.  There is also sufficient space in the 
structure to model Lipid II in an adjacent site (Lovering et al., 2007).  Addition of 
disaccharide units to the reducing end of an extending polymer positions the 
elongating glycan chain in the donor site and Lipid II in the acceptor site (Lovering 
et al., 2007) (Figure 4.1).   
 
Figure 4.1: Spatial representation of Lipid II analogues modelled into the donor and acceptor 
sites of S. aureus PBP2 transglycosylase domain.  The putative catalytic residues Glu-M1 and Glu-
M3 (M, conserved motif) are shown in stick forms.  The Lipid II analogues (stick forms) are modelled 
into the donor or acceptor subsites of the catalytic site.  The yellow arrow shows the direction of the 
elongating glycan chain.  The membrane interface (black line), the transmembrane domain (blue 
block) and the missing polypeptide (blue dashed line) are displayed.  Modified from Lovering et al. 
(2007). 
 
Based on inferences taken from the lysozyme mechanism of "-1,4-glycosidic bond 
cleavage between MurNAc and GlcNAc components of a glycan chain and structural 
details of the transglycosylase domain, Lovering et al. (2008a) and (2007) have 
proposed a mechanism for transglycosylation.  In this model, the placement of 
substrates positions the C4 hydroxyl group of the accepter GlcNAc for deprotonation 
by the conserved catalytic glutamate of motif 1, which acts as a base.  The resulting 
nucleophile concomitantly attacks the C1 of the donor MurNAc acyl-phosphate 
linkage in an SN2-like reaction.  This causes an inversion of configuration at the C1 
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anomeric carbon, from an #-linked precursor to a "-1,4-glycosidic bond-linked 
product.  The undecaprenyl pyrophosphate leaving group is then free to diffuse away 
from the active site. 
 
The conserved Glu of motif 3 could have different roles in the transglycosylation 
mechanism depending on its undefined protonation state (Figure 4.2).  In a 
protonated state (glutamic acid), it could donate a proton to the departing 
undecaprenyl pyrophosphate or coordinate the pyrophosphate group via a hydrogen 
bond (Lovering et al., 2007).  Alternatively, in a deprotonated state, the glutamate 
residue could stabilise the pyrophosphate moiety by an indirect interaction, mediated 
through the co-ordination of either a divalent cation (Lovering et al., 2007) or an 
arginine residue (as suggested by the crystal structure of S. aureus MGT complexed 
with moenomycin (Heaslet et al., 2009)).   
 
For subsequent rounds of transglycosylation, the newly synthesised product needs to 
be translocated into the donor site (according to the processive model (Barrett et al., 
2007; Yuan et al., 2007)).  It is believed that the pyrophosphate moiety has a higher 
affinity for the donor site (which contains conserved positively charged residues 
locating to the pyrophosphate binding region) compared to the acceptor site, thus 
promoting translocation (Lovering et al., 2007). 
 
The proposed transglycosylase catalytic mechanism (Figure 4.2) will require 
validation by future work.  
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Figure 4.2: Proposed mechanism for transglycosylation.  The elongating glycan chain is the donor; 
the Lipid II monomer is the acceptor.  The Glu residues are shown as part of the designated conserved 
motif of the transglycosylase domain (TG).  The conserved Glu of motif 1 (magenta) deprotonates the 
C4 hydroxyl group of the acceptor, which concomitantly attacks the C1 of the donor, causing an 
inversion in configuration to form "-linked products.  Three potential situations are shown for the role 
of the conserved Glu of motif 3 (green).  (i) It can donate a proton to the leaving undecaprenyl 
pyrophosphate group, or it can indirectly stabilise the pyrophosphate moiety of the leaving group 
through the coordination of (ii) a metal ion (blue) or (iii) an arginine residue (red).  Adapted from 
Lovering et al. (2007). 
 
4.1.3. Current strategies to analyse transglycosylase activity 
 
4.1.3.1. Substrate and derivatives 
 
The advent of the ability to synthesise lipid-linked intermediates of peptidoglycan 
has revolutionised the study of the transglycosylase activity.  Although the 
availability of Lipid II remains restrictive, the incorporation of a radioactive or 
fluorescent group into the substrate enables limiting amounts to be used whilst 
maintaining a high sensitivity of detection.  In many cases, derivatives of Lipid II are 
used.  However, structural modifications of Lipid II can interfere with activity of the 
enzyme, impeding or elevating it.  This poses the question of whether these substrate 
analogues are appropriate to obtain a realistic representation of the native activity of 
the enzyme.  Ye et al. (2001) discovered that transglycosylases in E. coli membranes 
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had a preference for a Lipid II analogue containing a betulaheptaprenyl lipid chain 
(35 carbon atoms) over the natural substrate.  The shorter lipid chain minimises the 
possibility of aggregation as observed with the 55-carbon chain of the undecaprenyl 
constituent of Lipid II (Ye et al., 2001).   
 
4.1.3.2. Radioactivity-based assays 
 
There are various radioactivity-dependent assays that have been employed to 
functionally and kinetically characterise transglycosylase activity.  As previously 
described, gel electrophoresis can be used to separate radiolabelled glycan polymers, 
allowing chain length and processivity to be addressed (Barrett et al., 2007; Yuan et 
al., 2007).  Paper chromatography can also be employed to separate products of 
transglycosylation; glycan polymers remain immobile on the chromatogram whilst 
Lipid II migrates.  Given that the Lipid II substrate is labelled either radioactively or 
with fluorescence, the products of transglycosylation can be detected and quantified.  
Paper chromatography with radiolabelled substrates was used by Terrak and 
Nguyen-Distèche (2006) to characterise S. aureus MGT. 
 
4.1.3.3. Fluorescence-based assays 
 
High performance liquid chromatography (HPLC) can be used to analyse the 
polymerisation of Lipid II (labelled with fluorescence before or after a 
transglycosylation reaction), monitored by the appearance of a peak representing 
glycan polymers and the disappearance of a Lipid II peak.  This technique was 
applied by Heaslet et al. (2009) to determine the effect of different mutations on the 
activity of S. aureus MGT and has been used by Schwartz et al. (2002) to kinetically 
characterise E. coli PBP1b.  Schwartz et al. (2002) have also developed a continuous 
fluorescence assay to assess transglycosylase activity, where the polymerisation of 
dansyl-Lipid II is coupled to a muramidase that ultimately results in a decrease in 
fluorescence signal.  Liu and Wong (2006) have employed a nitrophenol Lipid II 
analogue to characterise S. pneumoniae PBP1b spectrophotometrically, where a 
series of reactions leads to the production of nitrophenol, which can be monitored by 
absorbance at 405 nm.   
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4.1.4. The future of transglycosylase assays 
 
The development of a high-throughput assay system to assess transglycosylase 
activity with the natural unmodified substrate is desirable to allow the rapid 
characterisation of transglycosylases.  Ultimately, this system will enable a vast 
library of inhibitors to be screened with immediate results, which will have 
significant implications for the future discovery of antagonists of the 
transglycosylase antimicrobial target.  The design of such an assay system is 
addressed in this Chapter.  
 
4.2. Experimental aims 
 
• To over-express and purify S. aureus Monofunctional Glycosyl Transferase 
(MGT), an appropriate control enzyme for transglycosylase activity 
 
• To develop a spectrophotometric assay for the detection of transglycosylase 
activity 
 
• To establish optimal assay conditions and to kinetically characterise the 
transglycosylase activity of S. aureus MGT and S. pneumoniae PBP1a using 
the novel spectrophotometric assay 
 
• To establish an efficient method for the enzymatic synthesis of [14C]-labelled 
Lys-Lipid II 
 
• To analyse products of MGT and PBP1a-dependent transglycosylation using 
SDS-PAGE separation with [
14
C]-labelled Lys-Lipid II and a novel, non-
radioactive detection system 
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4.3. S. aureus MGT as a control enzyme for transglycosylase 
activity 
 
The transglycosylase activity of S. aureus MGT, devoid of its membrane anchor, has 
been characterised, kinetically (Terrak and Nguyen-Distèche, 2006) and structurally 
(Heaslet et al., 2009).  MGT has a single functional domain exhibiting 
transglycosylase activity, common to Class A PBPs, but concomitantly lacks the 
penicillin-binding domain.  The monofunctionality and established activity of this 
enzyme make it a suitable control enzyme for the analysis of transglycosylase 
activity. 
 
4.3.1. Establishment of expression constructs for the wild-type and the 
active-site mutant of MGT  
 
The expression construct pET46::mgt, carrying the truncated mgt gene encoding 
D68-R268 (equivalent in length to the N-terminally truncated MGT characterised by 
Terrak and Nguyen-Distèche (2006)) in the pET46 Ek/LIC vector, was provided by 
T. Clarke.  Upon expression, S. aureus MGT-!67 (devoid of the first 67 amino acid 
residues of the N-terminus) contained a vector-encoded N-terminal hexa-histidine 
tag, and is referred to as MGT from here onwards. 
 
In future assays, to attribute any activity detected to MGT-dependent 
transglycosylation, a catalytically inactive form of MGT was required for 
comparative purposes.  A glutamate residue (E100 in the MGT sequence) is present 
in the first conserved motif of all Class A PBPs and MGTs.  Terrak and Nguyen-
Distèche (2006) have confirmed that this residue is essential for transglycosylase 
activity in vitro: S. aureus MGT-E100Q exhibits a 500-fold reduction in activity 
compared to the wild-type enzyme.  The absence of the conserved glutamate residue 
essentially renders the transglycosylase inactive, a desirable property for future 
studies. 
 
Quik-Change site-directed mutagenesis (Section 2.3.10) was used to replace the 
glutamate-100 residue with glutamine (E100Q).  The primers for mutagenesis were 
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identical to those used by Terrak and Nguyen-Distèche (2006) (Table 4.1).  Sequence 
analysis of the constructs (using primers in Table 2.2) following the mutagenesis 
identified the presence of the specified mutation; the plasmid containing the desired 
mutation was termed pET46::mgt-E100Q (recombinant protein designated MGT-
E100Q).   
 
Primer name Sequence (5’-3’) 
E100Q sense CCTTTATTTCAATGCAAGATGAACGATTCATC 
E100Q antisense GTAGAATCGTTCATCTTGCATTGAAATAAAGG 
Table 4.1: Primers for MGT site-directed mutagenesis of S. aureus mgt.  The modified codon for 
the desired mutation is highlighted in bold type.   
 
4.3.2. Expression and purification of wild-type MGT and MGT-
E100Q 
 
MGT and MGT-E100Q were expressed in E. coli BL21 Star (DE3) cells harbouring 
the pRosetta plasmid under autoinduction at 25°C (Section 2.4.2.1). The recombinant 
proteins over-expressed solely in the insoluble fraction of the cells, from which they 
were extracted (Section 2.4.2.2) and purified by IMAC (Section 2.4.3.1) and size 
exclusion chromatography (Section 2.4.3.2) in the buffer 50 mM sodium phosphate, 
0.5 M NaCl, 20 % glycerol (w/v), pH 7.6. Fractions from different stages of the 
extraction and purification were analysed by SDS-PAGE (Figure 4.3).  The 
molecular weight of the truncated MGT is 23.4 kDa. MGT was stored in 50 % (v/v) 
glycerol at -20°C (freezing at -80°C was detrimental to enzyme activity). 
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Figure 4.3: Purification of S. aureus MGT by immobilised metal chelate affinity 
chromatography and size exclusion chromatography.  (a) 12 % SDS-PAGE Coomassie-stained gel 
analysis of the extraction of MGT from the insoluble fraction and subsequent IMAC purification.  Mr, 
molecular weight markers (kDa); lane S, soluble cytoplasmic cellular fraction; lane IS, insoluble 
cellular fraction; lane BL, solubilised proteins from the insoluble fraction before loading onto the 
IMAC column; lane FT, flow-through; lane 15 mM, buffer with 15 mM imidazole; lane 300 mM, 
buffer with 300 mM imidazole. (b) The chromatogram of size exclusion chromatography using the 
Superose 6 10/300 GL column.  The peak (i) denotes aggregated material eluting in the column void 
volume and peak (ii) identifies the elution of MGT. (c) 12 % SDS-PAGE Coomassie-stained gel 
analysis of the final purity of MGT. Mr, molecular weight markers (kDa); lane 1, purity of MGT 
following IMAC and size exclusion chromatography.   
 
MGT and MGT-E100Q exhibited similar properties: expressing to comparable levels 
and requiring a high salt concentration to remain soluble at high protein 
concentrations. 
 
The MGT recombinant protein was highly similar to that used by Terrak and 
Nguyen-Distèche (2006), who were able to detect MGT-dependent transglycosylase 
activity.  Therefore, it was anticipated that MGT would also demonstrate glycan 
chain polymerising activity. 
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4.4. Discontinuous spectrophotometric assay for the detection of 
transglycosylase-dependent undecaprenyl pyrophosphate 
production 
 
The monofunctional transglycosylases and Class A PBPs are responsible for the 
transglycosylation of the Lipid II substrate (as reviewed by Sauvage et al. (2008a)).  
They catalyse the formation of a "-1,4-glycosidic bond between the MurNAc unit (at 
the reducing end of an extending glycan chain) and the GlcNAc unit (of the incoming 
Lipid II substrate) with the concurrent release of undecaprenyl pyrophosphate 
(Perlstein et al., 2007).  The discontinuous production of undecaprenyl 
pyrophosphate (indicative of a transglycosylation reaction) can be coupled to a 
continuous spectrophotometric assay as outlined in Figure 4.4.  Dephosphorylation 
of undecaprenyl pyrophosphate by an undecaprenyl pyrophosphate phosphatase 
generates undecaprenyl phosphate and inorganic phosphate (Pi).  The undecaprenyl-
pyrophosphate-phosphatase-dependent Pi release can be linked to the phosphorolysis 
of a chromogenic nucleoside, 7-methyl-6-thioguanosine.  This reaction is catalysed 
by purine nucleoside phosphorylase (PNP) to form 7-methyl-6-thioguanine, giving a 
spectrophotometric signal at 360 nm (Webb, 1992). 
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Figure 4.4: A continuous spectrophotometric assay for inorganic phosphate release.  A product from the transglycosylation reactions is undecaprenyl pyrophosphate.  An 
undecaprenyl pyrophosphate phosphatase dephosphorylates undecaprenyl pyrophosphate generating undecaprenyl phosphate and Pi.  The latter product is involved in the 
phosphorolysis of 7-methyl-6-thioguanosine, catalysed by purine nucleoside phosphorylase, giving an intense signal at 360 nm. 
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4.5. The undecaprenyl pyrophosphate phosphatase coupling 
enzyme for undecaprenyl pyrophosphate production 
 
4.5.1. Selection of the undecaprenyl pyrophosphate phosphatase 
 
A number of undecaprenyl pyrophosphate phosphatases have been identified in E. 
coli including UppP, YbjG, YeiU and PgpB, having the essential role of 
undecaprenyl phosphate regeneration (Tatar et al., 2007).  Touzé et al. (2008) have 
kinetically characterised the phosphatase-specific activity of E. coli PgpB in vitro.  
For this reason, E. coli PgpB was the employed undecaprenyl pyrophosphate 
phosphatase in the assays.  
 
4.5.2. Expression and purification of PgpB 
 
The expression construct pTrcHis60::pgpB (IPTG-inducible; encoding ampicillin 
resistance) was a gift from T. Touzé (Université Paris-Sud), which encodes a 
recombinant protein of wild-type E. coli PgpB (an integral membrane protein with 
six transmembrane-spanning helices) with a C-terminal hexa-histidine tag (denoted 
PgpB).  Following the experimental procedures for protein expression as detailed by 
Touzé et al. (2008), the over-expression of PgpB was not apparent.  Therefore, a 
novel method for PgpB over-expression was developed. 
 
PgpB was expressed in E. coli BL21 (DE3) under 0.5 mM IPTG induction (Section 
2.4.1.1).  Following induction, the cells were cultured at 10°C for 48 h 
(supplemented with ampicillin after the first 24 h) prior to cell harvesting.   
 
The target protein was extracted from the E. coli membranes and purified using the 
generalised method of IMAC described in Section 2.5.5 with specific alterations.  
Given the low yield of PgpB over-expression, PgpB was purified from the 
membranes extracted from 2 L culture (as opposed to 1 L).  The protein was purified 
by IMAC in the buffer: 1 ! PBS, 0.1% (w/v) DDM, pH 7.6 supplemented with 0.75 
M NaCl (Figure 4.5a).  
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Following IMAC, the fractions containing PgpB at the highest level of purity were 
combined and subjected to size exclusion chromatography (Section 2.5.5.3) to 
further purify PgpB and to remove any aggregated material.  The chromatogram and 
the final purity of PgpB are demonstrated in Figure 4.5b and c.  PgpB was stored in 
50 % (v/v) glycerol at -20°C; enzymes stored at -80°C were inactive. 
 
Figure 4.5: Purification of E. coli PgpB by immobilised metal chelate affinity chromatography 
and size exclusion chromatography.  (a) 12 % SDS-PAGE Coomassie-stained gel analysis of the 
extraction of PgpB from the membrane cellular fraction and IMAC purification.  Mr, molecular 
weight markers (kDa); lane TM, total membrane fraction; lane IM, membrane proteins remaining 
insoluble following detergent treatment; lane SM, detergent-solubilised membrane proteins prior to 
incubation with IMAC resin; lane FT, flow-through; lanes 10 mM and 300 mM, buffer with 10 mM 
and 300 mM imidazole respectively. (b) Chromatogram of size exclusion chromatography using the 
Superose 6 10/300 GL column.  The peak (i) identifies the elution of PgpB. (c) 12 % SDS-PAGE 
Coomassie-stained gel analysis of the purity of the final product of PgpB purification. Mr, molecular 
weight markers (kDa); lane 1, purity of PgpB following IMAC and size exclusion chromatography 
with an expected molecular weight of 30.3 kDa.   
 
4.5.3. Preliminary characterisations of E. coli PgpB phosphatase 
activity 
 
A prerequisite to the development of the discontinuous coupled assays for 
monitoring transglycosylation was to establish the suitability of PgpB as an 
undecaprenyl pyrophosphate phosphatase in vitro.  A continuous spectrophotometric 
assay, outlined in Section 2.8.1.1, was evaluated to ensure Pi release was dependent 
on the presence of all assay components, specifically PgpB and undecaprenyl 
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pyrophosphate (the natural substrate of PgpB).  Control reactions monitoring the 
activity of PgpB with undecaprenyl phosphate (product of PgpB activity) and Lys-
Lipid II (substrate of the transglycosylases) was also assessed, to confirm that these 
compounds were not substrates of PgpB and did not interfere with PgpB-catalysed 
dephosphorylation of undecaprenyl pyrophosphate.  To ensure a false positive signal 
was not produced, Pi was absent from all reaction buffers.  Figure 4.6 shows the 
continuous spectrophotometric time course, displaying the results of these analyses. 
 
Line 
Assay components 
present at time 0 min 
Assay component 
added at point (a) 
Assay component 
added at point (b) 
 
Pi detection reagents PgpB 
Undecaprenyl 
pyrophosphate 
 
Pi detection reagents 
Undecaprenyl 
pyrophosphate 
PgpB 
 Pi detection reagents, 
PgpB 
Lys-Lipid II 
Undecaprenyl 
pyrophosphate 
 Pi detection reagents, 
PgpB 
Undecaprenyl 
phosphate 
Undecaprenyl 
pyrophosphate 
 
Figure 4.6: A continuous spectrophotometric time course for E. coli PgpB dependent 
dephosphorylation of undecaprenyl pyrophosphate measured by Pi release.  The table describes 
the assay components present at time 0 min, and at points of addition (a) and (b).  The Pi detection 
reagents are 1 unit PNP and 400 µM MESG.  The final concentration of PgpB in each assay was 
constantly 1.78 !M.  A final concentration of 200 !M of undecaprenyl pyrophosphate, undecaprenyl 
phosphate or Lys-Lipid II was added to the assays.   
 148 
Figure 4.6 conclusively demonstrates that Pi release was dependent on the presence 
of both PgpB and its natural substrate, undecaprenyl pyrophosphate.  The presence of 
Lys-Lipid II or undecaprenyl phosphate had no adverse effect on PgpB activity in 
vitro (e.g. product inhibition).  The findings of Touzé et al. (2008) were confirmed: 
undecaprenyl phosphate was not a substrate of PgpB.  This signifies that PgpB 
generates one Pi for every turnover of undecaprenyl pyrophosphate, important 
information for the calculating kinetic rates from the Pi-dependent changes in 
absorbance. 
 
4.5.4. Kinetics of dependence of E. coli PgpB on undecaprenyl 
pyrophosphate 
 
The rates of PgpB-specific activity have previously been analysed with a variety of 
substrates (Touzé et al., 2008).  Despite this, the phosphatase activity of PgpB was 
kinetically characterised with its natural substrate in the assay system described in 
Section 2.8.1.1, where an alternative Pi detection system was employed compared to 
that published in literature (see Touzé et al. (2008)).  Various concentrations of 
undecaprenyl pyrophosphate were added to the reactions, which were initiated by the 
addition PgpB to a final concentration of 1.78 !M.  Assays were performed in 
duplicate at each substrate concentration. 
 
The kinetic profile of PgpB with undecaprenyl pyrophosphate is displayed in Figure 
4.7.  There is a hyperbolic relationship between the initial enzyme velocity (v0) and 
the substrate concentration, enabling the data to be fitted to the Michaelis-Menten 
equation (Equation 1) (Appendix B1) to determine kcat and Km by non-linear 
regression. 
 
 
Equation 1     
 
 
 
 
 
 
v
0
=
V
max
S[ ]
K
m
+ S[ ]
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Figure 4.7: Kinetics of dependence of E. coli PgpB phosphatase activity with its natural 
substrate.  Average initial velocity (based on two data sets) of PgpB-dependent Pi release is plotted 
versus [undecaprenyl pyrophosphate].  The R
2
 value is 0.99, signifying the data was well-fitted to the 
Michaelis-Menten equation. 
 
The kinetic parameters of PgpB-dependent Pi release are presented in Table 4.2. 
 
Kinetic constants 
Substrate 
Km
a
 (µM) kcat
a
 (min
-1
) kcat/Km (s
-1
M
-1
) 
Undecaprenyl 
pyrophosphate 
191.90±17.23 7.29±0.23 633.14  
Table 4.2: Kinetic constants of E. coli PgpB catalysed Pi hydrolysis from undecaprenyl 
pyrophosphate.  PgpB-dependent dephosphorylation was monitored by the change in absorbance at 
360 nm using the assay described in Section 2.8.1.1.  The data was fitted to Equation 1 by non-linear 
regression, enabling kinetic constants to be derived. 
 a
Values ± standard error of duplicate reactions. 
 
The activity of PgpB is significantly enhanced in the presence of phospholipids.  The 
phospholipids are proposed to influence the arrangement of undecaprenyl 
pyrophosphate within a micelle, presenting it as a better substrate, as opposed to 
directly stimulating the enzyme (Touzé et al., 2008).  Reproduction of these findings 
was trialled with the phospholipids cardiolipin and phosphatidyl glycerol, under the 
same assay conditions described in Section 2.8.1.1.  The presence of 1 mM 
cardiolipin or 1 mM phosphatidyl glycerol improved the rate by approximately 5-
fold, a result similar those published (5.4-fold and 5.2-fold increase respectively) 
(Touzé et al., 2008).  In combination, the effect of cardiolipin and phosphatidyl 
glycerol was additive.  These have future implications for the development of a 
continuous spectrophotometric assay for transglycosylation (Section 4.13.7). 
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4.6. Establishing the protocol of the discontinuous 
spectrophotometric assay for transglycosylation detection 
 
4.6.1. Experimental parameters dictated by the MGT control enzyme 
 
To establish whether the discontinuous PgpB-coupled assay is a plausible method for 
monitoring transglycosylase activity, the activity of the control enzyme, MGT, was 
assessed.  The assay conditions were designed to maintain MGT in a stable state.  
MGT relied on a high [NaCl] or [detergent] to remain soluble; 0.1% (w/v) DDM was 
included in the discontinuous assay.  MGT was unstable (signified by precipitation) 
at temperatures approaching 30°C; the discontinuous assays were performed at 20°C.   
 
4.6.2. Experimental design 
 
The details of the discontinuous-coupled continuous assays are described in Section 
2.8.1.2.  The basic reaction buffer was comprised of 20 mM Tris, 10 mM MgCl2, 
0.1% (w/v) DDM, pH 8.0.  Lys-Lipid II (synthesis described in Section 2.7.3), the 
transglycosylase substrate, was present at concentrations varying between 0-1.47 
mM.  Addition of the transglycosylase initiated the reactions, which were performed 
at 20ºC.  The reaction was stopped by heat denaturation at 60ºC for 10 min.  The 
insoluble material was pelleted by centrifugation.  A fraction of the total reaction 
volume was added to the continuous spectrophotometric assay components (20 mM 
Tris, 150 mM NaCl, 0.1 % (w/v) DDM, 1 unit PNP and 400 !M MESG, pH 7.5) 
where any Pi present in the sample (originating from the Lys-Lipid preparation) 
would be immediately eliminated.  A baseline absorbance was monitored at 360 nm 
prior to the addition of PgpB to a final concentration of 4.4 !M.  The activity of 
PgpB was recorded until a plateau was reached.  The total change in absorbance 
between the baseline and plateau represented the total PgpB-dependent Pi release 
from undecaprenyl pyrophosphate, which in turn, signified the total undecaprenyl 
pyrophosphate produced by MGT-dependent transglycosylation.   
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4.6.3. Derivation of kinetic constants 
 
In vitro, transglycosylases perform de novo synthesis of glycan chains and require 
two Lipid II substrate molecules to bind into the active site as described by Scheme 
2. 
 
Scheme 2   
 
A kinetic equation (Equation 2) can be derived from Scheme 2 (Appendix B2) on the 
assumption that rapid equilibrium kinetics exist and that Km1 and Km2 are equilibrium 
constants.  It is also assumed that the substrate remains unchanged over the initial 
rate measurements, which are based on the formation of Lipid IV from two 
molecules of Lipid II.   
 
Equation 2    
 
 
4.7. Characterisation of MGT transglycosylase activity using the 
discontinuous spectrophotometric assay 
 
4.7.1. Initial trials to determine transglycosylase activity 
 
The assay system outlined in Sections 4.6.2 was used to analyse MGT and MGT-
E100Q transglycosylation activity, establishing it as a suitable method for the 
discontinuous detection of Lipid II polymerisation.  Figure 4.8 displays the 
continuous spectrophotometric time course of PgpB-dependent Pi release in the 
presence of the discontinued transglycosylation reactions of MGT and MGT-E100Q.  
The results conclusively show that the reaction of MGT with Lys-Lipid II led to the 
generation of undecaprenyl pyrophosphate, the substrate for PgpB-dependent Pi 
release, indicating transglycosylation had occurred.  Conversely, MGT-E100Q did 
not exhibit any transglycosylation activity, signified by the absence of PgpB activity 
in the continuous assay.   
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Figure 4.8: A continuous spectrophotometric time course for PgpB-dependent Pi release from 
MGT-generated undecaprenyl pyrophosphate.  At 0 min, all reaction components, including the 
discontinued transglycosylation reactions of MGT (     ) and MGT-E100Q (     ), were present, with 
the exception of PgpB, which initiated the dephosphorylation of undecaprenyl pyrophosphate at point 
(a).  The transglycosylase was present at a final concentration of 155 !M in the discontinuous assays 
with 0.67 mM Lipid II.  The discontinuous assays were performed at 20°C for 6 min.   
 
This initial characterisation of MGT and MGT-E100Q confirmed the findings of 
Terrak and Nguyen-Distèche (2006): MGT is capable of using a substrate that 
differentiates from the natural at the pentapeptide stem (S. aureus Lipid II has a 
pentaglycine branch); the glutamate at residue 100 is important for the catalytic 
activity of MGT.   
 
4.7.2. Generation of a time-dependent profile for MGT 
transglycosylation.   
 
At a fixed concentration of enzyme and substrate, a time-course of MGT activity was 
established, displayed in Figure 4.9.  Following the protocol outlined in Section 
4.6.2, a discontinuous assay of MGT activity was initiated with sampling at discrete 
time points. The undecaprenyl pyrophosphate generated from the MGT-dependent 
transglycosylation reactions was quantified using the continuous spectrophotometric 
assay.  
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Figure 4.9: Time-dependent undecaprenyl pyrophosphate release reaction profile of MGT-
catalysed transglycosylation.  Following the defined time point sampling of the transglycosylation 
reactions, quantification of undecaprenyl pyrophosphate via PgpB-dependent Pi release provided an 
indirect measurement of MGT activity. MGT and Lipid II concentrations were constant at 155 !M 
and 0.67 mM respectively in the discontinuous assays.  The profile was generated based on duplicated 
reactions.  [Undecaprenyl pyrophosphate] relates to the concentration in the discontinuous assay.   
 
Over the specified time-course, the initial rate of undecaprenyl pyrophosphate 
production was linear, representing the steady-state phase of the reaction.  The 
reaction was approaching, but did not reach completion, signified by the curvature of 
the line fitted towards the production of 0.56 mM undecaprenyl pyrophosphate at 24 
min.   
 
Determination of the steady-state phase of MGT-dependent undecaprenyl 
pyrophosphate release was the preliminary stage towards the kinetic characterisation 
of MGT activity. 
 
4.7.3. Establishing the kinetic profile of MGT using the discontinuous-
coupled spectrophotometric assay 
 
The kinetic parameters of MGT-dependent undecaprenyl pyrophosphate generation 
were investigated.  The reactions were performed with different concentrations of the 
Lys-Lipid II substrate, according to the protocol described in Section 2.8.1.2.1. An 
end time point of 8 min (situated in the steady-state phase, Figure 4.9) was 
employed.  Figure 4.10a and b display the relationship between MGT activity and 
Lipid II concentration and the Lineweaver-Burk plot respectively, taken from the 
 154 
data set of one day.  The dependence of MGT velocity on substrate concentration 
exhibited day-to-day variation but with the same general trend: at low Lipid II 
concentrations there was a sigmoidal dependence on Lipid II and at high Lipid II 
concentrations the transglycosylase became inhibited.   
 
 
Figure 4.10: Kinetics of Lipid II dependence of S. aureus MGT transglycosylase activity.  (a) 
Initial velocity of MGT-dependent undecaprenyl pyrophosphate release (v0) plotted versus [Lys-Lipid 
II].  (b) Lineweaver-Burk plot of the data from (a).  [MGT] was present at 155 !M.  At each substrate 
concentration, the initial velocity determinations were performed in duplicate.  
 
The data in Figure 4.10 could not be fitted to Equation 2 due to the severe 
susceptibility to substrate inhibition displayed by MGT, thus kinetic constants could 
not be determined.  A model for MGT activity is described in Section 4.13.2.2 and 
from this, a kinetic equation has been derived to endeavour to establish the kinetic 
parameters.  
 
4.7.4. Investigating the effect of Lipid I on MGT activity 
 
MGT is known to catalyse the transglycosylation of Lipid II to form a polymerised 
glycan chain (Terrak and Nguyen-Distèche, 2006).  The stereochemistry of Lipid II 
indicates that Lipid I, lacking the GlcNAc component of Lipid II, should not be a 
suitable substrate.  This is demonstrated in Figure 4.11, where the formation of a !-
1,4-glycosidic bond would enforce a constrained conformation, given the 
requirement of the lipid chains to be situated in the membrane.  However, if Lipid I 
were to reach the active site of MGT, what would be the consequence of this 
interaction?  This was investigated in a single experiment.  
  
(a) (b) 
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Figure 4.11: The stereochemistry of Lipid I and Lipid II transglycosylation.  (a) The formation of 
a !-1,4-glycosidic bond between the MurNAc and GlcNAc moieties of adjacent Lipid II molecules.  
This bond conformation ensures the synthesis of straight glycan chains. (b) The formation of a !-1,4-
glycosidic bond between the MurNAc moiety of adjacent Lipid II and Lipid I molecules.  As depicted 
in the figure, in order for this bond to occur, the lipid anchor of Lipid I would need to be positioned in 
an opposite plane to the membrane containing Lipid II.  The conformational constraints are likely to 
prevent this reaction from occurring. 
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In two parallel experiments, 275 !M MGT was incubated for 20 min at 20°C with 
and without 2.96 mM Lys-Lipid I.  Addition of Lys-Lipid II to a final concentration 
of 0.33 mM initiated the reactions, adjusting the MGT and Lys-Lipid I to final 
concentrations of 155 !M and 1.67 mM respectively, making the Lipid I 
concentration 5-fold greater than the Lys-Lipid II concentration.  Aliquots were 
sampled at time points of 0, 10, 20 and 30 min to assess for transglycosylase activity 
following the protocol established in Section 2.8.1.2.  It was previously established 
that Lys-Lipid I did not impede PgpB activity.  Figure 4.12 displays the time course 
of MGT activity in the presence and absence of Lys-Lipid I. 
 
Figure 4.12: The interference of Lys-Lipid I with MGT-catalysed release of undecaprenyl 
pyrophosphate from Lys-Lipid II.  A time-course of MGT activity with 0.33 mM Lys-Lipid II, in 
the presence (     ) and absence (     ) of a pre-incubation with Lys-Lipid I (to a final concentration of 
1.67 mM in the reaction).  Reaction profile generated based on duplicate reactions. 
 
Figure 4.12 clearly demonstrates that in the presence of Lys-Lipid I, MGT 
transglycosylation was inhibited.  This is likely to be a result of competitive 
inhibition, where the Lipid I and Lipid II would be competing for the same site of 
MGT, given the similarities in their structures.  The results also demonstrate that 
Lys-Lipid I is not a suitable substrate.  If it were, at the point of Lys-Lipid II addition 
at 0 min, the generation of undecaprenyl pyrophosphate would have been evident.   
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4.8. The characterisation of the bifunctional S. pneumoniae PBP1a 
transglycosylase activity 
 
The in vitro activities of the transglycosylase domains of various Class A PBPs have 
been well characterised, kinetically and structurally, with and without the N-terminal 
membrane anchor (E. coli PBP1b for example (Schwartz et al., 2002; Sung et al., 
2009; Terrak et al., 1999)).  However, the characterisation of the Class A S. 
pneumoniae PBP1a has proved a greater challenge.  In the following sections, the in 
vitro activity of the full-length PBP1a transglycosylase domain is revealed, and the 
kinetic parameters are investigated. 
 
4.8.1. Establishment of S. pneumoniae PBP1a transglycosylase activity 
 
The assay outlined in Section 2.8.1.2 for the discontinuous-coupled 
spectrophotometric detection of undecaprenyl pyrophosphate release was applied to 
assess the activity of PBP1a, PBP1a-"30 (devoid of the membrane anchor) and 
PBP1a-E91Q (mutation of the glutamate in the first conserved transglycosylase motif 
to glutamine, analogous to the MGT-E100Q mutation).  The discontinuous 
transglycosylase reactions were performed and analysed for the presence of 
undecaprenyl pyrophosphate in the continuous spectrophotometric assay.  The rate of 
PBP1a-dependent transglycosylation was immediately identified as being extremely 
slow, where long incubations (on an hour timescale) were necessary for significant 
levels of undecaprenyl pyrophosphate release.  Figure 4.13 displays the continuous 
time course of PgpB-dependent Pi release from undecaprenyl pyrophosphate, which 
was generated by transglycosylation reactions of PBP1a variants in the discontinuous 
assays.   
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Figure 4.13: Continuous spectrophotometric time course of PgpB-dependent Pi release from 
PBP1a-generated undecaprenyl pyrophosphate. The discontinuous reactions were performed over 
a 3 h time period at 20°C in the presence of 77 µM enzyme and 0.56 mM Lys-Lipid II.  The 
transglycosylase activities of PBP1a (     ), PBP1a-"30 (     ) and PBP1a-E91Q (     ) were determined, 
where at time 0 min, all assay components (including the discontinuous transglycosylation reaction) 
were present with the exception of PgpB, which was added at time (a) to initiate the 
dephosphorylation of undecaprenyl pyrophosphate, a product of transglycosylase activity.   
 
Figure 4.13 conclusively demonstrates the transglycosylase activity of PBP1a, which 
was not an artefact of the assay.  PBP1a-E91Q did not exhibit any transglycosylase 
activity, an expected result given the mutation of an essential glutamate residue in 
the transglycosylase active site.  PBP1a-"30 did not show evidence of 
transglycosylase activity, signifying that the removal of 30 amino acid residues from 
the N-terminal of PBP1a had a detrimental effect on transglycosylase activity.  
 
4.8.2. Establishment of a discontinuous time course for S. pneumoniae 
PBP1a-dependent transglycosylase activity 
 
A time-dependent profile of PBP1a transglycosylase activity was established after 
ensuring that the generation of undecaprenyl pyrophosphate did not impose product 
inhibition.  The discontinuous assays were performed according to Section 2.8.1.2.  
The ability of two different detergents to facilitate transglycosylase activity were 
evaluated in the reaction buffer: 0.5 % (w/v) CHAPS and 0.1% (w/v) DDM.  
Aliquots of the reaction were sampled on an hourly basis.  Figure 4.14 displays the 
time-course of PBP1a activity in the two different experiments. 
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Figure 4.14: A discontinuous time-dependent profile of PBP1a transglycosylase activity.  A 
reaction between Lys-Lipid II (0.56 mM) and PBP1a (77 µM) was sampled at defined time points and 
the undecaprenyl pyrophosphate produced was quantified.  The time courses were determined from 
duplicate discontinuous assays in buffer that differed by the presence of either 0.5 % (w/v) CHAPS     
(     ) or 0.1 % (w/v) DDM (     ).  
 
From the transglycosylase time-course (Figure 4.14), the reaction of PBP1a with 
Lys-Lipid II (in buffers containing both detergents) did not reach completion 
(discussed in Section 4.13.3.1).  PBP1a was purified in the presence of 0.03 % (w/v) 
DDM and the detergent used in the reaction buffer was additional.  The plateau of 
transglycosylase activity appearing towards the 6 h incubation in the presence of the 
CHAPS detergent signified the gradual inactivation of PBP1a, probably a result of 
detergent-imposed aggregation.  PBP1a exhibited a steady state of activity in the 
presence of DDM over the entire time course.  Consequently, DDM was the 
detergent used in future experiments.  The time course conclusively demonstrates 
that under the specified assay conditions, the rate of PBP1a transglycosylation was 
extremely slow, which will be addressed in subsequent sections. 
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4.8.3. Kinetic characterisation of the transglycosylase activity of S. 
pneumoniae PBP1a  
 
The kinetics of PBP1a transglycosylase activity were investigated using the 
established protocol described in Section 2.8.1.2.  The enzyme concentration was 
held constant at 77 µM, with the Lys-Lipid II concentration ranging from 0-1.11 
mM.  The discontinuous assays were stopped after a 3 h incubation (time point in the 
steady state phase, Figure 4.14) and the total undecaprenyl pyrophosphate generated 
was established.  Figure 4.15 shows the kinetic profile of PBP1a.   
 
Figure 4.15: Kinetics of Lipid II dependence on S. pneumoniae PBP1a transglycosylase activity.  
Initial velocity of PBP1a-dependent undecaprenyl pyrophosphate release (v0) plotted versus [Lys-
Lipid II]. [PBP1a] was present at 77 !M.  At each substrate concentration, the initial velocity 
determinations were performed in duplicate. 
 
Figure 4.15 clearly demonstrates that the maximum concentration of Lipid II used 
was insufficient to even begin to saturate the enzyme.  This prevented the fitting of 
Equation 2 to the data.  As a consequence, the kinetic parameters, Km1, Km2 and kcat, 
could not be derived.   
 
The relationship between velocity versus substrate concentration shows no 
significant deviation from linearity.  This observation could be rationalised in two 
ways.  The first, it could be assumed that Km2 was much greater than Km1, thus the 
relationship would obey the Michaelis-Menten equation (detailed in Appendix B2).  
The second, Equation 2 has been derived based on the assumption that initial rates of 
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transglycosylation were being measured, where two molecules of Lipid II were 
required to bind to the active site, and that the generation of the transglycosylase 
product, Lipid IV, was the rate limiting step (Scheme 2).  If it were assumed that the 
rate-limiting step was before the binding of the second Lipid II substrate, the kinetics 
of transglycosylation would also obey the Michaelis-Menten equation (Appendix B2 
for details).  Given the apparent linear relationship between velocity and substrate 
concentration and that there was no evidence for the approach of Vmax, it can be 
further assumed that the Km was much greater than the substrate concentrations 
tested.  Thus, both explanations would obey Equation 3. 
 
 
Equation 3   
 
 
The gradient of the linear region (Figure 4.15) is equal to kcat/Km, giving a value of 
0.34 s
-1
M
-1
.  
 
4.9. Optimisation of S. aureus MGT and S. pneumoniae PBP1a 
transglycosylase assay conditions 
 
The assay conditions for monitoring transglycosylase activity were basic and not 
optimised to enhance the transglycosylation activity of MGT and PBP1a.  
Consequently, the rates observed would not be fast enough to be physiologically 
relevant.  Various parameters were therefore investigated to enhance the turnover of 
substrates. 
 
4.9.1. Establishing the effect of temperature on transglycosylation 
activity 
 
The temperature selected to perform the assays was based on the denaturation of 
MGT at temperatures reaching 30°C.  PBP1a was stable at higher temperatures and 
its transglycosylase activity was compared at 20°C and 37°C.  At the higher 
temperature, PBP1a activity was not enhanced. 
v
0
=
V
max
S[ ]
K
m
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4.9.2. The effect of metal ions on transglycosylase activity 
 
It has been established that metal ions are essential for transglycosylase activity in 
PBPs and MGTs: in the presence of EDTA, the transglycosylase activity is abolished 
(Schwartz et al., 2002; Terrak and Nguyen-Distèche, 2006).  Terrak and Nguyen-
Distèche (2006) have shown the stimulation of MGT transglycosylase activity with 
different concentrations of metal ions.  Schwartz et al. (2002) have demonstrated the 
effect of various metal ions on the activity of the bifunctional E. coli PBP1b, and 
revealed that the presence of 10 mM CaCl2 enhances E. coli PBP1b 
transglycosylation by 6-fold compared to the MgCl2 standard.  The rates of MGT and 
PBP1a-dependent transglycosylation were analysed (using the assay described in 
Section 2.8.1.2) in the presence of 10 mM MgCl2 and CaCl2.  The observed and 
relative rates are displayed in Table 4.3. 
 
Enzyme Metal ion vobs (nmol/min/mg) krel 
Mg
2+
 3.19 1 
MGT 
Ca
2+
 5.65 1.8 
Mg
2+
 7.85 ! 10
-2
 1 
PBP1a 
Ca
2+
 5.61 ! 10
-2
 0.7 
 
Table 4.3: Relative rates of MGT and PBP1a catalysed transglycosylation in the presence of 
different metal ions.  MGT and PBP1a transglycosylation reactions were performed for 10 min and  
3 h respectively. 10 mM MgCl2 or CaCl2 substituted the metal ion present in the transglycosylase 
buffer (Section 2.8.1.2.1).  Following the incubations, the undecaprenyl pyrophosphate generated was 
determined using the spectrophotometric assay.  The rates observed (vobs) and the relative rate 
constants (krel) (with reference to Mg
2+
) are shown.  The rates are based on duplicated discontinuous 
reactions. 
 
The results show that MGT-dependent transglycosylase activity was enhanced 
almost 2-fold in the presence of Ca
2+
 compared to Mg
2+
.  Terrak and Nguyen-
Distèche (2006) also found that MGT activity was marginally enhanced by the 
presence of Ca
2+
.  Ca
2+
 has an apparent negative influence on the rate of S. 
pneumoniae PBP1a transglycosylase activity.  These results show that different 
transglycosylases have varying sensitivities to metal ions. 
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4.9.3. Does native peptidoglycan influence S. aureus MGT and S. 
pneumoniae PBP1a activity? 
 
It has been documented that Class A PBP transglycosylases, such as E. coli PBP1a 
(Barrett et al., 2007) and PBP1b (Schwartz et al., 2002), exhibit a lag phase.  In 
vitro, upon initiation of a transglycosylase reaction, glycan chains do not exist and 
the enzyme has to perform de novo polymerisation of Lipid II forming a short 
polymeric glycan strand.  In vivo, however, transglycosylases are ‘primed’ by a pre-
existing polymerised precursor (Schwartz et al., 2002).  Therefore, the 
transglycosylase activities of PBP1a and MGT were assessed in the presence of 0.1 
% (w/v) E. coli peptidoglycan (prepared by T. Clarke) (using the assay system 
described in Section 2.8.1.2) to analyse whether existing glycan chains provide a 
scaffold for elongation.  An increase in undecaprenyl pyrophosphate generation was 
not observed, signifying the transglycosylase activities were not enhanced. 
 
4.9.4. Do the presence of lipids common to the bacterial inner 
membrane promote MGT and PBP1a transglycosylation? 
 
Given that cardiolipin and phosphatidyl glycerol greatly improve the 
dephosphorylation activity of the integral membrane protein PgpB, the 
transglycosylase activity of MGT and PBP1a was assessed in the presence of these 
lipids, which provide a more membrane-like environment.  The discontinuous assays 
were performed (as in Section 2.8.1.2) with the addition of 1 mM of either 
cardiolipin or phosphatidyl glycerol.  Neither lipid had a positive effect on the rate of 
MGT or PBP1a transglycosylase activity. 
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4.9.5. Modulation of transglycosylase activity by additives that 
enhance the solubility of enzyme and substrate 
 
It has been well established that the detergent octaethylene glycol monodecyl ether 
(referred to as Decyl PEG) and dimethyl sulfoxide (DMSO) enhance the 
transglycosylase activity of MGTs and PBPs in aqueous solution (Offant et al., 2010; 
Schwartz et al., 2002; Terrak and Nguyen-Distèche, 2006).  Under these conditions, 
a membrane-like environment is created, promoting the solubility of substrate and 
the fusion of substrate and enzyme micelles (Schwartz et al., 2002).  Omission of 
either Decyl PEG or DMSO has been shown to dramatically reduce the 
transglycosylase activity of MGT (Terrak and Nguyen-Distèche, 2006), indicating 
their effects are additive.  The influence of Decyl PEG and DMSO on the 
transglycosylase activities of MGT and PBP1a was therefore investigated. 
 
4.9.5.1. Establishing the effects of Decyl PEG and DMSO on S. aureus 
MGT-dependent transglycosylation 
 
The transglycosylation activity of MGT was analysed (using the assay system in 
Section 2.8.1.2) in the presence of varying concentrations of either Decyl PEG (0-20 
! CMC) or DMSO (0-20 % (v/v)).  Decyl PEG had a detrimental effect on MGT 
transglycosylase activity, with inhibition occurring at high concentrations.  A similar 
effect has been documented for E. coli PBP1b (Schwartz et al., 2002).  DMSO had a 
positive effect on transglycosylase activity (Figure 4.16a).  As it has been 
documented that MGT requires the presence of both Decyl PEG and DMSO for 
optimum activity (Terrak and Nguyen-Distèche, 2006), the combined effect of Decyl 
PEG and DMSO was established; the DMSO concentration providing the greatest 
level of transglycosylase activity (20 % (v/v)) was assayed with a range of Decyl 
PEG concentrations (Figure 4.16b).     
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Figure 4.16: Effect of Decyl PEG and DMSO on MGT transglycosylase activity.  The 
discontinuous assay for MGT transglycosylation was performed for 8 min (as in Section 4.7.3) in the 
presence of the specified concentrations of (a) DMSO (% (v/v)) and (b) Decyl PEG (! CMC) with 20 
% (v/v) DMSO.  The activities are expressed as the total absorbance change at 360 nm due to Pi 
release from undecaprenyl pyrophosphate (primary y-axis) and the concentration of undecaprenyl 
pyrophosphate in the discontinuous assays corresponding to the absorbance change (secondary y-
axis).  Values represent the mean of duplicate reactions.  
 
Figure 4.16a demonstrates that upon increasing the DMSO concentration in the 
assays, the rate of MGT activity also increased, signifying that the activity of the 
enzyme was maintained even at 20 % (v/v) DMSO (the percentage providing 
optimum activity).  Figure 4.16b shows that the transglycosylase activity in assays 
containing 20 % (v/v) DMSO were further increased by the addition of Decyl PEG, 
the concentration of which did not significantly influence the transglycosylase rate 
beyond a concentration of 1 ! CMC.  The transglycosylation reactions with 20 % 
(v/v) DMSO (Figure 4.16a) and 20 % (v/v) DMSO with 0 ! CMC Decyl PEG 
(Figure 4.16b) were identical incubations, despite yielding different amounts of 
undecaprenyl pyrophosphate.  This can be attributed to the day-to-day variation in 
data as previously described (Section 4.7.3), which is discussed in Section 4.13.5. 
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4.9.5.2. Establishing the effects of Decyl PEG and DMSO on S. pneumoniae 
PBP1a-dependent transglycosylation 
 
The individual effects of Decyl PEG and DMSO on the transglycosylase activity of 
PBP1a were analysed in a similar manner as described in Section 4.9.5.1 (the effect 
of Decyl PEG on transglycosylase activity was established in the absence of DMSO).  
The results are displayed in Figure 4.17. 
Figure 4.17:  Effect of Decyl PEG and DMSO on PBP1a transglycosylase activity.  The 
discontinuous assay for PBP1a transglycosylase activity was performed for 3 h (as in Section 4.8.3) in 
the presence of the indicated concentrations of (a) DMSO (% (v/v)) and (b) Decyl PEG (! CMC).  
The primary and secondary y-axes show the total change in absorbance at 360 nm measured using the 
spectrophotometric assay and the corresponding concentration of undecaprenyl pyrophosphate 
generated in the discontinuous assays respectively.  Values represent the mean of duplicate reactions.  
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Figure 4.17 demonstrates that with the full-length PBP1a, in contrast to MGT, Decyl 
PEG (in the absence of DMSO) had a positive effect on the transglycosylase activity, 
which was optimum at 20 ! CMC Decyl PEG (22 mM).  This could signify that the 
detergent enhances the stability of PBP1a via the membrane anchor, a feature that is 
absent in the MGT construct.  PBP1a transglycosylase activity, similar to MGT, 
concurrently increased with the percentage of DMSO in the assay buffer, with 20 % 
(v/v) DMSO resulting in maximum activity observed.  The cumulated effect of 20 ! 
CMC Decyl PEG and 20 % (v/v) DMSO had a further positive impact on the 
transglycosylase activity.  The amount of DMSO or Decyl PEG required to improve 
transglycosylase activity appears to be enzyme specific.  For example, Offant et al. 
(2010) have found that Thermotoga maritima PBP1a-"33 transglycosylase activity is 
optimised in the presence of 2.5-5 ! CMC Decyl PEG with 20 % (v/v) DMSO.  
These concentrations of additives may need further optimisation for the full-length T. 
maritima PBP1a transglycosylase activity. 
 
Based on the parameters varied in the above sections, the optimum assay conditions 
for in vitro PBP1a transglycosylase activity were: 20 mM Tris, 10 mM MgCl2, 0.1 % 
(w/v) DDM, 22 mM Decyl PEG, 20 % (v/v) DMSO, with a 30 sec sonication upon 
initiation with enzyme.  An identical buffer system can be used for optimum activity 
of MGT, with the exchange of 10 mM MgCl2 for CaCl2.  These conditions can be 
applied in future analyses to increase the level of transglycosylase activity observed, 
reducing the amount of limiting enzyme and substrate used and minimising the level 
of background noise.  
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4.10. Does the transglycosylase domain of the Class A S. 
pneumoniae PBP1a function independently of the 
transpeptidase domain? 
 
4.10.1. Transglycosylase activity of PBP1a variants 
 
To investigate the dependency of the transglycosylase activity on a fully functioning 
transpeptidase domain, the transglycosylase activities of wild-type PBP1a and its 
corresponding transglycosylase (E91Q) and transpeptidase (S370A) active site 
mutants were assayed.  Discontinuous transglycosylase reactions were performed 
with the Lys-Lipid II substrate and combinations of enzymes in the optimised buffer 
system (Section 4.9).  The protocol from Section 2.8.1.2 was further modified: total 
reaction volume, 25 !L; volume of reaction added to the spectrophotometric assay, 
20 !L; enzyme concentration, 56 !M; Lys-Lipid II concentration, 0.32 mM.  Assays 
were discontinued after 0 h (to determine background levels) and 2 h.  The results are 
displayed in Figure 4.18, showing the total change in absorbance and the 
corresponding levels of undecaprenyl pyrophosphate generated. 
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Figure 4.18: The transglycosylase activity of PBP1a variants.  The transglycosylase activities of PBP1a, PBP1a-E91Q, PBP1a-S370A and the combined active site mutants 
were assessed (the reactions are labelled on the x-axis of the Figure, where Lys-Lipid II is abbreviated to Lipid II). The level of undecaprenyl pyrophosphate generated after 0 
h (!) and 2 h (!) is displayed in terms of total absorbance change due to PgpB-dependent Pi release following spectrophotometric determinations (primary y-axis) and the 
corresponding [undecaprenyl pyrophosphate] (µM) in the discontinuous assays (secondary y-axis).  Concentrations of each enzyme were equivalent in the reactions.  Control 
reactions comprised of 0 h time points and enzyme only and substrate only incubations.  Values represent the mean ± standard deviation of triplicate reactions. 
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Figure 4.18 clearly identifies that the transglycosylase domain works independently 
of the transpeptidase domain.  The transglycosylase domain of PBP1a-S370A, 
devoid of an active transpeptidase domain, in the presence or absence of 
transpeptidation (a product of PBP1a-E91Q activity), exhibited near equivalent 
levels of activity compared to the wild-type enzyme.  At 0 h, the level of activity 
detected in the enzyme and substrate incubations corresponded to that of the Lipid II 
only control, where substrate degradation contributed to the presence of 
undecaprenyl pyrophosphate observed.  The enzyme PBP1a-E91Q, with a mutation 
of an essential transglycosylase active site residue was incapable of 
transglycosylation as anticipated: the level of undecaprenyl pyrophosphate present 
was analogous to the Lipid II only control.   
 
4.10.2. Statistical analysis of PBP1a-dependent transglycosylation using 
Student’s two-tailed t-test 
 
To determine the statistical significance of the variants of PBP1a-dependent 
transglycosylation, Student’s t-test was performed on the data from Section 2.10.1. 
For clarity of the comparisons, the [undecaprenyl pyrophosphate] produced from the 
0 h incubation was subtracted from the level of undecaprenyl pyrophosphate 
generated after the 2 h incubation, shown in Figure 4.19, where the results from the 
statistical evaluation are also displayed. 
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Figure 4.19: Statistical analysis of the transglycosylase activity of PBP1a active site variants.  To 
reveal the [undecaprenyl pyrophosphate] generated specific to transglycosylase activity, the 
[undecaprenyl pyrophosphate] produced from the 0 h incubations of the controls and PBP1a variants 
with Lys-Lipid II was subtracted from the [undecaprenyl pyrophosphate] produced after the 2 h 
incubations of equivalent reactions (Figure 4.18).  The primary and secondary y-axes represent the 
absorbance change at 360 nm due to Pi release from undecaprenyl pyrophosphate and the 
corresponding concentration of undecaprenyl pyrophosphate respectively. The constituents of each 
reaction are labelled on the x-axis of the Figure.  Values represent the corrected mean ± standard 
deviation of triplicate reactions.  Student’s two-tailed t-test was performed to determine any statistical 
relevance between data sets as detailed on the Figure.  With the exception of the specified incubations 
with PBP1a-E91Q (see Figure), all statistical comparisons of either the Lipid II only or enzyme only 
controls with both Lipid II and enzyme combined, gave p values of <0.0001 (not shown on Figure).  
 
 
The results of the statistical analysis are discussed in Section 4.13.3.4. 
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4.11. Analysis of transglycosylation products by SDS-PAGE 
 
SDS-PAGE separation of glycan polymer products of transglycosylation can reveal 
valuable information about the transglycosylase under investigation.  Information 
regarding the product length and distribution, substrate specificity and roles of 
specific residues in catalysis can be established using this technique (Barrett et al., 
2007).  Initially developed by Schägger and von Jagow (1987) to separate proteins of 
low molecular weight, the SDS-PAGE system was modified by Barrett et al. (2007) 
to analyse polymerised transglycosylation products. 
 
4.11.1. Synthesis of [14C]-labelled Lys-Lipid II 
 
A means of the detection of glycan chains on the SDS-PAGE gel involves the 
incorporation of a radiolabel, and this is achieved via the Lipid II precursor.  The 
protocol for [
14
C]-GlcNAc-labelled Lys-Lipid II synthesis was based upon the 
syntheses of [
14
C]-GlcNAc-labelled Lipid II by Bertsche et al. (2005) and non-
radiolabelled Lys-Lipid II (reported in Section 2.7.3) .  Following the experimental 
procedure described below and detailed in Section 2.7.7, if every reaction proceeded 
to completion then the [
14
C]-GlcNAc-labelled Lys-Lipid II synthesised would have a 
specific activity of 1940 disintegrations per minute (dpm)/nmol.   
 
4.11.1.1.  Experimental details and rational of [14C]-GlcNAc-labelled Lys-
Lipid II synthesis 
 
The synthesis of radiolabelled Lipid II took place in a final volume of 3.5 mL and 
was performed in the reaction buffer: 0.1 M Tris, 5 mM MgCl2, 1 % (v/v) Triton X-
100, pH 8.0.  5.67 µmol (1.62 mM) undecaprenyl phosphate was incubated with 3.5 
mg/mL M. flavus membranes and a total of 6.96 µmol (2 mM) of UDP-MurNAc-
pentapeptide.  The undecaprenyl phosphate limited the total Lipid I and Lipid II 
ultimately synthesised to 5.67 µmol.  Addition of 5 µCi [
14
C]-UDP-GlcNAc (317 
mCi/mmol, supplied in 200 µL, with a concentration of 78.88 µM) provided      
15.78 nmol of ‘hot’ UDP-GlcNAc to the reaction.  140 µg E. coli MurG (expressed 
and purified according to Ha et al. (1999)) was used to supplement the reaction to 
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further facilitate the transfer of GlcNAc from UDP to the MurNAc-C4-hydroxyl of 
Lipid I.  The reaction was incubated for 1 h at 37°C. ‘Cold’ UDP-GlcNAc was then 
added to the incubation, making the total concentration of 35 mM ‘hot’ and ‘cold’ 
UDP-GlcNAc.  The reaction was incubated for a further 2 h at 37°C with intermittent 
mixing.  The reaction was stopped by the addition of 3.5 mL 6 M pyridinium acetate 
(pH 4.2) and 7 mL n-butanol and the lipids were extracted as for non-radiolabelled 
Lipid II (Section 2.7.3.1).  [
14
C]-GlcNAc-labelled Lys-Lipid II was purified using a 
similar approach to non-radiolabelled-Lys-Lipid II as described in Section 2.7.7.2. 
 
On the assumption that 15.78 nmol [
14
C]-UDP-GlcNAc reacted with 5.67 µmol  
Lipid I as a result of MurG activity in the first hour of incubation, 5.65 µmol Lipid I 
would remain, which would be converted to Lipid II by the non-radiolabelled UDP-
GlcNAc in the second stage of the incubation.  If each reaction went to completion, 
and any Lipid II synthesised was not polymerised by the PBPs within the M. flavus 
membrane preparation, a total of 5.67 µmol of [
14
C]-GlcNAc-labelled Lys-Lipid II 
would be produced containing 5 µCi.  This is equivalent to a specific activity of 1940 
dpm/nmol.  The [
14
C]-GlcNAc-labelled Lys-Lipid II is referred to as [
14
C]-Lys-Lipid 
II from here onwards. 
 
4.11.1.2.  Determination of [14C]-Lys-Lipid II purity and concentration 
 
TLC was performed to analyse the purity and concentration of [
14
C]-Lys-Lipid II 
(Section 2.7.8).  The concentration of [
14
C]-Lys-Lipid II was established by 
comparing the intensity of the iodine-stained [
14
C]-Lys-Lipid II band from a 15 µL 
sample to standards of non-radiolabelled Lys-Lipid II with known concentrations.  
Figure 4.20 displays the TLC plate following staining with iodine and the specific 
band due to [
14
C]-Lys-Lipid II imaged by autoradiography.   
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Figure 4.20: TLC plate and the corresponding autoradiograph of [
14
C]-Lys-Lipid II. (a) An 
iodine-stained TLC of [
14
C]-Lys-Lipid II with non-radiolabelled Lys-Lipid II standards.  Lanes 1-5, 
3.48, 6.96, 10.43, 13.91, 17.39 nmol Lys-Lipid II respectively; lane 6, [
14
C]-Lys-Lipid II preparation.  
The bands representing Lipid II (i) and contaminating lipid (ii) are indicated.  (b) An autoradiograph 
of [
14
C]-Lys-Lipid II from (a) following an exposure time of 48 h, using a tritium storage phosphor 
screen and imager.   
 
Figure 4.20 clearly demonstrates that [
14
C]-Lys-Lipid II was synthesised.  
Undecaprenyl phosphate, a major component involved in Lipid II synthesis 
represents the lipid contaminating the [
14
C]-Lys-Lipid II preparation (marked by (i) 
on the figure).  This could be removed by integrating further wash steps during 
purification.  The intensities of the Lipid II standards and the [
14
C]-Lys-Lipid II band 
were measured by pixel analysis using ImageJ software (Abràmoff et al., 2004).  
Figure 4.21 shows the standard curve of different amounts of Lipid II with their 
corresponding intensities following iodine staining.  The mean grey value at 0 nmol 
Lipid II represents the background pixel intensity.   
 
 
 
(i) (i) 
(ii) 
(a) (b) 
1        2        3        4         5               6 
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Figure 4.21: Iodine-stained Lipid II pixel analysis.  The iodine-stained Lipid II standards from the 
TLC (Figure 4.20) were subject to ImageJ pixel analysis, where mean grey values were estimated, 
representing arbitrary units of intensities.  The amounts of Lipid II were plotted against the mean grey 
values.  A trend-line has been fitted to the data by linear regression to extrapolate the quantity of 
[
14
C]-Lys-Lipid II from the relative intensity of the band on the TLC (equation shown on graph). 
 
From the pixel analysis, the concentration of [
14
C]-Lys-Lipid II can be calculated.  
The iodine-stained band had a mean grey value of 49.15, which, according to Figure 
4.21, is equivalent to 22.76 nmol [
14
C]-Lys-Lipid II (resulting from the 15 µL 
sample).  This gives an estimated concentration of 1.52 mM [
14
C]-Lys-Lipid II.  The 
stock of [
14
C]-Lys-Lipid II had 152 cpm/µL, resulting in a specific activity of 100 
cpm/nmol, a value significantly lower than anticipated (1940 dpm/nmol).   
 
4.11.2. SDS-PAGE analysis of glycan chain polymerisation by the 
transglycosylase activities of MGT and PBP1a 
 
The SDS-PAGE gel system for visualising glycan chains was prepared according to 
the method developed by Barrett et al. (2007) with minor adjustments as described in 
Section 2.8.2.  
 
 
 
y = 1.52x + 14.54 
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The transglycosylase assays (Section 2.8.2.2.1) of variants of MGT (MGT and 
MGT-E100Q) and PBP1a (PBP1a, PBP1a-E91Q, PBP1a-!30 and PBP1a with 
ampicillin) were performed with enzyme concentrations of 155 µM and 77 µM 
respectively. Given the low specific activity of the [
14
C]-Lys-Lipid II substrate, a 
concentration of 4.4 mM was used to ensure a signal was detected following 
autoradiography.  Optimised buffer systems were used (Section 4.9), with Decyl 
PEG omitted because it was shown to cause irregular migration of Lipid II through 
the SDS-PAGE gel.  The reactions were incubated for 4 h at 20°C and stopped by 
heat denaturation.  Following SDS-PAGE, the gels were dried without fixing.  
Radiolabelled products were visualised with a tritium phosphor screen for an 
exposure period of 2 weeks.  The results from the autoradiograph are shown in 
Figure 4.22. 
 
Figure 4.22: SDS-PAGE analysis of [
14
C]-Lys-Lipid II polymerisation catalysed by MGT and 
PBP1a variants.  Incubations of the various transglycosylases with [
14
C]-Lys-Lipid II were run on a 9 
% T/2.6 % C (T, total percentage concentration of acrylamide and bis-acrylamide; C, percentage of 
the cross-linker bis-acrylamide) SDS-PAGE gel.  The resultant autoradiographs are shown, labelled 
with the assay constituents.  Assays were performed in the presence of (LII) and absence of (
___
) [
14
C]-
Lys-Lipid II.  (a) Transglycosylation by MGT variants.  (b) Transglycosylation by PBP1a variants.  
The controls are represented by the lanes of [
14
C]-Lys-Lipid II only and enzyme only.  Unpolymerised 
[
14
C]-Lys-Lipid II and the glycan chains are indicated as (i) and (ii) respectively.  Radioactivity was 
detected using a tritium phosphor screen and imager. 
LII 
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Despite the poor resolution of glycan chain separation displayed in Figure 4.22, 
conclusions can be drawn. Polymerised glycan chains migrate through the SDS-
PAGE gel with dependence on their chain length.  [
14
C]-Lys-Lipid II migrates 
towards the bromophenol dye front.  Figure 4.22a demonstrates the transglycosylase 
activity of MGT, where [
14
C]-Lys-Lipid II has been replaced by a high molecular 
weight species.  MGT-E100Q did not catalyse the polymerisation of [
14
C]-Lys-Lipid 
II, confirming the results observed in Section 4.7.1.   
 
The transglycosylation activities of the PBP1a variants are shown in Figure 4.22b, 
which also validate the findings from the discontinuous spectrophotometric assays 
(Section 4.8.1).  PBP1a and PBP1a in the presence of ampicillin (inhibiting the 
transpeptidase activity) were capable of transglycosylation as demonstrated by the 
appearance of higher molecular weight species.  The activity of PBP1a was clearly 
slow: the vast majority of [
14
C]-Lys-Lipid II remained unpolymerised after 4 h.  
PBP1a-E91Q and PBP1a-!30 did not catalyse [14C]-Lys-Lipid II polymerisation as 
indicated by the sole presence of [
14
C]-Lys-Lipid II, which was coincident with the 
[
14
C]-Lys-Lipid II only control. 
 
4.11.3. Time dependency of MGT and PBP1a transglycosylation  
 
The polymer size distribution profiles of the transglycosylases were analysed in a 
time dependent manner.  MGT and PBP1a were incubated with [
14
C]-Lys-Lipid II 
(as described in Section 2.8.2.2.1).  Aliquots were sampled at specified time intervals 
and quenched by heat denaturation.  Figure 4.23 shows the time-dependent 
transglycosylation profile of (a) MGT and (b) PBP1a following SDS-PAGE and 
autoradiography. 
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Figure 4.23:  SDS-PAGE analysis of transglycosylase product distribution with time.  
Autoradiographs of SDS-PAGE-separated glycan chains on a 9 % T/2.6 % C gel.  (a) Time-dependent 
transglycosylation by MGT.  (b) Time-dependent transglycosylation by PBP1a.  Incubation times are 
displayed on the figure.  Unpolymerised [
14
C]-Lys-Lipid II and the glycan chains are indicated as (i) 
and (ii) respectively.  Radioactivity was detected using a tritium phosphor screen and imager.  [MGT], 
155 µM; [PBP1a], 77 µM; [[
14
C]-Lys-Lipid II], 4.4 mM. 
 
A size distribution profile of transglycosylase activity over time was not established 
because the different length polymers were not discretely resolved.  Figure 4.23a 
shows that the level of [
14
C]-Lys-Lipid II decreased with time as the amount of 
MGT-polymerised product increased.  At 0 min there appeared to be a slight degree 
of polymerisation, which probably resulted from a time lapse between initiating the 
transglycosylation reaction, sampling and MGT-denaturation.  By 1 h, all of the 
[
14
C]-Lys-Lipid II had been converted into a polymerised product.   
 
Figure 4.23b demonstrates that following an incubation with PBP1a, there was a 
gradual increase in intensity of the polymerised glycan chains with time, which was 
absent at 0 h.  At the 24 h time point, [
14
C]-Lys-Lipid II still existed, indicative of 
extremely slow PBP1a transglycosylase activity.  The high molecular weight 
polymerised glycan chains appeared to increase in relative molecular weight with 
time.  This could signify the production of longer glycan chains or be an artefact of 
the unresolved polymers.  
 
Separating the different length polymers to a suitable resolution is a prerequisite for 
further enzymatic characterisations using this technique. 
 0 h  
0 
min 
(a) (b) 
(ii) 
(i) 
(ii) 
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1 
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20 
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4.12. A novel approach for the visualisation of glycan chains 
separated by SDS-PAGE 
 
To eliminate the requirement of a radiolabel for the detection of glycan chains on an 
SDS-PAGE gel, a new approach was developed.  Transglycosylated glycan chains 
exhibit a common feature: pentapeptide side stems.  The antibiotic vancomycin can 
bind to the terminal of the pentapeptide, providing the residues at positions 4 and 5 
are D-Ala-D-Ala (Nieto and Perkins, 1971).  This attribute can be exploited in a 
polymer detection system by using a fluorescent analogue of vancomycin: VanFL (a 
BODIPY FL conjugate of vancomycin).  Vancomycin does not bind to a tetrapeptide 
stem, making it a necessity to eliminate transpeptidase or D,D-carboxypeptidase 
activity prior to the transglycosylation of Lipid II. 
 
4.12.1. Suitability of VanFL for the detection of pentapeptide side stems 
 
Initial trials were performed to establish whether VanFL was sufficiently sensitive to 
detect glycan polymers via the pentapeptide side stem.  Following SDS-PAGE and 
fluorescence detection, unbound VanFL was shown to run with the gel front.  When 
pre-incubated with a pentapeptide fragment of L-Ala-"-D-Glu-L-Lys-D-Ala-D-Ala, 
VanFL exhibited different migratory properties signifying binding.  VanFL-bound 
Lys-Lipid II ran in an equivalent position to unbound VanFL on the SDS-PAGE, 
preventing the two from being distinguished.  Consequently, VanFL must be used in 
limiting amounts to prevent a fluorescence signal appearing due to unbound VanFL.   
 
The components of the optimised buffer system (Section 4.9) for MGT and PBP1a 
activity were assessed to analyse their influence on VanFL migration through the 
SDS-PAGE gel.  In the presence of Decyl-PEG, VanFL migration was retarded, 
whereas DMSO prevented a discrete band of VanFL fluorescence.  As a result, both 
components were omitted from transglycosylase assays. 
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4.12.2. SDS-PAGE analysis of glycan chains with VanFL detection 
 
SDS-PAGE gels were prepared as described in Section 2.8.2.1.  Transglycosylation 
reactions of MGT variants (MGT and MGT-E100Q) and PBP1a-S370A were 
performed with 2 mM Lys-Lipid II (Section 2.8.2.2.1).  The transpeptidase activity 
of PBP1a was eliminated by using the transpeptidase active site mutant of PBP1a, 
which has near-equivalent levels of transglycosylase activity to the wild-type 
(Section 4.10).  A polymerisation of 4.4 mM [
14
C]-Lys-Lipid II by MGT was also 
performed.  Following a 4 h incubation at 20°C, the enzymes were removed by heat-
denaturation and centrifugation and the glycan chains were incubated with 24 µM 
VanFL (Section 2.8.2.2.2).  The SDS-PAGE separation of VanFL-bound to MGT 
products of transglycosylation is shown in Figure 4.24. 
 
 
Figure 4.24: VanFL detection of polymerised glycan chains.  Products of transglycosylation with 
bound VanFL were separated on a 9 % T/2.6 % C SDS-PAGE gel.  VanFL fluorescence was detected 
using GeneSnap Gel Doc with a blue light converter and filter for the detection of VanFL 
fluorescence at 512 nm.  Radioactivity was detected using a tritium phosphor screen and imager.       
(a) An autoradiograph of MGT-polymerised [
14
C]-Lys-Lipid II (lane 1) and the equivalent VanFL 
fluorescence (lane 2).  VanFL fluorescence was detected prior to gel-drying and autoradiography. (b) 
Fluorescence of VanFL bound to Lys-Lipid II (lane 1) and to the products of MGT-E100Q (lane 2) 
and MGT (lane 3) activity.  Unpolymerised Lys-Lipid II and the glycan chains are indicated as (i) and 
(ii) respectively. 
 
1       2 1       2        3 
(a) (b) 
(ii) 
(i) 
(ii) 
(i) 
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Figure 4.24a conclusively shows that binding of VanFL enables the detection of 
MGT transglycosylation products.  VanFL fluorescence was detected at an 
equivalent position to the [
14
C]-labelled glycan chains on the autoradiograph.  Figure 
4.24b coincides with the results obtained using [
14
C]-Lys-Lipid II, where VanFL-
bound high molecular weight species appeared in the incubation of Lys-Lipid II with 
MGT, but were absent in the incubation with MGT-E100Q.  Transglycosylation 
products of PBP1a-S370A were not detected by VanFL fluorescence.  PBP1a-S370A 
catalysed transglycosylation at a very slow rate.  After the 4 h incubation, few 
transglycosylated products would have been made, especially in the absence of 
DMSO and Decyl PEG.  Therefore, the sensitivity of VanFL is not sufficient to 
detect the activities of transglycosylases with slow rates of catalysis.   
 
The binding of VanFL to pentapeptide side stems is an effective technique of 
detecting products of transglycosylation (given sufficient quantities are present).  
Analysis of glycan chain size and distribution by VanFL was hindered by poor 
separation on SDS-PAGE gels, a problem previously encountered (Sections 4.11.2 
and 4.11.3).   
 
4.13. Discussion and future work 
 
The work presented in this Chapter provides a valuable foundation for the future 
kinetic characterisations of the transglycosylases.  The following section discusses: 
the biological explanations and implications of the results obtained; strategies to 
resolve issues encountered; future work. 
 
4.13.1. The discontinuous spectrophotometric assay for the detection of 
transglycosylase activity 
 
4.13.1.1.  The success of the discontinuous spectrophotometric assay 
 
In literature, transglycosylase activity is detected by one of two methods: either with 
radiolabelled or fluorophore-labelled substrates (examples included in Offant et al. 
(2010), Schwartz et al. (2002) and Terrak and Nguyen-Distèche (2006)).  The 
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discontinuous spectrophotometric assay system developed in this Chapter has 
provided a novel technique for the kinetic characterisation of transglycosylase 
activity, in a simple, time-efficient manner, with the use of natural substrates.  The 
efficacy of the assay has been proven by the detection of the elusive transglycosylase 
activity of S. pneumoniae PBP1a in addition to that of S. aureus MGT.  The assay 
enables rates of transglycosylase activity to be evaluated in a discontinuous fashion, 
but information regarding the length of polymers produced cannot be extrapolated.  
Ultimately, it would be desirable to develop the assay from a discontinuous to a 
continuous spectrophotometric detection system for transglycosylase activity (further 
discussed in Section 4.13.7). 
 
4.13.1.2.  An identified limitation of the assay system 
 
A recognised limitation of the assay is that heat inactivation of the transglycosylases 
may not have occurred instantaneously.  Quenching the reactions with EDTA was 
evaluated, but the enzymes retained a small degree of activity.  Inhibition with the 
transglycosylase antibiotic, moenomycin, would have been more effective.  
Flavomycin, a combination of antibiotic compounds including moenomycin, was 
assessed as a means to quench the transglycosylase reactions but was shown to have 
no inhibitory effects on the transglycosylase activity.  Moenomycin can be extracted 
from flavomycin with a final yield of 1.92 % (w/w) (Adachi et al., 2006).  This 
apparently low abundance of moenomycin in flavomycin and the obligatory high 
concentrations of Lipid II required in the transglycosylase assays meant that the 
competition of moenomycin versus Lipid II was too weak to register an inhibitory 
effect.  The use of ramoplanin as an inhibitor of MGT activity was also evaluated, 
where it is postulated to bind as a dimer to Lipid II between the membrane and the 
disaccharide component, sequestering the substrate (Hamburger et al., 2009).  In the 
presence of NaCl, a requirement of the assays, ramoplanin formed a precipitate, 
documented as the polymerisation of the ramoplanin-Lipid II complex, forming 
insoluble fibrils (Lo et al., 2000).  
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4.13.2. Kinetic characteristics of S. aureus MGT transglycosylase 
activity 
 
4.13.2.1.  Features of the MGT kinetic profile 
 
The dependence of MGT transglycosylase activity on Lipid II concentration (Figure 
4.10) demonstrated a sigmoidal approach to Vmax, culminating with a reduction of 
enzyme activity at higher substrate concentrations.  MGT has two binding sites: one 
for the elongating glycan chain (donor site) and one for the incoming Lipid II 
substrate (acceptor site).  At time 0, both binding sites will be free of substrate.  
Upon the addition of substrate, Lipid II binding to the donor site may induce a 
conformational change, facilitating the binding of the Lipid II substrate at the 
acceptor site.  This would be advantageous if the binding of the two substrates to the 
donor and acceptor sites occurred in an ordered manner.  
 
An alternative explanation for the initial sigmoidal dependence of velocity on 
substrate concentration is that the detergent concentration was inhibitory at low 
substrate concentrations.  At constant detergent concentrations, with a low 
concentration of Lipid II, there would be an excess of detergent micelles devoid of 
substrate compared to at high Lipid II concentrations.  The crowding caused by 
‘empty’ micelles could interfere with the enzyme activity.  High concentrations of 
detergent have been documented to detrimentally affect the activity of PgpB (Touzé 
et al., 2008) and E. coli PBP1b (Schwartz et al., 2002).  The excess detergent is 
believed to reduce the surface concentration of the substrate as opposed to directly 
inhibiting the enzyme (Schwartz et al., 2002; Touzé et al., 2008). 
 
Beyond the approach of Vmax (at approximately 0.5 mM Lys-Lipid II), MGT 
exhibited severe substrate inhibition.  The classical explanation of substrate 
inhibition is that at high substrate concentrations, the substrate binds in a manner that 
is catalytically incompetent.  Alternatively, if the binding of substrates A and B (to 
the transglycosylase donor and acceptor sites respectively) occurs in an ordered 
mechanism (e.g. A then B), the binding of B to the acceptor site first could prevent 
the binding of substrate A to the donor site and result in inhibition.  Given the 
processive model for transglycosylation (Yuan et al., 2007), newly synthesised 
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products are not released until a threshold chain length is reached (Wang et al., 
2008), indicating that the donor site would generally have substrate A bound 
(Schwartz et al., 2002).   
 
In the assays subsequent to the discovery of MGT substrate inhibition, the 
concentration of Lipid II in the discontinuous spectrophotometric assay was lowered 
to 0.40 mM.  Thus, in S. aureus, in vivo, the concentration of substrate at which the 
MGT is working at its maximum rate must be finely tuned to avoid the immediate 
substrate inhibition following the approach of Vmax. 
 
4.13.2.2.  A kinetic model of MGT activity to derive kinetic constants 
 
A kinetic model describing the characteristic kinetic features of MGT is shown in 
Scheme 3, where Lipid II is the substrate in both donor and acceptor subsites.  The 
enzyme E, combines with the Lipid II substrate, S, in the donor site forming an 
enzyme substrate complex, ES.  A second molecule of Lipid II binds to the acceptor 
site, forming the reactive enzyme substrate complex, ES2.  This complex has two 
fates: substrate inhibition with the formation of ES3, or the formation of product, P, 
and free enzyme, E.  As transglycosylation progresses past the initial formation of 
Lipid IV, the processive model dictates that the substrate in the donor site will 
change by the addition of the disaccharide moiety, thus complicating the scenario 
and is not described by the model in Scheme 3.  However, the assumption is made 
that the constantly polymerising substrate can be ignored as only the initial rates of 
the reaction are being considered. 
 
 
 
 
 
 
Scheme 3 
 
A kinetic equation (Equation 4) can be derived from the reaction scheme (as 
described in Appendix B3) based on the assumption that rapid equilibrium kinetics 
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exist and that Km1 and Km2 are equilibrium constants.  To ensure this mechanism is 
valid, further analyses need to be performed during pre-steady state kinetics, using 
stopped flow experiments for example. 
 
 
 
 
Equation 4   
 
This equation was applied to fit the MGT kinetic data (of Figure 4.10) to establish 
the kinetic constants.  The outcome is displayed in Figure 4.25. 
 
Figure 4.25: The kinetics of Lipid II dependence of MGT-catalysed transglycosylation. (a) A plot 
of MGT-dependent velocity as a function of substrate concentration.  The data was fitted by non-
linear regression to Equation 4 using Graph Pad PRISM 5, with constraints that all parameters must 
be greater than 0 and the initial value of Vmax equal to 0.594 (estimated by non-linear regression from 
the Lineweaver-Burk plot of (b)) (R
2
=0.93).  (b) Lineweaver-Burk plot of Equation 4 (R
2
=0.76). 
 
It is evident from the R
2
 values that the data does not sufficiently correlate with 
Equation 4.  It is also clear that it is likely that there are insufficient data to allow a 
reliable fitting of Equation 4 to the data in Figure 4.25a.  Approximate rough 
estimates of the kinetic parameters could be extracted (Table 4.4); however, their 
validity requires further experimentation as evidenced by the smaller Ks value 
compared to Km2 and the excessively high standard errors that characterise the values 
of the constants. 
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Kinetic constants 
Substrate 
Km1
a
 (mM) Km2
a
 (mM) Ks
a
 (mM) kcat
a
 (s
-1
) 
kcat
a
/Km
a
 
(s
-1
M
-1
) 
Lys-Lipid II 
9.12 ! 10
-4
 
±4.15 
0.44±3.57 
9.75 ! 10
-2
 
±0.95 
13.16 ! 10
-3 
±0.12 
28.92 
Table 4.4: Kinetic parameters of MGT-catalysed transglycosylation.  The data was fitted to 
Equation 4, enabling kinetic constants to be derived. 
a
Values ± standard error based on duplicate 
reactions. 
 
Assuming rapid equilibrium kinetics exist, it may be that the first subsite had a 
higher affinity for the substrate than the second binding site.  This is plausible given 
that a processive model for transglycosylation exists.  However, considering the 
standard errors of similar values, this speculation requires some considerable further 
validation.   
 
The kinetic constants of MGT reported here are comparable with the values obtained 
by Terrak and Nguyen-Distèche (2006).  In the presence of different metal ions, kcat 
was found to vary between 6.3 ! 10
-3
 and 13.0 ! 10
-3
 s
-1
 (Terrak and Nguyen-
Distèche, 2006), which is highly similar to that obtained from the spectrophotometric 
assay (13.2 ! 10
-3
 s
-1
).  There are significant differences between the kcat/Km, which 
can be accounted for by the fact that the published data was characterised by 
Michaelis-Menten kinetics with one substrate binding, whereas the data reported 
here was characterised by a two substrate binding model with substrate inhibition.   
 
4.13.2.3.  Specificity of the MGT substrate 
 
The natural substrate of S. aureus MGT is Lys-Lipid II with a penta-glycine branch 
from L-Lys (Schleifer and Kandler, 1972).  In this study, the substrate provided for 
MGT was Lys-Lipid II, a near-natural substrate.  The absence of a penta-glycine 
branch on Lys-Lipid II could contribute to the observed substrate inhibition of MGT; 
the branch could sterically prevent the substrate from binding in an aberrant manner.  
Previous investigations have shown that MGT is capable of catalysing glycan chain 
polymerisation of Lipid II with varying pentapeptide side chains, for example meso-
DAP-Lipid II (Terrak and Nguyen-Distèche, 2006).  However, studies have not been 
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performed with the natural substrate of MGT, thus the specificity of MGT for the 
amino acids residing in the pentapeptide side chain has yet to be evaluated.  Future 
investigation will decipher whether the pentapeptide side chain is involved in 
recognition by the transglycosylase domain.   
 
4.13.2.4.  A structural explanation for Lipid I inhibition of MGT 
transglycosylation 
 
The competitive inhibition displayed by Lipid I is likely to arise from the obstruction 
of the natural substrate binding sites of MGT.  The transglycosylase domain has two 
binding sites: one for the donor strand (elongating glycan chain) and one for the 
incoming acceptor (Lipid II) (Lovering et al., 2007) (Figure 4.26a).  Following the 
incubation of MGT with a vast excess of Lipid I, both binding sites were likely to 
have bound Lipid I.  This situation is displayed in Figure 4.26b. Lipid I in the 
acceptor site cannot perform a transglycosylation reaction because it lacks a GlcNAc 
moiety, the C4-hydroxyl group of which forms the linkage to the adjacent muramyl 
sugar ring of the substrate in the donor site. The minimal activity detected could have 
resulted from Lipid II accessing the acceptor site (with Lipid I or Lipid II in the 
donor site), enabling a transglycosylation reaction to occur. 
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Figure 4.26: The binding of substrates in the donor and acceptor sites of the transglycosylase 
catalytic cleft.  (a) A transglycosylation reaction can occur when an elongating glycan chain is 
situated in the donor site, with an incoming Lipid II molecule in the acceptor site.  (b) 
Transglycosylation does not occur between Lipid I (shown) or Lipid II in the donor site with Lipid I in 
the acceptor site.  The structural similarities between Lipid I and Lipid II could allow the former 
molecule to be recognised by residues lining the active site cleft, thus competing with Lipid II for 
binding.  
 
The similar structural features present in Lipid I and Lipid II enable the former 
compound to act as an inhibitor, whilst enabling the latter to act as a substrate.  This 
finding has two implications: (a) structure based drug design of the transglycosylases 
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could be centred on a Lipid I analogue and (b) the specificity of the putative flippase 
must distinguish between Lipid I and Lipid II to prevent the former reaching the 
extracellular side of the membrane.  
 
4.13.3. Kinetic characteristics of S. pneumoniae PBP1a transglycosylase 
activity 
 
4.13.3.1.  The time-dependent profile of PBP1a transglycosylation 
 
The time course of PBP1a-dependent transglycosylation did not reach completion 
after 6 h (Figure 4.14).  If PBP1a were only capable of catalysing a single 
transglycosylation reaction between two molecules of Lipid II, Lipid IV would be 
formed without further extension.  As a result one molecule of undecaprenyl 
pyrophosphate would be generated for every two Lipid II molecules 
transglycosylated.  At maximum, 0.28 mM undecaprenyl pyrophosphate would be 
produced from 0.56 mM Lys-Lipid II.  This is far from the concentration obtained 
after a 6 h transglycosylation reaction containing CHAPS detergent, where 
hyperbolic curve signified the reaction was nearing an end point.  The use of CHAPS 
has been documented as a successful solubilising detergent for various PBPs, 
including S. pneumoniae PBP2a devoid of its membrane anchor (Di Guilmi et al., 
1999).  However, purification of S. pneumoniae PBP1a, PBP2b and PBP2x in 
CHAPS caused aggregation, identified via size exclusion chromatography.  A similar 
observation has been made upon purification of T. maritima PBP1a (Offant et al., 
2010).  Therefore, it is likely that CHAPS promoted enzyme denaturation, preventing 
the complete transglycosylation of Lipid II by PBP1a.  In buffer containing DDM, 
PBP1a transglycosylation produced approximately 0.28 mM undecaprenyl 
pyrophosphate after 6 h.  At this time point, the enzyme appeared to be catalysing 
undecaprenyl pyrophosphate production with steady-state kinetics.  Therefore, it can 
be deduced that PBP1a produces glycan chains, which are longer than Lipid IV.   
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4.13.3.2.  The dependence of PBP1a transglycosylation on Lipid II 
concentration 
 
The Lipid II dependence of PBP1a transglycosylase activity demonstrates that 
despite the high concentrations of Lys-Lipid II in the assays, Vmax was not reached.  
This has implications for the Km, which would be high under the assay conditions 
used (speculated to be greater than 1.11 mM), signifying that PBP1a would have a 
low binding affinity for Lipid II in at least one of the substrate binding sites 
(assuming rapid equilibrium kinetics exist).  This result is unexpected given the low 
copy number of Lipid II in vivo (van Heijenoort et al., 1992).   
 
The rate of PBP1a transglycosylase activity measured in vitro, far from matches the 
rate expected in vivo.  During the log phase, S. pneumoniae divide with a rate of (µ) 
20-30 min (Tuomanen, 2006).  At the highest substrate concentration tested, 1.11 
mM Lys-Lipid II, PBP1a transglycosylation proceeded with a turnover value of 1.44 
h
-1
, measured over 3 h.  This is equivalent to the turnover of one molecule of 
substrate per enzyme molecule every 42 min.  Di Guilmi et al. (2003b) determined 
that S. pneumoniae PBP2a has a kcat value of 1.55 ! 10
-4
 h
-1
, which corresponds to 
the turnover of one substrate molecule by one molecule of enzyme approximately 
every 9 months!  The turnover number of PBP1a activity at subsaturating 
concentrations is over 9,000 fold greater than the kcat of PBP2a, although both rates 
are vastly insufficient to support bacterial growth.  The turnover of enzymes 
upstream of the transglycosylases must also be considered.  For example, Hu et al. 
(2003) established E. coli MurG, responsible for the intracellular formation of Lipid 
II from Lipid I and UDP-GlcNAc, has a kcat value of 837 min
-1
.  This is significantly 
faster than the turnover of PBP1a (and PBP2a), and would lead to the accumulation 
of peptidoglycan precursors. Given that there are estimated to be only 1000-2000 
Lipid II molecules per bacterial cell (E. coli) (van Heijenoort et al., 1992), either 
Lipid II is synthesised and subsequently degraded (an energetically unfavourable 
process), or the transglycosylases rapidly polymerise Lipid II.  The latter option 
signifies that either the remaining S. pneumoniae Class A PBP (PBP1b) is 
responsible for the majority of glycan chain formation in vivo or the transglycosylase 
activity of PBP1a (and PBP2a) is substantially greater than estimated from the in 
vitro experiments. Since the presence of either PBP1a or PBP2a is essential for        
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S. pneumoniae viability (Hoskins et al., 1999), the latter option is probable 
(discussed in the following section). 
 
The kcat/Km of PBP1a was determined (based on the assumptions made in Section 
4.8.3 and Appendix B2): 0.34 s
-1
M
-1
.  S. pneumoniae PBP2a (devoid of cytoplasmic 
and transmembrane regions) has a catalytic efficiency of 1 ! 10
-3
 s
-1
M
-1
 (Di Guilmi 
et al., 2003b), 340 orders of magnitude lower than the value for PBP1a.  The N-
terminal truncation of PBP2a construct could account for this discrepancy, which 
may compromise catalytic efficiency.  
 
4.13.3.3.  PBP1a-!30 transglycosylase activity 
 
PBP1a-!30 did not exhibit any transglycosylase activity, which could be explained 
by the instability of the construct (Section 3.8.1.3).  Different levels of truncation 
would establish the minimum requirement of the transmembrane anchor.  Di Guilmi 
et al. (1998) have shown that PBP1a-!37 (devoid of the N-terminal 37 amino acid 
residues encompassing the transmembrane domain) was able to bind the inhibitor 
moenomycin, indicating that with this degree of truncation (and presumably the !30 
truncation analysed here), the active site was in at least a near-native conformation.  
Studies by Sung et al. (2009) have established that the transglycosylase activity of 
full-length E. coli PBP1b is greater than its counterpart devoid of the transmembrane 
anchor and have proposed that the transmembrane helix is essential for protein-
protein and protein-lipid interactions (stabilising the enzyme within its natural 
environment) as opposed to having an involvement in substrate recognition.  The 
role of the transmembrane domain of HMW-PBPs will require further exploration by 
future work.   
 
4.13.3.4.  Statistical analysis of PBP1a transglycosylase activity 
 
The statistical analysis of the transglycosylase activity of PBP1a variants revealed 
that the undecaprenyl pyrophosphate produced from incubations of either PBP1a or 
PBP1a-S370A with substrate was substantially significantly different from the 
corresponding enzyme only and Lys-Lipid II only controls (Figure 4.19).  This 
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demonstrated that undecaprenyl pyrophosphate generation was dependent on the 
presence of transglycosylase and substrate.  The results also demonstrated that the 
transglycosylase domain was capable of functioning independently of the 
transpeptidase domain.  The transglycosylase activity of PBP1a-E91Q (with 
substrate) compared to the enzyme only and Lys-Lipid II only controls gave p values 
of <0.3 and <0.15 respectively, indicating that the signal generated by this mutant, 
attributed to its activity, was not significantly different to that of the controls.   
 
The measurements of product generated after a 2 h incubation of enzyme and 
substrate demonstrated that PBP1a had similar levels of activity compared to PBP1a-
S370A and PBP1a-S370A with PBP1a-E91Q.  However, with p values of <0.04 and 
<0.02 respectively, these results indicated that there was a significant difference 
between the activities, where the wild-type enzyme produced a lower amount of 
undecaprenyl pyrophosphate.  The transglycosylase activity of PBP1a-S370A and 
PBP1a-S370A with PBP1a-E91Q were highly similar (p<0.5).  The results suggest 
that when the transglycosylase activity acts in concert with the transpeptidase 
activity present on the same enzyme molecule, the rate of former activity is reduced, 
compared to if the transglycosylase domain is present in a separate entity devoid of 
transpeptidase activity (in the presence or absence of transpeptidation).  This 
outcome is not unreasonable: if the model proposed by Sung et al. (2009) is correct, 
the transglycosylase domain feeds the polymerising glycan chain (and thus the 
pentapeptide stem) to the transpeptidase domain.  A transpeptidation reaction with an 
adjacent pentapeptide stem could momentarily hinder further transglycosylation until 
the reaction were complete.  The functional dependency of the transpeptidase activity 
on transglycosylation is investigated in Chapter 5. 
 
4.13.3.5.  Factors influencing the rate of PBP1a-dependent transpeptidation 
 
Numerous factors could cause the unrealistic rate of PBP1a transglycosylation.  The 
presentation of the Lys-Lipid II substrate within a detergent micelle may not have 
been suitable, where detergent molecules could mask substrate recognition sites.  
The composition of the Lipid II pentapeptide side chain could be important in 
substrate recognition.  Lys-Lipid II (substrate containing a pentapeptide chain of     
L-Ala-"-D-Glu-L-Lys-D-Ala-D-Ala) was used as a substrate for S. pneumoniae 
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PBP1a.  This differentiates from the S. pneumoniae-specific pentapeptide chain, 
which contains an iso-Gln in the corresponding position of D-Glu (and the existence 
of stem branches (Garcia-Bustos and Tomasz, 1990)).  X-ray crystal structures of 
transglycosylases complexed with the Lipid IV mimetic moenomycin (Figure 1.12) 
reveal that few contacts are made with rings A and D, which are proposed to 
represent the positions of the pentapeptide side chains (Lovering et al., 2008b).  
Thus, it is not believed that the transglycosylases distinguish between Lipid II 
substrates at the peptide stem level.  The transglycosylase activity of PBP1a could be 
analysed with peptide stem variants of Lys-Lipid II to validate this theory.  
 
Optimisations of the assay conditions (discussed in the following sections) enhanced 
the activity of PBP1a to an extent, by providing a more membrane-like environment.  
In vivo, it is expected that factors present in the membranes (such as activating lipids 
or proteins) or environmental conditions promote PBP1a activity, which are absent in 
the in vitro assays.  These features are discussed in detail with reference to the 
transpeptidase activity of PBPs in Section 5.12.4. 
 
4.13.4. Optimisation of assay conditions enhance S. aureus MGT and S. 
pneumoniae PBP1a transglycosylase activity 
 
In vitro, transglycosylase activity is greatly influenced by the assay conditions, 
including various additives, metal ions and pH, which are enzyme-specific.  MGT 
and PBP1a exhibited different sensitivities to metal ions: MGT had a preference for 
Ca
2+
, whereas PBP1a favoured Mg
2+
.   
 
In vitro, transglycosylases perform de novo polymerisation of Lipid II.  This process 
is believed to be inefficient (Schwartz et al., 2002) and can result in a delay in the 
formation of glycan chain products as documented in the transglycosylase reactions 
of E. coli PBP1a (Barrett et al., 2007) and PBP1b (Schwartz et al., 2002).  It is likely 
that an extended cleft (identified by crystal structures of transglycosylases with 
bound moenomycin (Section 1.9.1.4) (Heaslet et al., 2009; Lovering et al., 2007)) 
for interactions with an elongating glycan chain is not utilised by the initial Lipid II 
(Schwartz et al., 2002).  Upon synthesis of the short oligosaccharide primer, the 
transglycosylase adds Lipid II units in a processive manner (Barrett et al., 2007) with 
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steady state kinetics (Schwartz et al., 2002).  As a result of these findings, the 
transglycosylase activities of MGT or PBP1a were evaluated in the presence of E. 
coli peptidoglycan, which was proposed to provide a starting material for 
transglycosylase extension.  The transglycosylase activities of MGT and PBP1a were 
not enhanced.  Born et al. (2006) have also demonstrated that E. coli PBP1a cannot 
incorporate radiolabelled-Lipid II into existing sacculi via transglycosylation.  The 
insoluble nature and Gram-negative origin of the peptidoglycan, with its post-
transglycosylation modifications was likely to impede its purpose of supplying 
glycan chains.  Pre-polymerisation of Lipid II by MGT could establish the preference 
of existing glycan chains as a substrate for the donor site of PBP1a or MGT. 
 
The combination of Decyl PEG and DMSO improved the transglycosylase activity 
of MGT and PBP1a (Section 4.9).  Decyl PEG is a detergent and thus its role in the 
assays could be to increase the solubility and stability of the transmembrane region 
of Lys-Lipid II and integral membrane proteins. DMSO is a small amphiphilic 
molecule that is believed to enhance the solubility of Lipid II (Schwartz et al., 2002).  
It has been demonstrated that DMSO promotes the fluidity and permeability of 
membranes (Gurtovenko and Anwar, 2007), thus DMSO could also enhance micelle 
permeability and fusion.  MGT activity was reduced in the presence of Decyl PEG 
alone, where excess detergent micelles devoid of Lipid II could have interfered with 
the rate at which the enzyme encountered the substrate (Schwartz et al., 2002).   
 
4.13.5. Reducing the day-to-day variation of data 
 
Although the kinetic trends exhibited by MGT and PBP1a transglycosylase activity 
were replicable on a day-to-day basis, the data was not.  This can be explained in one 
of two ways, both in reference to the lipid substrate.  The first, Lys-Lipid II was 
stored in volatile solvents: chloroform/methanol/water 2:3:1 (v/v).  Upon sampling, 
the solvents could have evaporated from the stock, gradually increasing the 
concentration of Lys-Lipid II.  Alternatively, the variability in data could have arisen 
from the insufficient redissolution of Lys-Lipid II, following the removal of solvents.  
Both issues could be resolved by immediately removing the solvents after 
concentration calculations and solubilising the lipid in a suitable storage buffer.   
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4.13.6. Analysis of products from transglycosylation by SDS-PAGE 
 
The synthesis of [
14
C]-Lys-Lipid II was successful, but the specific activity was 
almost 20-fold less than anticipated.  This could have resulted from either the low 
availability of Lipid I (the precursor to Lipid II) in the synthesis or from the low 
activity of MurG.  A better approach would be to synthesise [
14
C]-Lys-Lipid II from 
a known amount of Lipid I provided from a separate synthesis (as performed by 
Bertsche et al. (2005)).    
 
The SDS-PAGE analysis of glycan chain lengths was hindered by the severe 
smearing of substrate and transglycosylase products through the gel.  This occurred 
regardless of whether or not the samples were heat denatured (to remove protein) 
prior to loading.  The level of purity of the buffers used may have contributed to this 
issue.  Until the glycan chains are efficiently resolved, characterisation of the 
transglycosylases using this method cannot be achieved.  In spite of this, the SDS-
PAGE gels did reveal and confirm features of the MGT and PBP1a transglycosylases 
established by the spectrophotometric assays: 
 
• MGT transglycosylation of 66 nmol Lys-Lipid II was complete before 1 h 
• PBP1a transglycosylation of 66 nmol Lys-Lipid II was not complete after an 
overnight incubation (enzyme denaturation is a likely cause) 
• The transglycosylase active site mutants of PBP1a and MGT (E91Q and 
E100Q respectively) were incapable of transglycosylation 
• PBP1a transglycosylation can proceed in the absence of a functioning 
transpeptidase domain 
 
The use of VanFL to detect SDS-PAGE separated glycan chains by fluorescence was 
possible provided that sufficient amounts of polymer were present.  To improve the 
sensitivity and specificity of detecting glycan chains by fluorescence, the precursor, 
Lipid II, could be covalently labelled with a fluorescent molecule (such as 
dansylated-Lipid II as described by Di Guilmi et al. (2003b)).  This would ensure 
that each disaccharide moiety of the glycan chains would be labelled with 
fluorescence. 
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4.13.7. Towards a continuous spectrophotometric assay of 
transglycosylase activity 
 
E. coli PgpB is the undecaprenyl pyrophosphate phosphatase coupling enzyme that 
forms the link between the discontinuous transglycosylase assay and continuous 
spectrophotometric assay for Pi generation.  Following expression and purification of 
PgpB, a sufficient quantity of enzyme with a high rate of phosphatase activity was 
not available to support a continuous assay for transglycosylation.  PgpB expression 
levels would be a primary aspect to improve.  Alternatively, a different source of the 
undecaprenyl pyrophosphate phosphatase activity could be investigated.  Analyses of 
PgpB activity revealed that the phospholipids cardiolipin and phosphatidyl glycerol 
greatly enhanced the activity of the enzyme.  Further optimisations of the conditions 
for PgpB activity could augment the phosphatase activity, including trials of pH 
dependence and the presence of DMSO or Decyl PEG.   
 
The level of the coupling enzyme activity is not the only factor to be considered 
when developing a continuous spectrophotometric assay; the rate of 
transglycosylation must be fast enough to detect on a suitable timescale.  The 
spectrophotometric assays are performed in 200 µL reactions, over 10 times greater 
than the volume of the discontinuous assays described here (Section 2.8.1.2).  
Consequently, the total quantities of enzyme and substrate required would need to be 
substantially higher, which may not be feasible given their limited availability. 
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4.13.8. A high-throughput screening technique for the rapid analysis of 
transglycosylase activity 
 
The initial characterisations of MGT and PBP1a transglycosylase activity presented 
in this Chapter have provided the basis for future investigations.  A number of 
factors influencing the transglycosylase activity need to be addressed to fully 
characterise MGT and PBP1a, including: 
 
• Substrate specificity 
• Optimal buffer conditions (pH, metal ion, DMSO, Decyl PEG, potentially 
having a cumulative effect) 
• Roles of essential active site residues 
• Effect of reconstitution into liposomes (a more membrane-like environment) 
• Significance of the mutations T103S and A124T on PBP1a transglycosylase 
activity.  These two mutations are the only sequence differences in the 
transglycosylase domains of the penicillin-sensitive S. pneumoniae D39 
PBP1a and the penicillin-resistant S. pneumoniae 5204 PBP1a  
 
Development of a 96-well plate spectrophotometric assay for undecaprenyl 
pyrophosphate generation would enable the parallel screening of a variety of 
parameters in a time-efficient manner.  Manually, the assays could be set-up in a 96-
well PCR plate with a total reaction volume of 15 µL in each well, comparable to the 
transglycosylase assays described in this Chapter.  The PCR plate could be incubated 
in a PCR machine at a specified temperature (even with a gradient across the plate) 
for a specified amount of time.  Following heat denaturation, the plate could be 
centrifuged to pellet any precipitated protein.  A multi-channel pipette could then be 
used to transfer 13 µL of the supernatant to a Pi-detection-spectrophotometric assay 
in a 96-well plate.  A plate reader could monitor the absorbance over the course of 
the assay.  Generation of Pi following the addition of an undecaprenyl pyrophosphate 
phosphatase would signify the presence of undecaprenyl pyrophosphate and thus 
transglycosylase activity.      
 
This high-throughput system could ultimately be applied to screen for 
transglycosylase inhibitors, a preliminary step in the discovery of new antibiotics. 
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4.14. Conclusion 
 
A novel spectrophotometric assay for transglycosylase activity has been developed, 
contributing to the preliminary characterisations of S. aureus MGT and S. 
pneumoniae PBP1a.  The assay system will facilitate the elucidation of kinetic 
parameters of all transglycosylases.  It also provides an excellent basis for future 
work to establish the precise mechanism of transglycosylation in terms of substrate 
recognition and catalysis. 
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Chapter 5. Enzymology of transpeptidation: assay 
development towards the kinetic characterisations of the 
penicillin-binding domain of Streptococcus pneumoniae 
PBP1a, PBP2b and PBP2x 
 
5.1. Introduction 
 
For almost half a century, since the inhibition by penicillin led to their discovery, the 
PBP transpeptidases have been recognised as essential enzymes involved in 
maintaining the integrity of the bacterial cell wall (Tipper and Strominger, 1965).  
The penicillin-binding domain of the PBPs is an established target for antimicrobial 
inhibition by #-lactam antibiotics (Ghuysen, 1991).  Consequently, much effort has 
been implemented to biochemically characterise the PBPs, to further the 
understanding of this important group of antimicrobial targets in terms of their 
enzymology and from the perspective of antibiotic development.  The following 
sections discuss the existing knowledge of the PBP catalytic mechanism and the 
current strategies to analyse transpeptidase activity. 
 
5.1.1. Transpeptidation and D,D-carboxypeptidation 
 
The penicillin-binding domain of HMW-PBPs and LMW-PBPs is responsible for 
transpeptidation and D,D-carboxypeptidation (or endopeptidation) respectively 
(Ghuysen, 1991).  Not aforementioned is the potential ability of these enzymes to 
also perform activities of each other to varying extents.  This is plausible given the 
analogous catalytic residues and conserved sequence motifs of the penicillin-binding 
domains of different PBP classes.  Examples include Streptomyces R61 D,D-
peptidase, capable of transpeptidation and D,D-carboxypeptidation (Kumar and 
Pratt, 2005), and E. coli PBP4, capable of D,D-carboxypeptidation and 
endopeptidation (Clarke et al., 2009). It is likely that substrate specificity, e.g. the 
ability to bind an acceptor peptide strand, defines the predominant role of each PBP 
in vivo.  
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The present understanding of the mechanistic enzymology of the three-state model 
for transpeptidation and D,D-carboxypeptidation is illustrated in Figures 5.1 and 5.2 
respectively. The residues involved in substrate binding and catalysis remain 
controversial.  During the formation of the acyl enzyme intermediate, it is believed 
that the conserved Lys of the first motif and the conserved Ser (Tyr in Streptomyces 
R61 D,D-peptidase) of the second motif are involved in a proton relay system (Lee et 
al., 2001; Rhazi et al., 2003).  The $-amino group of Lys (motif 1) is poised in a 
deprotonated state to abstract a proton from the active site serine "OH (motif 1), 
which concomitantly performs a nucleophilic attack of the donor carbonyl carbon 
(Macheboeuf et al., 2006; Nicola et al., 2005; Sauvage et al., 2007).  The "OH of Ser 
(motif 2) could participate in the protonation of the leaving group nitrogen (Rhazi et 
al., 2003).  The subsequent Ser "O could recover a proton from the protonated Lys $-
amino group (Rhazi et al., 2003).  Alternatively, in the deacylation step, Ser/Tyr "O 
(motif 2) (or a deprotonated Lys of motif 3 (Nicola et al., 2005)) could abstract a 
proton from the acceptor (either an amino group or water), activating it for the attack 
of the acyl enzyme intermediate (Lee et al., 2001; Nicola et al., 2005).  Eventually, a 
proton would be back donated to the active site serine (Rhazi et al., 2003).  Clearly, 
further experiments are required to decipher the precise mechanistic details and 
assign roles of the residues in this complex reaction.  
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Figure 5.1: Proposed mechanism for transpeptidation.  The pentapeptide stem of the peptidoglycan is displayed.  During acylation, Lys (motif 1) abstracts a proton from 
the catalytic Ser (motif 1), which concomitantly attacks the donor carbonyl carbon of the penultimate D-Ala (Stem peptide 1), forming an acyl-enzyme intermediate and 
releasing the terminal D-Ala.  In the deacylation step, the acceptor !-amino group of the third position L-Lys (Stem peptide 2) (or the amino group of a branching enzyme 
from L-Lys) cleaves the acyl-enzyme intermediate by forming a cross-link with Stem peptide 1, concurrently regenerating the active site Ser. 
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Figure 5.2: Proposed mechanism for D,D-carboxypeptidation.  The pentapeptide stem of the peptidoglycan is shown.  The acylation step proceeds as for transpeptidation 
(Figure 5.1).  During deacylation, the acyl-enzyme intermediate is hydrolysed by the attack of a water molecule (instead of the amino group of an adjacent peptide stem), 
regenerating the active site serine and releasing a tetrapeptide stem, without the formation of a peptide bond. 
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5.1.2. Existing strategies to monitor transpeptidation or D,D-
carboxypeptidation 
 
The development of appropriate and sensitive techniques to detect transpeptidase 
activity is paramount to gain a comprehensive insight into the kinetic properties of 
the PBPs, information from which could contribute towards the design of novel 
drugs against these antimicrobial targets.  The following sections discuss the current 
kinetic assays for the analysis of transpeptidase or D,D-carboxypeptidase activity. 
 
5.1.2.1. D-ala release assays 
 
Transpeptidase or D,D-carboxypeptidase reactions result in the release of the 
terminal D-Ala from the peptidoglycan pentapeptide stem.  From as early as 1972, 
the detection of D-Ala has been a means of monitoring these activities.  This 
technique is limited by its simplicity; D-Ala released from transpeptidation or D,D-
carboxypeptidation cannot be distinguished.  There are numerous methods to detect 
D-Ala release.  Preliminary experiments performed by Mirelman et al. (1972) 
followed the incorporation of UDP-MurNAc-L-Ala-D-iso-Glu-L-Lys-D-Ala-[
14
C]-
D-Ala into crude membrane preparations of Micrococcus luteus and the PBP-
dependent release of [
14
C]-D-Ala was monitored.  An alternative method to monitor 
D-Ala release is to couple the amino acid to a chromogenic assay, such as the one 
described later in this Chapter. 
 
5.1.2.2. Peptide thioester pseudosubstrates 
 
PBPs can exhibit thioesterase activity, where the hydrolysis of peptide thioester 
substrates can be monitored spectrophotometrically by a decrease in absorbance at 
250 nm, which can be further sensitised by reacting the free thiol groups with 4,4'-
dithiodipyridine (detected at 324 nm) (Wilkin et al., 1993).  The hydrolysis of the 
thioester substrates (donors) can be coupled concomitantly with transpeptidation 
reactions using amino acid substrates (acceptors) (Jamin et al., 1993; Wilkin et al., 
1993).  This approach can be used to monitor the effect of inhibitors, where the 
thioester acts as a reporter substrate.  The inhibition of S. pneumoniae PBP2x by 
arylalkylidene rhodanine derivatives has been examined using this technique 
(Zervosen et al., 2004). 
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5.1.2.3. Substrate analogue and inhibitor binding assays 
 
Substrate analogue and inhibitor binding studies are common techniques to measure 
acylation and deacylation rates of PBPs.  For example, the formation of an acyl-
enzyme intermediate with a substrate analogue or inhibitor can be determined by 
measuring the decrease of the intrinsic protein fluorescence (due to quenching) using 
stopped-flow apparatus (Jamin et al., 1993; Josephine et al., 2006).  Deacylation 
rates can be determined by labelling a PBP with [
3
H]-benzylpenicillin, followed by 
an analysis of the amount of radioactivity retained by the protein over time (Pagliero 
et al., 2004).  A rapid technique to calculate binding constants has been developed by 
Stefanova et al. (2010).  This approach involves the immobilisation of PBPs to a 
surface and subsequent labelling with a biotin-ampicillin conjugate.  Treatment with 
a streptavidin-horseradish peroxide conjugate followed by a reaction with a 
fluorogenic substrate enables the detection of the PBPs.  This provides the basis of a 
competition-binding assay where inhibitors compete with biotin-ampicillin for 
interactions with the PBP.   
 
5.1.2.4. High Performance Liquid Chromatography (HPLC) analysis of 
transpeptidase products 
 
HPLC analysis is the single technique that is able to distinguish between 
transpeptidase and D,D-carboxypeptidase products, which have different retention 
times depending on their retardation in the column material.  The quantities of 
transpeptidation and hydrolysis products separated by HPLC can be measured by 
integration of the peak area, thus providing ratios for transpeptidase and D,D-
carboxypeptidase activity (Wilkin et al., 1993).  Vinatier et al. (2009) have described 
a method where products of D,D-peptidation and transglycosylation can be detected 
by fluorescence during HPLC separation.  D-Cys is incorporated into the 
pentapeptide chain of the peptidoglycan precursor, replacing the penultimate D-Ala.  
Following an incubation with a PBP, the products are treated with fluorescein 
maleimide, fluorescently labelling D-Cys.   
 
Vollmer and colleagues (Bertsche et al., 2005; Born et al., 2006) have used HPLC to 
separate radiolabelled products of transglycosylase and transpeptidase activities.  
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Using this technique, the specificities of E. coli PBP1a (Born et al., 2006) and 
PBP1b (Bertsche et al., 2005) catalysed reactions were analysed using different 
acceptor strands for transpeptidation.   
 
5.1.3. The future of transpeptidase assays 
 
The assays described above aim to elucidate the complex transpeptidation reactions.  
However, kinetic information regarding the transpeptidase activity of many HMW-
PBPs remains scarce.  The recent, highly sensitive HPLC assays designed by 
Vollmer and co-workers (Bertsche et al., 2005; Born et al., 2006) to simultaneously 
analyse transglycosylation and transpeptidation reactions should have stimulated 
substantial progress in the analysis of HMW-PBPs.  However, this has not transpired.  
A key explanation for this is that activity from isolated HMW-PBPs is often 
undetectable or weak in vitro owing to a lack of understanding of the preferred 
substrates (Pratt, 2008) and the absence of a membrane environment.  Thus, 
establishing the optimum conditions for transpeptidation to occur remains 
challenging but is fundamental for advances in this area of research.   
 
The work presented in this Chapter aims to investigate the transpeptidase activities of 
the S. pneumoniae !-lactam resistance determinants.  These enzymes are of 
particular interest as they are the target of antimicrobial activity but are also the 
source of the !-lactam resistance mechanism.  Different assays have been designed 
to analyse transpeptidase activity and rely on the ability to detect the hydrolysis of 
the terminal D-Ala from the peptidoglycan pentapeptide stem as summarised in 
Figure 5.3. 
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Figure 5.3:  Features of transpeptidation exploited to monitor transpeptidase activity in this 
Chapter.  The generation of a tetrapeptide stem or D-Ala was used to analyse transpeptidase (or D,D-
carboxypeptidase) activity by two different techniques labelled on the Figure. 
 
5.2. Experimental aims 
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5.3. Detection of transpeptidase or D,D-carboxypeptidase activity 
using SDS-PAGE 
 
The penicillin-binding domains of S. pneumoniae PBP1a, PBP2b and PBP2x 
catalyse transpeptidation (forming a cross-link between two adjacent peptide side 
chains) and potentially D,D-carboxypeptidation (hydrolysing the terminal peptide 
bond of the peptide side chains) to undefined extents (see Section 5.1.1) (reactions 
reviewed by Sauvage et al. (2008a)).  In both situations, the resulting peptidoglycan 
will consist of either penta- or tetrapeptide side chains and it is this aspect that can be 
exploited to identify transpeptidase or D,D-carboxypeptidase activity.  
 
The SDS-PAGE technique of analysing the products from transglycosylation using 
VanFL, the fluorescent derivative of vancomycin (as described in Section 4.12), can 
be further developed to detect transpeptidation or D,D-carboxypeptidation.  The 
vancomycin constituent of VanFL binds to the penultimate and ultimate D-Ala 
residues of the peptidoglycan pentapeptide stem (Nieto and Perkins, 1971), enabling 
the fluorescence detection of polymerised glycan chains separated by SDS-PAGE.  
VanFL is incapable of binding to the tetrapeptide stem.  Therefore, in situations 
where the terminal D-Ala residue of a glycan chain peptide stem has been 
hydrolysed, either by transpeptidation or D,D-carboxypeptidation, the fluorescence 
signal resulting from VanFL binding would be reduced and a discrete fluorescence 
band that runs at the gel front would signify the presence of unbound VanFL.  A 
drawback to this detection technique is that VanFL-bound Lipid II runs at the same 
position as unbound VanFL on the SDS-PAGE gel.  This prevents analysis of 
transpeptidation or D,D-carboxypeptidation on the Lipid II monomer.  
 
S. aureus MGT was utilised to provide the glycan chain substrate, which can be 
separated by SDS-PAGE (established in Section 4.12.2).  The full-length PBP1a, 
PBP2b and PBP2x and their equivalent membrane-spanning truncates were 
incubated with polymerised substrate at 20°C for 3 hours (experimental details in 
Section 2.9.3).  The glycan chain products were incubated with VanFL and separated 
by SDS-PAGE for the analysis of transpeptidase or D,D-carboxypeptidase activity.  
Figure 5.4 summarises the VanFL fluorescence signal detected following the various 
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incubations.  VanFL was used in limiting amounts, ensuring that all VanFL bound to 
the pentapeptide side chains.  Any unbound VanFL resulted from its inability to bind 
to the tetrapeptide side chain. 
 
Figure 5.4: SDS-PAGE analysis of PBP-dependent transpeptidation or D,D-carboxypeptidation.  
Polymerised glycan chains were provided by MGT transglycosylation of Lys-Lipid II, prior to 
incubation with the transpeptidase variants.  Following enzyme inactivation and removal, VanFL was 
added to each reaction, the products were separated by SDS-PAGE and VanFL-specific fluorescence 
was detected using GeneSnap Gel Doc with a blue light converter and filter (Section 2.9.3).  VanFL is 
present in each lane in addition to the stated components; the reactions containing both Lipid II and 
MGT refer to the product of transglycosylation, glycan chains; the PBPs originate from S. pneumoniae 
unless otherwise stated.   
 
The results from the fluorescence based SDS-PAGE gel analyses are inconclusive: 
the lanes containing the S. pneumoniae PBPs show little deviation in fluorescence 
from the glycan chain only control.  Transpeptidase or D,D-carboxypeptidase 
activity of the S. pneumoniae PBPs was not apparent, but the activity could be 
present at considerably low levels. The control enzyme E. coli PBP4, a highly active 
D,D-carboxypeptidase (and endopeptidase) (Clarke et al., 2009), clearly 
demonstrated D-Ala hydrolysis from the pentapeptide stem of the glycan chains; 
there is a substantial loss of fluorescence signal in the glycan chain expected region 
of the gel, and there is an intense fluorescent band at the gel front signifying unbound 
VanFL.  The PBP4 control exemplifies that this technique is valid for demonstrating 
the hydrolysis of the terminal D-Ala from a pentapeptide stem of a polymerised 
glycan chain, but relies on an enzyme with extensive D-Ala hydrolysis activity.   
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____ E. coli 
PBP4  
PBP2b 
PBP2b-
"39 
PBP2x 
PBP2x-
"48 
PBP1a-
"30 
         Glycan chains 
PBP1a 
 209 
5.4. Continuous spectrophotometric assay for PBP transpeptidase 
or D,D-carboxypeptidase-dependent D-Ala release 
 
The penicillin-binding domains of PBPs are capable of hydrolysing the terminal D-
Ala from the peptidoglycan pentapeptide side chain through either transpeptidase or 
D,D-carboxypeptidase activity.  The generation of D-Ala could be followed by two 
continuous spectrophotometric assays outlined in Figure 5.5.   
 
Assay (a) couples the esterification of D-Ala with D-Lac via the D-Ala-D-Lac ligase, 
VanA, with the concomitant conversion of the ATP cofactor to ADP and Pi.  The 
production of ADP (assay ai), a substrate of pyruvate kinase, is then coupled to the 
dephosphorylation of phosphoenolpyruvate to pyruvate (yielding ATP).  Pyruvate, in 
turn, is reduced to lactate by lactate dehydrogenase using the NADH cofactor, which 
is oxidised to NAD
+
, monitored by a change in absorbance at 340 nm.  Alternatively, 
the released Pi (assay aii) can be linked to the phosphorolysis of the chromogenic 
nucleoside MESG by PNP (as described in Section 4.4) releasing ribose-1-phosphate 
and 7-methyl-6-thioguanine giving a spectrophotometric signal at 360 nm.   
 
Assay (b) is a recognised method of detecting D-Ala release from D,D-
carboxypeptidases (Gutheil et al., 2000).  It relies on the oxidative deamination of D-
Ala catalysed by D-amino acid oxidase (DAAO) with the formation of pyruvate, 
NH3 and H2O2.  Horseradish peroxidase (HRP) oxidises H2O2 to O2 with the 
simultaneous breakdown of Amplex Red to resorufin giving a change in absorbance 
at 555 nm.  Assay (a) was designed to combat issues with false positive signals 
produced from the breakdown of Amplex Red in assay (b) under long incubation 
times in the buffer system used.   
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Figure 5.5: Continuous spectrophotometric assays for D-Ala release.  (a)  VanA catalyses the ligation of D-Ala and D-Lac, with the concomitant use of ATP, which is the 
source of spectrophotometric analysis.  (i) Pyruvate kinase utilises ADP, converting phosphoenol pyruvate to pyruvate, and generating ATP.  Pyruvate is reduced to lactate, 
catalysed by lactate dehydrogenase with the concurrent oxidation of NADH to NAD
+
, detected by a change in absorbance at 340 nm.  (ii) Pi is involved in the phosphorolysis 
of 7-methyl-6-thioguanosine catalysed by purine nucleoside phosphorylase, generating 7-methyl-6-thioguanine, which can be monitored by absorbance at 360 nm. 
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Figure 5.5 (continued): Continuous spectrophotometric assays for D-Ala release. (b) D-amino acid oxidase catalyses the oxidation of D-Ala to pyruvate, producing 
hydrogen peroxide.  Horseradish peroxidase uses hydrogen peroxide to catalyse the breakdown of Amplex Red to resorufin, which absorbs strongly at 555 nm.  
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The assays outlined above are specific for D-Ala release only and do not provide a 
means of distinguishing between transpeptidation and D,D-carboxypeptidation. 
 
5.5. The D-Ala-D-Lac ligase coupling enzyme for D-Ala detection 
 
The kinetic characteristics of VanA (Appendix C1), having a minimal preference for 
D-Ala in its second substrate binding site, make it a suitable D-Ala-D-Lac ligase for 
use in the coupled assays for D-Ala release. 
 
5.5.1. Expression and purification of VanA 
 
The vector pET28d::vanA (E. faecalis vanA cloned into the pET28d vector) was 
provided by S. Batson.  VanA was expressed and purified according to Batson 
(2010) (described and illustrated in Appendix C2). 
 
5.5.2. Characterisation of the VanA-coupled assay for D-Ala 
hydrolysis by Pi release 
 
To establish that the VanA-coupled assay was capable of monitoring D-Ala release 
in a continuous manner, a control enzyme known to hydrolyse D-Ala from the 
peptidoglycan peptide stem was required.  This role was fulfilled by the 
Actinomadura sp. R39 D,D-peptidase (kindly provided by J-M. Frère, Univeristy of 
Liège), a well-characterised water-soluble (loosely membrane associated) Class C 
PBP that exhibits D,D-carboxypeptidation and transpeptidation in vitro (Granier et 
al., 1992).  The dependence on all assay components for the detection of D-Ala was 
confirmed by the continuous spectrophotometric assay time course (Figure 5.6) 
(experimental details in Section 2.9.1.1).  Reactions initiated in the absence of a 
single assay constituent (Figure 5.6, point (a)) did not show a change in absorbance 
at the specified wavelength until the omitted component was introduced (Figure 5.6 
point (b)).  D-Ala release was reliant on the presence of D,D-peptidase and the 
peptidoglycan fragment substrate.  The antibiotic ampicillin, demonstrated the !-
lactam-sensitivity of the PBP.  The S. pneumoniae PBPs of future interest require the 
presence of detergent to remain soluble.  Consequently, 0.1 % (w/v) DDM was 
assessed in the coupled assay and confirmed not to influence the coupling enzymes.   
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Line 
Assay components present 
at time 0 min 
Assay component 
added at point (a) 
Assay component 
added at point (b) 
 Pi detection reagents, VanA, 
D-Lac, ATP, D,D-peptidase 
UDP-MurNAc-meso-
DAP-pentapeptide 
n/a 
 Pi detection reagents, VanA, 
D-Lac, ATP, UDP-MurNAc-
meso-DAP-pentapeptide 
D,D-peptidase n/a 
 Pi detection reagents, 
ampicillin, VanA, D-Lac, ATP, 
D,D-peptidase 
UDP-MurNAc-meso-
DAP-pentapeptide 
D-Ala 
 Pi detection reagents, VanA, 
D-Lac, D,D-peptidase 
UDP-MurNAc-meso-
DAP-pentapeptide 
ATP 
 Pi detection reagents, D-Lac, 
ATP, D,D-peptidase 
UDP-MurNAc-meso-
DAP-pentapeptide 
VanA 
 Pi detection reagents, VanA, 
ATP, D,D-peptidase 
UDP-MurNAc-meso-
DAP-pentapeptide 
D-Lac 
 
 
Figure 5.6: Continuous spectrophotometric time course demonstrating the dependence on assay 
components for the detection of Actinomadura R39 D,D-peptidase activity.  The embedded table 
describes the assay components present at time 0 min, and at points of addition (a) and (b).  Pi 
detection agents: 1 unit PNP, 400 µM MESG.  [UDP-N-acetylmuramyl-L-Ala-"-D-Glu-meso-DAP-D-
Ala-D-Ala] (abbreviated to UDP-MurNAc-meso-DAP-pentapeptide) was 100 µM and [Actinomadura 
R39 D,D-peptidase] was 35 nM in each reaction.  
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The VanA-coupled assay exhibited a lag phase prior to the steady state velocity, 
where the substrate of VanA, D-Ala, from the initial reaction of the coupled 
sequence, was accumulating.  This is a feature occasionally observed in enzyme-
coupled assays and is caused by coupling enzyme insufficiency.  The lag phase 
(dependent on the coupling enzymes, not the initial enzyme (Easterby, 1973)) could 
be minimised by additional VanA.  The length of the linear, steady state velocity 
period (determined by the initial enzyme) was sufficient to allow rate measurements 
to be calculated.  It was ensured that the D,D-peptidase reaction remained rate-
limiting at the highest substrate concentrations and further addition of VanA did not 
enhance the rate of D-Ala production. 
 
5.6. Kinetic characterisation and substrate specificity of 
Actinomadura R39 D,D-peptidase using the VanA-coupled 
assay system for detection of D-Ala release 
 
The suitability of the VanA-coupled assay system for the kinetic characterisation of 
PBP-mediated transpeptidase and D,D-carboxypeptidase activity was established 
using Actinomadura R39 D,D-peptidase.  This enzyme has been characterised in 
detail, both kinetically (Anderson et al., 2003) and structurally (Sauvage et al., 
2005).  Anderson et al. (2003) have examined the activity of the enzyme with 
various synthetic peptidoglycan mimetic substrates by monitoring the hydrolysis of 
the peptide bond spectrophotometrically.  Two of the synthetic peptide substrates 
used were: D-#-Aminopimelyl-$-D-Alanyl-D-Ala and $-Aminohexanoyl-D-Alanyl-
D-Ala.  Both represent peptide analogues of the three amino acids at the terminal of 
the peptidoglycan stem peptide.  The former is a mimetic analogue of Actinomadura 
peptidoglycan (i.e. meso-DAP-D-Ala-D-Ala positions 3-5 of the stem peptide), 
whereas the latter is a peptide analogue of Gram-positive peptidoglycan (i.e. L-Lys-
D-Ala-D-Ala positions 3-5 of the stem peptide).  Although the D,D-peptidase rapidly 
hydrolyses both substrates, the Actinomadura R39 D,D-peptidase shows specificity 
towards the amino acid at position 3 of the peptidoglycan peptide side chain, 
suggesting recognition of meso-DAP is key to the reaction catalysed (Anderson et 
al., 2003).  
 
 215 
Similar to the peptidoglycan analogues utilised by Anderson et al. (2003), two UDP-
linked peptidoglycan precursors were used as substrates for the kinetic 
characterisation of Actinomadura R39 D,D-peptidase: UDP-N-acetylmuramyl-L-
Ala-"-D-Glu-meso-DAP-D-Ala-D-Ala and UDP-N-acetylmuramyl-L-Ala-"-D-Glu-
L-Lys-D-Ala-D-Ala (provided by A. Catherwood).  The structures of these substrates 
vary only at position 3 of the pentapeptide side chain, where the former substrate has 
a carboxyl group present on the $-carbon atom in addition to the $-amino group of 
the third position L-Lys in the latter substrate, generating a meso-DAP residue. 
 
The kinetic characterisation of Actinomadura R39 D,D-peptidase with UDP-N-
acetylmuramyl-L-Ala-"-D-Glu-meso-DAP-D-Ala-D-Ala was completed using the 
assay outlined in Figure 5.5aii (experimental details in Section 2.9.1.1.2), and the 
equivalent characterisation with the near identical substrate UDP-N-acetylmuramyl-
L-Ala-"-D-Glu-L-Lys-D-Ala-D-Ala was performed using the assay depicted in 
Figure 5.5ai  (experimental details in Section 2.9.1.1.1).  Extreme phosphate 
contamination present in the latter substrate (resulting from co-elution during 
purification) dictated that D-Ala release was detected by monitoring ADP release.   
 
A hyperbolic relationship was displayed between the D,D-peptidase initial velocity 
and the substrate concentration of both UDP-linked-N-acetylmuramyl pentapeptide 
substrates (Figure 5.7).  Consequently, the kinetic data was fitted to the Michaelis-
Menten equation by non-linear regression (Equation 1) to solve kcat and Km. 
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Figure 5.7: Kinetics of dependence of Actinomadura R39 D,D-peptidase on UDP-linked-N-
acetylmuramyl pentapeptide substrates.  Velocity of Actinomadura R39 D,D-peptidase-dependent 
D-Ala release (established by the VanA-coupled assay system) at different substrate concentrations.  
(a) Initial velocity plotted versus [UDP-N-acetylmuramyl-L-Ala-"-D-Glu-meso-DAP-D-Ala-D-Ala] 
(referred to as UDP-MurNAc meso-DAP pentapeptide).  (b) Initial velocity plotted versus [UDP-N-
acetylmuramyl-L-Ala-"-D-Glu-L-Lys-D-Ala-D-Ala] (referred to as UDP-MurNAc L-Lys 
pentapeptide).  [Actinomadura R39 D,D-peptidase] was constant at 35 nM.  Data were fitted by non-
linear regression to Equation 1. 
(a) 
(b) 
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The kinetic parameters of Actinomadura R39 D,D-peptidase with the UDP-linked 
peptidoglycan fragments are presented in Table 5.1. 
 
Kinetic constants 
Substrate Assay 
Km
a
 (µM) kcat
a
 (s
-1
) 
kcat
a
/Km
a
      
(s
-1
M
-1
) 
UDP-N-
acetylmuramyl-
L-Ala-"-D-Glu-
meso-DAP-D-
Ala-D-Ala 
D-Ala release 
by Pi 
detection 
(Figure 5.5aii) 
22.04±3.40 7.52±0.40 3.41 ! 10
5
 
UDP-N-
acetylmuramyl-
L-Ala-"-D-Glu-
L-Lys-D-Ala-D-
Ala 
D-Ala release 
by ADP 
detection 
(Figure 5.5ai) 
495.80±64.15 11.98±0.56 2.41 ! 10
4
 
 
Table 5.1:  Kinetic parameters of D-Ala hydrolysis catalysed by Actinomadura R39 D,D-
peptidase.  The D-Ala hydrolysis was monitored by the assay system stated, referring to the reaction 
pathway displayed in Figure 5.5a.  The kinetic constants were derived according to Equation 1, 
following fitting of the data by non-linear regression (using Graph Pad PRISM 5) with R
2
 values of 
0.96 and 0.98 for the substrates UDP-N-acetylmuramyl-L-Ala-"-D-Glu-meso-DAP-D-Ala-D-Ala and 
UDP-N-acetylmuramyl-L-Ala-"-D-Glu-L-Lys-D-Ala-D-Ala respectively. aValues ± standard error. 
 
In support of the kinetic data collected by Anderson et al. (2003), the data presented 
in Table 5.1 demonstrates that Actinomadura R39 D,D-peptidase has a selective 
specificity for a meso-DAP residue residing at position 3 in the pentapeptide chain of 
the UDP-linked peptidoglycan precursor.  D-Ala is hydrolysed from the UDP-linked 
peptidoglycan fragment with a kcat/Km of 15! greater magnitude when the $-carbon 
atom is supplemented with a carboxyl group in addition to the $-amino group.  The 
higher kcat/Km arises from the lower Km, with a minimal difference between the two 
values of kcat for the different substrates.  This suggests that the third position of the 
pentapeptide side chain is subject to a specific recognition by the enzyme.  Structural 
analyses of Actinomadura R39 D,D-peptidase by Sauvage et al. (2005) and 
Dzhekieva et al. (2010) have confirmed the presence of a suspected binding pocket 
specific for the D-#-aminopimelyl side chain (discussed in Section 6.1.3.1, Figure 
6.1), which features a hydrophobic cleft for the short carbon chain and strong 
hydrogen binding for the polar terminus of the amino acid residue (Sauvage et al., 
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2008b).  The latter attribute could significantly contribute to the difference in Km of 
D,D-peptidase with the two substrates used in this study, where the additional 
carboxyl group of the meso-DAP side chain could promote stronger hydrogen 
bonding to the PBP-active site in comparison to that of L-Lys. 
 
5.7. Spectrophotometric assays for the detection of D-Ala release 
by S. pneumoniae Class A and B PBPs 
 
5.7.1. Substrate selection 
 
To maximise the probability of observing activity from the penicillin-binding domain 
of Class A and B PBPs (a rare experience in vitro), a substrate most resembling the 
natural substrate was essential.  In reference to S. pneumoniae PBPs, monomeric or 
polymerised Lys-Lipid II fulfilled this role (D-Glu replaced the S. pneumoniae-
specific iso-Gln (Garcia-Bustos and Tomasz, 1990) at position 2 of the Lys-Lipid II 
pentapeptide side chain as the latter form was unavailable).  Soluble peptidoglycan 
fragments (such as a UDP-MurNAc pentapeptide) were not employed to examine the 
full-length PBP activity because they may have lacked a component vital for 
substrate recognition by these enzymes.   
 
5.7.2. The Amplex Red assay: a sensitive system for D-Ala detection 
 
The continuous spectrophotometric VanA coupled assay can be used to characterise 
PBPs with high rates of catalysis.  Enzymes exhibiting low rates of catalysis could be 
monitored using the VanA-coupled assay system in a discontinous manner.  
Difficulties arise when the enzyme of interest has a slow rate of catalysis, and uses a 
substrate of high expense in limited supply (i.e. Lipid II).  
 
The Amplex Red assay (Figure 5.5b) was employed to monitor D-Ala release by the 
transpeptidase activities of the S. pneumoniae Class A and B PBPs.  This assay is 
five times more sensitive for D-Ala detection than the VanA-coupled assay (compare 
the molar extinction coefficients of the absorbing molecules in the assays shown in 
Figure 5.5).  The increased sensitivity of the Amplex Red assay was crucial to 
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optimise the detection of the PBP D-Ala hydrolysis activity, which was anticipated 
to be low in vitro.   
 
The Amplex Red assay is well-established and has been used to characterise the 
D,D-carboxypeptidase activity of various PBPs including E. coli PBP5 (Stefanova et 
al., 2002), E. coli PBP4 (Clarke et al., 2009) and N. gonorrhoeae PBP3 (Peddi et al., 
2009).  The assay has been fully characterised and factors such as the production of 
H2O2 have been confirmed not to interfere with the functioning of the assay 
constituents (Clarke et al. (2009) and Clark (2008) for details).  For the purposes of 
this study, the presence of 0.1 % (w/v) DDM in the assay, essential for maintaining 
lipid and membrane protein solubility, was investigated and shown to have no effect 
on the coupling system.  
 
5.8. Development of a discontinous spectrophotometric assay for 
the D-Ala release activity of S. pneumoniae PBP1a, PBP2b and 
PBP2x  
 
5.8.1. Production of polymerised Lipid II substrates 
 
To establish whether the D-Ala hydrolysis activities of S. pneumoniae PBP1a, 
PBP2b and PBP2x have a substrate preference for a polymerised glycan chain 
(reminiscent of the peptidoglycan structure) over the monomeric Lipid II subunit, 
synthesis of the former substrate was required.  This was achieved by incubating 
MGT or PBP1a-S370A with Lys-Lipid II; both enzymes have validated active 
transglycosylase domains (Chapter 4).   
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5.8.1.1. Discovery of a contaminating enzyme with D-Ala hydrolysis 
activity 
 
The Amplex Red assay was used to confirm the anticipated minimal background 
levels of D-Ala contamination following transglycosylation.  Unexpectedly, both 
MGT and PBP1a-S370A demonstrated significant D-Ala hydrolysis activity (despite 
lacking active transpeptidase domains), which was not an artefact of the assay or D-
Ala contamination in the enzyme or Lipid II preparations.  Incubation of the 
transglycosylases with a 10-fold excess concentration of ampicillin prior to the 
addition of Lys-Lipid II dramatically reduced the production of D-Ala in the MGT 
and PBP1a-S370A reactions.  Inhibition by a !-lactam is a specific property of the 
penicillin-binding proteins, signifying that the contaminating protein was a PBP, the 
sole source of which would have been from the E. coli host upon target protein 
expression.  The inability to totally eliminate the D-Ala hydrolysis activity in the 
MGT preparation indicated that more than one contaminating PBP could have been 
present with different !-lactam sensitivities. 
 
5.8.1.2. Investigating the identity of the contaminating D-Ala hydrolysing 
enzyme 
 
In an attempt to identify the contaminating E. coli PBP by its molecular weight, the 
preparations of MGT and PBP1a-S370A were pre-incubated with BOCILLIN FL 
(see Section 3.7) and analysed by SDS-PAGE.  The SDS-PAGE gel failed to 
highlight any contaminating protein with BOCILLIN FL-dependent fluorescence.  In 
a comparative assay to that involving ampicillin (Section 5.8.1.1), it was found that 
BOCILLIN FL was incapable of reducing or eliminating the D-Ala hydrolysis 
activity.  The large fluorescent constituent of BOCILLIN FL could have sterically 
prevented the reaction with the active site serine of the contaminating PBP.  
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5.8.1.3. Removal of the contaminating D-Ala hydrolysis activity  
 
Despite the identity of the enzyme responsible for the contaminating D-Ala 
hydrolysis activity remaining elusive, it needed to be eradicated so as not to interfere 
with future PBP characterisation studies. Developing a purification method that 
ensured the elimination of the contaminating enzyme from the MGT and PBP1a-
S370A preparations would imply its absence from the other PBP protein 
preparations. 
 
MGT and PBP1a-S370A were purified using IMAC under denaturing conditions 
(2M urea), but this resulted in protein aggregation and precipitation.  MGT was also 
purified in the presence of ampicillin to inactivate the D-Ala hydrolysis activity.  
This successfully reduced the level of the contaminating D-Ala hydrolysis activity, 
although a significant level remained, comparable to that contaminating the PBP1a-
S370A enzyme preparation.  There are many other possible solutions to eliminate the 
contaminating activity, which are discussed later in this Chapter.  
 
Regardless of the persistent contaminating D-Ala hydrolysis activity in the enzyme 
preparations required to make the glycan chain substrates, the transpeptidase/D,D-
carboxypeptidase activities of S. pneumoniae PBP1a, PBP2b and PBP2x were 
analysed.  Appropriate control experiments eliminated the impact of the 
contaminating D-Ala hydrolysis activity, ensuring that any activity detected was 
specific to the PBP under investigation. 
 
5.8.2. Duration of enzyme incubations with substrate 
 
Long incubation times of the S. pneumoniae PBP1a, PBP2b and PBP2x with the 
Lys-Lipid II substrate were essential to allow the maximum opportunity to detect D-
Ala hydrolysis.  6 h and 18 h incubations were completed at 20°C and D-Ala 
hydrolysis was detected using the Amplex Red assay (Section 2.9.2.1 for 
experimental details).  The 6 h incubations gave changes in absorbance that could not 
be reliably distinguished from background levels, whereas a significant increase in 
absorbance was detected following the 18 h incubations.   
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5.8.3. Experimental design 
 
A detailed account of the experimental procedures for measuring the D-Ala 
production by S. pneumoniae PBP1a, PBP2b and PBP2x, including their equivalent 
active site mutants (PBP1a-S370A, PBP1a-E91Q, PBP2b-S391A, PBP2x-S337A) is 
described in Section 2.9.2.1.  Briefly, 45 µM of each PBP (or 120 µM MGT) was 
incubated for 18 h at 20°C with the specified substrate (either Lys-Lipid II or a 
polymerised form obtained through a pre-incubation of Lys-Lipid II with MGT or 
PBP1a-S370A).  Lys-Lipid II was present at a final concentration of 0.33 mM (prior 
to any enzymatic processing i.e. transglycosylation), ensuring the concentration of 
available pentapeptide chains was identical in each reaction.  The buffer used was 
that optimised for PBP1a transglycosylation (Section 4.9): 20 mM Tris, 1 mM 
MgCl2, 0.1 % (w/v) DDM, 22 mM Decyl PEG, 20 % (v/v) DMSO, pH 8.0.  
Following the overnight incubation, the protein was inactivated by heat denaturation.  
This method was chosen over !-lactam inactivation because the protein needed to be 
removed prior to D-Ala analysis by the Amplex Red assay.  The precipitated material 
was pelleted by centrifugation and the presence of D-Ala in the supernatant was 
determined using the Amplex Red assay.   
 
5.9. Analysis of PBP1a-dependent transpeptidation or D,D-
carboxypeptidation.  
 
5.9.1. D-Ala release activity of PBP1a 
 
PBP1a is a bifunctional enzyme, capable of transglycosylation (established in 
Chapter 4) and transpeptidation.  Under the assay conditions described above, the 
ability of the penicillin-binding domain to hydrolyse D-Ala, either from a monomeric 
or polymeric Lys-Lipid II substrate, was assessed.  The results are presented in 
Figure 5.8, displaying the raw experimental data, and the corrected data (revealing 
the level of activity specific to the enzyme of interest, irrespective of background 
signals).  
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Figure 5.8 (following page): S. pneumoniae PBP1a-dependent D-Ala release.  Variants of PBP1a 
were incubated with Lys-Lipid II and MGT-polymerised Lys-Lipid II for 18 h. The Amplex Red 
assay determined the level of D-Ala release resulting from either transpeptidation or D,D-
carboxypeptidation.  The primary y-axis shows the absorbance change at 555 nm due to the presence 
of D-Ala and the secondary y-axis shows the corresponding [D-Ala] in the discontinuous assay.  The 
lanes are labelled with the reaction components and have been designated a number.  The raw 
experimental data (!) (a) and the corrected data (!) (b) are shown.  The corrected data was 
established by subtracting the raw value of the controls (enzyme only and Lipid II only) away from 
the raw value of the combined enzyme with Lipid II incubations, giving a true estimation of D-Ala 
release activity.  Enzyme only and Lys-Lipid II only controls are represented in lanes 1-8. The 
reactions of MGT with Lipid II (lane 9), and PBP1a-S370A with Lipid II (lane 13), enzymes only 
capable of transglycosylation, show significant levels of contaminating D-Ala hydrolysis activity 
present in the enzyme preparations.  To correct for this, the raw value of [D-Ala] generated upon 
incubation with Lipid II and MGT or PBP1a-S370A (lanes 9a and 13a respectively) was subtracted 
from the raw data of reactions incubated with an additional PBP (lanes 12a, 14a and 15a) (further to 
the subtraction of the value for the enzyme only control).  The black-dashed line on lane 10b signifies 
the level of PBP1a-dependent D-Ala release allowing for an equivalent level of contaminating D-Ala 
hydrolysis activity as in the PBP1a-E91Q preparation (if the activity observed in the presence of 
glycan chains is a result of the contaminant, lane 12b; see text).  Values represent the mean ± standard 
deviation of the raw (a) and corrected (b) data, based on triplicate reactions. 
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Figure 5.8: S. pneumoniae PBP1a-dependent D-Ala release.  Legend on previous page. 
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The known contaminating D-Ala hydrolysis activity present in the MGT and PBP1a-
S370A preparations (lanes 9 and 13 respectively) leads to difficulties in interpreting 
the D-Ala hydrolysis activity of PBP1a variants.  The contaminant appeared to be 
absent in the PBP1a-E91Q preparation; D-Ala production was not detected in the 
incubation of PBP1a-E91Q with Lipid II (lane 11b).  The existence of the 
contaminant in the PBP1a preparation was evaluated by addressing the theory that in 
the sole presence of glycan chains (and absence of Lipid II monomers), PBP1a and 
PBP1a-E91Q should have equivalent D-Ala release activities because only the 
transpeptidase domains would be functional.  Therefore, any additional activity 
observed in the PBP1a incubations would be a consequence of a contaminating 
activity.  MGT was used to polymerise Lys-Lipid II to completion prior to incubation 
with PBP1a (lane 15) or PBP1a-E91Q (lane 12).  The levels of D-Ala release in the 
incubations are comparable, suggesting that the contaminant was absent in the 
PBP1a preparation.   
 
A point to note is that the contaminating D-Ala activity was evident in incubations 
where glycan chains were generated (MGT, lane 9; PBP1a-S370A, lane 14), but was 
not apparent in incubations where glycan chains were absent (PBP1a-E91Q with 
Lipid II, lane 11).  The contaminant, therefore, could have had a substrate preference 
for glycan chains.  Thus, the D-Ala release activities presumed to be attributed to the 
transpeptidase domain of PBP1a-E91Q when in the presence of glycan chains (lanes 
12 and 14) (discussed below) could in fact have been a result of the contaminating 
activity.  The incubation of PBP1a with MGT-polymerised glycan chains (lane 15b) 
yielded ~9 µM D-Ala.  On the assumption that the 9 µM D-Ala produced was a 
product of the contaminating activity in the PBP1a preparation, the incubation of 
PBP1a with Lys-Lipid II still produced a further 19 µM (lane 10b, black-dashed 
line), thus implying D-Ala hydrolysis specific to PBP1a activity.   
 
In order to evaluate the results further, the assumption is made that the contaminating 
activity was not present in the PBP1a-E91Q and PBP1a preparations.  This is based 
on the absence of contaminating activity in the PBP1a-E91Q incubation (with Lipid 
II, lane 11) and the comparison of D-Ala release activities of PBP1a-E91Q and 
PBP1a in the presence of glycan chains (lanes 12 and 15 respectively). 
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5.9.2. Investigating the substrate preference of the transpeptidase 
domain of PBP1a 
 
The preferential substrate of PBP1a was determined using active site mutants of the 
enzyme: PBP1a-E91Q (capable of transpeptidase/D,D-carboxypeptidation only) and 
PBP1a-S370A (capable of transglycosylation only).  No D-Ala hydrolysis activity 
was detected upon incubation of PBP1a-E91Q with Lys-Lipid II (lane 11), signifying 
the lipid monomer alone was not a suitable substrate. 
 
To assess whether PBP1a-E91Q could perform transpeptidation/D,D-
carboxypeptidation using a polymerised glycan chain, the enzyme was incubated in 
two separate reactions, each having a different source of the polymerised Lys-Lipid 
II (derived from either MGT or PBP1a-S370A activities, lanes 12 and 14 
respectively).  The results from both incubations are clear: the presence of both 
PBP1a-E91Q and polymerised glycan chains significantly increased the level of D-
Ala detected, indicative of transpeptidase/D,D-carboxypeptidase activity.  Thus, the 
penicillin-binding domain of PBP1a required the presence of glycan chains, to either 
act as a substrate or to stimulate the transpeptidase activity.  A similar result has been 
found for E. coli PBP1a; transpeptidation by this enzyme was delayed until a glycan 
chain substrate was provided (Born et al., 2006).  It is important to note that the rate 
of MGT-mediated Lys-Lipid II transglycosylation was much greater than the 
equivalent activity performed by PBP1a-S370A (exemplified by Figure 4.23).  
Therefore, unlike incubations with MGT, Lys-Lipid II polymerisation by PBP1a-
S370A would not have reached completion prior to the addition of the 
transpeptidase/D,D-carboxypeptidase.  Consequently, fewer glycan chains would be 
present and monomeric Lys-Lipid II would remain.  In spite of this, there was little 
difference between the total D-Ala produced when PBP1a-E91Q was incubated with 
either MGT (lane 12) or PBP1a-S370A (lane 14) derived glycan chains.  There are 
three potential explanations for this: 
 
• PBP1a-E91Q has a higher preference for PBP1a-S370A derived glycan chains 
over those produced from MGT, which may be of a different length.  
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• The glycan chain concentration may be high enough in both reactions so as not to 
limit the rate of D-Ala hydrolysis activity of PBP1a-E91Q.   
 
• Transpeptidation could occur between two adjacent glycan chains, or between a 
glycan chain and monomeric Lys-Lipid II.  The transpeptidase may require the 
glycan chain for substrate recognition and transient reaction with the active site 
serine, but it may have less selectivity for the attacking nucleophile, (either Lys-
Lipid II or a polymerised form) or vice versa.  Born et al. (2006) have found that 
E. coli PBP1a is capable of performing transpeptidation reactions between glycan 
chains and sacculi or peptidoglycan precursors (UDP-MurNAc-tri/tetra/penta-
peptides).  The use of Lys-Lipid II as a transpeptidase acceptor substrate could be 
determined by monitoring the incorporation of [
14
C]-labelled Lipid II by PBP1a-
E91Q into a polymerised glycan chain, which could be analysed by SDS-PAGE.  
 
5.9.3. Evaluation of the transglycosylase dependency of PBP1a 
transpeptidation 
 
It has been established that the transglycosylase domain of PBP1a can function in the 
absence of transpeptidase activity (Section 4.10).  However, are the two activities 
linked?  To address this question, the D-Ala release activity of PBP1a was compared 
to the D-Ala release activity of PBP1a-E91Q in the presence of PBP1a-S370A.  Lys-
Lipid II was used as the substrate in both incubations, which would be polymerised 
by the transglycosylase activity of the enzymes; PBP1a and PBP1a-S370A have near 
equivalent levels of transglycosylase activity (Section 4.10), thus the substrate 
compositions would be equivalent (a mixture of glycan chains and monomeric Lys-
Lipid II).  The level of D-Ala produced by PBP1a (lane 10b) was significantly 
greater (by ~19 µM D-Ala) than that produced by PBP1a-E91Q (lane 12b) (despite 
these enzymes having equivalent activities in the presence of MGT-polymerised 
substrate, lanes 12b and 15b).  Additionally, PBP1a in the sole presence of glycan 
chains (produced by MGT) (lane 15b) generated less D-Ala compared to PBP1a with 
Lipid II (lane 10b).  This last finding is comparable to the observation made by 
Bertsche et al. (2005): in the presence of pre-formed glycan chains (and absence of 
Lipid II), E. coli PBP1b-catalysed transpeptidation proceeded with a 12-fold lower 
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rate compared to the simultaneous transglycosylation and transpeptidation of Lipid II 
by the same enzyme.  These results cumulatively imply that the D-Ala hydrolysis 
activity of PBP1a is enhanced when functioning in concert with the transglycosylase 
activity on the same enzyme molecule. 
 
If the D-Ala activity observed upon incubation of PBP1a-E91Q with a glycan 
polymer (lanes 12b and 14b) was solely due to the contaminating activity, this would 
indicate that the transpeptidase domain of PBP1a-E91Q was not functional in the 
absence of an active transglycosylase domain on the same enzyme entity.  This result 
would be comparable to that found by Born et al. (2006): E. coli PBP1a with an 
inactive transglycosylase domain was unable to catalyse transpeptidation.  
 
The crystal structure of E. coli PBP1b has lead to the proposal that the 
transglycosylase domain feeds the newly polymerised glycan chain to the 
transpeptidase domain (Sung et al., 2009).  The results concur with this hypothesis, 
where the rate of D-Ala hydrolysis activity is likely to be enhanced if the donor 
substrate is being directed to the transpeptidase active site.  Given that the 
transpeptidase activity of S. pneumoniae PBP1a (data shown here), E. coli PBP1a 
(Born et al., 2006) or E. coli PBP1b (Bertsche et al., 2005) was either reduced or 
absent when concomitant transglycosylation was not possible, this could suggest that 
the primary role of these bifunctional PBPs in a cell is to form nascent cross-linked 
peptidoglycan from Lipid II.  Their secondary role could be to integrate the newly 
formed peptidoglycan into the existing sacculi (an activity that would not require 
transglycosylation), which could be the main responsibility of the monofunctional 
transpeptidases, allowing for cell elongation and division.  
 
To conclude, the results clearly demonstrate that the penicillin-binding domain of 
PBP1a performs D-Ala hydrolysis activity in the presence of ongoing 
transglycosylation by the same enzyme molecule.  Intervening factors, such as the 
contaminating D-Ala hydrolysis activity present in some enzyme preparations, 
complicate the interpretation of results and prevent further conclusions being drawn. 
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5.10. Analysis of PBP2b-dependent transpeptidation or D,D-
carboxypeptidation.  
 
PBP2b is a high molecular weight Class B penicillin-binding protein (Sauvage et al., 
2008a), performing the role of transpeptidation (and potentially D,D-
carboxypeptidation to a lesser extent (discussed in Section 5.1.1)) in S. pneumoniae 
peptidoglycan.  The D-Ala hydrolysis activity of PBP2b was analysed with two 
different substrates: Lys-Lipid II and MGT-polymerised Lipid II (prepared as in 
Section 2.9.2.1).  Figure 5.9 presents the results of PBP2b-dependent D-Ala 
hydrolysis activity.   
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Figure 5.9: S. pneumoniae PBP2b-dependent D-Ala release.  Variants of PBP2b were incubated with Lys-Lipid II and MGT-polymerised Lys-Lipid II for 18 h.  Refer to 
Figure legend 5.8 for a detailed description of the Figure.  Enzyme only and Lys-Lipid II only controls are represented in lanes 1-6.  Lanes 9a and 11a were corrected by lane 
7a to account for the contaminating D-Ala hydrolysis activity in the MGT preparation (see Figure legend 5.8). Values represent the mean ± standard deviation of the raw (a) 
and corrected (b) data, based on triplicate reactions.  
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With the knowledge that there was variability in the enzyme preparations with 
regards to a contaminating D-Ala hydrolysis activity, caution must be applied when 
analysing the results.  The contaminating D-Ala hydrolysis activity was evidently 
absent from the PBP2b-S391A enzyme preparation; no D-Ala activity was detected 
following the incubation of PBP2b-S391A with Lipid II (lane 10b) or glycan chains 
(lane 11b).  Therefore, it can be assumed that the contaminant was absent from the 
PBP2b preparation.   
 
The PBP2b-S391A mutant clearly demonstrated its incapability of D-Ala hydrolysis 
in the presence of Lys-Lipid II or a polymerised glycan chain (lanes 10b and 11b 
respectively).  This was anticipated because the active site serine, an essential residue 
in the transpeptidase/D,D-carboxypeptidase activity, had been replaced by an inert 
residue, alanine (Section 3.3.6).  On the contrary, the wild-type PBP2b exhibited D-
Ala release activity with both Lys-Lipid II (lane 8b) and the MGT-produced glycan 
chains (lane 9b) with a greater than 2-fold preference for polymerised glycan chains 
over the monomeric counterpart. 
 
5.11. Analysis of PBP2x-dependent transpeptidation or D,D-
carboxypeptidation.  
 
S. pneumoniae PBP2x is a high molecular weight Class B, monofunctional PBP, 
sharing a similar role to PBP2b (Sauvage et al., 2008a).  Under the assay conditions 
described in Section 2.9.2.1, the D-Ala release activity of PBP2x was analysed.  The 
results are displayed in Figure 5.10. 
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Figure 5.10: S. pneumoniae PBP2x-dependent D-Ala release.  Variants of PBP2x were incubated with Lys-Lipid II and MGT-polymerised Lys-Lipid II for 18 h.  Refer to 
Figure legend 5.8 for a detailed description of the Figure.  Enzyme only and Lys-Lipid II only controls are represented in lanes 1-6.  Lanes 9a and 11a were corrected by lane 
7a to account for the contaminating D-Ala hydrolysis activity in the MGT preparation (see Figure legend 5.8).  Values represent the mean ± standard deviation of the raw (a) 
and corrected (b) data, based on triplicate reactions.  
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PBP2x did not exhibit transpeptidase/D,D-carboxypeptidase-dependent D-Ala 
hydrolysis when either Lys-Lipid II (lane 8) or a polymerised glycan chain (lane 9) 
were tested as the potential substrates.  It is worthy to note that no contaminating D-
Ala hydrolysis activity was present in the enzyme preparations of PBP2x (lanes 8 
and 9) or PBP2x-S337A (lanes 10 and 11).   
 
Factors that could explain the apparent inactivity of PBP2x (and the low activities of 
PBP1a and PBP2b) are described later in the Chapter.   
 
5.12. Discussion 
 
For clarity, the experimental results obtained have been discussed throughout this 
Chapter.  The following section discusses the transpeptidation/D,D-
carboxypeptidation detection systems developed in this Chapter in terms of: the in 
vivo relevance of the activity rates obtained, the suitability of the detection 
techniques and the strategies to overcome problems encountered. 
 
5.12.1. Establishment of transpeptidation/D,D-carboxypeptidation by 
two novel detection methods 
 
Two novel techniques were developed for the identification of the 
transpeptidase/D,D-carboxypeptidase activity of PBPs.  The first was fluorescence 
analysis of VanFL-bound glycan chains following treatment with a 
transpeptidase/D,D-carboxypeptidase and SDS-PAGE separation.  The activity was 
detected by a reduction of VanFL binding (and hence fluorescence), which relied 
upon the absence of the terminal D-Ala of a pentapeptide side chain within the 
glycan chain.  The second was a continuous spectrophotometric assay that used a 
VanA coupling system to monitor D-Ala hydrolysis, a consequence of 
transpeptidation/D,D-carboxypeptidation.  Both techniques are valid approaches for 
establishing and monitoring transpeptidation/D,D-carboxypeptidation, but have two 
significant limitations: the rate of PBP-catalysis needs to be high enough to detect 
activity and the techniques cannot distinguish between D,D-carboxypeptidation and 
transpeptidation.  The high sensitivity of the Amplex Red assay enabled                    
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S. pneumoniae PBP transpeptidation/D,D-carboxypeptidation to be detected and 
additionally identified the presence of a D-Ala hydrolysing enzyme contaminating 
various protein preparations.   
 
5.12.2. The E. coli D-Ala hydrolysing contaminant 
 
The contaminating enzyme, believed to be a PBP originating from the E. coli 
expression system, could have caused an underestimation of the true S. pneumoniae 
PBP D-Ala hydrolysis activity observed (by reducing the availability of the 
substrate) and will impede all future transpeptidase analyses of the PBPs (using the 
detection systems described) by causing ambiguity in the results.  Therefore, its 
elimination becomes a priority.   
 
5.12.2.1.  Properties of the contaminating enzyme 
 
Substantial contaminating D-Ala hydrolysis activity was identified in two protein 
preparations: MGT and PBP1a-S370A.  Two factors ensured that these enzymes 
were not responsible for the activity observed.  The first, sequence analysis validated 
the absence of a penicillin-binding domain or an active site serine residue within the 
penicillin-binding domain of MGT and PBP1a-S370A respectively.  The second 
factor was that the enzymes could not bind BOCILLIN FL (where wild-type PBP1a 
could).  Inclusion of ampicillin in the reactions of Lys-Lipid II with these enzymes 
caused virtually total elimination of the contaminating activity, identifying the 
contaminant as a probable PBP.  
 
It is likely that the contaminating PBP was a D,D-carboxypeptidase and not a 
transpeptidase.  Mengin-Lecreulx et al. (1999) have demonstrated that the over-
expression of S. aureus MurE (responsible for the incorporation of L-Lys onto the 
third position of Lipid II peptide stem) in E. coli resulted in the replacement of 50 % 
meso-DAP-containing peptidoglycan stem peptides with L-Lys.  Transpeptidation 
was still detected.  However, the acceptor in the cross-linking reaction was found to 
be exclusively meso-DAP, suggesting that the E. coli transpeptidases could not use 
L-Lys in an equivalent manner (although the stem peptide containing L-Lys could 
act as a donor) (Mengin-Lecreulx et al., 1999).  The incubations with the PBPs 
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described here employed Lys-Lipid II as a substrate.  Therefore, from the findings of 
Mengin-Lecreulx et al. (1999), E. coli transpeptidases would not be able to use the 
L-Lys-containing stem peptides as acceptor substrates.  Thus, only D,D-
carboxypeptidase activity would have been possible. 
 
5.12.2.2.  Identification of the contaminant 
 
The primary step in the total elimination of the contaminating D-Ala hydrolysis 
activity would be the identification of the responsible enzyme.  This could be 
achieved by mass spectrometry: proteins separated by SDS-PAGE could be excised 
from the gel, subjected to a tryptic digest, and the products analysed by electrospray 
ionisation tandem mass spectrometry (ESI-MS/MS).  This procedure could be 
performed in duplicate, with and without pre-treatment of the protein sample with 
ampicillin (this antibiotic has been shown to inhibit the activity of the contaminant, 
presumably by covalently interacting with the catalytic Serine residue).  Following 
ESI-MS/MS analysis, detection of an ion that differs by the molecular weight of 
ampicillin between the two protein samples could lead to the identification of the E. 
coli PBP contaminant. 
 
5.12.2.3.  Potential strategies for the removal of the contaminant 
 
Further purification strategies could be undertaken to remove the contaminant 
including affinity, ion exchange, and hydrophobic interaction chromatography.  For 
example, it has been well documented that PBPs have varying affinities for different 
textile dyes, and this property has been exploited in the successful purification of 
many PBPs including E. coli PBP5 (van der Linden et al., 1992) and a soluble form 
of S. pneumoniae PBP2x (Laible et al., 1992) by dye-affinity chromatography.  
Experimental conditions (such as ionic strength and pH) could influence the affinity 
of the PBP for a particular dye, and thus a purification procedure could be 
established.  This technique could be developed for the removal of the contaminating 
enzyme in the MGT or PBP1a-S370A preparations.  
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The elimination of the contaminating E. coli PBP from the MGT and PBP1a-S370A 
preparations by purification is hindered by a single factor for each enzyme: MGT 
requires detergent or a high concentration of NaCl to remain stable, enhancing 
hydrophobic interactions and thus the potential association with the PBP; PBP1a-
S370A is situated in a detergent micelle to remain soluble, where the surrounding 
detergent would promote any protein-protein interactions (ionic detergents could be 
used to disrupt this interaction, but are often denaturants).  
 
5.12.3. Do the levels of D-Ala hydrolysis detected represent the true 
activity of the PBPs in vivo? 
 
In vivo, the rate of transpeptidation must be substantial to support bacterial growth, 
although the extent of the cross-linking is species specific (Bugg, 1999).  In the 
absence of cross-linking activity, the peptidoglycan becomes weak and susceptible to 
rupture, a property caused by !-lactam antibiotics (Macheboeuf et al., 2006).  In 
vitro, detection of activity from the penicillin-binding domain is a rare event; in this 
study, minimal levels of activity have been detected from the transpeptidase domain 
of PBP1a and PBP2b, with PBP2x demonstrating no activity under the conditions 
provided following an 18 h incubation.  PBP1a, for example, after an 18 h incubation 
with 10 nmol Lys-Lipid II, turned over one molecule of D-Ala every 1.23 days.  
Evidently, after 18 h, the enzymes are likely to have lost activity in vitro, but this rate 
would still be vastly insufficient to sustain bacterial growth.  This signifies there 
were underlying factors preventing the native rate of PBP activity in vitro.  Minimal 
knowledge of the optimal activity conditions and preferential substrates has hindered 
progress in the kinetic characterisation of the transpeptidase activity.  The following 
section provides explanations for the low rates of S. pneumoniae PBP1a, PBP2b and 
PBP2x transpeptidase/D,D-carboxypeptidase activities detected in these experiments, 
which must be considered in future analyses. 
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5.12.4. Factors contributing to the sub-physiological rate of the 
transpeptidase activities of S. pneumoniae PBP1a, PBP2b and 
PBP2x 
 
Kinetic characterisation of S. pneumoniae PBP1a, PBP2b and PBP2x 
transpeptidation was thwarted by the inability to detect sufficient levels of D-Ala 
release activity.  Numerous factors could be responsible for the absence of 
significant enzyme activity and are discussed below.   
 
5.12.4.1.  Purification renders the protein inactive 
 
The isolation and subsequent purification of the PBP from the membrane could 
disrupt its native-like conformation, where the distortion in structure could prevent 
the enzyme functioning with optimal activity.   
 
PBP2x appeared totally inactive upon incubation with potential substrates; the same 
was not true for PBP1a and PBP2b.  Given that PBP1a, PBP2b and PBP2x were 
prepared in identical ways (Chapter 3), it seems unlikely that the purification method 
would cause the complete inactivation of the latter enzyme and not the former 
enzymes.  BOCILLIN FL was able to covalently modify the active site serine of the 
PBP2x transpeptidase domain (Figure 3.14), where the active site must resemble a 
native-like structure for this to occur.  This suggests that the enzyme had at least a 
vague resemblance to the native conformation.   
 
The detergents used in the purification of PBP1a, PBP2b and PBP2x, sodium 
deoxycholate and DDM, are renowned for their ability to extract and purify 
membrane-bound enzymes in a functional form (Seddon et al., 2004).  Therefore, it 
seems unlikely that they would severely disrupt the performance of the enzymes; 
different detergents could be used to address this.    
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5.12.4.2.  Purification removes a component of the bacterial membrane 
essential for activity. 
 
In their natural environment, the membrane proteins are surrounded by lipids and 
proteins, some of which are known to enhance enzyme activity.  For example, a 
combination of cardiolipin and phosphatidyl glycerol has a positive impact on the 
catalysis rate of PgpB (Touzé et al., 2008).  The PBPs may have an essential lipid 
requirement, which is diminished upon purification.   
 
5.12.4.3.  An element responsible for enhancing the PBP activity in vivo is 
absent in vitro 
 
Peptidoglycan synthesis is a highly organised process, controlled by a myriad of 
enzymes acting in complexes at different points during the cell cycle.  Examples 
include: the recruitment of PBPs to the divisome complex enabling nascent 
peptidoglycan expansion (Vicente et al., 2006) and the enhancement of E. coli PBP2 
activity in the presence of RodA (Ishino et al., 1986).  Other elements have been 
found to boost PBP activity.  For example, the outer membrane lipoproteins, LpoA 
and LpoB, residing in the periplasmic space, are essential for stimulating the 
transpeptidase activities of E. coli PBP1a and PBP1b respectively (Paradis-Bleau et 
al., 2010; Typas et al., 2010).  An equivalent element has not yet been identified in 
Gram-positive bacteria.  It is therefore highly plausible that a PBP-associating 
component essential for the transpeptidase activities of S. pneumoniae PBP1a, 
PBP2b and PBP2x exists but was absent in the in vitro assays.  E. coli PBP1b has 
elevated activity when functioning as a dimer  in vitro (Bertsche et al., 2005).  The 
high concentrations of enzymes used in the assays are likely to have permitted 
homodimerisation.  However, PBP1a, PBP2b or PBP2x may form heterodimers in 
vivo.   
 
5.12.4.4.  Substrates tested were not suitable for optimum PBP1a, PBP2b or 
PBP2x activity 
 
In the experiments conducted, Lipid II (with a pentapeptide side chain of L-Ala-"-D-
Glu-L-Lys-D-Ala-D-Ala) was trialled as a substrate in its monomeric and 
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polymerised form.  An equivalent Lipid II molecule is the precursor to S. 
pneumoniae peptidoglycan, but has a single difference: the D-Glu at the second 
amino acid residue position of the pentapeptide chain is replaced by iso-Gln in S. 
pneumoniae (Garcia-Bustos and Tomasz, 1990).  This variation could reduce the 
substrate recognition of the S. pneumoniae PBPs.  Additionally, tripeptide and 
branched peptide stems are significant constituents of S. pneumoniae peptidoglycan 
(Garcia-Bustos and Tomasz, 1990); the preference of these acceptor substrates 
during transpeptidation has yet to be determined.  
 
The results indicate that the PBPs have different substrate specificities.  Both PBP1a 
and PBP2b were capable of utilising polymerised glycan chains as substrates, 
whereas only PBP2b could perform D-Ala hydrolysis using Lipid II as a substrate.  
These differences could arise through distinct substrate recognition mechanisms.  It 
has been proposed that the transglycosylase domain of PBP1a directs the 
polymerising glycan chain to the transpeptidase domain.  PBP2b does not have a 
transglycosylase domain, thus would require a different mechanism of substrate 
recognition.    
 
5.12.4.5.  The assay conditions were not optimal for transpeptidase activity 
 
The assay conditions employed corresponded to the optimised conditions for the 
transglycosylase activity of PBP1a.  The optimum temperature and buffer system for 
activity is likely to vary between the different transpeptidases, which can now be 
established for PBP1a and PBP2b following the detection of activity.  
 
The presence of the detergent, although essential for the membrane protein and lipid 
solubility, could interfere with the PBP activity by obscuring sites on the substrate or 
enzyme, essential for recognition purposes.  The assays could be performed in the 
presence of different detergents to address this factor.  
 
The factors described above detail potential explanations for the minimal PBP 
activity observed, which must be taken into consideration before future analyses.  
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5.13. Future work  
 
The work presented in this Chapter has provided the foundation towards the future 
kinetic characterisations of the transpeptidase activities of the S. pneumoniae PBPs 
and those from other bacterial species.  The following section describes methods to 
further develop an understanding of how the transpeptidase domains of S. 
pneumoniae PBP1a, PBP2b and PBP2x function in vivo. 
 
5.13.1. Distinguishing between the transpeptidase and D,D-
carboxypeptidase activities of the penicillin-binding domains of 
Class A and B PBPs. 
 
The techniques described in this Chapter enable the detection of activity from the 
penicillin-binding domain of the PBPs via D-Ala hydrolysis from the pentapeptide 
stem of a peptidoglycan precursor.  However, these methods do not differentiate 
between D-Ala hydrolysis resulting from transpeptidation or D,D-
carboxypeptidation, limiting the full characterisation of these enzymes.  
  
5.13.1.1.  In-gel strategies to distinguish between transpeptidation and D,D-
carboxypeptidation 
 
At the current separation resolution of the glycan chains following SDS-PAGE, it is 
impossible to differentiate between products of transpeptidation or D,D-
carboxypeptidation upon VanFL detection (Section 5.3).  Discrete separation of the 
glycan chains would enable the two activities to be distinguished.  Polymerised 
glycan chains treated with a D,D-carboxypeptidase would simply show a reduction 
of fluorescence signal in relation to the untreated glycan chains.  Glycan chains 
treated with a transpeptidase would show a different separation pattern following 
SDS-PAGE due to the formation of cross-links between chains.  This latter factor 
would be sensitised by the use of [
14
C]-labelled Lipid II, although D,D-
carboxypeptidation could not be detected in this way. 
 
 241 
5.13.1.2.  Development of a fluorescence or absorbance based assay to 
distinguish between levels of transpeptidation and D,D-
carboxypeptidation 
 
Transpeptidation reactions form cross-links between the fourth position D-Ala and 
the third position L-Lys/meso-DAP of adjacent pentapeptide side chains in 
peptidoglycan (Figure 5.1).  This eliminates the free #-amino group of the third 
position amino acid residue.  Quantification of the free #-amino group could be 
achieved by labelling with a fluorescent or chromogenic molecule, thus establishing 
the level of transpeptidation.  Figure 5.11 displays the outline of this proposed assay 
system.  The reaction of free amino groups with 2,4,6-trinitrobenzene sulphonic acid 
(TNBS) leads to an increase in absorbance at 345 nm, which can be followed 
spectrophotometrically.  Following a transpeptidation reaction, it is important to 
eliminate the D-Ala hydrolysed from these experiments, where the free amino-group 
of D-Ala could be labelled.  D-Ala could be converted to pyruvate by DAAO, 
releasing NH3 and H2O2.  Freeze-drying the reaction would remove NH3, which also 
has the potential to react with TNBS.  The reaction could be reconstituted into an 
appropriate buffer system (excluding buffers with an amino group e.g. Tris) and the 
reaction with TNBS monitored.   
 
The level of transpeptidation and D,D-carboxypeptidation could be quantified using 
putative natural substrates (following a reaction with and without a transpeptidase) 
by comparing the amount of free #-amino groups with the total concentration of D-
Ala released (established by the Amplex Red assay in a parallel reaction). 
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Figure 5.11: An approach to distinguish between transpeptidation and D,D-carboxypeptidation.  The terminal tripeptide of the peptidoglycan pentapeptide stem is 
shown.  Following a transpeptidation or D,D-carboxypeptidation reaction, the terminal D-Ala is liberated, the amine group of which can be eliminated by D-amino acid 
oxidase.  A transpeptidation reaction eliminates the amine group (i), whilst amine (ii) is free to react with TNBS, which can be monitored by an absorbance change at 345 nm. 
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5.13.2. A high-throughput screening process for the rapid analysis of 
transpeptidase/D,D-carboxypeptidase activity.   
 
The transpeptidase activities of S. pneumoniae PBP1a, PBP2b and PBP2x are poorly 
understood.  Various factors need to be addressed to fully characterise the enzymes 
including:  
 
• Optimal assay conditions (e.g. temperature, pH, metal ions, detergent, 
membrane-like environment) 
• Minimal structural requirements of enzyme (e.g. analyse the activity of 
membrane truncated PBPs) 
• Minimal structural requirements of the substrate (e.g. use diverse 
peptidoglycan fragments as substrates) 
• Substrate specifications of !-lactam resistant PBPs (e.g. analyse 5204 PBPs 
with branched or unbranched pentapeptide side chain substrates) 
 
The establishment of D-Ala hydrolysis activities by S. pneumoniae PBP1a and 
PBP2b provides the initial step towards their full characterisation.  To address the 
factors discussed above using the assay set-up described would be extremely time-
consuming.  Development of the assays into a 96-well plate format (described in 
Section 4.13.8) would allow high throughput screening of activity (by D-Ala release) 
under various parameters in a time-efficient manner.  
 
5.14. Conclusion 
 
In summary, two techniques for the detection of PBP-dependent 
transpeptidation/D,D-carboxypeptidation have been developed, adaptations of which 
will enable the differentiation between these two activities.  The continuous 
spectrophotometric assay designed to monitor D-Ala release has been used to 
kinetically characterise Actinomadura R39 D,D-peptidase with findings comparable 
to those in literature.  Initial studies have revealed the elusive activities of the 
penicillin-binding domains of PBP1a and PBP2b, thus providing a foundation for 
future investigations into this complex area of research.  
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Chapter 6. Preliminary crystallisation studies of 
Staphylococcus aureus MGT and Streptococcus pneumoniae 
PBP1a, PBP2b and PBP2x 
 
6.1. Introduction 
 
6.1.1. X-ray crystallography 
 
The three-dimensional structure of proteins can provide valuable insights into how 
the macromolecule functions and interacts with its surroundings.  There are three 
techniques in modern biophysics that can determine the 3D-architecture of proteins 
to at least a near atomic resolution: nuclear magnetic resonance spectroscopy 
(NMR), electron microscopy (EM) and X-ray crystallography.  The RCSB Protein 
Data Bank (PDB: www.rcsb.org) is an online database documenting the 3D-
structures of proteins and nucleic acids.  To date, the PDB statistics reveal that there 
are just over 68,000 protein structures deposited in this database, approximately 
60,000 of which were determined by X-ray crystallography.  Therefore, since the 
1946 Nobel Prize for Chemistry (awarded to Sumner, Northrup and Stanley) 
recognised the importance of the discovery that enzymes can be crystallised, X-ray 
crystallography has developed into a profound biophysical technique of choice for 
the establishment of protein structure.  
 
X-ray crystallography relies on the target protein associating in a periodic array 
forming a crystal lattice (Sawyer and Turner, 1999).  Exposure of the crystal to 
intense X-rays causes the incident beam to scatter in different directions with 
different intensities.  This can be recorded as an X-ray diffraction pattern, which 
holds the information regarding the protein 3D-structure (Sawyer and Turner, 1999).  
There is one major limitation of this technique concerning the structural information 
obtained: the in vitro crystal lattice of the target protein represents a single static 
structure sampled by the protein, which does not necessarily reflect the native state 
of the protein in vivo (Acharya and Lloyd, 2005). 
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6.1.2. Crystallisation of membrane proteins: the challenge 
 
This Chapter focuses towards obtaining crystal structures of the full-length integral 
membrane proteins of S. pneumoniae PBP1a, PBP2b and PBP2x.  Structural 
characterisations of membrane proteins remain to be an appreciable challenge.  They 
represent approximately one-third of the proteins encoded in the genome (Krogh et 
al., 2001), yet only 1.1 % of the structures in the PDB correspond to membrane 
proteins (www.rcsb.org).  Since the first crystal structure of an integral membrane 
protein, a photosynthetic bacterial reaction centre in 1984 (Deisenhofer et al., 1984), 
merely 764 membrane protein structures have been solved, only 266 of which are 
unique (at the time of writing) (Membrane Proteins of Known 3D Structure: 
http://blanco.biomol.uci.edu/Membrane_Proteins_xtal.html). The discrepancy 
between the numbers of crystal structures of soluble and membrane proteins arises 
from the complexity of the latter.  This imbalance must be surmounted to enable a 
full understanding of the membrane proteome (Loll, 2003). 
 
6.1.3. Current X-ray crystal structures of PBPs 
 
Until recently, PBP crystal structures were based on the enzymes devoid of their 
membrane anchor, and not on the full-length counterparts, and because of this, the 
role of the transmembrane domain has not been appreciated.  In 2009, the structure 
of the first full-length Class A PBP, E. coli PBP1b, was established (Sung et al., 
2009).  It is anticipated that the recent advances in membrane protein 
crystallography, including specifically designed high-throughput screens, will 
facilitate the elucidation of further full-length PBP structures.  
 
The crystal structures of apo- and ligand-bound forms of various membrane 
truncated HMW and LMW-PBPs and MGTs reveal: the positioning of the conserved 
motifs; an insight into residues involved in substrate binding; residues proposed to 
catalyse the enzyme-specific reactions; an explanation for different properties 
displayed between the same enzyme of two different bacterial strains (i.e. penicillin-
resistant and non-penicillin resistant).  These findings are illustrated in the following 
section using appropriate examples.  
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6.1.3.1. Substrate-binding pocket 
 
The crystal structure of Actinomadura R39 D,D-peptidase (Sauvage et al., 2005) (the 
activity of which is discussed in Section 5.6) has revealed a distinctive pocket 
located at the bottom of the active site.  The pocket is defined by residues W139, 
D142, Y147, R351 and M414 as shown in Figure 6.1.  The former 3 residues belong 
to a unique domain of Class C PBPs, and the latter two belong to the penicillin-
binding domain.  It has been proposed that these residues are involved in substrate 
specificity, favouring the binding of meso-DAP (a natural constituent of 
Actinomadura R39 peptidoglycan) instead of L-Lys at the third position of the 
pentapeptide stem of a peptidoglycan fragment (Sauvage et al., 2005).  The substrate 
preference is supported with kinetic data (Section 5.6). 
 
Figure 6.1: Actinomadura R39 D,D-peptidase substrate-binding pocket.  The catalytic serine is 
acylated with the !-lactam nitrocefin (cyan).  The conserved motifs 1-3 are blue, red and yellow 
respectively.  The hydrophobic residues constituting the substrate-binding pocket are magenta.  
Adapted from Sauvage et al. (2005). 
 
6.1.3.2. Residues involved in substrate binding and catalysis 
 
The crystal structures of transglycosylases (in apoenzyme and moenomycin-bound 
forms) and the transpeptidases and D,D-carboxypeptidases (in apoenzyme, inhibitor 
and substrate-mimetic bound forms) have revealed residues potentially involved in 
substrate recognition and catalysis of transglycosylation (Sections 1.9.1 and 4.1.2), 
transpeptidation and D,D-carboxypeptidation (Sections 1.9.2 and 5.1).  
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6.1.3.3. Structural discrepancies between an enzyme of two different 
bacterial strains 
 
S. pneumoniae R6 and 5204 are penicillin-sensitive and resistant strains respectively 
(Section 3.1).  The absence of a !-lactamase in S. pneumoniae infers that the 
penicillin-binding domains must remodel and modify the transpeptidase active site to 
confer !-lactam resistance (Hakenbeck et al., 1999).  Figure 6.2 shows the crystal 
structure of the PBP2b active site from the R6 and 5204 strains.  In the R6 PBP2b 
structure, two small !-strands (!3a and !3b) connect the !-strands !3 and !4.  In 
5204 PBP2b, four mutations locate to this interconnecting region, involving the 
amino acid conversion of Asp or Ala to Gly.  In the 5204 PBP2b structure, !3a and 
!3b are untraceable on the electron density map, signifying a considerable increase 
in flexibility due to these mutations.  This degree of flexibility surrounding the active 
site, in addition to mutations affecting the charge and polarity of the catalytic cleft, 
impose that the enzymes must employ differential means of substrate and antibiotic 
recognition (Contreras-Martel et al., 2009). 
 
Figure 6.2: The active site of PBP2b from a penicillin sensitive (R6) and resistant (5204) strain 
of S. pneumoniae.  The catalytic serine of the first conserved motif (blue) is shown in stick form.  The 
green dashed lines indicate the residues with a high level of flexibility, which were not traceable on 
the electron density map.  Adapted from Contreras-Martel et al. (2009).  
 
These examples demonstrate the important role of X-ray crystallography in the 
structural and mechanistic characterisations of the PBPs.   
"4 
!3b 
"9 
"5 
!4 
!3a 
  !3 
Ser 
PBP2b-R6 
"4 
"9 
"5 
!4 !3 
Ser 
PBP2b-5204 
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6.2. Experimental aims 
 
• To crystallise S. pneumoniae PBP1a-#30, PBP2b-#39, PBP2x-#48 and S. 
aureus MGT-#67 
 
• To crystallise the native S. pneumoniae PBP1a, PBP2b and PBP2x and the 
corresponding transpeptidase active site serine mutants 
 
• To crystallise liganded S. pneumoniae PBP variants 
 
6.3. Crystallisation of S. pneumoniae PBP1a-#30, PBP2b-#39, 
PBP2x-#48 and S. aureus MGT 
  
The crystal structures of S. pneumoniae PBP1a, PBP2b, PBP2x and S. aureus MGT 
devoid of membrane anchors, in apoenzyme and ligand bound forms, exist in 
literature.  Crystallisation of these enzymes was attempted to gain a higher resolution 
of structural data and to establish possible conditions for future co-crystallisation 
experiments.  Although others exist, examples of the known crystallisation 
conditions for the enzymes under investigation are displayed in Table 6.1. 
 
Enzyme 
Protein 
concentration 
(mg/mL) 
Ligand 
Crystallisation 
conditions 
Structural 
resolution 
(Å) 
Reference 
S. 
pneumoniae 
PBP1a-#36 
5 Tebipenam 
50mM MES, 4-
6mM zinc sulphate, 
pH 6.8, 20°C 
2.7 
Yamada et 
al. (2008) 
S. 
pneumoniae 
PBP2b-#34 
Not stated Apoenzyme 
1.4 M ammonium 
sulphate, 20°C 
3.29 
Contreras-
Martel et 
al. (2009) 
S. 
pneumoniae 
PBP2x-#48 
20 Apoenzyme 
0.1 M sodium 
acetate, 1.0-1.3 M 
ammonium 
sulphate, pH 4.6, 
25°C 
2.4 
Gordon et 
al. (2000) 
S. aureus 
MGT-#67-
E100Q 
10 Moenomycin 
0.1M sodium 
acetate, 0.2M NaCl, 
30% 2-methyl-2,4-
pentanediol, pH 
4.6, 22°C 
2.1 
Heaslet et 
al. (2009) 
Table 6.1: Successful crystallisation conditions yielding crystal structures of the enzymes under 
investigation.  The crystal structure of S. pneumoniae PBP1a-#36 was based only on the 
transpeptidase domain. 
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6.3.1. Investigating new crystallisation conditions 
 
To improve the resolution of the existing crystal structures, new crystallisation 
conditions were explored.  Protein crystallisation is often referred to as a ‘black art’, 
where conditions for nucleation and crystal growth are highly protein-specific and 
the change in a single variable can prevent crystal formation (Chayen, 2004).  In 
spite of this, sparse matrix screens are often employed, which consist of conditions 
that are tailored towards those that have successfully generated crystals.  There are 
numerous commercially available sparse matrix screens for soluble proteins, four of 
which were used to establish crystallisation conditions of S. pneumoniae PBP1a-#30, 
PBP2b-#39, PBP2x-#48 and S. aureus MGT-#67 (referred to as MGT from here 
onwards): Wizard I screen (Emerald Biosciences); Newcastle I screen (University of 
Newcastle); Clear Strategy I screen (Molecular Dimensions); Index screen (Hampton 
Research).  Two additional screens were trialled to crystallise MGT: JCSG-plus 
(Molecular Dimensions) and PACT-premier (Molecular Dimensions).  The 
Honeybee 963 crystallisation robot was used as an automated facility to set up the 
crystallisation screens in a 96-well plate format.  Initial screenings were prepared 
using the sitting drop vapour diffusion method (Section 2.10.1).  The buffer and the 
concentration of the individual enzymes are shown in Table 6.2. 
 
Enzyme 
Enzyme concentration 
(mg/mL) 
Enzyme buffer 
S. pneumoniae PBP1a-#30 10 20 mM HEPES, pH 7.5 
S. pneumoniae PBP2b-#39 10, 40 20 mM HEPES, pH 7.5 
S. pneumoniae PBP2x-#48 10, 40 20 mM HEPES, pH 7.5 
S. aureus MGT 10, 30 
20 mM HEPES, 250 mM 
NaCl, pH 7.5 
Table 6.2:  Enzyme buffer and concentration in the crystallisation trials.  PBP1a-#30, PBP2b-
#39 and PBP2x-#48 were purified as described in Chapter 3.  MGT was purified as described in 
Chapter 4.  In the absence of detergent PBP1a-#30 was not stable at high protein concentrations and 
MGT required a minimal of 250 mM NaCl to prevent protein precipitation.   
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The crystallisation screens were incubated at 18°C and periodically monitored every 
24 h for 1 week and every 48 h during the following month.  The initial screens gave 
an indication of successful precipitants for the crystallisation of the enzymes, with 
the exception of PBP1a-#30.  It was likely that this enzyme was unstable (Section 
3.8.1.3), preventing associations in an ordered array, and therefore was excluded 
from future crystallisation trials.  Figure 6.3 shows the spherulites and microcrystals 
of PBP2b-#39, PBP2x-#48 and MGT that developed in the conditions stated. 
 
Figure 6.3: Spherulite and microcrystal formation of S. pneumoniae PBP2b-#39, S. pneumoniae 
PBP2x-#48 and S. aureus MGT.  The sitting drop method of vapour diffusion was used with 
commercial sparse matrix screens.  The precipitant composition is stated.   
 
6.3.2. Fine-screening of crystallisation conditions to improve crystal 
size and morphology 
 
The spherulites of PBP2b-#39, the needle-like crystals of PBP2x-#48 and the 
microcrystals of MGT were unsuitable for diffraction.  In-house screens (Section 
2.10.3.1) were designed to induce crystallisation (PBP2b-#39) and to reduce the 
level of nucleation (PBP2x-!48 and MGT) concurrently with improving crystal size 
and morphology.  The crystal screen promoting spherulite or crystal formation was 
adjusted by a maximum of 0.6 M precipitant concentration and 1 pH unit above and 
below the original value, whilst the protein concentration and temperature remained 
constant.  Screening was performed using the hanging drop vapour diffusion method 
0.1M HEPES, pH 7.5  
2 M Ammonium acetate 
2 % (v/v) PEG 400  
30 mg/ml protein 
PBP2b-#39 PBP2x-#48 MGT 
0.1M Sodium acetate 
trihydrate, pH 4.5  
2 M Ammonium sulphate 
40 mg/ml protein 
0.1M Sodium acetate 
trihydrate, pH 4.5  
3 M Sodium chloride 
40 mg/ml protein 
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in a 24-well plate format.  Three different ratios of enzyme to precipitate were used: 
1:1, 2:1, and 1:2.  The crystal screens were monitored as before. 
 
The improvement of crystal size and morphology was achieved for PBP2x-#48 only.  
A precipitate formed instantly in every condition of the MGT trials.  Crystallisation 
of a new protein batch of MGT was trialled in the conditions that provided the initial 
microcrystals, with no reproducibility.  Globular clusters of microcrystalline fibres of 
PBP2b-#39 appeared, showing no deviation from the original spherulites obtained. 
 
The PBP2x-#48 crystals were observed after 1 month.  At the higher pH and 
precipitant concentration, a significant degree of nucleation was observed with a 
tendency to form long thin crystals.  However, under certain conditions, crystals of a 
suitable thickness for diffraction studies were produced, shown in Figure 6.4. 
 
Figure 6.4: Crystal formation of S. pneumoniae PBP2x-#48.  Crystals were obtained using the 
hanging drop method with in-house screens.  The precipitant composition is stated.   
 
A single protein crystal (from Figure 6.4a) was disrupted from the cluster, transferred 
to a cryoprotectant (mother liquor with 30 % glycerol), and mounted in a nylon loop.  
The crystals were flash frozen in liquid nitrogen and transported to the Diamond 
synchrotron radiation facility (Oxford).  A complete data set was collected (600 
images), and due to the time constraints of this project, the data was processed by 
Professor Vilmos Fülöp.  All data were indexed and integrated with MOSFLM 
0.1M Sodium acetate 
trihydrate, pH 4.5  
2.6 M Sodium chloride 
40 mg/ml protein 
2:1 protein:screen 
0.1M Sodium acetate 
trihydrate, pH 5.0  
2.6 M Sodium chloride 
40 mg/ml protein 
2:1 protein:screen 
(a) (b) 
 252 
(Leslie, 1992) and scaled using the SCALA (Evans, 2006).  The data collection and 
processing statistics are shown in Table 6.3.  The structure of PBP2x-#48 was solved 
by molecular replacement using the PHASER program (McCoy et al., 2007) with the 
coordinates of the previously established structure of PBP2x-#48 (PDB code: 
1QME) (space group P41212) (Gordon et al., 2000).  The crystals belonged to the 
space group P3121 with one molecule in the crystallographic asymmetric unit, which 
gave a solvent content of 66 %.  Although the crystal form established here was 
different from the deposited structure in the PDB, the resolution was poorer.  
Therefore, no further analysis was pursued.   
 
Data collection PBP2x-#48 
Synchrotron radiation, Diamond, beamline I24 
Detector Pilatus 6M 
Wavelength (Å) 0.9778 
Space group P3121 
Unit cell parameters 
a = b (Å) 
c (Å) 
 
100.17 
187.33 
Molecule per asymmetric unit 1 
Matthews coefficient (Å3 Da-1) 3.6 
Solvent content by (%) 66 
Resolution range (Å) 79-2.8 (2.95-2.80) 
Total observations 154316 (20024) 
Unique reflections 26590 (3763) 
Average I/$(I) 5.0 (1.5) 
Rsym (%)
a
 0.222 (1.028) 
Completeness (%) 97.4 (96.1) 
Table 6.3: Data collection and refinement statistics for PBP2x-#-48.  Values in parentheses refer 
to the highest resolution shell.  I, Intensity unit; $; standard deviation.  aRsym = %j%h|Ih,j - <Ih>|/%j%h<Ih> 
where Ih,j is the jth observation of reflection h, and <Ih> is the mean intensity of that reflection. 
 
The PBP2x-#48 structure is shown in Figure 6.5. 
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Figure 6.5: Crystal structure of S. pneumoniae PBP2x-!48. (Gordon et al., 2000).  (a) Structure of PBP2x-!48.  The arrow marks the position of the catalytic Ser.  (b) 
Close up of the active site.  The penicillin-binding domain conserved residues are shown in a stick format and are labelled accordingly.   
C 
N 
Ser-337 
Lys-340 
Ser-395 
Asn-397 
Ser-548 
Lys-547 
Gly-549 
(a) (b) 
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6.3.3. Refinement of the crystallisation conditions of PBP2b-!39 
 
It was anticipated that further refinement of the crystallisation conditions that yielded 
the predominant PBP2b-!39 spherulites would ultimately generate single crystals.  
The Additive Screen and the Silver Bullet Screen (Hampton Research) were 
employed to introduce small molecules that have been shown to promote crystal 
lattice formation by stabilising and altering the solubility properties of the protein 
and by manipulating the protein-protein and protein-solvent interactions.  Two 
mother liquors were trialled in conjunction with the screens (as stated in Figure 6.6).  
The sitting drop vapour diffusion method was performed and the different screens 
were applied according to the manufacturer’s instructions (Section 2.10.3).  1 µL of 
40 mg/mL PBP2b-!39 in a total drop size of 2 µL was used.   
 
Two conditions of the Additive Screen promoted the formation of crystals, displayed 
in Figure 6.6.  The large crystal (indicated with an arrow) was divided for analyses.  
One part was washed in mother liquor (of the remaining solution in the reservoir 
from the well the crystal originated from) and subjected to SDS-PAGE analysis.  The 
results of the SDS-PAGE are shown in Figure 6.6b, where a Coomassie-stained 
protein band at the molecular weight of PBP2b-!39 signified the crystal was protein 
and not a salt artefact.  The remaining part of the crystal was frozen in cryoprotectant 
(mother liquor with 30 % (v/v) glycerol) and mounted onto the in-house X-ray 
facility for diffraction studies.  A diffraction pattern was produced (again proving the 
crystal was of protein origin), but the resolution was insufficient to extract any 
detailed structural information.  Neither crystallisation conditions were reproducible.   
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Figure 6.6: Successful S. pneumoniae PBP2b-!39 crystal formation using the Additive Screen.  
(a) PBP2b-!48 crystals obtained in two different crystallisation conditions (stated).  (b) SDS-PAGE 
analysis of a portion of the crystal (identified with an arrow) from (a). 
 
6.4. Crystallisation of S. pneumoniae PBP1a, PBP2b and PBP2x 
 
Crystallisation of integral membrane proteins is notoriously difficult.  To date, full-
length crystal structures of S. pneumoniae PBP1a, PBP2b and PBP2x do not exist.  
The following sections discuss attempts to rectify this situation. 
 
6.4.1. Sparse matrix screens for membrane proteins 
 
The sparse matrix screens available for soluble proteins present conditions that are 
often not suitable for membrane protein crystallisation.  The Iwata group of the 
Membrane Protein Laboratory at the Diamond Light Source (Oxford) have designed 
crystallisation screens, which are targeted towards membrane protein crystallisation: 
MemStart (48 conditions), MemSys (48 conditions) and MemGold (96 conditions) 
(Molecular Dimensions). 
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6.4.2. Initial crystallisation trials 
 
In an analogous system to the soluble counterparts, crystallisations of PBP1a, PBP2b 
and PBP2x (in DDM or LDAO) (purified as described in Chapter 3) were trialled 
using the sitting drop vapour diffusion method (Section 2.10.1) in a 96-well plate 
format using the three membrane protein crystallisation screens, with incubation at 
18°C and 4°C.  Initial trials were performed with protein concentrated to 20 mg/mL 
using centrifugal protein concentrators with a molecular weight cut-off of 100 kDa, 
to limit the coincident concentration of detergent (DDM micelle Mr, ~40-75 kDa 
(Anatrace-Affymetrix); protein Mr, ~80 kDa; protein-micelle complex Mr, ~140 
kDa).  Following periodic monitoring of the crystal screens, no condition provided 
evidence of protein crystallisation.   
 
6.4.3. An adaptation in protein preparation favours crystal formation 
 
Two major influences on membrane protein crystallisation are homogeneity of the 
protein preparation and the detergent (size, concentration, properties) (as reviewed 
by Loll (2003) and Privé (2007)).  The crystallisation trials were repeated as before 
with a single modification: following size exclusion chromatography, the protein 
fraction corresponding to the peak of absorbance maxima at 280 nm (representing 
the highest protein purity in an unaggregated state) on the chromatogram, was 
selected and submitted to the crystallisation trial, without prior concentration of the 
protein.  The protein concentrations of the peak fractions were: PBP1a, 1 mg/mL; 
PBP2b, 2 mg/mL; PBP2x, 1 mg/mL.  The detergent was present just above the CMC.  
This alteration proved to be successful, leading to the formation of PBP1a and 
PBP2b crystals (Figure 6.7). 
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Figure 6.7: Crystals of S. pneumoniae PBP1a and PBP2b.  Crystals were obtained using the sitting 
drop method with sparse matrix screens.  The arrow indicates the protruding PBP1a crystal that was 
isolated and frozen.  The precipitant composition is stated.  Protein buffer solution; 20 mM Tris, 0.15 
M NaCl, 0.03 % (w/v) DDM. 
 
PBP2b crystals were analysed during the course of consecutive days.  Towards the 
end of each day, the crystals began to disappear, although the subsequent day, they 
would reappear with an improved size.  Following a weekend, the crystals had 
completely dissolved.  It is believed that temperature fluctuations in the 18°C room 
were responsible. 
 
The crystal protruding from the PBP1a cluster (indicated by the arrow on Figure 6.7) 
was sequestered and frozen in cryoprotectant.  Unfortunately, the crystal did not 
survive the freezing process.   
 
Efforts to reproduce the crystal formation in identical conditions were unsuccessful, 
owing to the potential variability in a myriad of parameters. 
 
6.4.4. Crystallisation of PBP1a, PBP2b and PBP2x variants in the 
presence of ligands 
 
Crystallisation trials of PBP1a, PBP2b and PBP2x and the corresponding 
transpeptidase active site serine mutants were performed in the presence and absence 
of a 10-fold molar excess of the ligands ampicillin and Lys-Lipid II (solubilised in 
the equivalent buffer to the protein) respectively.  The protein-ligand solutions were 
PBP2b 
0.1 M Ammonium sulphate  
0.1 M Glycine, pH 3.8 
28 % (w/v) Triethylene              
glycol 
0.1 M Sodium chloride /                                
0.1 M Cadmium chloride 
0.1 M Tris pH 8.0 
33 % (v/v) PEG 400 
0.1 M Potassium chloride 
0.02 M Tris pH 7.0 
20 % PEG (w/v) 4000  
0.22 M Sodium citrate 
0.1 M Tris pH 8.0 
35 % (v/v) PEG 400 
PBP1a 
 258 
incubated at 20°C for 1 h prior to preparing the crystallisation screens.  
Crystallisation conditions were screened in an analogous method to the native 
apoenzymes.  Crystal nucleation and growth were not apparent.   
 
6.5. Discussion and future work 
 
The purpose of this Chapter was to establish optimal crystallisation conditions for S. 
aureus MGT and the variants of S. pneumoniae PBP1a, PBP2b and PBP2x, with the 
ultimate aim of obtaining structural information to relate to the catalytic mechanism.  
The following sections discuss the results, parameters that influence membrane 
protein crystallisation and future work.  
 
6.5.1. S. pneumoniae PBP1a-!30, PBP2b-!39, PBP2x-!48 and S. 
aureus MGT crystallisations 
 
The crystallisation of the soluble enzymes had mixed results.  PBP1a-!30 did not 
provide any indication of nucleating.  This enzyme is predicted to be unstable due to 
the location of the truncation and its poor expression levels.  Additionally, detergent 
monomers may not have been eliminated from the protein preparation (following 
extraction from the membranes), which would not be compatible with the crystal 
screens for soluble proteins.  A single condition, out of 576 sparse matrices at two 
protein concentrations, provided protein crystals of MGT.  The difficulty of MGT 
crystallisation was comparable to the studies by Heaslet et al. (2009), where crystals 
of MGT-E100Q only were of a suitable quality for diffraction.  The stability of MGT 
is problematic, where a high salt content is essential to prevent the protein 
precipitating out of solution.   
 
It was evident that the conditions required for PBP2b-!39 to crystallise were almost 
suitable given the spherulite formation under variations of the same crystal screen.  
The additives 1.0 M Potassium sodium tartrate tetrahydrate or 50 % (v/v) PEG 400 
promoted crystallisation, and analysis of the crystal proved it was comprised of 
protein.  The insufficient resolution of the diffraction data possibly resulted from the 
disruption of the crystal lattice upon freezing in an inappropriate cryoprotection 
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condition.  Screening of alternative cryoprotectants could solve this problem, 
enabling high-resolution data to be obtained. 
 
PBP2x-!48 reproducibly crystallised under the conditions described, which were 
similar to those in literature.  Fine screening of the crystallisation conditions by 
subtly varying the pH and precipitant concentration enabled the growth of crystals 
with size and morphology suitable for diffraction studies.  A single protein crystal in 
the space group P3121 diffracted to 2.8 Å.  Further optimisations could improve on 
this resolution.  In spite of a higher resolution crystal structure in literature, the 
established crystallisation conditions are important for future work.  Ligands could 
be co-crystallised with the protein, or alternatively, soaked into a pre-formed crystal 
lattice of the protein to provide valuable structural and binding information.  
  
6.5.2. The challenges of membrane protein crystallisation 
 
Membrane proteins crystals are notoriously difficult to grow, reproduce and generate 
a crystal structure for a number of reasons.  Following expression and purification, 
the yield and purity of membrane proteins is often not sufficient for crystallisations, 
where a high concentration of monodisperse protein of near homogeneity is required 
(Caffrey, 2003).  The amphiphilic nature of membrane proteins dictates the 
requirement for detergents.  The choice of detergent, in terms of size, concentration 
and properties, is empirical to ensure the structural integrity of the protein is 
maintained in an unaggregated state, suitable for crystallisation (Loll, 2003).  The 
phase behaviour of detergents can impede crystal development, which is affected by 
environmental conditions including temperature and the presence of precipitants 
(Reiss-Husson and Picot, 1999).  In a vapour diffusion experiment, the protein and 
detergent concentration will rise in parallel (Caffrey, 2003), where the detergent will 
be in a transition between monomeric and micellar solution (Loll, 2003).  Phase 
separation commonly occurs where the micellar solution spontaneous separates into 
two liquid phases: detergent rich and detergent depleted, which is defined at the 
consolution boundary (Loll, 2003; Reiss-Husson and Picot, 1999).  Generally, 
integral membrane proteins locate to the detergent rich phase, which can cause 
denaturation (Loll, 2003; Reiss-Husson and Picot, 1999).  
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Upon obtaining membrane protein crystals, difficulties in generating a structure are 
encountered.  The packing of the detergent molecules in a crystal lattice is commonly 
disordered and infers that the membrane protein crystals are highly solvated 
(Carpenter et al., 2008).  Consequently, the crystals are fragile, diffract to low 
resolution and are subject to radiation damage during the diffraction experiment 
(Carpenter et al., 2008).   
 
6.5.3. Choice of detergent during membrane protein crystallisation 
 
The crystallisations of the full-length membrane proteins were trialled in the 
presence of two different detergents, DDM and LDAO, at concentrations just above 
the CMC.  Both detergents have a C12 alkyl chain (from structural comparisons), but 
produce micelles of substantially different sizes.  LDAO and DDM have an 
aggregation number of ~76 and ~78-149, with a micelle size of ~17 kDa and ~40-75 
kDa, respectively (information from Anatrace, Affymetrix).  The small micelle size 
of LDAO confers a smaller belt around the hydrophobic regions of the membrane 
protein.  Potentially, this could allow for more interprotein interactions within a 
crystal lattice and ultimately crystals could be produced that provide a better 
diffraction pattern (Privé, 2007).  The large micelle size of DDM would be expected 
to mask large areas of the exposed polar surfaces of the protein.  In spite of this, 
DDM was employed in these trials due to its ability to maintain the proteins in a 
stable, native conformational state in addition to its proven success in the 
crystallisation of a myriad of membrane proteins.  Membrane protein crystals were 
only generated in the presence of DDM (Figure 6.7), where the properties of LDAO 
probably inferred gradual protein denaturation, a common attribute of this detergent 
(Privé, 2007).  Upon reproducibility of the membrane protein crystals, detergents of 
similar properties could be trialled to improve protein contacts within the crystal 
lattice (Privé, 2007). 
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6.5.4. S. pneumoniae PBP1a, PBP2b and PBP2x crystallisations 
 
Crystals of S. pneumoniae PBP1a and PBP2b were obtained when the detergent 
concentration was just above the CMC (DDM, 0.03% (w/v)), irrespective of the low 
protein concentration.  The cryoprotectant conditions for PBP1a were not suitable to 
protect the crystal during the freezing process, thus further conditions should be 
screened prior to freezing to ensure ice crystals do not materialise.    
 
The crystal formation of PBP2b was interfered by subtle temperature fluctuations 
that ultimately inhibited crystal growth.  Temperature has a greater impact on 
membrane protein crystals compared to soluble protein crystals, due to the 
dependence of temperature on the detergent CMC.  The high detergent content in the 
crystal lattice of membrane protein crystals dictates that fluctuations in the effective 
detergent concentration can impact the growing crystals (Barnard et al., 2007). 
 
Crystallisation experiments of the wild-type PBPs and the corresponding 
transpeptidase active site serine mutants were trialled in the presence of ligands 
(ampicillin and Lys-Lipid II respectively) with no success.  The ligands were 
employed to stabilise the inherent flexibility of the membrane proteins and to provide 
information on substrate binding.  Crystal formation of PBP1a-S370A in the 
presence of Lys-Lipid II could have been hindered due to the active transglycosylase 
domain, which potentially could have polymerised the substrate.  A double mutant 
consisting of active site transpeptidase and transglycosylase mutations should be 
used in future co-crystallisation experiments. 
 
6.5.5. The reproducibility of crystal nucleation and growth 
 
Both soluble and membrane protein crystals obtained in the vapour diffusion 
experiments, with the exception of PBP2x-!48, were not reproducible.  There are a 
number of explanations for this phenomenon including variations in: protein 
preparation; protein concentration; temperature; detergent concentration; detergent 
impurities; precipitant concentration.  Additionally, the dodeca-histidine tag on all 
the S. pneumoniae PBP variants would have introduced a further degree of disorder, 
potentially affecting crystal contacts.  Only six of the twelve histidine residues could 
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be cleaved from the protein (Figure 3.1).  Therefore, new constructs need to be made 
to enable the removal of the full twelve histidine residues.   
 
The precise conditions of the labile supersaturated state determining crystal 
nucleation are often very sensitive and difficult to reproduce.  Microseeding could be 
used to bypass the crystal nucleation stage.  In this technique, small crystals or 
‘seeds’ are introduced into a pre-equilibrated hanging drop in the metastable zone of 
supersaturation (Bergfors, 2003).  Growth from the seeds produces crystals that 
follow the same lattice symmetry as the original seed. 
 
6.5.6. Crystallisation of proteins with large soluble tags 
 
The crystallisation of membrane proteins could exploit soluble fusion tags integrated 
onto the protein for purification purposes; examples include maltose-binding protein 
(MBP) and green fluorescent protein (GFP) tags.  Permitting that conformational 
heterogeneity is not introduced, the readily crystallising soluble tag could act as a 
scaffold, inducing crystallisation of the membrane protein.  This approach has been 
documented for the co-crystallisation of MBP with S. aureus SarR (Liu et al., 2001), 
Saccharomyces cerevisiae MATa1 homodomain (Ke and Wolberger, 2003) and the 
ectodomain of the human T-cell leukaemia virus I envelope protein gp21 (Kobe et 
al., 1999). The attachment of scaffold proteins to the full-length (or truncated) PBPs 
could promote crystallisation of these recombinant membrane proteins allowing co-
crystal structures to be solved.   
 
6.5.7. A novel technique to eliminate the requirement of detergent in 
membrane protein crystallography 
 
SMALP technology (Section 3.8.2.1) provides a new route to the solubilisation and 
purification of membrane proteins in a stable, monodisperse state in a detergent-free 
environment.  The homogenous discoidal structure of the SMALP could promote 
protein interactions in an ordered array, which could lead to the formation of crystal 
nuclei. 
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6.6. Conclusion 
 
The initial stage in the determination of a crystallographic structure is the growth of 
crystals suitable for diffraction, which is regarded as the rate-limiting step from 
protein to structure for both soluble and integral membrane proteins.  Conditions 
were identified that were conducive to the crystallisation of the S. pneumoniae PBPs 
(full-length and devoid of the membrane anchor) and S. aureus MGT, which should 
be pursued to reproduce the crystal nucleation and growth conditions.  The recent 
advances in crystallisation methods and high-throughput screening procedures are 
anticipated to rapidly expand the number of solved membrane protein structures, 
enhancing the understanding of the membrane proteome and providing information 
for structure-based drug design.  
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Chapter 7. General discussion and conclusions 
 
This Chapter addresses the principal findings of this project with reference to the 
main objectives outlined in Section 1.11, and highlights areas where further 
investigation is necessary.   
 
7.1. Production of S. pneumoniae "-lactam resistance determinants 
 
The primary focus of this work was to investigate the kinetic and structural 
characteristics of S. pneumoniae PBP1a, PBP2b and PBP2x.  These enzymes are 
highly clinically relevant, being the target of "-lactam antibiotics and mediating the 
resistance to this important class of antibiotics.  Thus, the initial objective was to 
establish protocols that enabled the expression, solubilisation and purification of 
these full-length membrane proteins (and variants thereof) in suitable quantities for 
forthcoming analyses.  The PBPs, S. pneumoniae D39 and 5204, full-length and 
devoid of the membrane anchor, and transglycosylase and transpeptidase active site 
mutants, expressed to high levels in E. coli BL21 Star (DE3) pRosetta cells.  The 
exception was PBP1a-!30; the expression levels were low probably owing to the 
instability of the construct.  Sodium deoxycholate was found to be the ideal detergent 
to extract the full-length membrane proteins from the membranes.  Each variant of 
the "-lactam resistance determinants was purified by IMAC and size exclusion 
chromatography (PBP2b-!39 and PBP2x-!48 were further purified by anion 
exchange) with enzyme-specific adaptations to optimise the purity.  Each PBP, 
except the transpeptidase catalytic mutants, was able to bind BOCILLIN FL, 
indicating that the transpeptidase active site was in a sufficiently native conformation 
to react with the substrate analogue.  Accordingly, it was anticipated that the 
enzymes had been prepared in a catalytically active form.   
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7.2. The enzymology of transglycosylation 
 
7.2.1. The development of a spectrophotometric assay for 
transglycosylase activity 
 
Lipid II is the final monomeric intermediate in the peptidoglycan synthetic pathway, 
and is the substrate of the PBPs and MGTs.  Recently established protocols have 
enabled suitable quantities of Lipid II to be synthesised, facilitating the study of the 
final stages of peptidoglycan biosynthesis, which has been hindered in part due to the 
limited substrate availability.   
 
Chapter 4 details the development of a novel spectrophotometric assay to rapidly 
analyse the transglycosylation activities of Class A HMW-PBPs and MGTs with 
their natural substrate, Lipid II.  Transglycosylation results in the formation of a "-
1,4-glycosidic bond between the MurNAc moiety of an elongating glycan chain and 
the GlcNAc moiety of Lipid II, with the concomitant release of undecaprenyl 
pyrophosphate (Lovering et al., 2007).  The generation of this latter product was 
exploited in the measurement of transglycosylase activity; it was coupled to an 
undecaprenyl pyrophosphate phosphatase (E. coli PgpB), which dephosphorylates 
undecaprenyl pyrophosphate.  The liberated terminal Pi was monitored by the 
phosphorolysis of a chromogenic substrate, MESG.  This assay was used in a 
discontinuous manner to successfully establish transglycosylase activity from S. 
aureus MGT and S. pneumoniae PBP1a.   
 
Given the transglycosylases exhibit substantial activity and that PgpB can be 
prepared in sufficient quantities, this assay has the potential to measure 
transglycosylation continuously.  Further development of this spectrophotometric 
assay for use in a plate reader with a 96-well plate would enable a myriad of 
parameters to be assessed promptly with regards to transglycosylase activity 
(examples include pH and metal ion dependency, substrate specificity, effects of 
inhibitors, protein complexes), which could significantly contribute to the 
understanding of this complex stage of peptidoglycan biosynthesis. 
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7.2.2. Characterisation of S. aureus MGT catalysed transglycosylation 
 
MGT was employed as a control enzyme for transglycosylation; the construct devoid 
of the membrane anchor has proven activity (Terrak and Nguyen-Distèche, 2006).  
Using the designed spectrophotometric assay for transglycosylation, kinetic 
characteristics of MGT were investigated.  It was revealed that at low substrate 
concentrations, the velocity of MGT transglycosylase activity exhibited a sigmoidal 
dependence on substrate concentration, and at high substrate concentrations, MGT 
was subjected to severe substrate inhibition.  A model was designed to describe these 
characteristics, to which the kinetic data was applied in an attempt to extract kinetic 
constants.  Further data points are needed to improve the fit of the data to the model.   
 
7.2.3. Characterisation of S. pneumoniae PBP1a catalysed 
transglycosylation 
 
Transglycosylation activities of the full-length integral membrane protein, S. 
pneumoniae PBP1a and the corresponding active site mutants, were explored using 
the spectrophotometric assay.  It was immediately recognised that under the 
experimental conditions trialled, the rate of transglycosylation was extremely slow 
and the generation of a velocity versus substrate plot revealed that Vmax was not 
reached despite using Lipid II concentrations that caused inhibition of MGT activity.  
The rates were vastly insufficient to support bacterial growth; the in vitro conditions 
did not suitably recreate the required conditions for transglycosylation.  Many factors 
could influence the transglycosylation activity of PBP1a including the formation of 
protein and lipid complexes, which could stabilise and activate the enzyme in its 
natural environment.   
 
Transglycosylation by the transglycosylase putative catalytic mutant was 
undetectable, validating the importance of this residue.  PBP1a transglycosylation 
was not dependent on transpeptidase activity, although in the absence or uncoupling 
of the transpeptidation reaction, the rate of transglycosylation was augmented, which 
was found to be statistically significant in vitro.  It is plausible that transpeptidation 
and transglycosylation reactions of the bifunctional enzyme do not occur 
concomitantly, thus the catalysis of a reaction in one domain could momentarily 
hinder the activity of the other domain.  
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7.2.4. Optimisation of S. aureus MGT and S. pneumoniae PBP1a 
transglycosylase activity 
 
In an attempt to recreate the in vivo conditions and to optimise the rates of 
transglycosylation by MGT and PBP1a, various experimental parameters were 
considered including: temperature; metal ion specificity; presence of lipids; presence 
of Decyl PEG and DMSO.  These factors influenced the transglycosylase activity of 
MGT and PBP1a to varying degrees.  Further conditions should be trialled to 
augment the activity of MGT and PBP1a in vitro.   
 
7.3. The enzymology of transpeptidation  
 
7.3.1. The development of a spectrophotometric assay for D-Ala 
release 
 
Transpeptidation results in the formation of a cross-link between the fourth position 
D-Ala of a donor stem peptide and either the amino acid at the third position of an 
adjacent acceptor stem peptide (direct) or by a branching peptide appendage from 
this third position residue (indirect) (as reviewed by Vollmer et al. (2008a)).  The 
terminal D-Ala of the donor stem peptide is released concomitantly, and can be used 
to follow transpeptidation in a novel continuous spectrophotometric assay as detailed 
in Chapter 5.  The generation of D-Ala can be coupled to the ligation of D-Ala with 
D-Lac, catalysed by VanA, in an ATP-dependent reaction.  The release of ADP or Pi 
can be measured spectrophotometrically.  This assay was successfully employed to 
characterise Actinomadura R39 D,D-peptidase, which demonstrated a substrate 
preference for peptidoglycan fragments with meso-DAP residing at the third position 
of the peptide stem as opposed to L-Lys, coincident with published literature 
(Anderson et al., 2003).  The main limitation of this assay is that the D-Ala released 
from transpeptidation or D,D-carboxypeptidation cannot be distinguished.  This 
could be solved by the quantification of free peptide stem amino groups; an 
experimental strategy is discussed in Chapter 5. 
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7.3.2. Detection of transpeptidation by S. pneumoniae primary 
resistance determinants 
 
The interactions of "-lactam antibiotics with HMW-PBPs have been well studied, 
but presently, there are few experimental protocols that can analyse transpeptidation 
by HMW-PBPs with the natural substrate.  Consequently, the specificities of the 
interactions involved are poorly understood.  The sensitive Amplex Red assay was 
used to detect D-Ala release from PBP1a, PBP2b and PBP2x catalysed reactions.  
The discontinuous assays described in Chapter 5 attempted to produce an 
environment conducive to transpeptidation in vitro using the established optimal 
conditions for PBP1a-catalysed transglycosylation.  The current hypothesis for the 
ultimate stages of peptidoglycan biosynthesis is that transglycosylation precedes 
transpeptidation (Born et al., 2006).  This was investigated using monomeric Lipid II 
and polymeric forms (produced through MGT or PBP1a-S370A dependent 
transglycosylation reactions).  D-Ala release (representative of transpeptidation or 
D,D-carboxypeptidation) was detected in incubations with PBP1a and PBP2b; both 
enzymes exhibited a substrate preference for polymerised glycan strands over the 
monomeric Lipid II.  The results also suggested that transpeptidation catalysed by 
PBP1a (similar to E. coli PBP1a (Born et al., 2006) and E. coli PBP1b (Bertsche et 
al., 2005)) demonstrated a dependency for concomitant transglycosylation reactions 
catalysed by the same enzyme molecule.  This coincides with the model proposed by 
Sung et al. (2009): the nascent transglycosylation product is directed to the 
transpeptidase domain.  Failure to detect D-Ala release by PBP2x was interesting; it 
raises questions regarding the difference in substrate specificity of the HMW-PBPs, 
which may relate to their defined roles during different stages of the cell cycle i.e. 
PBP2b is involved in the biosynthesis of peptidoglycan during elongation and PBP1a 
and PBP2x are involved in division (Morlot et al., 2003).  These enzymes are 
recruited to multiprotein complexes (Scheffers and Pinho, 2005) and this association 
with auxiliary proteins may be required to promote the activity of the PBPs as 
documented for E. coli transpeptidases (Paradis-Bleau et al., 2010; Typas et al., 
2010).   
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In S. pneumoniae, it has been estimated that ~50 % peptidoglycan stem peptides are 
involved in cross-linking (Garcia-Bustos and Tomasz, 1990).  The D-Ala released by 
PBP1a and PBP2b over the 18 h incubation did not coincide with or approach this 
value.  Thus, the level of transpeptidation detected would be substantially inadequate 
to support the integrity of the cell wall.  PBP1a and PBP2b had a preference for 
peptidoglycan polymers that were not characterised definitively.  It is possible that 
the enzymes required defined polymer lengths, which were present as only a small 
fraction of the total substrate preparation.  Additionally, S. pneumoniae PBPs may 
have an acceptor substrate preference for peptidoglycan tripeptide stems as these 
constitute up to 30 % of the peptidoglycan composition (Garcia-Bustos and Tomasz, 
1990).  These points highlight the gaps in the understanding of how the PBPs 
recognise their substrates. 
 
Chapter 5 describes the preliminary results towards the full kinetic characterisation 
of the transpeptidase activity of S. pneumoniae "-lactam resistance determinants.  
Future work is required to establish in vitro conditions that will enable the PBPs to 
exhibit substantial activity.  This will facilitate further characterisations that could 
contribute to an elevated understanding of the enzymology of PBP1a, PBP2b and 
PBP2x and the resistance mechanisms that they employ.    
 
7.4. Towards the structural characterisations of S. pneumoniae 
PBP1a, PBP2b and PBP2x 
 
To fully understand the mechanisms of substrate recognition and catalysis of HMW-
PBP-mediated transglycosylation and transpeptidation, structural information of 
these enzymes in complex with peptidoglycan fragments is required.  Recent 
progress has been made in the area of membrane protein crystallisation and the first 
PBP structure with a transmembrane domain has been solved (E. coli PBP1b (Sung 
et al., 2009)).  This structure and others of truncated PBPs (e.g. S. aureus PBP2 
(Lovering et al., 2007)) have been essential in shedding light on the transglycosylase 
catalytic mechanism.  Chapter 6 details attempts to crystallise full-length PBPs and 
equivalent enzymes devoid of the membrane-spanning domain in apo and liganded 
forms to various levels of success.  The apoenzyme PBP2x-!48 formed crystals, 
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which diffracted to 2.8 Å.  Full-length membrane protein crystals were obtained for 
PBP1a and PBP2b.  However, the conditions conducive to crystallisation were not 
reproducible, a common problem encountered.  Further screening of crystallisation 
and cryoprotectant conditions for the PBPs is required for the pursuit of valuable 
structural information. 
 
7.5. Conclusion 
 
The recalcitrant nature of S. pneumoniae PBPs in vitro has thwarted appreciable 
efforts to biochemically characterise these enzymes.  The work presented in this 
thesis has provided successful strategies to detect transglycosylase and 
transpeptidase activities of the PBPs, providing an excellent foundation for further 
work to unravel the mysteries of this complex family of antimicrobial targets.   
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Appendix A 
 
Lys-Lipid II purification 
 
Lys-Lipid II was synthesised and purified as described in the Materials and Methods.  
The TLC of Lys-Lipid II purification is displayed in Figure A1. 
 
Figure A1: TLC of fractions from anion exchange purification of Lys-Lipid II.  Lys-Lipid II was 
synthesised and purified as described in Section 2.7.3.  Samples were loaded on to the silica plate in 
chloroform/methanol/water 2:3:1 (v/v).  Chromatography was performed in 
chloroform/methanol/water/0.88 ammonia 88:48:10:1 (v/v) and the resulting silica plate was stained 
with iodine vapour (Section 2.7.4).  BL, total lipid before loading on to the DEAE column; FT, flow 
through; %, % (v/v) solvent B (chloroform/methanol/1 M ammonium bicarbonate 2:3:1 (v/v)).  Each 
lane was loaded with the equivalent of a 500 µL sample from the fraction collected, with the 
exception of BL, where 50 µL was sampled.  Separated components from the synthesis are labelled on 
the diagram.  Arrows mark the position of sample loading on the silica plate and the solvent front.  
BL FT 0 % 5 % 10 % 15 % 20 % 25 % 30 % 50 % 100 % 
Position 
of loading 
Triton X-100 
Components of M. 
flavus membranes 
and undecaprenyl 
phosphate 
degradation 
Undecaprenyl 
phosphate 
Lipid II 
degradation 
Lipid II 
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Appendix B1 
 
Derivation of the Michaelis-Menten equation to determine kinetic 
constants 
 
The Michaelis-Menten model states that an enzyme, E, combines with substrate, S, 
forming an enzyme-substrate complex, ES.  ES has two possible fates: it can 
dissociate to E and S or proceed to form product, P.  The initial rate depends on [S], 
which is in large excess over [E].  Upon measuring initial reaction rates, it can be 
assumed that the product does not revert back to the initial substrate as it has not has 
not accumulated to an appreciable concentration.  This is described in the model: 
 
 
E[ ]+ S[ ]
k1
k-1
! "!!# !!! ES[ ]
k2
! "! E[ ]+ P[ ]
 
 
The initial rate, v0, can be determined by the linear region of a curve at the beginning 
of the reaction (product formation over time): 
 
(1)    
dp
dt
= v0=k2 ES[ ]
 
 
At Vmax (on a initial velocity over [substrate] profile), the enzyme catalytic sites are 
saturated with substrate: 
 
(2)    Vmax=k2 ET[ ]  
 
The kinetic constant k2 can be referred to as kcat. 
 
Using the assumption that steady state kinetics exist, the concentration of ES stays 
constant and the rates of formation and dissociation of ES are equal: 
 
(3)    k1 E[ ] S[ ]=k2 ES[ ]+k-1 ES[ ]  
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(4)    
k
2
+k
-1
k
1
=
E[ ] S[ ]
ES[ ]  
 
The Michaelis constant, Km, can be defined as: 
 
(5)    
K
m
=
k
2
+k
-1
k
1 , thus: 
 
(6)    
K
m
=
E[ ] S[ ]
ES[ ]  
 
(7)    
E[ ]=
K
m
ES[ ]
S[ ]  
 
The total enzyme concentration is equal to unbound and substrate-bound enzyme: 
 
(8)    ET[ ]= E[ ]+ ES[ ]  
 
Substituting the expression for [E] (equation 7) into equation 8: 
 
(9)    
E
T[ ]=
K
m
ES[ ]
S[ ]
+ ES[ ]
 
 
(10)    
E
T[ ]= ES[ ]
K
m
S[ ]
+1
!
"#
$
%&  
Multiplying everything by the rate constant k2: 
 
(11)    
k
2
E
T[ ]=k2 ES[ ]
K
m
S[ ]
+1
!
"#
$
%&  
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Substituting v0 (1) and Vmax (2) into equation 11 gives the Michaelis-Menten 
equation: 
 
(12)    
V
max
=v
0
K
m
S[ ]
+1
!
"#
$
%&  
 
(13)    
v
0
=
V
max
K
m
S[ ]
+1
!
"#
$
%&  
 
(14)    
v
0
=
V
max
S[ ]
K
m
+ S[ ]  
 
Determination of kinetic constants 
 
Km is equal to the substrate concentration at which v0 is half its maximal rate (Vmax).   
 
At [S] much lower than Km, the rate is directly proportional to [S], given by: 
 
(15)    
v
0
=
V
max
S[ ]
K
m  
 
At [S] much greater than Km, the rate is maximal and independent of [S]: 
 
(16)    v0 = Vmax  
 
The kinetic constants were determined by plotting a velocity substrate profile.  Given 
that Michaelis-Menten kinetics were obeyed (equation 14), a hyperbolic curve was 
fitted to the data by non-linear regression using a statistical program, GraphPad 
PRISM 5.  PRISM was used to derive the values of Km and kcat from the data. 
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Appendix B2 
 
Derivation of Michaelis-Menten kinetic constants from an enzyme 
reaction involving two substrates 
 
Initial velocity measurements of transglycosylase reactions involves the binding of 
two Lipid II molecules in vitro, as described by the reaction scheme below: 
 
 
Scheme A 
 
The initial rate can be defined by: 
 
(1)    
dp
dt
=v0=kcat[ES2 ]
 
 
At Vmax, the enzyme catalytic sites are saturated with substrate: 
 
(2)    Vmax=kcat ET[ ]  
 
A kinetic equation can be derived from Scheme A on the assumption that the 
substrate of the reaction remains unchanged over the initial rates measured, and that 
rapid equilibrium kinetics exist. 
 
The kinetic constants from the model can be derived: 
 
(3) (a) 
K
m1
=
E[ ] S[ ]
ES[ ]   (b) 
K
m2
=
ES[ ] S[ ]
ES
2[ ]   
 
 
 
 
 
E[ ]+ S[ ]! "!# !! ES[ ]! "!# !! ES2[ ]!"! E[ ]+ P[ ]
Km1 Km2 
kcat +[S] 
-[S] 
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The total enzyme concentration is equal to the concentration of enzyme in unbound 
and substrate bound forms: 
 
(4)    ET[ ]= E[ ]+ ES[ ]+ ES2[ ]  
 
Each term of equation 4 was written in terms of [ES2], using equations 3ab as 
follows: 
 
[ES2]:    [ES2] 
 
[ES]:   
ES[ ]=
K
m2
ES
2[ ]
S[ ]   
 
[E]:   
E[ ]=
K
m1
ES[ ]
S[ ]  
 
Substituting in the term for [ES]: 
E[ ]=
K
m1
K
m2
ES
2[ ]( )
S[ ]
S[ ]  
E[ ]=
K
m1
K
m2
ES
2[ ]
S[ ]
2
 
 
Therefore, substituting the above equations for [E], [ES] and [ES2] into equation 4, 
[ET] can be described in terms of kinetic constants, [S] and [ES2]: 
 
(5)   
E
T
=
K
m1
K
m2
ES
2[ ]
S[ ]
2
+
K
m2
ES
2[ ]
S[ ]
+ ES
2[ ]
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(6)   
E
T[ ]= ES2[ ]
K
m1
K
m2
S[ ]
2
+
K
m2
S[ ]
+1
!
"
#
$
%
&
 
 
Multiplying both sides of the equation by kcat: 
 
(7) 
k
cat
E
T[ ]=kcat ES2[ ]
K
m1
K
m2
S[ ]
2
+
K
m2
S[ ]
+1
!
"
#
$
%
&
 
 
Substituting v0 (1) and Vmax (2) into equation 7: 
 
(8) 
V
max
=v
0
K
m1
K
m2
S[ ]
2
+
K
m2
S[ ]
+1
!
"
#
$
%
&
 
 
Rearranging equation 8: 
 
(9) 
v
0
=
V
max
K
m1
K
m2
S[ ]
2
+
K
m2
S[ ]
+1
!
"#
$
%&  
 
Multiplying both sides of the equation by [S]2/[S]2: 
 
(10)   
v
0
=
V
max
[S]
2
K
m1
K
m2
+K
m2
[S]+[S]
2
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Determination of kinetic constants for transglycosylation by PBP1a 
 
It could be interpreted that a linear relationship existed between PBP1a catalysed 
transglycosylation with the substrate concentrations tested (as described in Figure 
4.15).  Based on the assumption that Km1 was substantially smaller than Km2, the 
product of these two constants would approximate to 0 mM.  Therefore, Equation 10 
essentially reduces down to the Michaelis-Menten equation (Equation 11abc). 
 
(11)(a) 
v
0
=
V
max
[S]
2
K
m2
[S]+[S]
2
 (b) 
v
0
=
V
max
[S]
2
(K
m2
+[S])[S]  (c) 
v
0
=
V
max
[S]
K
m2
+[S]  
 
The linear trend indicated that the rate was directly proportional to the substrate 
concentration.  As the approach of Vmax was far from evident on the velocity versus 
substrate plot (Figure 4.15), it can be assumed that the substrate concentrations 
trialled were much less than Km2 (Equation 12).   
 
(12)    
v
0
=
V
max
[S]
K
m2  
 
Scheme A describes the binding of two substrates to the enzyme followed by the 
conversion of the substrate into product, which is considered to be the rate-
determining step.  This scheme was used to derive Equation 10.  However, the rate-
determining step could be before the binding of the second substrate as described by 
Scheme B. 
 
 
Scheme B  
 
In this situation, the generation of product is faster than the rate-determining step, 
thus the initial rate can be defined by: 
 
(13)    
dp
dt
=v0=kcat[ES]
 
 
[E]+[S]! "!# !! [ES]
+[S]
-[S]
! "!!# !!! [ES2 ]!"! [E]+[P]
K
m
k
cat
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Equation 13 can be used to derive the Michaelis-Menten equation (as described in 
Appendix B1): 
 
(14)    
v
0
=
V
max
[S]
K
m
+[S]  
 
At [S] much lower than Km, the rate is directly proportional to [S], given by: 
 
(15)    
v
0
=
V
max
S[ ]
K
m  
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Appendix B3 
 
Determining kinetic constants for a proposed model of two substrate 
binding with substrate inhibition 
 
The kinetics of MGT (Section 4.7.3) did not satisfy the Michaelis-Menten model for 
two substrate binding, thus the kinetic properties were described by the proposed 
model:  
 
 
 
 
 
 
The initial rate can be defined by: 
 
(1)    
dp
dt
=v0=kcat[ES2 ]
 
 
At Vmax, the enzyme catalytic sites are saturated with substrate: 
 
(2)    Vmax=kcat ET[ ]  
 
A kinetic equation can be derived from the model above on the assumption that the 
substrate of the reaction remains unchanged over the initial rates measured, and that 
rapid equilibrium kinetics exist. 
 
The kinetic constants from the model can be derived: 
 
(3a) 
K
m1
=
E[ ] S[ ]
ES[ ]   (3b) 
K
m2
=
ES[ ] S[ ]
ES
2[ ]  (3c) 
K
s
=
ES
2[ ] S[ ]
ES
3[ ]  
 
ES
3[ ] 
K
m
1
!
"
!
!
#
!
!
!
 
E[ ]+ S[ ]! "!# !! ES[ ]! "!# !! ES2[ ]!"! E[ ]+ P[ ]
Ks 
Km1 Km2 
kcat +[S] 
-[S] 
+[S]  -[S] 
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The total enzyme concentration is equal to the concentration of enzyme in unbound 
and substrate bound forms: 
 
(4)    ET[ ]= E[ ]+ ES[ ]+ ES2[ ]+ ES3[ ]  
 
Each term of equation 4 was written in terms of [ES2], using equations 3abc as 
follows: 
 
[ES2]:    [ES2] 
 
[ES]:   
ES[ ]=
K
m2
ES
2[ ]
S[ ]   
[E]:   
E[ ]=
K
m1
ES[ ]
S[ ]  
 
Substituting in the term for [ES]: 
E[ ]=
K
m1
K
m2
ES
2[ ]( )
S[ ]
S[ ]  
E[ ]=
K
m1
K
m2
ES
2[ ]
S[ ]
2
 
 
[ES3]: 
    
ES
3[ ]== ES3[ ]=
ES
2[ ] S[ ]
K
s  
 
Therefore, substituting the above equations for [E], [ES], [ES2] and [ES3] into 
equation 4, [ET] can be described in terms of kinetic constants, [S] and [ES2]: 
 
(5)   
E
T[ ]=
K
m1
K
m2
ES
2[ ]
S[ ]
2
+
K
m2
ES
2[ ]
S[ ]
+ ES
2[ ]+
ES
2[ ] S[ ]
K
s  
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Rearranged to give: 
(6)   
E
T[ ]= ES2[ ]
K
m1
K
m2
S[ ]
2
+
K
m2
S[ ]
+1+
S[ ]
K
s
!
"
#
$
%
&
 
 
Multiplying both sides of the equation by kcat: 
 
(7)   
k
cat
E
T[ ]=kcat ES2[ ]
K
m1
K
m2
S[ ]
2
+
K
m2
S[ ]
+1+
S[ ]
K
s
!
"
#
$
%
&
 
 
Substituting v0 (1) and Vmax (2) into equation 7: 
 
(8)    
V
max
=v
0
K
m1
K
m2
S[ ]
2
+
K
m2
S[ ]
+1+
S[ ]
K
s
!
"
#
$
%
&
 
 
Rearranging equation 8: 
(9)    
v
0
=
V
max
K
m1
K
m2
S[ ]
2
+
K
m2
S[ ]
+1+
S[ ]
K
s
!
"#
$
%&  
 
(10)    
v
0
=
V
max
S[ ]
K
m1
K
m2
S[ ]
+K
m2
+ S[ ]+
S[ ]
2
K
s
!
"#
$
%&  
 
(11)    
v
0
=
V
max
S[ ]
K
m2
K
m1
S[ ]
+1
!
"#
$
%&
+ S[ ] 1+
S[ ]
K
s
!
"#
$
%&
 
 
The kinetic parameters were determined by plotting the assay data as a velocity-
substrate profile.  The statistical program GraphPad PRISM 5 was used to fit the data 
to equation 11 and to extract values for the kinetic constants.   
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Appendix C1 
 
Kinetic parameters of VanA (Batson, 2010) 
 
 
(a) 
VanA Substrate at 
subsite 1 Km1
a
 (mM) 
D-Ala 1.40±0.23 
 
(b) 
VanA Substrate at 
subsite 2 Km2
a
 (mM) kcat (min
-1
) kcat/Km
a
 (mM
-1
min
-1
) 
D-Ala 194.30±29.90 118.52 0.16±0.005 
D-Lac 1.76±0.19 16.76 9.52±0.03 
 
Table C1: Kinetics of VanA.  (a) The kinetic constraints of the exclusive binding of D-Ala in the 
first subsite.  (b) The kinetic constraints of binding D-Ala or D-Lac into the second subsite.  Data 
taken from Batson, (2010), calculated by using data obtained from ADP-coupled release assays. 
aValues ± standard error  
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Appendix C2 
 
The expression and purification of E. faecalis VanA 
 
E. faecalis VanA was expressed and purified according to Batson, (2010).  The 
vector pET28d::vanA (E. faecalis vanA cloned into the pET28d vector conferring 
kanamycin resistance) (supplied by S. Batson) was used to express VanA in E. coli 
BL21 Star (DE3) pRosetta by induction with 1 mM IPTG for 3 hours following a 
growth at 37°C that had reached an OD of 0.5.   
 
Crude lysates containing the expressed VanA were prepared and were applied to a 
chelating Ni2+ sepharose column (Ni Sepharose High Performance, GE Healthcare) 
(equilibrated in 50 mM HEPES, 300 mM NaCl, 10 mM imidazole, 10 % (v/v) 
glycerol, pH 7.5) and enabled the purification of VanA on the basis of its vector-
encoded histidine tag by elution with 125-250 mM imidazole.  The eluate containing 
partially purified VanA was applied to a size exclusion column (Superdex 75 26/60) 
equilibrated in 50 mM HEPES, 150 mM KCl, pH 7.5 in the final purification 
procedure.  Figure C2 demonstrates the purification of VanA to complete 
homogeneity. 
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Figure C2: Chromatogram of size exclusion chromatography and a 12 % SDS-PAGE analysis 
of VanA purification.  (a) The pre-equilibrated Superdex 75 26/60 column was injected with partially 
purified VanA following IMAC, at elution volume 0 mL.  (b) SDS-PAGE Coomassie-stained gel 
analysis of the eluted fraction from size exclusion chromatography representing absorbance maxima 
at 280 nm.  Mr, molecular weight markers (kDa); lane 1, final level of VanA purity following the two 
purification techniques.  The arrow shows the position of VanA (38.4 kDa). 
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